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The identification of a causal link between infection with specific types of human 
papillomavirus (HPV) and the development of cervical cancer has stimulated considerable 
interest in the development of HPV vaccines, especially for use in deve/oping countries, 
where the disease burden is high and resources for widespread screening and follow-up 
procedures are limited. 
As the major structural protein of the HPV capsid, L 1 is the antigen of choice for the 
development of prophylactic vaccines for HPV. L 1 has the ability to self-assemble Into virus-
like particles (VLPs) which are highly immunogenic, and can induce protection from 
papil/omavirus challenge in various animal models. Human phase 2 clinical trials with HPV-
16 VLPs have produced encouraging results. The production expense of VLPs, however, 
makes them unlikely candidates for large-scale use In developing countries. Because 
affordabillty is a key factor for vaccine production in South Africa, this study assessed the 
potential of Mycobacterium bovis bacille Calmette-Guerin (BCG) as a HPV vaccine vehicle. 
BCG is the live, attenuated M. bovls strain, which is routinely used to immunise against 
infection with M. tuberculosis. A number of factors contribute to the cost-effectiveness of 
recombinant BCG (rBCG) vaccines: complicated purification procedures are not required, its 
potent adjuvant properties prevent the need for additional adjuvants, an extensive cold chain 
for maintenance of efficacy is not required, and distribution networks already exist. A variety 
of viral, bacterial and parasitic antigens have been successfully expressed in BCG, inducing 
both humoral and cell-mediated responses. In experimental models rBCG has proven to 
elicit protective immunity against Lyme disease, pneumococcal infection, and cutaneous 
leishmaniasis. rBCG expressing cotton tall rabbit papillomavirus L 1 has been shown to 
partially protect rabbits from CRPV challenge, indicating that rBCG has potential as a vector 
for a prophylactic HPV vaccine. 
In this study, rBCG expressing the L 1 capsid protein of the H PV-16 was evaluated as a 
candidate prophylactic HPV vaccine. The expression and immunogenicity of three HPV-16 
L 1 gene variants, namely L 1R (full-length gene), L 1NLS- (a 66 base-pair 3' truncation of L 1R to 
remove the nuclear localisation signal [NLS]), and L 1sCG (a synthetic gene with codons 
optimised for expression in BCG) were assessed in rBCG. The L 1R, L1NLS-, and L1SCG 
genes were cloned into a panel of 8 E. coli - mycobacterial expression vectors, resulting in 
20 clones which were introduced into BCG (Tokyo and Pasteur substrains) by 
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electroporation. The expression vectors differed with respect to promoters utilised for foreign 
gene expression. foreign protein export. and were either integrative or extrachromosomal. 
A high frequency of genetic instability was observed in many of the BCG recombinants 
immediately after electroporation. which was evident by L 1 gene excisions; and as a result. 
only 12 of the 20 L 1-expression vectors could be Introduced into BCG in their intact form. 
The 8 unstable plasm ids were clones of pMV261 NT. p2619. pAB26, and pSMT3, which have 
two common features: they are extrachromosomal (copy number of 5) and they drive foreign 
gene expression with the hsp60 promoter. The integration-profICient plasmids (pMV361 and 
pN1V192), which also drive foreign gene expression with hspSO, were however stably 
maintained. Clones derived from the extrachromosomal vectors, pCB112 and pCB119, 
which drive foreign gene expression with the M. leprae 18kDa and mtrA promoters, 
respectively, were more stable in BCG than their hsp6O-driven counterparts. This superior in 
vitro stability may be a consequence of the weak in vitro activity of the M. leprae 18kOa and 
mtrA promoters. Restriction enzyme analysis and sequencing of the unstable expression 
plasmids revealed that the gene deletions present in these constructs ranged from deletions 
spanning the entire L 1 gene and promoter region, to smaller deletions within the L 1 gene. 
These gene excisions were never found to occur at exactly the same sites. Stable 
constructs were sequenced, and surprisingly, no small gene deletions 0 r significant point 
mutations were detected. 
Recombinants that appeared stable after transformation were assessed by PCR or 
restriction enzyme mapping after a further 16 and 24 generations of growth in liquid medium 
containing antibiotics. The BCG recombinants containing integration-proficient vectors were 
genetlcaily stable (100% stable after 16 generations), despite having the strong hsp60 
promoter. The BCG c onstrocts derived from the p CB112 extrachromosomal vector were 
relatively stable (4 out of 5 cultures were 100% stable after 16 generations). BCG 
constructs derived from the pCB119 vector were the least stable (3 out of 5 cultures were 
unstable after 16 generations; between 12% and 90.1 % these cultures had lost of the L 1 
gene). When grown without antibiotic selection. the integrated vectors were m ore stably 
maintained than the extrachromosomal constructs. On average, 85% of the bacteria in the 
cultures containing integrating vectors were still antibiotic resistant after 26 generations of 
selection-free growth. but only 25% of the bacteria in the cultures containing 
extrachromosomal constructs remained antibiotic resistant. 
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It was assumed that the observed plasmid instability was a consequence of high levels of L 1 
expression, however, the level L 1 protein production by rBCG was usually too low to be 
detected «0.3% of total rBCG protein). mRNA quantification studies deemed L 1 
transcription to be efficiently taking place in all rBCG-L 1 constructs tested. rBCG containing 
the extrachromosomal vectors, p112L 1e and p119L 1e, produced higher levels of L 1 mRNA 
than p361 L 1e; which is likely due to the multiple copy nature of the former plasmids. 
p119L 1e produced more L1 mRNA than p112L1e, implying that the mtrA promoter (in 
p119L1e) is more active than the M. leprae 18kOa promoter (in p112L1e) in vitro. Codon 
optimisation of L 1, to reflect commonly utilised BCG codons, did not increase L 1 production 
to detectable levels, suggesting that the apparent low expression of L 1 is also not due to 
inefficient translation. A high rate of degradation by proteases is suggested for L 1's apparent 
low expression. 
Immune responses elicited by rBCG-L 1 were investigated in guinea pigs and mice. Although 
both humoral and cell-mediated immunity were assessed In guinea pigs, the focus was on 
the ability of rBCG-L 1 to generate antibodies specific to HPV-16 L 1, as the aim of this 
research was to investigate the possibility of utilising rBCG-L 1 as a prophylactic vaccine for 
HPV. The mouse studies focused on the in vivo CTL responses elicited to rBCG-L 1, by 
measuring the level of protection in a recombinant vaccinia virus-HPV-16 L 1 (rW-L 1R) 
challenge model. The combined results from the guinea pig and mouse studies 
demonstrated that immunisation with rBCG-L 1 successfully elicited VLP-specific antibody 
and cell-mediated immune responses that were dependent on expression vector, dose, route 
of immunisation and L 1 variant. Three or more rBCG-L 1 immunisations were required for 
the induction of a strong antibody response. On the other hand, a single inoculum of purified 
HPV-16 L 1 VLP elicited high levels of antibodies to L 1. In guinea pigs the rBCG-361 L 1e and 
rBCG-119L 1e constructs induced the highest serum antibody levels, while the rBCG 
constructs utilising the pCB112 expression vector conSistently elicited the weakest antibody 
responses. When administered at the 2x106 cfu dose, all rBCG-L 1 constructs successfully 
induced L 1-specific DTH reactions, which is evidence of BCG's potent cellular immunity 
adjuvant properties. The observation that rBCG-112L 1 BCGe (codon optimised L 1) elicited 
higher levels of antibodies than rBCG-112L 1e (native L 1) suggests that codon optimisation 
increased the expression of L 1, or that CpG-lslets on the optimised gene increased this 
recombinant's immunogenicity. The observation that the anti-L 1 antibody levels elicited by 
rBCG-361L 1e and rBCG-119L 1e were of similar magnitude, and that rBCG-119L 1BCGe did not 
elicit Significantly more antibodies than rBCG-119L 1e, suggests an upper threshold level of 
L 1 expression In BCG. The removal of the L 1 NLS enhanced the immune response over 
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full-length L 1; this was apparent by the enhanced antibody response induced to L 1 in guinea 
pigs by rBCG-112L 1NLS-, and by the superior protective ability of rBCG-361L 1NLS-ln the rVV-
L 1 mouse challenge model. VLP-specific antibodies were detected in the vaginal secretions 
of a number of animals Immunised with rBCG-361L1., rBCG-119L1. and rBCG-119L1acGe. 
Wild-type BCG-primed guinea pigs elicited enhanced L 1-specific antibody responses, when 
compared with non-primed animals, easing concerns that prior vaccination with wild-type 
BCG could adversely affect the immunity Induced to recombinant BCG vaccines. rBCG-L 1 
did not elicit detectable neutralising antibodies in guinea pigs, which Implies that VLPs or 
capsomeres were not formed within BCG. 
Immunisation of mice with rBCG-L 1 elicited antigen-specific C08+ responses, and antigen-
specific cytotOXicity, and L 1-speclfic antibody responses. Furthermore, these mice were 
afforded L 1-speclfic protection of up to 98.89% from challenge with rVV-L 1R, confirming the 
Induction of strong C08+ CTL responses. 
In conclusion, rBCG-L 1 has produced good preliminary Immunogenicity data in small 
animals. However, the L 1 production and stability of these vaccine candidates would need 
to be improved before these rBCG-L 1 would be of clinical use. 
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Chapter 1: Introduction to Human Papillomavirus 
1.1. HISTORICAL OVERVIEW 
The infectious nature of warts has been suspected for many centuries. In 1907, Ciuffo 
suggested the viral aetiology of human skin warts by experiments demonstrating the 
transmission of warts from man to man by the inoculation of a cell-free extract of wart tissue 
(reviewed in Burns, 1992). In 1933 the first papillomavirus (PV) was described by Richard 
Shope. Shope recognised the cottontail rabbit papillomavirus (CRPV) as the a etiological 
agent responsible for cutaneous papillomatosis in the cottontail rabbit (Shope, 1933). The 
first electron microscopy identification of papillomavirus particles occurred in 1949; and the 
structure of the papillomavirus genome was elucidated in 1963, however, further 
characterisation was slow, since a tissue culture system for the propagation of PVs did not 
exist (reviewed in zur Hausen, 1996). 
One of the main reasons for the current interest in human papillomaviruses was the 
discovery of their relationship to carcinoma of the cervix. Although a cytologiC feature of 
cervical HPV infection, called "koilocytotic atypia·, was observed and named in a study by 
Koss and Durfee in 1956, the association with HPV infection was not yet recognised. It was 
only suggested in 1975 by zur Hausen, that PVs may playa role In the induction of cervical 
cancer (zur Hausen, 1975). 
1.2. CLASSIFICATION, NOMENCLATURE AND TAXONOMY 
Historically, papillomaviruses and polyomaviruses were grouped together as papovaviruses; 
however, papillomaviruses are now seen as a family of their own. PVs are widespread in 
nature and have been isolated from humans, cattle, rabbits, horses, dogs, non-human 
primates, mice, sheep, birds and deer (reviewed in Howley and lowy, 2001). Traditionally, 
each virus was named firstly after its natural host, as the host range of single PVs is usually 
very restricted and they rarely or never cross the species barrier. PVs from one species 
were further classified Into supergroups, subgroups, and types according to the sequence 
homologies of the E6, E7, and l1 open reading frames (ORFs). The PV taxonomic 
classification has recently been revised, introducing the terms "genus· and "species·. The 
supergroup is now referred to as a genus (different genera share less than 60% nucleotide 
sequence homology of the l1 gene), subgroups are now called species (species within a 
genus have 60-70% homology), the traditional classification Into "types· has persisted (types 
2 
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within a species have 71-89% L1 nucleotide sequence homology). So far over 100 HPV 
types have been identified, with 80 types fully characterised (de Villiers et al., 1997,2004). 
A1pha-paplllomavlrus: 
PVs associated with mucosal surfaces. 
Indudes genital HPVs, HPVs found in oral 
and laryngeal papillomas, and some 
cutaneous types that occasionally 
infect mucosal surfaces. 
Gamma-papiliomavirus: 
Cutaneous HPV types. 
Figure 1.1. The papillomavirus phylogenetic tree. This phylogenetic tree is based on the L 1 
gene sequences from 118 PV types. The numbers at the end of each branch identify HPV types, 
while the animal PVs are abbreviated. The numbers at the inner semicircles represent the 
papillomavirus species, while the outermost semicircles represent the genera. Modified from de 
Villiers et al. (2004). 
HPVs can be subdivided according to their tendency to affect either cutaneous or mucosal 
epithelia, and then further grouped according to their propensities to cause malignancy. 
Lesions induced by different types of anogenital HPVs show great variation in their risk for 
malignant progression; anogenital HPVs are therefore broadly classified into high-risk HPVs, 
3 
such as types 16. 18. 31. and 33, and low·risk HPVs. including typos 6 and 11 (whICh are 
very ra rely found in malignant tumours) (zur Hausen and de Viniers. 1994). 
1.3. PV STRUCTURE AND NUCLEIC ACIDS 
1.3.1. Virion structure 
PVs are small (-55nm In diameter) non-enveloped viruses with Icosahedra l symmetry; 
consisting of a protein capsid which encapsulates a double·strflnded. Circular DNA genome. 
The capsid consists of 72 pentamerlC capsomer~s that are arranged on a T=7 icosahedral 
lattice. with fil l except the COllontai l rabbit papil lomavirus displaying a d (fight) hand skew 
lattice (Baker el al . 1991 . Plist,"r and fuchs. 1994) . 
Figure 1.2. A th,oo-dtmens,onal Image 
reconstructK;.n from cryoeteClron mi<;ros<;oplC 
analysis of a pflpll10mavlfus part i<;te From 
Bakereral (199t) 
1.3.2. Genome Organisatio.n and Function 
The PV genome consists of between 7500 find 8(00 base pa,rs, and forms a chromaHn-l,ke 
complex by assoc,ating with cel lu lar his tones. All protein·encodlng stlquences are located 
on one or the DNA strands. whiCh contains at least 8 open reading !rames (DRfs) All PVs 
share a s'mllar gen'"tlC organlsal'on (see Figure 1 3). wh ICh can be dlvidod In10 three basic 
regions' (1) an early (E) region . encoolng protems lrlvolved in DNA repHcal ion, transcnption 
and 0011 tranSformation: (2) the Iflte region . encoc"'9 the capsid proteins: and (3) the non-
cod,ng region, the long conl/ol reg ion (LCR). which contatns contro l elements lor 
lranscnption and replication (Howley and lowy 2001: Paler el al .. 1994). 
, 
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Figure 1.3. Organisation of a 
papillomavirus genome. The bars 
represent the open reading frames 
of the early (E) genes, the late el) 
genes, and the long control region 
(lCR). Modified from lowy and 
Howfey (2001). 
Table 1.1. Summary of the functions of the ORFs of HPV. 
ORFs Function 
L1 Major capsid protein 
L2 Minor capsid protein 
E1 Initiation of viral DNA replication (Chow and Broker, 1994). 
E2 Transcriptional regulator with replication functions (zur Hausen and de Villiers, 1994). 
E4 HPV-16 E4 causes the collapse of the cytokeratin network, possibly to aid the release of 
virions (Roberts at aI., 1993). E4 can cause the arrest of the G2 phase of the cell cycle 
(Nakahara at a/., 2002) 
E5 E5 has weak transfonning activity and is able to interact with growth factor receptors 
(Howley and lowy, 2001). 
E6 Transfonning activity. Binds and promotes degradation of the cellular tumour 
suppressor protein, p53 (Schmitt at aI., 1994). 
E7 Transfonning activity. Binds to the retinoblastoma protein, a tumour suppressor protein 
(Schmitt at aI .• 1994). 
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Genes encoding the capsid proteins, L 1 and L2 
The late region of the PV genome contains two ORFs, encoding the major capsid protein 
(L 1) and minor capsid protein (L2). Capsid synthesis and virus assembly occurs only in 
terminally differentiated keratinocytes (Ullman and Emery, 1996). The L 1 protein represents 
about 80-90% of the viral protein. it has an average molecular weight of about 55 kDa (504 
amino acids [aaD and is the most highly conserved of all the PV proteins. In a number of 
systems, both eukaryotic (Kimbauer et al., 1992; Rose et al., 1993; Hagensee et al., 1993; 
Sasagawa et al., 1995) and bacterial (Nardelli-Haefliger et al., 1997), L 1 proteins alone have 
been shown to self-assemble into non-infectious, empty capsid-like structures that closely 
resemble native virions. 
L2 proteins have a molecular weight of approximately 76kDa (473 aa) and are not as well 
conserved as L 1. Although L2 is not required for VLP assembly, the co-expression of L 1 and 
L2 increases the VLP yield by about four-fold in the baculovirus system (Klmbauer et al., 
1993), and by about 100-fold In mammalian cells (Hagensee et al., 1993). L2 is able to bind 
to DNA, indicating a possible role In binding viral DNA during viral particle assembly (Zhou et 
al., 1994). It is suggested that the HPV capsid consists of a ratio of 12 L2 molecules to 360 
(72 pentamers) molecules of L 1 (Kimbauer et al. 1993). 
PV virions infect cells via a clathrin-dependent receptor-mediated endocytic pathway (Day et 
al., 2003). Although VLPs containing only L 1 are sufficient for enabling infection, L2 can 
enhance Infection by facilitating virion entry, and plays a role in determining HPV tropism 
(Kawana et al., 2001; Yang et al., 2003). The finding that neutrallsing antibodies can be 
generated to L2 following immunisation with capsids, suggests that the L2 protein is 
positioned at the surface of the virion (Heino et al., 1995; Roden et al., 1994). 
Both the L 1 and L2 proteins have nuclear localisation signals (NLS) to facilitate the 
translocation of these proteins to the nucleus. The NLS of HPV-16 L 1 consists of clusters of 
basic amino acids (KRKKRK, aa 499 to 504; KRK, aa 484-486; and KR, aa 499 and 500), 
located at the carboxy terminus (Zhou et al., 1991c). The HPV-16 L2 NLS (RKRRKR) is 
situated at aa 456 to 461 (Zhou et al., 1991c). Nelson et al. (2000, 2003) found that HPV 
capsomeres are recognised by the karyopherin (Kap) a,2 adapter, and are then translocated 
from the cytoplasm to the nucleus via the Kap a,2131-mediated pathway. They established 
that L 1 binds to the Kap 133 and Kap 132 import receptors via interaction with its NLS. 
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l A . UFE CYCLE 
Transml""Io" of HPV" '" tooih,,,,od by tho pre"enoe of "br(tded ep,theh". "lIowing tho 
,nfectlon of Ine basal keralinocytes of squamous eprthelia The basal c~ls are the o"ly cells 
in the squamous epithelium capable 01 dIVIding. the VIrUS must therefore infect Ihls layer In 
order 10 induc;e a lesIon whIch can persist Th,s ,5 followed by Imectoon which can be latent, 









Figure 1.4. The IIIe cyc le of papillomavlIlls. Inteetion 01 a basal ep~he llal cell (1. 2), loIlowed by 
endocytOSis, virat DNA uncoaung (3). and transport to the nucleus (4 ) TranscriptIon 01 earty 
ge<1e5 (5), translallOn (6) and Vilal tephca~on (7) ,n basal and suprabasat eplthei<a l cells 
Vegt!tatIVe viral DNA replicatIOn (a) , late gene transcnpllOn (9). prooucdon of capsid prOlelfl5 (10) 
and assembly 01 y,nons (1 ' ) take place in d:f!erefltJated 1<e<atlllOCY:es Nl)(:lear breakdown (12) 
and release 01 YIIUS then occurs (13). From Howley and lowy (200 ' ) 
The wat transcnptlonal aChY"y IS regulated al a low level and VIIat DNA rep lication only 
occurs when Ihese basal and parabasal cells enter Ihe S phase of the cell cycle The VIIal 
genome IS matnlamed at low copy numbef1> less than 20·50 per cell After the cel ls ascend 
, 
tMy leave tM cell cycle and unllergo progressive dlfferenllallon. In Inlec1e11 cens. the 
progression 01 the differenllaticlJl program of the epithelium becomes relarded. resu~ing in an 
increased thickness of the spinous cells (reviewed in Chow and Sraller, 1994). This leads \0 
various grades 01 papillomatosis and epithelial hyperplasia. During the promera~ve phase, 
viral DNA replica~on and synthesIS of slructural proteins remains resm<;ted This restridion 
is wease<! upon entry into lhe dmerenliating cells layers. where ve{jl!lative VIral DNA 
replication, structural protein S)'!llhesis. and \/Irion parl ide assembly take plaa! Mali!lnant 
CDJ1Verllion 01 OOJll!ln lesions leads to the termination 01 vegeta~ve PV replication (Tak:hman 
and laPorta. 1987). 
SiflCe Iytk; replica~on does not take place in the basal keratlnocytes. the germinative cells 01 
the epithelium are protected lrom the cytopathic effeels caused by late gene products.. 
Virions are only produced in the temtinally d ifferen~ated cells . whk:h are lawr shed Into the 
environment. ensuring the spread of the virus. and the cont inued growth 01 the host 
keratinocytes (Taichman and LaPor1a. 1987). 
1.5. EPIOEMIOlOGY ANO OISEASE 
1.5.1 . HPV associated di5~se5 
Human papillomaviruses are extremely widespread. i!fld due to The numerous ditferenltypes 
almost everybody w iM come into conTael WITh HPV d unf\g their lifehme. T he spectrum of 
diJllcai mandestaTions associated With HPV ranges from iffiymptomatk: to benign and 
malignanT lesions. the most oommon being the production of warts. whk;h are benign 
Tumours. Clinical manifestations associated WIth the different types can be divided into 
cutaneous (common wart. plantar wart. fiat wart et<;.) and mucosal manifestations (genITal 
warts. cervical cancer. respN"atory papillomas etc.) (reviewed in Howley and Lowy. 2001). 
There IS a strong association between lhe HPV type and clin ical manifestation (see Table 
1.2) A number of HPV types Induce bemgn seH-limitl"!J proliferations of the s~ i n and 
mucosa. These lesions usually regress. either spontaneously or after treatment They are 
classed as klw_nsk viruses as they are never detected In Inviffiive carcinomas. HPV types 6 
and 11 are Iow-r1s~ viruses that cause genital warts: howeller. they are occasionally 
;,osoei3l...:l wilh low_grade cervical ;ntraep~heliat neopla5ia (CIN) (G reo, el .. ! .. 1995). Some 
" 
HPV rypos are a$$OCiated with the development of invasive cancOf$: these are ~nown as 
hogIHtsk viruses 
Tabla 1.2. HPV lypoS and major d'mcal manifestation. From Lowy and HoweIy (2001). 
Cnnic:;al type 
Skflwam 




Reddksh-broWfl pllqU8S of 




Exopll)'lic condyloma (any sota) 
Flet condyloma (~~ carvlx) 
IkM9nood papulosls 










Oral ca ... 1y 
Focal epllnel/al M)'P8.plasi3 
InlectKIM wilh genlla l l.ocl HPVs 





HPV·3. +10 •• 28, ~I 
HPV·5. ·8. -9, .12, ·14, -15, .17. ·19, ·20, ·21. 
·22. ·23. ·2. , ·25. -38. _37. -38, ~7, ~9 
HPV-7 
All 11&'1". HPV. 
HPV-3. ·11 




HPV -33.-35.-39.-51 . ·52.· 56.-53. ·59.-tIe 









1.5.2. Cancer of the ceNix 
In 1995 the World Health Organisation (WHO) doclared HPV a human carcinogen 
(IntemaHonal Agency fat Research on Cancer {tARC]. It is now accepted that certaon HPV 
types, such as HPV-t6 and HPV-t 8. play an important role In anogonital carcinogonosls. 
Ilspedaliy in carcinoma 01 the cervix (Clifford ef al. 2003: Bosch el aI. 1995). Cervical 
cancer Is the second most prevalent cancer worldwide and the most common cancer in 
dllveloping countnes (International Agency for Research on Cancer [tARC] 1999). Annually. 
approXimately 500 000 womcn are diagnosed with ccrvlcal cancer and there are OV!lr 
200.000 deaths from thiS disease each ye~r. of wh ich. 80% O<;(;ur in developing countries 
SutrSaharan Africa is the area of highest cervical cancer monality rates, wuh age-
standardised rates (ASRs) ranging between 10.7 (Wllst!lrn Africa), 24.3 (Eastmn Africa) and 
17.1 (South Africa) (Pisani elal .. 1993) More recently. the risk In South African women was 
found to be even higher. With an ASR of 30.5 per 100 000 (Silas ef al.. 1998) 
In an altempl to identify the most prevalent HPV types aSSOCIated with invaSive cervical 
cancer, Clifford et al (2003) collated pl.lb lished data from 85 studies. With a tota l of 10058 
cases (8550 squamous cell carcinoma (SeC). 1508 adeno..and adcnosquamous·carcinoma 
(ADC). The overal l dOl!!Clion of HPV DNA In the cancer samples was 83-89%. The most 
prevalent HPV types, in order of decreasing prevalence. were HPV-16, -18. -45, -31 , -33.-
58. -52. -35, -59. -56. -6 , -51 , -68. -39, -82. -73, -66 and -70, In SCC the HPV prevalence 
was 873%; HPV-16 was the most common type (46-63%) followed by HPV-18 (10-14%) .. 
45 (2-8%). -31 (2-7%) and -33 (3-5%). In Asia. however, HPV-5!l (6%) and HPV-52 (4%) 
were id!lntlfied frequently, The HPV prevalence was lower in ADC (76.4%), where HPV-18 
(37-41 %) was Ihe most common type. fol lowed by HPV-16 (26-36%) and -45 (5-7%). In 
South Africa. HPV-16 was the most frequenlly detected type in cervica l cancer biopsies 
(82%). fol lowed by HPV-18 (to";'). arld HPV 33 (10%) (Kaye/ al .. 2003) 
1,5.2, f Progression of mfection to cervical canc;er 
The first Slep In the development of cervical cancer is appearance of abnormal cells (non-
d;trernntiating basal-like ce lls) which rap/aces the normal cervica l epithelium This may 
regress , mmaln unchanged Of progrnss to high-grade squamous ln1raeplthelial lesions 
(HSILs) and InvaSive cervical cancer. The process Irom the appearance of the IIrst 
abnormalit;es to the developmenl 01 celVlCal cancer can take years. and It Is during this 
i"'crv,,t where thC$C ob"ermol,lic$ con be dcte<:ted by Pop emeor Dnd trooted (mviewed In 
LOW)' and Howley, 2001). Approximately 75% 01 detected SIL will not progress (41% will 
pel$lSl 3!1d 3<1% WJI regress) , wtJle oIlhe 25% thaI does progress, 10% WIll progress 10 
carCInoma", SIlU and 1% 10 InvaS!\Ie cancer (Braty or aI , 1997). 
(HS1L) 
Ce.VIC8tlntraep.thel l;ll1 Neoplas'a 
M,crornva, i"a Ca.clnoma 
Figure 1.5. A schematIC represental(ll\ 01 cerw:aI cancef pfe<:ur~ and !he 
vanous ternllno\og les that are used to refer to \hem MOd~recI from Lowy ;11'1(1 
How1ey (200t ) 
1 5.22. Evidence of a HPV-cerl'lcal cancer BssociB~on 
5evefal findings polnl to an HPV·cervlcal cancer assoeration 
• HPV DNA is conSistentlY detected III cervical cancer bIOpsies Dependtng on 
teclmrque used. thiS ran9es from 42 to 100',1, SlUdiM coordinated by me 
International A9ency for Research on Cancer of cervica l cancer In 22 eountfles 
idenhfled HPV DNA In 99 7% 01 IhMe cancers (Clifford el BI . 2003) Besides 
cemcal cancer. 50% of the biopsies from cancers of the ~ulva and penis are HPV. 
POSIIlve , and about 85% or anal cancers are HPV·POsitlve ( re~lewed In lur Hausen 
1996 IARC 1999) Tile HPV types toui'ld III cancers are usually the hlgn-nsk types 
" 
with HPV types 16 and 18 delaclad In llWt vast majority 01 callC8r samples. TIWt mere 
presence 01 HPV ONA. howe~9f, does nol prove an eliologlcallnvolvement. 
• HPV ONA is malnl<11nOd as an episome in 00"'90 produCllV9 lesIOnS. howeYOr. 
Integrated HPV ONA Is identIfied in inmor1allsed human keratlAOCytes . In cells lines 
Isolated Irom cervical neoplasms. and in 100% of squamous cell cancer bIIlCl ie!I 01 
!he cervIX (Cooper ot ai, 1991: Cullen or al. . 1991). 
• The E2 ORF ;5 usually dlsruptlld durl rIQ integration leading to disrupcion 01 thO E2 
repl'O'$$Of, which results in Olltl,·expression of the E6 and E7 oncoprolains (QJIIon er 
aI . I991) 
• E6 and E7 are consistentty expressed In cancer cails. These proMins Inl9ract wllh 
lumou. suppressor proteins and ant able 10 Immortalise human ce"s, Wr.en E6 II!1d 
E7 e)(pression is bIoel<ed In cervical cal'Cinoma cell lines. using complomemary RNA. 
eel growth IS .educed and lMI'e is a reversion 01 the malignant phenotype ('i()f! 
Knobel el;ll , 1968). 
1.5,3. Other Qrn;ers 
When alilhe global cancer inadoncos !haC have HPV associallOns 9<& 00d0d up. including. 
e&rvk<il cancer. causing a pprolcimalOly 5 .8% of .....or\<IWIde cancer. ~ 01 cancers 01 the 
penIS, vagll10l and Y\lIva. 65% 01 anal cancers. and 50% of O!!$Ophageal CSncet'$: 
approxtlnalaly 6-10% 01 tklt estimated 9 milton eas&s 01 cancer wortdWlde (elOduding BOO-
melanoma skin cancers) can be ~nked 10 HPV infaction (tARC. 1999). Women lrom 
dovoloping reg ions, l ike Letin Am&r1ca, Southwest AsIa, and Sub-Saharan Africa. /\;We tho 
highest prevalences of HPV-lnduCOO caneers, wilt1 20-24% of cartC(lrs anrltlutable 10 HPIJ 
(IARG.I999). 
Oesophageal cancer accounts lor the SIXlh highest number 01 cancer ooaths worIdwidu. 
SoutMm Afnca has Ihe h>ghesl age-standardised rate of oesophageal cancer mortality 
wo~dwldu in the mille populatlOll (ASR • 29.5) and tho socood highest in the fumale 
popuIal!on (ASR • 79) (PlSa,," ft IJI, 1993). Recent PCR data suggest:! 911 association 
botNOOfl HPV and oesophageal cancer as most aUlhors ha~e detected HPV in 
appro .... ate!y 50% 01 these tumOUf5 IMatsha 91 IJ/" 2002: R,ngst.om el ;II .• 2002). More 
SWdlUS have to be periOtmed as (!ata are ImltOO and results ~atY greatly between stUdios. A 
S~ on oasop/1ageal tardnoma samples from ChlnftMI pa~anl5 detected HPV-16 DNA In 
up 10 72% of the tumou~ and HPV·18 in U9 10 1~, I)oIh otten In thoe seme tumour (Li 8/ 81, 
2001) COOper 81 at ( 1995) detecled HPV DNA in 52% of South African Ofl$Ophageal 
rumoors, with Hpv·161n 84% 01 lhe HPV~ve C<lncelS Rllch,., and colleagues (R itchie 
el aI., 2003) $"blished thaI lhe prevalence 01 HPV DNA .n carcU10mas 01 Ihe oral cavity 
and oropharynx was 21%. of whICh 86~ was HPV.16 They found a higher nsk of HPV 
II1fedioo.n men. a-nd In patients w.th a hrstory 01 ~itaI selC 
The eMiMI evk\lIflce IOf the I.nk 01 HPV and sJun cancer is from SlUdieS on patients wll h EV 
There are about 20 HPV.ty;>es thaI are frequently deleeted In about 90'1(, 01 EV callOflrs (Zllf 
Hausen. 1996) (see Table 1.2) HPV may be an etJOlogoe age", in non-melanoma skin 
caReer and kerat08C8ntnomas as it Is delected In about 50% of these lesions. WIth a hl{jhe< 
Pr1lvalence In Immunosuppressed patients (l.lo\Ier.os 91 M .• 2002. FDI$lund at a/ .• 2002). 
More studies mUSt be done In th" field 10 confirm l hese results 
It is estimaled thaI HPV (malnfy HPV.16) Is ltSSooaled with 85% 01 the 44 000 caS8$ 01 anal 
cancer wo~dwlde (IARC. 1999), Oamsh and Swadish studies delected hlgh-risk HPV types 
In 100% of anal squamous ca-dnoma semples from homosexual men. while 58% and!lO% 
of aamples were HPV pos~ive from heterosexual men and womllfl. respecUYely (Frisdi. 
2002) 
About 50% 01 canc8f$ 01 the penis. vagina and vufva are associated with HPV inIe<:tion 
(tARe. 19991· Hf"V DNA" detocled in 42% of cases 01 penlle C<lfdnoma, 90% of d~plasia. 
and 100% 01 cases of condyloma. The PfV\Ialence 01 HPV IS differern In different hlstoiogfcal 
eaneer subtypes: HPV is detected In 34.9% of squamous 001 C<lrCHlOma, 33.3% 01 vefTUCOUS 
C3C11lO11la, 80% of basalood and tOO% 01 warty tumOlJf SUbtypes (Rubin et a/ .• 2001) 
1.6. IMMUNOLOGICAL ASPECTS OF HPV INFECTION 
1.6.1. N,tUTIOI immunity to HPV 
Although J'ntrIttne responses eieiloo to HPV irlocllons are uwa~y weak, due to limited 
exposure of vhf antigons to the IIl1mune system, the immune response does play an 
importanl role in the course of PV Infection. 3$ not all HPV infectiom lead to disease and 
$OI'Re HPV lesions regress spontaneously 
" 
76. t t Cell-mediated immlmlty 
Cell-mediated Immune responses are thought to play an Important role in HPV disease 
progression as individuals with cell.mediated immune deficienc,es. such as AIDS pat,ents 
and !mnsplan! reCIpients. have an Increased risk 0IIn7OOion With HPV (reviewed In Koutsky 
1997). and 01 developing ceO/ieal cancer (Petry fit al., 1994). 
Studies have shown Ihat regressing genital warts are characterised by an active cell-
mediated Immune response In which regressing tumours are onfiltrated With macrophages 
and T lymphocytes (Heller el ai. 2003; Coleman fit al .. 1994). In the CRPV model. 
SBlvakumal and coHeagues (1007) detected the Infiltration 01 mainly CDS' T cells Into the 
tlasal and suprabasallayers 01 tile ep1dermlS dunng wart regression. The human or genttal 
situation may be slighlly differen t: as mainly CD" T cells, were found both within the stroma 
and on the surface epithelium of regresSing genital warts . There Is also a slgnffieant 
Induction of immune accessory molecules, such as the major histocompallbility complex 
(MHC) dass II molecules and the intercellular adhesKln molecules (ICAM1) on keratonocytes; 
and E·selectin and VCAM I on th'" ",ndothel ial cells in these reglesslng wans (Coleman el 
al 1994) 
A number of human r cell epltopes have boen mappe-d to the HPV-I6 L1 E6 and E7 
prote ins (Strang at ai .. 1990: Stauss at ai, 1(92) T -wll responses to HPV E2. E6. E7 and 
II have been Identified in humans with ceO/ieal dysplaSia (Bontkes ar aI. 1999a: Bontkes fir 
al . 2000 Shepherd at ill .. 1996). but also in a large number women who have deared 
InfeClion (do GnJi,1 or al .. ' 999). HPV-16 E6-specifi c (Weltoffi ot al. 2003). l1-spec,fic 
(Shepherd er 81 . 19(6) and E2-specmc «(Ie Jcmg er ill .. 2002) interferon gamma (IFNh-
producing cilculabng T cells have been dcteCled In up to 60% oJ healthy individua ls. 
suggesting that circulating T cells may playa Iole In protection againsr persisrent HPV 
Infection and d,saaso progression The cervICal cyto~ ine patterns delected in women 
preceding clearance of infecllon oonsisred 01 the expression oI1FN-r lind Interteuk ln_4 (ll·4). 
whICh are indicative at a T-halper (Thl) type res~se (Scott et al .. 1999). Tho precise rolo 
of nalurally occurring HPV-specific cytotoxic T Iymphcocyle (CTl) Immunity must s\ili bo 
established as some studies show high HPV-CTL aClivity in patients ""th advanced ceNical 
disease. but not in women who have cleared HPV onfection (Bonl~es el ill .. 2000; Welters 91 
ai, 2003. Shepherd or al.. 19%). 
, 6. U . HumorilllfflllllHWty 
Numerous stud~ hilve looked InIO ttle lIM of HPV·speeilic anlObody detection lor 
diagnostiC. prCIgr1C)S\oI; and apldemiologlcal poJrpo5Ols. Seroi0gicai assays hava locused on 
respc>OS8S to HPV It , bul milny Sludoes have also delBCIed antibodies to l2, E2, E4 , E6. E7 
(diSQJssed below) 
Serum IIIG·pOsi~v"Y 10 HPV II increases W~n !netBilS!n1l SBVBMy 01 OIIIVical dIsease and 
with dl!iBase persistence (Wideroff It! iii, 1995. Carter Itl ill" 19961. NaturallllG antibodies 
to L I therafore do not seem to hava an InftUBnCa on BXfstlng 0BMCa1 dISease; suggasllnlJ 
that other mechanisms are involved CBNiCIIl lesIOn clearance. In a study by Widerotl 6( BI 
pgg5). antl·Lt anllbod>es wara detBCIed In 166% of HPV·16 positive but normaI-cytoIogy 
controls, comparad to 30,8% arid 52 4% 01 cases with low· arK! high-grade cervlCallesoons, 
respacli ..... y They also found Ihat Hpv· 16 VlP seropOsitivity Increased from 22% In 
sublects who wen! Hpv· 16 ONA.posltlVe once, 10 83.3% In those with per!)lslenl infections. 
Other sludills hllVe reponed Hpv·t6 VLP seropositvrties In up to 81% of women With nollh 
grade SiL (Kornbauer fI BI, 1994, Nonneomacner e/llI, 1995). Seropol'iitiv ily appear!) to be 
lower In patients with Invasiva cancer, perhaps dUB 10 me cassation of productr.1t HPV 
inlealOllln invaSIVe canoer cells (NonnenmachBt e/ 011, 1995) 
Cervical mucosailgA antibodlBS to HPV VtPs 01 the oncogenic HPV types. 16, 18. 31 and 
45. are at$O associated with HPV infeclion. Mucosal IgA antibodies to the oncogeuoc HPV 
VlPs hilVa beat delected in up to 72'10 at women with oncogeniC HPV inlBCIions (Sasagawa 
et ill , 2003; Wang Itt aI. 1996) A!r. wdh IgG 5efOPO$ItI1Idy. the mucosal tgA.posiWlty 
deaeilses WIIh P<OII.asslOI'1 to CtN It arK! III and cemcaI cancer Mucosal IgA antibocly 
respOnses ilia, therefore also. not ~k"'y 10 be involved WIU'l dISease cleillance, In a 
longitudinal study, Bontkes and colleagues (1999b1 inYBStigated the associallon belWBBn 
local and systamlc IgG and IgA immunity to HPV·16 VlPs In 125 patienla, The" data 
.howed that the cervocal IgG and lOA.. and systemIC IgG aOlibodies to vt~ dod not C(l(ralate 
with ViruS clear-dnte, t>ullhat systemIC IgA respOnses were aSlocl8ted with clearal>Ce Since 
the syslemlc IgA responses were nOl accompanied by cerviCal IgA responses, they lU{jge$\ 
thai the sysl&miC response IS a by·product of a successlul cell.medialed Immune raspOr'iSfI 
induced at lhe cervical lymph nodes, ~nd is mediated by eylo~lnes. However, hl/lTloral 
rB$ponSBS wi. likltly be Important to prel/ent new infection. In a study of female uni'lflrsity 
students. Ho el ill (20021 found that the presence Of both serum IgA and IgG antibod ies 10 
HPV.t6 VtPs was assocfated with a decreased risk for subsaq...ent Infection. and that thfs 
associa1lOO decreased as tt>e genef;.:: relatedness to Hpv·16 decreased 
Tho highesl ant~E6 and ·E1 antibody prevalences are found al in pahents wilh ifflaSNe 
cervICal cancer. and do nol correIale with !he de!octi()n of anfi.ll antitlo<li&s (de SarljO$G ef 
(J!, , 996. Ga<lr(lnstroom 1ft aC 1994; NOOlI'IellIT1acher el aI 1995). This is pemaps because. 
although E6 and E1 are early protOlns. the nonnal e~pression of These prot6lnS is 61srup1ed 
In high'ijrade cervical IntraepitheHal rompIasia (CIN). caUSHlQ them 10 be expressed 
consistently throughout tllIllosion (reviewed in zur Hausen 1987) HPV-16 E6 seropos.ilIYlty 
ranges from 2-60/0 In CIN patienls to 54.1-56% In ca~r pat!enlS (Nonnenmad1er el ai, 
1995: Sun el ai_, 1994). Antibody prevalences La Hpv·16 E7 range from 4 6-13% in control 
subjects. to 6·31% In CIN patients. to 43-63% In cancer pallents (de Sanjo5e et III . 1996: 
GaarellStroom at ai. 1994. Nonnenmacher et aI., 1995: Sun at ai , 1994). In women With 
CIN, MaraiS at aJ. (1991) found th at antibody prevalences 10 HPY·16 E21nerttased w~h age. 
while seropositivity 10 HPY-16 VLPs decreased w~h age In an in!eruslInQ Study. a cohort of 
women WIIh mild 10 moderate cervical dyskary05is were testod lor serum aflilbodies 10 HPV-
16 E1 for a period 01 up to 27 months (do Grul~ ellll , 1996). The hljjhOSt proportion of E1 
seropositive responder.> were those who had cleared Infection, whi le lho IoweSI respOndo~ 
had pernistenl infodion. IgG, was predominant in the women who had doal'l)d the infOClion. 
Pallents with ceM<::aI car<::'noma had equal amounts of IgG, lind IgG1> suggest'ng that 
clearance was assocaated w~h a coll-medaatod Th 1 respollSe. 
1.6.2. tmmuneevaslon 
The exposure of HPV viral anflllel15 to the hos!'! Immune system is restricted since thfl 
majority of HPV protOln expression oeeurs In the upper layers oIlhe op~hohum. and iysts 01 
lnfucted cells does not ocwr. bul rather a shedding 01 virus into 11\0 environmenl (Taichman 
and laPorta. 1981). This anliQOn reslridion is the reason why anllbodies 10 tile HPV capsid 
I'mteins. which are very i mmunogenic (Klrnbaoor fit III .. 1992). are often only dctacled III 
patiem WIth PmQressed celVlC8t lesions. where the 11 P'OieWl is hkely e~pressed III \he 
differentaa!ed eptthellum (WiI<strom et 81 .. 199:5). and also why It lakes so long for women 10 
semconvert (8 3 months) aIIer irlectlon is delOeIOtI (CMer eI III .• 1996)_ 
TheN:! 15 alSO o'lllleneo thai cervical carcinomas can hml !1Ie pres&lllallO<l c:l certain HPY 
ep,'OpOS. theroby doaoaslng I'OCOgnrtKlfl by ClLs Thrs IS maoo possible by rho down-
re-gula\ion of MHC d ass I exprMSIOIl (Hilder.> 81 81 .. 1994). and the down-regulation of the 
transportor prO\&lns. TAPI and TAP2. In ceMcal carcinoma eels (Evans ef aI., 2001a) TItiS 
Will hkoly place constfamts onlhe use of cenam I-IPV CTl ePltopes lor thfllmmunothe-rapy 01 
" 
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HPV-associated disease. Cervical cancer cells also promote the production of IL-4 and 
down-regulate the production of IFN-y in cancer-encountered T cells, by producing IL-10 and 
TGF~ (Sheu et al., 2001). 
1.7. VACCINES FOR HPV 
In 1993 the Wor1d Bank released a Wor1d Development Report addressing disease burden 
and cost-utility analysis of a variety of interventions to deal with health problems. The report 
evaluated 52 interventions and found that basic immunisations (BCG, DTP, OPV, and 
measles) were amongst the best health investments to make (Miller and Hinman, 1999). 
The cost of cervical cancer screening, follow-up, and treatment in the USA has been 
estimated at US $5 billion per year (IARC, 1999). In a study to determine the cost-
effectiveness of a prophylactic vaccine to high-risk HPV, Sanders and Taira (2003) 
calculated that a vaccine with a 75% efficacy, administered to all 12-year-old glr1s in the 
USA, would result in a life expectancy gain of 4.0 quality-adjusted life days per individual, 
and would prevent more than 1,300 deaths from cervical cancer In their lifetimes. Although 
the life expectancy gain seems small at the individual level, population benefits would be 
considerable. The calculated cost savings was US$ 22,755 per quality-adjusted life year 
(QALY). 
1.7.1. PV vaccine types and Immunogenicity studies 
Vaccines, traditionally, have been regarded as prophylactic, preventing new infection. In 
viral infections this is usually accomplished by the induction of neutralising antibody 
responses to surface epitopes of the virus. This has usually been achieved by the use of 
Inactivated or attenuated virus; however, this is not possible with PV due to the absence of a 
permissive culture system, and hence the Inability to propagate large amounts of virus (Lowy 
et al., 1994). PV prophylactic vaccines therefore focus on the use of the virus-like particles 
(VLPs), which are similar in structure to native virions, and can elicit neutralising antibodies 
and PV protection in various animal models and humans (described below). 
An estimated 300 million women, wor1dwide, are presently Infected with HPV (IARC, 1999); 
and if left untreated, a percentage of these women will develop HPV-associated cancers. 
Many HPV vaccine strategies therefore focus on eliminating existing HPV infection and HPV-
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associated tumours. These vaccines are predominantly aimed at inducing cell-mediated 
immunity to the ear1y PV proteins. The early proteins are good targets for therapeutic 
vaccines as they are produced in the basal layers of HPV-associated lesions (Durst at a/., 
1992), which are most likely to be infiltrated by lymphocytes. E6 and E7 are especially 
attractive targets as their expression is maintained during malignant progression (zur 
Hausen, 1987). 
1.7.1.1. VLPs and othar paptidas 
The most successful HPV prophylactic vaccine candidates, to date, are based on L 1 VLPs 
produced by recombinant baculovirus or yeast. In animal and human studies, VLP vaccines 
have been well tolerated and have induced high titres of neutralising antibodies (Brown at a/., 
2001: Christensen at a/., 1994: Harro at a/., 2001: Rose at a/., 1994b: Tobery at a/., 2003). 
Studies in the cow, rabbit and dog, have also shown that immunisation with homologous 
VLPs can protect against viral challenge (Breitburd at a/., 1995; Christensen at a/., 1996b; 
Kimbauer at a/., 1996; Suzich at al., 1995). It has been observed that only intact VLPs 
present the epitopes required to induce protective immunity, as studies using disrupted or 
denatured VLPs have induced low neutralising antibody responses, and have afforded little 
protection from challenge in animal models (Breitburd at a/., 1995; Suzich at a/., 1995; 
Kimbauer at a/., 1992). 
Ohlschlager at a/. (2003) demonstrated that HPV-16 pentameric capsomeres (10 amino acid 
truncation at the L 1 amino-terminal) were able to elicit CTL responses in mice, which were 
similar to that produced by intact VLPs, and that this immunity was capable of inducing 
regression of L 1-expressing tumours. Capsomeres were found to induce high-titre, type-
specific neutralising antibodies in mice; with neutralisation titres similar (HPV-11 
capsomeres) or 10- to 20-fold lower (HPV-33) than those induced by intact VLPs (Rose at 
a/., 1998; Fligge at a/., 2001). 
In cows, prophylactic and therapeutic immunisation against mucosal bovine papillomavirus 
(BPV) has been achieved. Immunisation with BPV-4 L2, BPV-4 E7 (Campo at a/., 1993), 
BPV-4 L 1/L2 VLPs or BPV-4 L 1 VLPs (Kimbauer at a/., 1996) achieved almost complete 
protection against BPV-4 infection; and also induced a therapeutic response, evident by the 
faster regression of lesions that had appeared. Immunisation of dogs or rabbits with L 1 
VLPs or L 1/L2 VLPs has successfully induced neutralising antibodies and protection against 
challenge with canine oral papillomavirus (COPV) (Suzich at a/., 1995) or CRPV (Breitburd at 
a/., 1995; Christensen at al., 1996b), respectively. Selvakumar at a/. (1995) stimulated 
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regression of papillomas in the CRPV model after immunisation with E1 or E2 protein. They 
found that the best predictor of wart regression was a T cell proliferative response to E2. 
In rhesus macaques, vaccination with HPV8 16 L 1 VLPs generated a strong neutralising 
antibody response and a strong L 18 specific Th2 response, measured by IL-4 production by 
CD4+ T cells (Tobery et al., 2003). Systemic immunisation of African green monkeys with 
HPV8 11 VLP in an alum adjuvant induced strong VLP8 specific neutral ising serum antibodies 
and significant neutralising antibodies in cervicovaginal secretions; suggesting that protection 
at the cervix may be possible by systemic VLP immunisation (Lowe et al., 1997). 
The mucosal administration of VLP has been investigated to specifically induce mucosal 
immunity. Oral immunisation of mice, by gavage, with HPV-11 VLPs elicited anti-L 1 serum 
IgG and IgA neutralising antibodies (Rose et al., 1999). Two groups showed that mucosal 
adjuvants could enhance VLP immunogenicity when administered mucosally. Gerber et al. 
(2001) demonstrated that anti8 VLP humoral responses in peripheral blood and in genital 
mucosal secretions were significantly improved when HPV8 16 and HPV-18 VLPs were 
administered orally with the c08 administration of a Escherichia coli heat8 1abile enterotoxin 
mutant or CpG DNA. Balmelli et aI. (1998) noted that systemic Immunisation of mice with 
HPV8 16 VLPs generated low titres of IgG in genital secretions, but no genital IgA could be 
detected. However, when VLPs, together with cholera toxin, were administered intranasally, 
they detected high tltres of anti-VLP IgA and IgG in saliva and genital secretions. Serum 
antibodies were also enhanced 1040ld by the use of cholera toxin. Antibodies in serum, 
saliva and genital secretions were strongly neutralising. They, however, found that oral 
immunisation of VLPs, even with the cholera toxin adjuvant, was inefficient at generating 
antibodies. 
The first VLP "proof of principle" phase 2 vaccine trial in humans showed very promising 
results. In a trial group consisting of about 2400 young women (aged 16-23), Koutskyand 
colleagues (2002) administered 3 doses of HPV8 16 VLPs or placebo. The trial participants 
were followed for an average of 17.4 months, during which genital samples were analysed 
every six months. The incidence of persistent HPV8 16 infection was 3.8 per 100 woman-
years at risk in the placebo group and 0 per 100 woman-years at risk in the vaccine group. 
The efficacy of the vaccine regimen was therefore 100% (95% CI = 908 100). HPV-16 VLP 
administration therefore reduced the incidence of HPV-16 infection, but it also appeared to 
reduce the development of HPV-16-related CIN. In January 2000, a GlaxoSmithKline-
coordinated phase 2 trial was started in which a bivalent HPV-16/HPV-18 VLP vaccine was 
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tested in humans (Harper et al., 2004; Billich, 2003). They reported a vaccine efficacy of 
91.6% (95% CI = 64.5-98) against incident infection, and 100% efficacy against persistent 
infection with HPV-16 and HPV-18. In addition, a vaccine efficacy of 92.9% (95% CI = 70.0-
98.3) was achieved against HPV-16/HPV-18-associated cytological abnormalities. In a 
phase 1 study in humans, HPV-11 VLPs were well tolerated and induced high levels of 
neutralising antibodies, as well as increased Iymphoproliferation to HPV-11 L 1. Interestingly, 
increased Iymphoproliferation was also generated to L1 from HPV-6, -16, and -18; which 
demonstrates that some T cell helper epitopes are conserved across HPV types (Evans et 
al.,2001a). Other phase 1 human trials have proven the safety and immunogenicity of HPV-
18 VLP (Ault et al., 2004), HPV-11 or HPV-16 VLPs (Fife et al., 2004), and HPV-6/11/16/18 
quadrivalent VLP (Villa et al., 2002) candidate vaccines. In a small study of HPV-6b VLP 
vaccination in human subjects, Zhang et al. (2000) observed complete regression of genital 
warts in 25 of the 33 subjects, suggesting the therapeutic use of VLP for this and other 
genital HPVs. 
The minor capsid protein, L2, has been used successfully in vaccine studies, either alone or 
in combination with L1, In L11L2 VLPs. L1/L2 VLPs, produced In baculovirus, form VLPs 
more effiCiently than when L 1 is used alone (Klrnbauer et al., 1993), however, L 1 VLPs are 
preferred as they are sufficient at Inducing strong neutralislng responses, without making the 
production process more complicated. Furthermore, since L2 is able to bind DNA non-
specifically (Zhou et al., 1994), it may Introduce DNA into the VLP preparations. Vaccination 
of rabbits and cows with L2 protein Is able to protect against challenge, indicating that L2 is 
able to elicit neutralising antibodies (Lin et al., 1992; Gaukroger et al., 1996). 
It is possible to fuse small peptides onto VLPs, to produce chima eric VLPs (cVLPs) that are 
similar to normal VLPs in structure and antigenicity. Two groups have shown that chimaeric 
HPV-16 L 1/L2 VLPs, to which E7 was fused, were able to protect mice against HPV-16 E7-
positive tumour challenge; they showed that this protection was mediated by MHC class 1-
restricted CTLs (Greenstone et al., 1998; Wakabayashi et al., 2002). Varsani et al. (2003a) 
demonstrated that HPV-16 cVLPs presenting an L2 epitope were able to elicit antibodies to 
both L 1 and L2 in mice. 
1.7.1.2. Live viral vectors 
VLP preparations are expensive to manufacture, and will likely not be utilised for widespread 
vaccination in developing countries. Numerous groups have therefore investigated the use 
of live vaccines as cheaper alternatives to VLPs. 
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Vaccinia virus is an attractive poxvirus vector due to its extensive use and relatively large 
capacity for foreign DNA. In 1991, Zhou and colleagues (1991a) demonstrated the 
generation of VLPs by recombinant vaccinia virus expressing HPV-16 L 1 and L2. Vaccinia 
virus expressing HPV-16 L 1 was then shown to elicit L 1 specific CTL immunity in mice (Zhou 
et al., 1991b). Protection against CRPV challenge was observed in rabbits immunised with 
recombinant vaccinia virus expressing CRPV L 1 (Lin et al., 1992). Vaccinia virus expressing 
the HPV-16 E6 protein has been used successfully to elicited E6-specific antibody, 
Iymphoproliferative and CTL responses in mice (Gao et al., 1994); and immunity elicited by a 
HPV-16 E7 vaccinia virus recombinant in mice was shown to induced regression of HPV-16 
immortalised tumours (Lamikanra et al., 2001 ). 
There are health concems about the use of vaccinia virus as there is a possibility of 
dissemination in immunocompromised individuals. The use of modified vaccinia Ankara 
(MVA), a replication deficient poxvirus vector, may overcome this problem (Baxby. 1993). 
An MVA-E2 recombinant was successfully used to treat E2-expressing tumours in rabbits 
(Rosales et al., 2000) and mice (Valdez et al., 2000). Interestingly, antibody responses, but 
not CTL responses were detectable in the rabbits, which suggested that antibody-dependent 
macrophage cytotoxicity played a dominant role in the regression of the tumours. 
In rhesus macaques, a replication-defective adenovirus vector expressing codon-optimised 
HPV-16 L 1 elicited strong Tc1 (cytotoxic T cells type 1) responses, as measured by 
production of IFN-y by CD8+ T cells and a lack of IL-4 production (Tobery et al., 2003). 
Although a humoral response was elicited, the titre of neutralising antibodies was very low. 
This is in contrast to vaccination with VLPs in the same animal study, which generated a 
strong neutralising antibody response but failed to induce a CD8+ T ceil-mediated IFN-y 
response. 
1.7. 1.3. Live bacterial vectors 
Attenuated avirulent, but invasive Salmonella strains have been investigated as delivery 
vehicles for a number of bacterial, viral, and mammalian antigens (Nardelli-HaefJiger et al., 
1996; Newton et al., 1989; Srinivasan et al., 1995; Vancott et al., 1996). Live Salmonella are 
effective at delivering heterologous antigens to both the mucosal and systemic immune 
systems, and can Induce cell-mediated, humoral and secretory IgA antibody responses 
(Vancott et al., 1996). Nardelli-HaefJiger et a/. (1997) demonstrated by electron microscopy 
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that HPV-16 L 1 expressed in recombinant attenuated S. typhimurium assembled into VLPs. 
This was the first demonstration that VLPs can self assemble in prokaryotes. They showed 
that nasal Immunisation of mice was effective at inducing systemic neutrallslng antibodies, 
and also oral and vaginal anti-VLP IgA and IgG, Indicating possible protection at mucosal 
sites. Revaz et al. (2001) demonstrated that mucosal vaccination of mice with recombinant 
attenuated S. typhimurium expressing HPV-16 L 1 induced anti-tumour Immunity, which was 
prophylactic and therapeutic. Immunisation of mice with recombinant Salmonella expressing 
HPV-16 E6 and E7 have also induced antibodies to these HPV proteins (Krul et al., 1996). 
Although researchers have experienced instability problems with recombinant Salmonella 
expressing L 1, more stable recombinants have been developed by using lethal vector 
systems and by codon-optimisation of L 1 (Baud et al., 2002). 
The Mycobacterium tuberculosis vaccine, Mycobacterium bovis bacille Calmette-Guerin 
(BCG), has attractive properties as a vaccine vector (see Chapter 2). A variety of viral, 
bacterial and parasitic antigens have successfully been expressed in BCG. In experimental 
models recombinant BCG (rBCG) has been shown to elicit protective immunity against Lyme 
disease, pneumococcal infection, and cutaneous leishmaniasis (Abdelhak et al., 1995; 
Langennann et al., 1994a; Stover et al., 1993). It has also been demonstrated that oral or 
intranasal immunisation with rBCG induces sustained systemic and mucosal specific 
immune responses (Langennann et al., 1994a). A study by Jabbar et al. (2000) reported 
that rBCG expressing HPV-6b L1 or HPV-16 E7 antigens were only weakly immunogenic 
when compared with protein vaccines, and immunisation with rBCG expressing HPV-16 E7 
was not able to protect against challenge with an E7-expresslng tumour. 
Listeria monocytogenes has also been investigated as a live bacterial vector for the 
expression of HPV genes. Lin et al. (2002) demonstrated the induction of an E7-specific 
CTL response in mice after oral administration with a L monocytogenes recombinant 
expressing HPV-16 E7. Vaccination with this recombinant was able to prevent tumour 
growth in mice, as well as cause regression of tumours. 
1.7.1.4. DNA 
DNA vaccines usually involve the intramuscular injection of plasmid DNA, or delivery of DNA 
into the epldennis using a gene gun. A DNA vaccine plasmid contains a gene encoding the 
antigen of interest, the expression of which is controlled by a mammalian promoter. This 
method of vaccination has successfully elicited antibody and cell-mediated responses in a 
number of preclinical studies, however, DNA vaccine potency in humans has been low 
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(reviewed in Liu, 2003). The cost of producing DNA vaccines is also higher than originally 
thought - it costs approximately US$ 0.6 million for the manufacture of a DNA vaccine for a 
phase 1 trial (Anna-Lise Williamson Department of Clinical Laboratory Science, University of 
Cape Town; personal communication). 
Rocha-Zavaleta and colleagues (2002) demonstrated the efficacy of DNA vaccines 
expressing HPV-16 L 1 in mice. They showed that intramuscular, subcutaneous and oral 
vaccination elicited systemic anti-L 1 IgG and vaginal IgA neutralising antibodies. The 
vaccine also elicited L 1-specific CTL responses, and slowed tumour growth after challenge 
with an L 1-expressing melanoma cell line. 
Rabbits immunised intramuscularly with plasmid carrying the CRPV L 1 gene generated high 
titres of neutralising antibodies, and were protected from CRPV challenge; indicating that L 1 
was presented in the correct conformational form to generate a protective response 
(Donnelly at al., 1996). In rhesus macaques, a HPV-16 L1 DNA vaccine generated a 
primarily Th1/cytotoxic T cell type 1 (Tc1) response, which was measured by the production 
of IFN-y by mainly CDS+ T cells (Tobery at al., 2003). Although a humoral response was 
elicited, the titre of neutralising antibodies was very low. 
Immunogenicity of DNA vaccines can be enhanced by codon modification. Liu at al. (2002) 
showed that a DNA vaccine containing a synthetic codon optimised HPV-16 E7 gene 
expressed highar levels of E7 in mammalian cells than non-optimised E7; and that mica 
immunised with the optimised vaccine produced significantly higher antibody and CTL 
responses, and showed enhanced tumour protection. When utilising a codon-optimised 
COPV E1 sequence in a DNA vaccine, Moore at al. (2002) could completely protect dogs 
against mucosal COPV challenge, however, all animals vaccinated with the wild-type E1 
developed papillomas. 
An novel way of delivering DNA is by encapsulation in biodegradable polymeric 
microparticles made of poly-D,L-Iactide-coglycolide. Plasmid DNA encapsulated in this 
manner, encoding HPV E6 and E7 epitopes, has been tested in mice and humans. Mice 
vaccinated with these microparticles were protected from E7 -tumour challenge. and in a 
phase II human trial, 43% of women showed lesion regression, compared to 27% in the 
placebo group (Habeck, 2003). 
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Chen at al. (2000) investigated prime-boost strategies involving a DNA vaccine and vaccinia 
virus, both expressing the chimera, Sig/E7/Lamp-1, consisting of HPV-16 E7 linked to the 
sorting signals of the lysosome-associated membrane protein-1 (LAMP-1). Although both 
the DNA and vaccinia vaccines could induce anti-tumour immunity individually, in mice, they 
found that sequential vaccination with the DNA vaccine and then recombinant vaccinia 
generated a very strong E7 -specific CDS+ T cell response. Kowalczyk et al. (2001) showed 
that a prime-boost strategy with a DNA vaccine and replication-defective adenovirus, both 
expressing HPV-16 L 1, successfully induced high antibody titres to intact VLPs. Although 
these vectors only produced marginal antibody titres on their own, when mice were primed 
Lm. with the DNA-L 1 vaccine and boosted Ln. with the replication-defective adenovirus-L 1 
recombinant, the mice produced antibodies similar to that elicited by two doses of VLP. IgA 
antibodies specific to HPV-16 VLPs were also induced in the vaginal cavities of these mice. 
1.7.1.5. HPV protain production in plants 
Another low-cost vaccine strategy is the oral or parenteral delivery of HPV antigens that have 
been produced in plants. Bacterial and viral antigens have successfully been produced in 
plants, and have been shown to generate humoral and mucosal immune responses in 
animals after oral administration (Haq at al., 1995; Richter at al., 1996; Thanavala at al., 
1995). Franconi and colleagues (2002) expressed the HPV-16 E7 protein in the Nicotiana 
banthamiana plant using a potato virus X-derived vector. Mice Immunised with the E7-
containing crude foliar extracts developed both humoral and cell-mediated responses and 
were protected from E7 -expressing tumour challenge. 
Three groups have recently demonstrated that VLPs of HPV-16 and HPV-11 can be 
produced In transgenic plants. Warzecha at al. (2003) demonstrated that HPV-11 VLPs 
made In transgenic potato tubers were weakly immunogenic when fed to mice. Biemelt at al. 
(2003) and Varsani at al. (2003b) demonstrated efficacy of producing HPV-16 L 1 VLPs in 
transgenic tobacco (Nicotiana tabacum), that were antigenically identical to baculovirus-
synthesised VLPs as assayed by confonnation-speciflc MAb binding, and were immunogenic 
if given to animals via gavage (Biemelt at al., 2003) or by injection (Varsani at al., 2003b). 
The feasibility of using a recombinant tobamovirus vector to make HPV-16 VLPs in N. 
banthamiana at yields ten times greater than in tobacco transgeniC for the same gene, was 
also demonstrated (Varsani at al., 2001; Varsani, 2003c) 
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1.7.2. Immunity summary and considerations for HPV vaccine strategies 
Due to the nature of HPV infection, with the absence of a systemic stage, mucosal immunity 
will intuitively be important to prevent and clear infection. There are various methods to 
stimulate immunity at mucosal surfaces, but generally, mucosal immunisation successfully 
induces mucosal immunity. Numerous mucosal vaccination strategies, including the use of 
mucosal adjuvants, have successfully been used to induce papillomavirus-specific genital 
immunity in animal models (some of these are described in section 1.7.1). 
A prophylactic vaccine would aim to provide neutralising antibody protection at genital 
mucosal surfaces. This protection is provided mainly by local secretory IgA antibodies 
(McGhee et al., 1992), but these antibody responses are short-lived. Elfgren et al. (1996) 
demonstrated that local IgA antibodies to HPV VLP disappeared soon (months) after 
successful conisation treatment, whereas systemic IgA persisted for longer (years). Mucosal 
IgA and IgG antibodies are frequently detected in women with persistent infection, and are 
not correlated with virus clearance (Sasagawa et al., 2003; Bontkes et al., 1999b), which 
suggests that mucosal antibodies are not effective at inducing regression of established 
lesions. These mucosal antibodies are possibly only present due to continuous stimulation 
by the persistent infection. Although seropositivity to HPV L 1 increases with increasing 
severity of cervical disease, if present before challenge, systemic antibodies can provide 
protection from mucosal PV challenge, as observed In experimental animal models 
(Kimbauer et al., 1996; Suzlch et al., 1995) and in natural infection In women (Ho et al., 
2002). The observed protection may be a result of sustained transudation of serum 
antibodies to the mucosa. 
Although much emphasis is placed on the development of neutralising antibodies at the site 
of infection, these antibody responses are usually not long-lasting, and sterilising immunity 
rarely occurs. Local cell-mediated responses will therefore be vital for elimination of infected 
cells (Ada, 1999). Therapeutic vaccines aim to eliminate these virus infected cells by 
generating CTL responses to antigens derived from endogenously processed viral proteins, 
which have been presented by MHC class I molecules. Therapeutic vaccines for HPV are at 
a much earlier stage of development than their prophylactic counterparts. Several studies 
substantiate the role of the ceil-mediated response in the clearance of HPV disease (these 
are described in detail in section 1.6.1.1): Individuals with cell-mediated Immune deficiencies 
have an increased risk of infection with HPV (Koutsky, 1997), regressing HPV-tumours are 
infiltrated with macrophages and T lymphocytes (Coleman et al., 1994; Heller et al., 2003), 
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HPV-specific circulating T cells are often detected in healthy individuals (Shepherd et a/., 
1996; Welters et a/., 2003), and anti-HPV IgG1 and IgG2 (de Gruijl et a/., 1996), and IFN-y 
and IL-4 are detected frequently in individuals who have cleared infection, suggesting the 
role of a cell-mediated Th1 response. Therapeutic vaccines would focus on developing 
cellular immunity to HPV early proteins; however, the observation by Zhang et a/. (2000), 
that immunisation with HPV-6 VLP may have caused regression of genital warts in human 
subjects, provided evidence the therapeutic potential of HPV L 1 should also be evaluated. 
The presence of natural antibodies to HPV early proteins can be detected a subset of 
women before the onset of invasive cervical disease, but these responses are generally low 
and do not provide protection from disease. In cancer patients, however, immunity to E6 and 
E7 increases, which provides evidence that these proteins are being exposed to the immune 
system; and suggests the potential of directing vaccines to these proteins. There is also 
increasing Interest in E2. More work must be done to determine the best antigen targets, 
vaccine types, and routes of immunisation. 
Studies in human volunteers showthatVLP-based vaccines, of types 6,11,16 and 18 (Fife 
et a/., 2004; Evans et a/., 2001b; Koutsky et a/., 2002; Villa et a/., 2002, Harper et a/., 2004), 
are safe and produce high antibody tltres in almost all vaccine recipients. The human HPV-
16 HPV (Koutsky et a/., 2002) and HPV-16/18 (Harper et a/., 2004) efficacy studies provided 
good evidence that VLPs will at least be partially effective in the prevention of HPV infection 
in humans (described above in section 1.7.1.1). 
HPV VLP vaccines will likely have to be multivalent, as virions from different HPV types are 
antigenically distinct from one another (Rose et a/., 1994a), and although, there does appear 
to be some cross-protection between Similar HPV types, these reactions are weak (Comblta 
et a/., 2002). In women, the presence of natural IgA and IgG antibodies to HPV-16 VLPs 
was found to be associated with a decreased risk for subsequent infection; and this 
association decreased as the genetiC relatedness to HPV-16 decreased (Ho et a/., 2002). 
Vaccination of mice with HPV-16, -31, -33, or -45 VLPs was shown to induce weak cross-
neutrallsing reactivity to pseudovirions of the closely related phylogenetic types (Bousarghin 
et a/., 2002a; Combita et a/., 2002). Cross-neutralislng reactivity was observed mainly 
between HPV types 16, 31, 33, and 58; however, It Is not known whether this cross-reactivity 
is sufficient to offer cross-protection in vivo. Bousarghln et a/. (2002b) Showed that cross-
neutralising could also be induced in humans after immunisation with VLP. This group 
investigated neutralising antibody responses against HPV-16, -18, -31, -33, and -58 after the 
administration of both HPV-16 and HPV-18 VLPs. They showed that 40% of the vaccine 
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recipients developed neutraJising antibodies against types other than those included in the 
vaccine. Evans et al. (2001 b) observed that the immunisation of humans with HPV-11 VLPs 
generated Iymphoproliferation to L 1 from HPV-6, -16, and -18; demonstrating the 
conservation of some T cell helper epitopes across HPV types. Bivalent and quadrivalent 
HPV VLP-based vaccine studies in women (Harper at al., 2004; Villa at al., 2002) have 
demonstrated that these candidate vaccines have the ability to produce antibodies to all the 
included H PV types. 
The distribution of HPV types compiled by Clifford et al. (2003) suggests that vaccinating 
against HPV-16 and HPV-18 should prevent over 70% of cervical cancer cases worldwide. 
In countries where types 16 and 18 are not as prevalent, other types could be included 
depending on prevalence in that country. 
The main target population for HPV vaccination would be adolescent girls, with an aim to 
induce prophylactic immunity just before they become sexually active. However, due to the 
risk of acquiring HPV at birth or early in life (Cason at al., 1995), it may be advantageous to 
deliver HPV vaccines at birth, with a possible booster dose just before the sexually active 
stage. Since men can act as reservoir for HPV infection (Bosch at al., 1996), both men and 
women would be vaccinated. Using mathematical models, Hughes at al. (2002) predicted 
the affect of a HPV vaccine program. Under a particular set of assumptions, they found that 
vaccinating men and women would result in a 44% decrease in prevalence of that specific 
HPV type; and that vaccinating only women would result in a reduction of 30%. 
An ideal HPV vaccine would be affordable, would protect from the most prevalent high-risk 
HPV types and/or clear the lesions caused by them, and would have a low incidence of side-
effects. VLPs, produced in yeast or baculovirus, meet most of these criteria; however, 
affordability will be a problem in developing countries. Further testing of alternate delivery 
systems, such as viral, bacterial, or DNA, or plant produced antigens, is therefore warranted. 
However, vaccines based on these systems may take longer than VLPs to become available 
for human use, as many are not currently utilised in large-scale vaccination strategies, and 
would require more thorough testing. 
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1.8. PROJECT MOTIVATION 
Our aim was to develop a prophylactic vaccine for HPV that would be affordable in South 
Africa and other developing countries, where the burden of HPV disease is at its highest. 
Due to the production expense of purified protein vaccines, such as VLPs, and therefore the 
unlikelihood of large-scale use of such vaccines in developing countries, we investigated the 
potential of recombinant BCG (rBCG) expressing an HPV antigen as a HPV vaccine. 
As the major structural protein of the HPV capsid, L 1 was the antigen of choice for the 
development of our HPV prophylactic vaccine candidates. The L 1 protein of HPV type 16 
was selected for this study, because HPV-16 is the most prevalent HPV type detected in 
cervical cancer biopsies in South Africa and worldwide (Clifford et al., 2003). A large body of 
work is available on the immunity elicited by L 1 VLPs, and many of these have been 
reviewed above. Several studies have demonstrated that L 1 VLP vaccines can induce high 
titres of neutralising antibodies in animals and humans (Brown et al .• 2001; Christensen et 
al .• 1994; Harro et a/., 2001: Rose et al .• 1994b; Tobery et al .• 2003). Many studies in animal 
models have also shown that immunisation with VLPs can protect against PV challenge 
(Campo et al .• 1993; Christensen et al., 1996b; Kimbauer et al., 1996; Suzich et al., 1995). 
More recently, phase 2 trials In humans have reported reduced incidences of HPV infection 
and HPV-related CIN in VLP vaccinated individuals (Koutsky et al .• 2002; Harper et al .• 
2004). It has also been demonstrated that immunisation with VLPs can induce CTL 
responses that are capable of inducing regression of L 1-expressing tumours In mice 
(Ohlschlager et al., 2003), BPV lesions in cows (Klmbauer et al .• 1996); and genital warts in 
humans (Zhang et al .• 2000). which suggests that L 1 could be used as a therapeutic vaccine 
for genital HPVs. 
BCG. the live, attenuated M. bovis strain. which Is routinely used to immunise against 
infection with M. tuberculosis. has many features that make it an attractive vaccine vehicle. 
These Include. a low Incidence of serious side effects. the ability to confer long-lasting 
immunity following a single immunisation, potent adjuvant properties, and a low production 
cost (Langermann et al., 1994; Stover et al., 1991). The motivation for the use of BCG will 
be discussed further in Chapter 2. 
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2.1. BCG THE TB VACCINE· HISTORY AND GENERAL FEATURES 
Mycobacterium bovis bacille Calmette-Gultrln (BCG) is the live, attenuated bovine tubercle 
bacillus, which is routinely used to immunise against infection with Mycobacterium 
tuberculosis. Since the 1920's, over 4 billion people have been immunlsed with this vaccine, 
in almost every country In the world (Plotkin and Plotkin, 1999). The BCG vaccine has also 
been proven to be protective against Infection with Mycobacterium leprae (Fine and 
Rodrigues. 1990; Karonga Prevention Trial Group. 1996); and has been used for 
Immunoprophylaxls and immunotherapeutic treatment of cancer in humans (Fuerst et al., 
1992b). 
BCG was made by Albert Calmette and CamYle Guerin. who sub-cultured virulent bovine 
tubercule bacillus for 13 years In medium containing glycerol. potato slices and ox bile 
(Plotkin and Plotkin, 1999). After 231 passages, this strain had lost its virulence by the 
deletion of large chromosomal regions. and it thus became the BCG strain (Smith and 
Starke, 1999; Mahairas et al., 1996). Live attenuated BCG was first given orally to infants in 
Paris in 1921, and was declared safe by the League of Nations in 1928. The use of BCG 
Increased with the introduction of new methods of administration, such as intradermal In 
1927, multiple puncture In 1 939, and scarification In 1 947. Since 1 974 t he World Health 
Organisation (WHO) has Included BCG In its Expanded Programme on Immunisation to 
combat disease, especially in children in developing countries. Only two countries. the 
United States of America and the Netherlands, have never vaccinated with BCG on a 
national scale (Smith and Starke, 1999). 
Despite widespread BCG vaccination, M. tuberculosis remains one of the pathogens 
responsible for the most death and disease In the world. BCG efficacy studies have 
produced vastly divergent results, with protection ranging from - 57% to 75% (Bloom and 
Fine, 1994). Based on the meta-analysis of 14 prospective efficacy trials and 12 case-
control studies. Coldi1z and colleagues (1994) concluded that BCG vaccination significantly 
reduces the number of tuberculosis cases and deaths. This study showed that BCG-
vaccinated individuals were afforded enhanced protection from M. tuberculosis infection 
(50% protection), pulmonary and disseminated tuberculosis (78% protection), tuberculous 
meningitis (64% protection), and death (71% protection). Factors contributing to the large 
variation between the BCG trials Include: (1) genetic diversity and different ages of 
vaccinated populations, (2) prior exposure to environmental mycobacteria. (3) the use of 
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different BeG substrains, (4) different vaccine preparation methods, and (5) different 
immunisation schedules, routes and doses (Hess and Kaufmann, 1999). 
2.2. BCG SUBSTRAINS 
The original BeG strain was distributed to labs throughout the world, at which culturing on 
different media and under different conditions resulted In the fonnation of variant substrains. 
These substrains differ in growth characteristics, colony morphology, biochemical activity, 
virulence in animals, and the ability to elicit delayed-type hypersensitivity responses. The 
Brazilian, Tokyo, Swedish, and Russian substrains have two large genomic deletions when 
compared to M. bovis, and they have secreted antigens and methoxymycolates; whereas, 
the Danish, Dutch, Glaxo, and Pasteur substrains have three large genomic deletions when 
compared to M. bovis, and have no secreted antigens or methoxymycolates (Mahairas at s/., 
1996; Smith and Starke, 1999). 
BeG substrains can also be loosely grouped into "weak" (Glaxo, Tokyo) and "strong" 
(Pasteur, Danish) substrains. The strong substrains are more immunogenic in various 
animal models, inducing a greater degree of cutaneous hypersensitivity, better protection 
from tuberculosis and greater granuloma fonnation. The "strong" substrains appear to elicit 
a higher degree of protection from tuberculosis; however, the "weak" substrains have a lower 
incidence of side effects, such as lymphadenitis and osteitis (reviewed in Smith and Starke, 
1999). 
2.3. FEATURES MAKING BCG A GOOD VACCINE VEHICLE FOR THE DELIVERY OF 
HETEROLOGOUS ANTIGENS 
Numerous features make BeG an attractive delivery vehicle for heterologous antigens: 
• BeG has a proven safety record 
BeG is currently the most widely used vaccine and has been given to billions of people 
worldwide with a very low incidence of serious complications (Hanson at aI., 1995). 
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• BCG is a potent adjuvant 
The adjuvant properties of BCG and its cell wall components have often been exploited in 
experimental vaccines in animals and man, being able to induce both humoral and cell-
mediated immune responses. 
• BCG is inexpensive to produce 
BCG is Inexpensive to produce as no complicated purification procedures are required. A 
dose of the BCG vaccine costs approximately ZAR 0.44 in South Africa (personal 
communication, Maureen Dennehy, State Vaccine Institute, South Africa); and about US$ 
0.06 per dose in America (labidl et al., 2001). Vaccine cost is particularly relevant when 
considering large-scale vaccination in developing countries. 
• BCG Is heat-stable 
BCG Is one of the most heat-stable of the vaccines In use, and does not require an 
extensive cold chain for maintenance of efficacy (Cirillo et al., 1995). This also helps to 
keep costs at a minimum. 
• BCG can be administered at birth 
BCG can be administered at or any time after birth and is unaffected by maternal 
antibodies (Hanson et aI., 1995). BCG is one of the six vaccines recommended by the 
Wor1d Health Organisation to administer to children (labidi at al., 2001). 
• A single dose of BeG can confer long-lasting Immunity 
A single BCG Inoculum can sensitlse for 5 to 50 years to tuberculoprotelns (Hanson et aI., 
1995). 
• BCG can be administered orally 
Oral or Intranasal administration Is of particular importance to confer protective immunity at 
mucosal sites to prevent entry of pathogens through the mucosa or to prevent colonisation 
of the mucosa (McNeela and Mills, 2001). Another advantage of these routes of 
vaccination, over the Intradennal or multiple puncture methods, Is that they do not require 
highly-trained personnel for vaccine administration, of whom there may be a shortage in 
developing countries. 
• BCG Is a live vaccine 
Recombinant BCG can be used simultaneously as an adjuvant and a vehicle to deliver 
antigens to the immune system. BCG replicates In vivo and thus continually delivers 
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antigens, which may elicit a more long-lived immune response than that of a simple 
mixture of adjuvant and antigen (AJdovini and Young. 1991). No protein purification or 
deactivation procedures are necessary. 
• BCG is susceptible to antibiotics 
Unlike live viral vaccine systems, BCG is susceptible to antibiotics. Infection can thus be 
controlled should any serious complications arise. 
• Distribution network 
Due to its widespread use, a worldwide distribution network exists, with medical officers 
that have BCG vaccine delivery experience (labidi at a/., 2001). 
2.4. POTENTIAL LlMITAnONS OF BCG AS A DELIVERY VEHICLE 
• large variations exist in the BCG vaccine efficacy against tuberculosis (mentioned above). 
If similar efficacy variations exist to a recombinant BCG (rBCG) vaccine, then these 
immune variations may be carried through to the foreign antigen expressed by rBCG. 
Worldwide rBCG vaccine production and delivery would have to be carefully monitored to 
prevent such efficacy variations. 
• Serious complications to BCG vaccines are very rare in Immunocompetent individuals; 
however, the number of immunocompromised patients has increased dramatically over the 
last two decades, mainly due to the HIV pandemic (Smith and Starke. 1999). Although the 
safety implications of vaccinating HIV-infected patients with BCG are not fully known, there 
could be a risk of disseminated BCG infections in these individuals (Dietrich at a/., 2003). 
live vaccines also have the potential of activating the immune system, which could 
consequently increase HIV replication (ljungman. 1999). The World Health Organisation 
currently recommends BCG immunisation in countries with a high risk of tuberculosis 
infection. including HIV-infected children. Unfortunately, no data are available on the 
protective efficacy of BCG in HIV-infected patients (ljungman, 1999). A possible solution 
to this concern is the use of in vitro replication-defective BCG auxotrophs; however, further 
BCG attenuation may decrease its ability to protect against tuberculosis (Chambers at a/., 
2000). 
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• A major technical problem is the observation of genetic instability of rBCG. Unstable 
recombinants will prove a large problem during large scale production. This is discussed 
further in Chapter 4. 
2.5. INTRACELLULAR MYCOBACTERIAL ANTIGEN PROCESSING AND IMMUNITY 
Mycobacteria are facultative intracellular bacteria that are able to survive and replicate in the 
phagosomes of antigen-presenting cells {APCs}. Both macrophages and dendritic cells 
(considered the most potent APCs) are able to endocytose mycobacteria (Jiao et al., 2002; 
Neyrolles et al., 2001 ; Thumher et al., 1997). 
Live mycobacteria a re able to evade t he immune response by inhibiting acidification and 
phagosome-lysosome fusion. Mycobacteria limit the trafficking of protein antigens from the 
phagosome to the cytosol, which prevents MHC class I presentation and recognition by 
CDS+ T cells. The delay of phagosome-iysosome fusion, also prevents the processing of 
mycobacterial antigens by MHC class II molecules, and thus delays the CD4+ T cell 
response to live mycobacteria (Neyrolles et al., 2001; Ramachandra et al., 2001). The 
mycobacterial phagosome, however, is a dynamic compartment, that Is accessible to the 
recycling endosomal pathway, that allows entry of transferring receptor, glycolipids 
(Neyrolles et al., 2001; Rhoades et al., 2003), and MHC class II molecules (Ramachandra at 
al., 2001) Into the phogosome. Trafficking of a limited number of mycobacterial glycolipids 
and lipoproteins from the phagosome to the cytosol is also known to occur (Neyrolles et al., 
2001). 
Once macro phages and dendritic cells are activated by T cells and IFN-y, phagosomaJ 
maturation occurs, and the mycobacteria are eliminated. Generally, the mycobacterial 
antigens are processed by the MHC class II molecules, and hence stimulate strong CD4+ T 
cell responses (Cheadle et al .• 2003; Kaufmann and Hess, 1999). BCG Is therefore a potent 
activator of a CD4 + T helper 1 (Th1 )-type immune response that is associated with secretion 
of interleukin-12 (IL·12) by macrophages and dendritic cells, and IFN-y and TNF-a. secretion 
by CD4+ T helper cells (Esser et al .• 2003; Mutls et al., 1993). 
One of the suggested reasons for BCG's inadequate ability to control M. tuberculosis 
infection, is its limited activation of coa+ CTL immune responses, however. M. tuberculosis 
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effectively stimulates CD8+ T cells by MHC class I antigen presentation (Hess and 
Kaufmann, 1999). The exact mechanisms that make M. tubefculosis more successful than 
BCG at making antigens accessible for MHC class I antigen presentation have not yet been 
fully elucidated. M. tuberculosis and BCG are able to perforate the phagosomal membrane 
allowing antigens to enter the cytosol (Kaufmann and Hess, 1999). however, this occurs 
several-fold more readily in M. tuberculosls-containing phagosomes (Teitelbaum et al., 
1999). Another possible mechanism Is due to the observation that M. tuberculosis, but not 
BCG. is able to escape from the phagosome (McDonough et. al., 1993); however this finding 
remains controversial. Recently, human group 1 CD1 molecules (CD1a, -d. -c) were 
identified that mediate MHC-Independent presentation of mycobacteria-derived lipid and 
glycolipid antigens to CD8+ T cells (Kawashima et al., 2003). These molecules are 
expressed I n intracellular endocytic compartments, where mycobacteria lipid antigens a re 
known to traffic, and are expressed almost exclusively on dendritic cells. 
2.6. EXPRESSION OF HETEROLOGOUS PROTEINS IN BeG 
2.6.1. Expression vectors 
The development of reliable methods for genetic manipulation of mycobacteria has been 
hindered by the slow growth of these organisms and their complex cell walls. BCG has a 
doubling time of 24 hours or longer, and can take 3-6 weeks to form a visible colony on solid 
medium (Ohara and Yamada, 2001). Their thick lipid-rich cells walls and their tendency to 
clump can make transformation with DNA problematic. In liquid culture. even in the 
presence of detergents, considerable clumping can occur. and colonies are often grown from 
a clump. rather than a single bacterium. 
In the late 1980's, first generation E. coH-mycobacterial shutUe vectors (shuttle phasmids) 
were developed. These consisted of mycobacterlophage and E. coli cosmld DNA. and were 
able to replicate In E. coli as plasmids, and insert foreign DNA into mycobacteria by infection 
(Jacobs et al., 1987). The system was Improved by Snapper et al. (1988). who developed a 
plasmid transformation system, by combining the mycobacterial replicon from the M. 
fOl1uitum pAL5000 plasmid with an E. coil replicon and a kanamycin-resistance gene. 
Although mycobacterial cells can be somewhat resistant to genetic manipulation. 
electroporation has overcome this problem and can efficiently allow entry of DNA into the 
cells by the formation of transient pores (Falkinham and Crawford, 1994; Jacobs et aI., 
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1991). Since the efficacy of this system was established, a number pAL500O-based shuttle 
vectors have been developed to improve stability, ease cloning, and to remove non-essential 
sequences (Ranes et a/., 1990; Stover eta I., 1991). Stover eta I. ( 1991) developed the 
pAL500O-derived multiple-copy number E. coli-mycobacterial shuttle vector, pMV261, which 
contains an E. coli plasmid origin of replication (Ori£), a mycobacterial plasmid origin of 
replication (OriM), a kanamycin resistance gene, a multiple cloning site, and the hsp60 
mycobacterial promoter for expression of heterologous genes. Numerous studies have 
utilised this vector and its derivatives, including this study. 
Due to in vivo plasmid stability concerns, integrative shuttle vectors were developed that 
stably insert heterologous DNA into the mycobacterial chromosome by either, transposition 
(Martin et a/., 1990), gene replacement by homologous recombination (Aldovini et a/., 1993; 
Husson et a/., 1990), or by utilising the site-specific integration system of a 
mycobacteriophage (Haeseleer et a/., 1992; Lee et a/., 1991). Stover and colleagues (1991) 
developed an integration-proficient vector, pMV361, by replacing the oriM region of pMV261 
with the integrase (int) gene and attachment site (attP) of the mycobacteriophage L5. While 
site-specific integrative vectors only exist as a single copy per cell, homologous 
recombination vectors can be present in several copies (Dellagostin et a/., 1993), however 
the latter method has the potential of undesirable gene replacement events. It is possible to 
introduce both integration-proficient and extrachromosomal vectors into the same cell, 
providing additional options for antigen expression. 
2.6.2. Factors affecting transcription 
One of the most important mechanisms regulating the expression of protein is the rate of 
transcription initiation, which is detennined by the strength of the promoter (Mulder et a/., 
1997). A good understanding of the strength and expression characteristics of the promoters 
is thus important for the regulation of expression of heterologous antigens In mycobacteria. 
Numerous promoters have been used successfully to drive heterologous gene expression in 
mycobacteria. These include: hsp60 and hsp70 from BeG. (Stover et a/., 1991), the M. 
leprae 18kDa antigen promoter (Dellagostin et al., 1993), the M. tuberculosis 19kDa antigen 
promoter (Stover et a/., 1993), mtrA from M. tuberculosis, the PAN promoter from M. 
paratuberculosis (Murray et a/., 1992), the a antigen promoter from M. kansasil (Matsuo et 
a/., 1990), the M. fortuitum j3-lactamase promoter (Pb/aF) (Himmelrich et a/., 2000), the M. 
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tuberculosis Erp antigen promoter (PelP) (Himmelrich at a/., 2000), and the groESIgroEL 1 
promoter from Streptomyces a/bus (Winter at aI., 1991). 
The promoters that are used most frequently, hsp60 and hsp70, are those of the 60kDa and 
70kDa heat-shock proteins (Hsps), respectively. Hsps belong to a family of stress proteins 
that are essential for nonnal mycobacterial growth, but are up-regulated during conditions of 
stress, such as those encountered in the intracellular environment (Bukau and Horwich, 
1998). These promoters have, however, been found to express heterologous antigens 
constitutively, driving foreign protein expression up to 10% of total BCG protein (Dellagostin 
at a/., 1995; Stover at a/., 1991). The M. lapree 18kDa antigen and M. tuberculosis mtrA 
promoters express foreign antigens relatively weakly in vitro, but are strongly induced in vivo 
to levels almost as high as those by hsp60 (Dellagostin at a/., 1995; Via at a/., 1996; Zahrt 
and Deretic 2000). The 18kDa, mtrA, and hps60 promoters have been used in this study, 
and have been discussed in more detail in Chapter 3. 
2.6.3. Factors affecting translation 
Factors likely to influence the translation efficiency of heterologous proteins In mycobacteria 
include the sequence of the ribosome-binding site, the structure at the 5' end of the mRNA, 
the sequence surrounding the Initiation codon, and the codon bias of the foreign gene 
(Burieln at a/., 1994). Mycobacteria utilise the initiation codon GUG as frequen1ly as they do 
AUG; the consequences of initiation codon choice are as yet unknown. Mycobacterial 
translation also utilises a Shlne-Dalgamo sequence similar to that of prokaryote organisms, 
which is situated upstream of the initiation codon. To avoid potential translation initiation 
problems, researchers have commonly expressed heterologous proteins as fusions with a 
short portion of the 5' end of the protein which Is naturally expressed by the promoter 
(Bur1eln at a/., 1994). Lime is known about mycobacterial expression regulation sequences 
situated downstream of the initiation codon, which could have possible Implica1l0ns when 
expressing foreign proteins (Mulder at a/., 1997). 
Codon optimisation has been utilised to increase foreign gene expression In a viral (Tobery 
at a/., 2003) and DNA-based (Liu at a/., 2002) vaccine systems. A few of studies of bacterial 
vacdne systems, including salmonella (Baud at aI., 2002) and BCG (Chujoh at a/., 2001; da 
Cruz at a/., 2001). have also utilised codon optimised genes to obtain efficient expression. 
Due to the high G+C content of the BCG sequence (approx. 65% G+C; Andersson and 
Sharp, 1996), codon bias will likely playa role in translation efficiency, however it does not 
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appear to be a key role as many genes with low G+C content are expressed at high levels in 
BCG, such as ospA of Borrelia burgdorferi (30% G+C; (Stover et a/., 1993) and 
Streptococcus pneumoniae PspA (38% G+C; Langermann et a/., 1994; McCool et a/., 2002). 
2.6.4. Post-translatlonal modification 
The rate of translation can also be influenced by the accumulation of protein, which in tum is 
dependent on the balance between post-translational modification and protein folding, and 
degradation by endogenous proteases (Buriein et a/., 1994). Incorrect folding or incorrect 
post-translational modification of foreign proteins can decrease protein stability by enhancing 
protease degradation, and consequently decrease apparent expression levels. It is plausible 
that these post-translational processes are responsible for the large differences observed in 
the expression levels of foreign proteins in BCG. The majority of the rBCG studies that have 
recorded a high production of foreign protein have expressed bacterial proteins, such as E. 
coli p..gal (10% of total BCG protein; Stover et a/., 1991), pneumococcal PspA (15% of total 
BCG protein; Langermann et a/., 1994), and Borrelia burgdorferi OspA (10% of total BCG 
protein; Fuerst at a/., 1992b; Stover at a/., 1993). The expression viral antigens in BCG, 
however, rarely reaches t he I evel of 1 % oft otal BCG protein (A1dovini and Young 1991; 
Mederie et a/., 2002; Winter et a/., 1991). Fuerst et a/. (1992a) observed that l3-gal was 
expressed to about 15% of total BCG protein, but HIV-1 gp120 was expressed at levels that 
were 200 times lower, even though the same BCG expression vector was utilised. 
The production of heterologous proteins into the cytoplasm of BCG restricts the availability of 
these proteins to the immune system, and can also limit protein production due to the 
accumulation and the possible toxicity of these proteins. Researchers have therefore 
produced fusion proteins consisting of a foreign antigen and a leader peptide which directs 
newly made proteins to the surface of the mycobacterial membrane, or out of the bacterium 
into the phagosome. The signal sequences of the BCG-derived a antigen (Stover at a/., 
1993), the a antigen of M. kanasii (Matsuo et a/., 1990), the 85A antigen of M. tuberculosis 
(Abomoelak et a/., 1999; Supply et a/., 1999), and the M. tuberculosis Erp antigen have been 
used to facilitate foreign antigen secretion. The signal sequence of the M. tuberculosis 
19kDa lipoprotein has been used extensively to direct foreign antigen to the surface of the 
mycobacterial membrane (Hlmmelrich et a/., 2000; Stover at a/., 1993). In general, short 
peptides (Honda et a/., 1995; Uno-Furuta et a/., 2003); proteins that are naturally secreted 
such as Toxoplasma gondii GRA1 (Supply at al., 1999), E. coli MalE (Himmelrich et a/., 
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2000), and L. monocytogsnss peO (Grode et a/., 2002); and naturally occurring membrane-
anchored proteins, such as Borre/ia burgdorfsri OspA (Stover st a/., 1993) and 
Streptococcus pnsumonias PspA (Langermann st a/., 1994) have successfully been 
processed by these two alternative antigen display systems. Some large proteins, and 
proteins that are naturally cytoplasmic in location, however, have failed to be exported 
(Abomoelak st a/., 1999; Bastos st a/., 2002), presumably due to being trapped on the inside 
of the cell wall. 
Targeting of foreign protein for export, or to the membrane of BCG generally has little effect 
on levels of protein production or leads to a decrease in expression when compared with 
cytoplasmic expression (AI Zarouni and Dale, 2002; Himmelrlch st a/., 2000; Langermann st 
a/., 1994). A few studies, however, have reported substantial increases in heterologous 
protein production when secreting foreign protein from BCG (AI Zarouni and Dale, 2002; 
Himmelrlch st a/., 2000). This increase in expression could be due to the reduced 
accumulation and hence the stimulation of translation, enhancer-like stimulation of 
transcription by the signal peptide, or decreased protease degradation due to efficient export 
or due to enhanCed protein stability by insertion into the cytoplasmic membrane as an 
Intermediate step in the export of the protein (AI Zarounl and Dale, 2002). 
Both the secretory and membrane-bound forms of heterologous antigen display have led to 
enhanced Immunogenicity when compared with cytoplasmically located proteins (Bastos st 
a/., 2002; Langermann st a/., 1994; Stover st a/., 1993). These superior immune responses 
are most likely attributable to an improved antigen availability to both MHC I and II 
molecules, and possibly to the immunogenlcity of the signal peptides themselves (Grode at 
a/., 2002; Horwitz st a/., 2000; Stover st a/., 1993). The a antigen and 19kDa peptides have 
been discussed in detail in Chapter 3. 
2.7. MOTIVATION FOR INVESTIGATING A RECOMBINANT BCG-HPV-16 L 1 VACCINE 
A variety of viral, bacterial, parasitic and human antigens have been successfully expressed 
in BCG; and in experimental models rBCG has elicited protective immunity against malaria 
parasites, Lyme disease, pneumococcal infection, measles, tetanus, cutaneous 
leishmaniasis, and listeriosis (Matsumoto st a/., 2000; Langermann st a/., 1994; Stover st a/., 
1993; Fennelly st a/., 1995; Fuerst st a/., 1992; Abdelhak st a/., 1995; Grode st a/., 2002). 
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The precise correlates of HPV protection and lesion regression may not be fully understood, 
but it is generally accepted that a prophylactic vaccine for HPV would aim to provide 
neutralising antibody protection in the genital tract. Studies have demonstrated that rBCG is 
able to elicit neutralising antibodies to a number of viral proteins (Bastos at a/., 2002; 
Fennelly at a/., 1995; Hiroi at a/., 2001; Chujoh at a/., 2001). It has also been shown that 
mucosal administration of BCG (such as oral or intranasal) effectively induces sustained 
specific mucosal immunity (Lagranderie at a/., 1998; Langermann at a/., 1994b; Blet at a/., 
2003). Nardelli-HaefUger at a/. (1997) demonstrated that HPV-16 L 1 expressed in 
recombinant attenuated S. typhimurium assembled into VLPs, suggesting the possibility that 
VLP or capsomere assembly could also take place in other bacterial systems, such as BCG, 
and thus display the necessary conformational epitopes for the induction of neutralising 
antibodies. Jabbar at a/. (2000) reported that HPV-6b L 1 and HPV-16 E7 BCG recombinants 
elicited antigen-specific DTH, T -proliferation and antibody responses, however, these 
Immune responses were weak when compared with protein vaccines; and immunisation with 
rBCG expressing HPV-16 E7 was not able to protect against challenge with an E7-
expressing tumour. They did not report on the ability of the HPV-6b antibodies to neutralise 
virus. rBCG expressing cotton tail rabbit papillomavirus (CRPV) L 1 has been shown to 
partially protect rabbits from CRPV challenge (Govan at a/., 2004), Indicating that rBCG has 
potential as a vector for a prophylactic HPV vaccina. 
If a neutralising antibody response fails to provide sterilising immunity, a cell-mediated 
response will be necessary for the elimination of infected cells. Selvakumar and colleagues 
(1997) detected the infiltration of mainly CD8+ T cells Into the basal and suprabasallayers of 
the epidermis during CRPV wart regression in rabbits; in contrast, mainly CD4 + T cells were 
found both within the stroma and on the surface epithelium of regressing human genital 
warts (Coleman at a/., 1994). Mycobacterial antigens are predominantly processed by MHC 
class II molecules, and thus BCG Is a potent activator of a CD4+ Th1-type cellular immune 
response (Esser at a/., 2003; Mutls at a/., 1993); however, numerous BCG recombinants 
have also elicited strong CD8+ CTL responses to heterologous antigens (Mederie at a/., 
2003; Honda at a/., 1995; Uno-Furuta at a/., 2003; Lim at a/., 1997). The rBCG dose, route 
of Immunisation, and antigen localisation, are factors which influence the Immune response 
to rBCG. These factors are reviewed in Chapters 3 and 5. 
Recombinant BCG vaccines are good candidates for vaccines intended for use in developing 
countries, because BCG is inexpensive to produce, and distribution networks already exist. 
The main HPV vaccination target population would be adolescent girls, however, it may be 
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advantageous to deliver HPV vaccines at birth, with a possible booster dose just before the 
sexually active stage, due to the risk of acquiring HPV at birth or early in life (Cason et aI., 
1995). BCG would be perfectly suited to a vaccination schedule such as this, as it Is 
routinely administered at birth, and is unaffected by maternal antibodies (Hanson at al., 
1995). 
The following sections of this report will describe the development of the BCG·L 1 
recombinants (Chapter 3), the stability of rBCG-L 1 (Chapter 4), the immunogenicity elicited 
by the rBCG·L 1 constructs (Chapter 5), and a vaccinia vlrus-L 1 murine challenge model 
(Chapter 6). Each chapter will contain a short review of the relevant literature for the work 
presented in that section. Finally, a general conclusion will be presented in Chapter 7. 
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3.1. INTRODUCTION 
Numerous E. coli-mycobacterial shuttle vectors have been developed to optimise the 
expression of heterologous antigens in mycobacteria, as discussed in Chapter 2. A good 
knowledge of the expression characteristics of the mycobacterial promoters and the features 
of the signal sequences present in the shuttle vectors is of importance as these will have a 
direct bearing on the regulation of expression 0 f t he foreign protein, and on t he immune 
responses elicited. The promoters, namely, BCG hsp60, M. leprae 18kDa and M. 
tuberculosis mtrA, and the signal peptides, namely, M. tuberculosis-derived 19kDa and BCG-
derived a antigen, were utilised in this study and are therefore briefly reviewed below. 
Furthermore, studies reporting the level and localisation of heterologous protein expression 
have been reviewed. 
3.1.2. PROMOTERS 
3.1.2.1. Hsp60 
Hsp60 belongs to a family of stress response proteins (heat-shock proteins) which are 
essential for normal bacterial growth, and are up-regulated during conditions of stress 
(Bukau and Horwich, 1998). The heat-shock proteins themselves are highly immunogenic 
and can stimulate both humoral and cellular responses (reviewed by PockIey, 2003). In 
particular, researchers have induced strong MHC class I-restricted CD8+ CTL responses to 
proteins that have been fused to heat-shock proteins (Cho et al., 2000; Suzue et aI., 1997; 
Suzue and Young, 1996). 
The hsp60 promoter is a very strong promoter; approximately five times stronger than the 
hsp70, PAN and 18kDa promoters. In M. smegmatis the hsp60, hsp70 and 18kDa 
promoters show s imiJar I evels of activity, which is a bout four times lower than that 0 f the 
hsp60 promoter in BCG (Medeiros et al., 2002). Batoni et al. (1998) investigated the activity 
of the hsp60 promoter in M. avium by using a 13-gal reporter system. They reported low 
hsp60 activity levels during the early growth phases of in vitro culture, Slightly induced levels 
during late log phase and maximal activity levels during stationary phase, suggesting that it 
is responsive to starvation stimuli. Batoni et al. (1998) showed that Hsp60 activity could be 
induced in liquid culture by a temperature shift from 37 to 45°C (four-fold increase in activity), 
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but not by a shift from 37-42OC. Stover and colleagues (1991) detected high constitutive 
expression of lacZ under the control of hsp60 in BCG, and found hsp60 to be inducible In 
vitro by heat (42OC) and acid (addition of H2P04 to pH 5). Curcic et al. (1994), however, 
could not significantly increase hsp60 activity by temperature increases. Hsp60 does not 
appear to be inducible by hydrogen peroxide, when it is expressed on a plasmid vector 
(Batoni et al., 1998; Stover at al., 1991), however, when expressed from an integrative 
vector, it is inducible With heat, acid and peroxide (Stover at al .• 1991). It was suggested that 
these differences in expression can be explained by the differences in the superheUcal state 
of the DNA, which may playa direct role in the regulation of gene expression (Mulder at al., 
1997). 
A number of studies have described a high, constitutive expression of heterologous antigens 
by the hsp60 promoter, With no upregulatlon upon entry into macrophages (Dellagostln at al., 
1995; Stover at aI., 1991; Via at al., 1996). Batonl at al. (1998). however. detected strong 
hsp60 induction after infection of macrophages, which was maximal after 3 hours and 
persisted for 7 days after Infection. 
3.1.2.2. M. Leprae 18kDa 
The M. Laprae 18kDa protein is related to the a crystalline family of low-molecular-weight 
heat-shock proteins (De"agostln et al., 1993). The M. lapraa 18kDa antigen promotar 
expresses foreign antigens relatively weakly in liquid culture, but is strongly induced in 
macrophages to levels that are almost as high as those of hps60 (Dellagostln at al., 1995; 
Zahrt and Deretlc, 2000). Contrary to the above, Medeiros at al. (2002) found that during 
liquid culturing of BCG, the 18kDa promoter had a relatively high level of activity; however, 
the authors noted that the promoter region in their constructs differed slightly to those used In 
the studies mentioned above. The 18kDa promoter functions relatively weill n E. coil (AI 
Zarouni and Dale, 2002; Medeiros at al., 2002). 
3.1.2.3. MtrA 
The AI. tuberculosis mtrA promoter is a response regulator that belongs to a two-component 
signal transduction system (mtrA-mtrB) (Curcic at al., 1994). Two-component signal systems 
are the major mechanisms used by bacteria for recognition of environmental COnditions, and 
hence influence the expression of virulence factors and other factors pertinent to adaptation 
in host cells (Curcic at al., 1994). 
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Zahrt and Deretic (2000) found the activity of the mtrA promoter to be different In BCG and 
M. tuberculosis. They noted a constitutive expression of mtrA in M. tuberculosis, with similar 
levels of activity In liquid culture and during expression in macrophages. When expressed in 
BCG, however, mtrA activity was very low in liquid culture, and was induced to a high level in 
macro phages, which was greater than the mtrA activity level in M. tuberculosis and similar to 
that of the hsp60 promoter. Via et al. (1996) also established the induction of mtrA In BCG 
during infection of macrophages. Curcic et at. (1994) found that, when expressed in M. 
Smegmatis or BCG in liquid culture, mtrA expression was as strong or stronger than that of 
hsp60. They unfortunately did not describe the growth phase at which they harvested the 
cells. Curcic and colleagues (1994) also noted that mtrA was more active when the cells 
were grown on solid medium than when in liquid medium. 
3.1.3. SIGNAL PEPTIDES 
3.1.3.1. Alpha «1) antigen 
The (1 antigen fonns part of a family of three proteins that show a high degree of homology at 
both amino acid and ONA level. The (1 antigen is also referred to as the 30kOa protein or 
antigen 85B. The other two proteins of this family have molecular masses of approximately 
32kOa, and are known as antigen 85A (32A protein) and antigen 85C (32B protein). This 
group of three proteins, referred to as the 30132kOa complex or the antigen 85 complex 
(Harth et al., 1996), are among the most abundantly exported mycobacterial proteins (Wiker 
and Harboe, 1992). Approximately 45% of extracellular mycobacterial protein belongs to this 
complex, with the 30kOa protein comprising the bulk (22%) of this. These exported proteins 
are found at the constant ratiO of 3:2:1 (3OkOal32A132B) (Harth et al., 1996). 
All three of the 30/32kOa complex proteins are fibronectin-binding proteins (Wiker and 
Harboe, 1992), and exhibit mycolic acid transferase activity (Belisle et at., 1997). The 
disruption of each individual gene in this complex causes impaired bacterial cells wall 
growth, but not cell death; while disruption of all the genes at once severely inhibits M. 
tuberculosis culture growth, and nearly achieves bacteriostatis (Harth at al., 2002). All three 
of these proteins are highly immunogenic, with the ability to induce both humoral and T cell 
responses (Wiker and Harboe, 1992). 
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The a antigen ORF encodes a polypeptide of 323 amino acids, consisting of a 40 amino acid 
signal sequence at the amino-tenninal, followed by a 283 amino acid mature protein. During 
the secretion process the signal sequence is cleaved off and the mature protein (30kDa) is 
released from the cell. The ORF has a G+C content of 64%, with a high G+C preference 
(86%) in the third codon position (Matsuo et a/., 1988). The a antigen exists as a monomer 
and is not modified post-translatlonally by either glycosylation or lipidation. It is also highly 
resistant to degradation by site-specific proteases (Harth et a/., 1996). 
Investigation of the localisation of the proteins of the 30/32kDa complex In M. tuberculosis-
infected monocytes revealed that these proteins were mainly present on the bacterial cells 
wall and in the phagosomal space, but there were also significant amounts in cytoplasmiC 
vacuoles (Harth et a/., 1996). Ramachandra et a/. (2001) demonstrated that MHC class II 
molecules formed complexes with a antigen within the p hagosomes (20 minutes after M. 
tuberculosis infection) and not in endocytic compartments after export of the a antigen from 
phagosomes. After 20 minutes these complexes could be detected on the plasma 
membrane. This system, however, Is not present to increase antigen presentation, but 
rather to inhibit MHC antigen processing as a mechanism for Intracellular survival, as heat-
killed M. tuberculosis were processed more rapidly by macrophages than live bacteria, and 
the phagosomes containing live M. tuberculosis contained fewer a antigen-MHC class II 
complexes. 
3.1.3.2. 19kDa lipoprotein 
Analysis of the 19kDa lipoprotein shows no obvious homology with other known proteins, 
and its biological function i s yet to bed etermined. It is primarily associated with the 
mycobacterial cell wall (Neyrolles e tal., 2001). The 1 9kDA antigen undergoes post-
translational modification consisting of cleavage of the signal peptide, glycosylation and 
acylation (Garbe et al., 1993). The 19kDa lipoprotein is very immunogenic, and can 
stimulate the innate immune response, including the generation of nitric oxide and IL-12, 
via Toll-like receptors (Brightbill et a/., 1999). 
After phagocytosis of live mycobacteria the 19kDa lipoprotein is produced and 
processed quickly; with the protein being exported from the phagosome and found 
throughout the infected cell in less than one hour after phagocytosis (Neyrolles et al., 
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2001 ). It is generally accepted that "phagosomal" bacteria, such as BCG, primarily 
stimulate CD4+ T cells via MHC class II antigen presentation; in contrast, antigens from 
-cytoplasmic" pathogens are available to MHC class I molecules and hence stimulate 
CD8+ T cells (Kaufmann and Hess, 1999). By and large, antigens present in the 
cytoplasm are directed by the TAP transporter to the endoplasmic reticulum, where they 
associate with MHC class I molecules; however, a TAP-independent pathway exists, 
during which antigens associate with class I molecules within the cell or on the cell 
surface following endocytosis. After the export of the 19kDa lipoprotein from the 
phagosome, it appears to be processed by this alternative mechanism, which appears to 
be dependent on its acylation (Neyrolles at 81., 2001 ). 
Recently, human group 1 CD1 molecules (CD1a, -d, -c) were identified that mediate MHC-
independent presentation of mycobacterlal-derived lipid and glycolipid antigens to CD8+ T 
cells (Kawashima at 81., 2003). These molecules are expressed in intracellular endocytic 
compartments where mycobacterial lipid antigens are known to traffic, and are expressed 
almost exclusively on dendritic cells. The fusion of a peptide epitope from the influenza 
virus NP with the 19kDa lipoprotein expressed by M. V8ccsa, rapidly delivered the 
influenza epitope for recognition by MHC class l-restricted CD8+ T cells. This MHC class 
I recognition was determined by the 19kDa lipoprotein, because antigen presentation 
was blocked with the removal of the lipid tail (Neyrolles at 81., 2001) 
Although the 19kDa lipoprotein activates innate and specific immunity during early 
Infection, it has been found to inhibit macrophage MHC class II expression and antigen 
processing during the later stages of infection, which effectively deaeases T cells 
recognition. This MHC class II inhibition is dependent on Toll-like receptor 2 and 
independent of Toll-like receptor 4 (Noss at 81" 2001). Some mycobacterial glycolipids 
are actively exported from the immature mycobacterial vacuole, and are transferred out 
of the macrophage in extracellular vesicles, by a process called exocytosis. These 
vesicles are phagocytosed by adjacent un-infected cells. "rhis cell-to-cell spread of 
mycobacterial components may explain the continuous immune response modulation at 
the infection foci, seen with M. tuberculosis Infection (Beatty at 81., 2000; Neyrolles at 81., 
2001). 
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3.1.4. LEVEL AND LOCALISATION OF HETEROLOGOUS PROTEIN PRODUCTION 
As mentioned in Chapter 2, the level of heterologous protein production in recombinant BCG 
depends on a number of factors including, promoter strength, signal peptides, and protein 
stability. 
Extrachromosomal expression vectors utilising the hsp60 promoter have produced the 
highest levels of cytoplasmically located foreign proteins in rBCG, however, these vectors 
are also the most unstable (AI Zarouni and Dale, 2002; Medeiros et a/., 2002). When under 
the control of hsp60 on extrachromosomal vectors, the E. coli l3-gal (Stover et a/., 1991) and 
BOn'Slia burgdorferi OspA proteins (Fuerst et a/., 1992; Stover et a/., 1993) accounted for 
over 10% (20ng/108 rBCG) of total BCG protein. Expression of l3-gal on an integrative vector 
utilising the same promoter was lower (Stover et a/., 1991), but this was not unexpected as 
only one copy of the integrative vector is present per cell. Substantially lower levels of OspA 
(1-5ng/108 rBCG) were produced when expressed as fusions with the a antigen or 19kDa 
lipoprotein (Stover et a/., 1993). When OspA was expressed without a signal peptide it was 
detected exclusively in the aqueous cytoplasmic fraction, while chimaerlc OspA-19kDa was 
located almost exclusively in the detergent-soluble fractions, indicative of a membrane 
association. Chimaeric OspA-a antigen was detected in the insoluble cell-wall fraction, and 
in the extracellular medium, but not in the detergent-soluble membrane fraction (Stover et a/., 
1993). Langermann et a/. (1994) reported the production of pneumococcal PspA at 15% 
(100ng/108 rBCG) of total BCG protein (hsp60, extrachromosomal vector). The levels of 
PspA were two- to five-fold lower when fused to membrane-directed signal sequences. The 
19kDa lipoprotein successfully directed PspA to the surface of the BCG cell wall; however, 
the PspA's native Signal could not facilitate export. Abomoelak et a/. (1999) found that the 
hsp60 promoter could drive expression of a pertussis toxin-tetanus toxin hybrid protein (S1-
TIC) to levels 10 times that of the same protein under the control of the antigen 85A 
promoter and signal peptide. The latter system was not able to export this protein, 
presumably due to its large size (75kDa). 
The addition of signal sequences (membrane or secretory) usually has little effect on protein 
production levels or leads to a decrease in expression when compared with cytoplasmic 
expression. A few studies, however, have detected substantial increases in protein 
production when using secretory signals. When expressing E. coli MalE protein in BCG 
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(extrachromosomal vector, PblaF promoter), Himmerlrich et al. (2000) found that the highest 
MalE producers by far were the BCG recombinants that secreted MalE. The highest MalE 
producer had two contiguous secretion signal sequences, while the lowest producer was the 
19kDa lipoprotein (membrane-directed) construct. The highest producer made 9 and 450 
times more MalE than the cytoplasmic and lipoprotein constructs, respectively. AI Zarouni 
and Dale (2002) reported that the expression of P-gal in BCG was relatively low when using 
the 18kDa promoter by Itself or with the 19kDa lipoprotein signal peptide, however, the 
addition of the antigen 85A secretion signal increased the expression 7 -fold. 
The expression of viral antigens in BCG rarely exceeds 1 % of total BCG protein. Production 
of HIV-1 p24 accounted for 0.1% of total BCG protein (extrachromosomal, hsp70, 
cytoplasmic) (AJdovlnl and Young, 1991), and HIV-1 Net accounted for 1% of total BCG 
protein (extrachromosomal, groESIgroEL1 promoter, cytoplasmiC) (Winter et al., 1991). 
rBCG expressing a synthetic SIV nef-gag operon on an extrachromosomal vector (PblaF 
promoter, cytoplasmic) expressed high amounts of Gag (approximately 1.11 % of total BCG 
protein), but this construct was unstable. W hen the same 0 peron was expressed on an 
Integrative vector It was stable, but it produced 8-fold less Gag (Mederte et al., 2002). 
BCG does not only have difficulty with the secretion of large proteins, some small proteins 
are also not able to cross the cell wall; however, at appears that the smaller the protein, the 
more likely It Is to be secreted. Short peptldes from the V3 region of HIV-1, which were 19 
and 15 amino acids (aa) in length, were not secreted when fused with the a antigen 
secretory Signal, but 12 and 11 aa peptides of the same region were secreted successfully 
(8.37-17.51lQ/ml In culture filtrate) (Chujoh et aI., 2001). Uno-Furuta at al. (2003) reported 
that a 12 aa epitope of the hepatitis C virus that fused to the a antigen signal was secreted 
more efficiently than a similar 16 aa long peptide. 
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3.2. STUDY OBJECnVES 
The objective of this chapter was to produce a panel of BCG recombinants expressing the L 1 
protein of HPV-16, with the intention of comparing the L 1 expression levels in vitro. The L 1 
gene was cloned into a number of E. coli - mycobacterial shuttle vectors, and these clones 
were then introduced into BCG. Care was taken to confirm BCG transformants, because 
plasmid instability was often detected in the BCG recombinants. BCG-HPV-16 L 1 
recombinants were assessed for their production of HPV-16 L 1 protein and mRNA. As the 
study evolved, more E. coli - mycobacterial shuttle vectors became available, and additional 
HPV-16 L 1 gene variants were investigated, which lead to the production and assessment of 
a large array of BCG recombinants. 
3.3. MATERIALS AND METHODS 
3.3.1. E. COLl- MYCOBACTERIAL SHUTTLE VECTORS 
A number of E. coil - mycobacterial shuttle vectors were utilised in this study, with the 
Intention of comparing foreign protein expression levels and immunogenicity. The main 
features of these vectors are tabulated below (Table 3.1). Maps of the vectors are available 
in Appendix C. The origins of these vectors are indicated in the footnotes of table 3.1. 
3.3.2. MYCOBACTERIAL SUBSTRAINS 
Two M. bovls BCG substrains were utilised, namely Tokyo and Pasteur. Freeze-dried 
ampoules of the BCG Tokyo substrain were obtained from the State Vaccine Institute, 
Pinelands, Cape Town, South Africa. BCG Pasteur 1172 P2 was obtained from the Statens 
Seruminstitut, Denmark. 
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Table 3.1. A summary of the general features of the E. coli - mycobacterial shuttle vectors that were utilised in the present study. 
Vector Promoter Fuslonlslgnal Other features Protein 
sequence expf'HSlon 
Extrachromosomal vectors 
pMV261 NT» BCG hsp60 
p261gb BCGhsp60 
RBS and 1" 6 codons of Tn903-derived aminoglycoside phospl}otransferase (aph) gene 
Hsp60 protein followed conferring kanamycin resistance (Kan'; as a selectable marker, 
by a multiple cloning site OriM from the pAL5000 plasmid, OriE from pUC19, MCS followed cytoplasmic 
(MCS) by a transcription terminator (nnABt1), copy number of 5. 
M. tuberwlosis-derived 
19kDa lipoprotein RBS 
and 5' signal peptide 
sequence (28 codons 
from the 5' end of the 
gene) 
BCG-derived a antigen 
as above (pMV261 derivative) export to bacterial surface 
References 
Stover st al., 1991 
Stover st al., 1993 
pAB2tf BCGhsp60 RBS, Signal sequence as above (pMV261 derivative) and structural gene (323 export into medium Stover at al., 1993 
codons) 
aph KanR gene, OriM from pAL5000, OriE, transcription 
terminator, copy number of 5. Obtained as a clone containing the 
M. tubelWlosis 19kDa lpoprotein (45 Plasmodium falciparum MSP-1 gene. A ~ gene Is also present, export to bacterial W. R. Jacobs (personal 
mtrA codons from the 5' end) which can be used as a nOrHIntibiotic in vivo selection system surface communication} 
pCB112d 
when used In a lysine auxotrophic BCG mutant. The latter system 
was not utilised in the present study. 
M.lepras 18/(Da a antigen (41 codons 
from the 5' end) as above 
BCG hsp60 
Hygromycin resistance gene (HygR) from Streptomyces 
111 6 as of Hsp60 protein hygroscopicus, OriM from the pAL5000 plasmid, OriE, 
transcription terminator, copy number of 5. 
IntegratJon-proficlent vectors 
export into medium W. R Jacobs (personal 
communication) 
cytoplasmic Garbe st al., 1994 
pNIV192C BCGhsp60 None Mycobacteriophage FRAT 1 integrase gene and attachment site, cytoplasmic aph KanR gene. copy number of 1, OriE. 
Haaseleer st al., 1992; 
Haeseleer st al., 1993 
pMV361 b BCG hsp60 
pMV261 derivative with OriM removed, attP attachment site and 
at Integ rase gene from mycobacterlophage L5, aph KanR gene. 
1 6 as of Hsp60 protein OriE, copy number of 1. Integration occurs at the 3' end of a cytoplasmic 
tRNA Sly gene, and does not disrupt the expression of this gene. 
a Dept. of Medical Microbiology, University CoUege London Medical School, London 
b Medlmmune, Inc. 
C P. Jacobs, Dept. of Medical Microbiology, University of Brussels 
d W. R. Jacobs, Dept. of Microbiology and Immunology, Albert Einstein College of Medicine 
Lee st al., 1991; Stover 
st al., 1991 
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3.3.3. SOURCE OF HPV-16 L1 GENES 
3.3.3.1. Rochester HPV-16 L 1 (L 1 R) 
An L 1 gene, designated L 1R (aa sequence identical to GenBank AF134175, Appendix E), 
was kindly supplied by Robert Rose (University of Rochester, Rochester, New York, USA) on 
the pVL plasmid (Rose at al., 1994). 
3.3.3.2. Synthetic L 1 with optimised codons for expression In BCG (L 1 BeG) 
An important factor influencing protein expression is the compatibility of the codons of the 
foreign gene with the codon usage of the expression system (as described in Chapter 2). 
Many HPV-16 L 1 codons are used infrequently by BCG, partly due to the high G+C% of the 
BCG sequence (approx. 65% G+C), and the low G+C% of HPV sequence (L 1 is approx. 
42% G+C) (Andersson and Sharp, 1996; Howley and Lowy, 2001). To explore the influence 
of codon usage on the expression of L 1 in this system, the HPV-16 L 1 gene was 
resyntheslsed (Geneart, Germany) to reflect commonly used BCG codons. The L 1 amino 
acid sequence utilised for the codon-optimised gene (L 1 BCG; Appendix E) was based on the 
L 1 Phil sequence (aa sequence identical to Genbank NC001526), which Touze at al. (1998) 
has showed to produce high VLP yields in the baculovirus expression system. This 
sequence differs by 8 amino acids when compared with the L 1 R sequence. 
3.3.4. L 1 PCR AND CLONING 
3.3.4.1. L 1 R (Full-length Rochester HPV-16 L 1) 
The HPV·16 L1R ORF (1.5 kb) was amplified by PCR from pVL using primers to facilitate 
directional insertion into the E. coli· mycobacterial shuttle vectors pMV261, pMV361, p2619, 
and pAB26 (Table 3.1). The upstream primer, 5'·GGAAGATCTGATGTCTCTTTGGCTG·3' 
(JM9), contained a Bgi II restriction enzyme recognition site (bold) and a start codon 
(undertined). The downstream primer, 5'·GAGCAAGCTTCTCGAGTTACAGCTTA·3' (JM7), 
contained a Hind III restriction enzyme site (bold) and a termination codon (undertined). The 
primers were produced by the DNA Synthesis Unit (Dept. of Molecular and Cell Biology, 
University 0 f Cape Town). PCR reactions were prepared a nd performed as described in 
Appendix A9. The PCR amplification product was cloned into the pMOS·blue vector using 
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the pMOS-blue TA cloning kit (Amersham. Bucklnghamshlre. UK), as described In Appendix 
AB.3. The resultant clone was called pM-L 1R. After restriction enzyme digestion of the pM-
L 1 clone with Bglli and Hind 1/1, the L 1 fragment was cloned into the Bam HI and Hind III 
sites of pUC19 (Bam HI and BgI II form compatible ends), forming pUC-L 1R. Refer to 
Appendix 0, Figure 01 for an illustration of the cloning strategy. 
The HPV-16 L 1R gene was amplified by PCR using primers to facilitate directional insertion 
into the E.coli-mycobacterial shuttle vectors, pCB112 and pCB119. The upstream primer, 5'-
GACGGGCCCATGTCTCTTTGGCTGC-3' (CBF), contained an Apa I restriction enzyme 
recognition site (bold) and a start codon (underlined). The downstream primer, 5'-CC 
ATCGATCTAGACTTACAGCTTAC-3' (CBR), contained a Cia I restriction enzyme site (bold) 
and a termination codon (underlined). The L1R gene was amplified from the pM-L1R 
plasmid. and was cloned into pGEM-T Easy vector (Promega. Madison WI. USA) as 
described in Appendix AB.3, to form pG-CBL 1 R. Refer to Appendix 0, Figure 02 f or an 
illustration of the cloning strategy. 
3.3.4.2. L 1NLS• (Rochester HPV·16 L 1 without a nuclear localisation signal) 
The L 1 NLS- gene was formed by a 66 base-pair (22 amino acid) truncation at the C-terminal 
of the HPV-16 gene to remove the nuclear localisation signal (NLS).The truncation was 
formed by designing a downstream PeR primer to terminate translation just before the NLS. 
The L 1 NLS- gene was amplified by PCR from pVL using primers to facilitate directional 
insertion into the E. coli - mycobacterial shutUe vectors, pMV261 , pMV361, p2619. and 
pAB26 (Table 3.1). The upstream primer, 5'-GGAAGATCTGATGTCTCTTTGGCTG-3' 
(JM9). contained a Bgl II restriction enzyme recognition site (bold) and a start codon 
(underlined). The downstream primer, 5'-GAGCAAGCIIIIATCCTAATGTAAATTTTGG-3' 
(JM10), contained a Hind III restriction enzyme site (bold) and a termination codon 
(underlined). The L 1 NLS· gene was amplified from the pVL by PCR, and was cloned into the 
pGEM-T Easy vector, forming pG-L 1NLr. Refer to Appendix 0, Figure 03 for an illustration 
of the cloning strategy. 
The HPV·16 L 1 gene was amplified by PCR using primers to facilitate directional insertion 
into the E. coli - mycobacterial shutUe vectors, pCB112 and pCB119. The upstream primer, 
5'-GACGGGCCCATGTCTCTTTGGCTGC-3' (CBF), contained an Apa I restriction enzyme 
recognition site (bold) and a start codon (underlined). The downstream primer, 5'-
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CCATCGA I I I ATCCT AA TGTAAA TTTTG-3' (CBRn, was used to truncate the L 1 gene just 
before the NLS. The downstream primer contained a Cia I restriction enzyme site (bold) and 
a termination codon (underlined). The L1NLS"" gene was amplified from pM-L1R. and was 
cloned into pGEM-T Easy, forming pG-CBL 1NLS-. Refer to Appendix D. Figure 02 for an 
illustration of the cloning strategy. 
3.3.4.3. L 1. (Rochester HPV-16 L 1 with the downstream EpiA tag) 
A DNA tag of 75 base pairs, named EpiA, was inserted downstream of the L 1 gene in some 
of the latterly-constructed vectors. EpiA contains a 9 amino acid epitope (lPNPLLGLD) from 
paramyxovirus SV5, which is recognised by the monoclonal antibody SV5-P-k, and a 10 
amino acid BALBlc mouse CTL epitope (RGPGRAFVTI) which originated from the V3 region 
of the HIV-1 envelope protein. 
The presence of EpiA has multiple applications when expressed as a fusion with L 1 in rBCG: 
The SV5-P-k monoclonal antibody epitope gives us an alternative method for evaluating 
translation of the L 1-EpiA transcript. Due to the situation of EpiA, downstream to L 1, 
expression of EpiA is indicative of read-through of the L 1 ORF. In mouse immunogenicity 
studies the CTL tag can be used as an altemative method to establish in vivo expression of 
the recombinant protein. The tag can also be used for the comparison of protein expression 
between vaccines which contain different foreign genes but the same epitope tag. Dr Will 
Boum (Department of Clinical Laboratory Science, University of Cape Town) is 
acknowledged for the construction of the EpiA tag. 
R L R G P G R A F V T I 
5 1 -eGA TTG CGC GGC CCG GGC CGC GCC TTC GTC ACC ATC 
T F K Q I P N P L L G L D 
Figure 3.1. The EpiA DNA sequence (only sense strand shown) and corresponding amino acid 
sequence (above). To facilitate cloning, Cia I sites (bold) were placed on either end of the tag. 
The BALB/c HIV eTL epitope is underlined with the solid line. The SV5-P-k monoclonal antibody 
epitope is underlined with the dotted line. 
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The L 1 tennination codon was removed to facilitate read-through into the EpiA tag. This was 
achieved by PCR amplification of the L 1 gene using a downstream primer that did not 
contain a tennination codon. The primers were also designed to facilitate cloning into the E. 
coli - mycobacterial shuttle vectors. The HPV-1S L 1 gene was amplified from pVL using the 
upstream primer, 5'-GGGCCCACAGCTGGTCGACATATGTCTCTTTGGCTGC-3' (L 1SF). 
which contained an Apa I enzyme site (bold), a Pvu II enzyme site (bold and underlined) and 
a start codon (underlined); and the downstream primer, 5'-ATCGATACAGCTTACGTTTTT 
TGCG-3' (L 1 SR), which contained a CIa I restriction enzyme site (bold). The PCR 
amplification product was cloned into the pGEM-T Easy vector fonning pG-L 1 S. Refer to 
Appendix 0, Figure D4 for an illustration of the cloning strategy. Refer to section 3.3.5.1 for 
cloning of EpiA into the E. coli - mycobacterial shuttle vectors. 
3.3.4.4. L 1aco. (BCG codon-optlmlsed HPV·18 L 1, with the downstream EplA tag) 
During the synthesis of L 1 BCG, restriction enzyme recognition sequences were added at the 
5' and 3' ends to facilitate cloning. Apa I and Pvu II enzyme sequences were added to the 5' 
end of the gene. while a CIa I sequence was added to the 3' end. L 1 BCG was designed 
without a stop codon to enable read-though Into the EplA tag. 
3.3.5. CLONING INTO E. COU - MYCOBACTERIAL SHUTTLE VECTORS 
3.3.5.1. Cloning Into pCB112 and pCB119 
• The full-length L 1 gene (L 1 R) and the truncated version (L 1 NtS-) were obtained by Apa I and 
CIa I digestion of pG-CBL1R and pG-CBL 1NLS-. respectively, and were then cloned into 
pCB112 and pCB119. after these vectors had also been digested with Apa I and CIa I. The 
resultant clones were p112L1R• p112L1N..s-, p119L1R, and p119L1NLS-. Refer to Appendix 0, 
Figure 05 for an Illustration of the cloning strategies . 
• The EpiA epitope tag was cloned Into t he CIa I site of pCB119 vector to fonn pCB119. 
(Appendix 0, Figure OS). The L 1 S gene (with stop codon removed) was cloned from pG-
L 1 S into pCB 119, using Apa I and CIa I digests. to fonn p119L 1. (Appendix O. Figure OS). 
L 1, was then sub-cloned from p119L 1, into pCB112 with Apa I/Hpa I digests, fonnlng 
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p112L 1. (Appendix 0, Figure 07). This cloning strategy inserted the L 1 gene In-frame of the 
transcription terminator present in the vectors just downstream of the multiple cloning site. 
• The L 1scG gene was cloned from the pSK-L 1BCG plasmid (Geneart, Germany) into pCB119. 
using Apa IICla I digests to form p119L 1 BCGe. The L1 BCG. fragment was t hen cut out of 
p119L1 scGe with Apa IIHpa I and subcloned into pCB112, forming p112L1 BCGe (Appendix 0, 
Figure 07). 
3.3.5.2. Cloning Into pMV381 and p2819 
• The L 1 R gene was obtained from pUC-L 1 R by partial digestion with Eca RI (an Eco RI site 
exists elsewhere in the L 1 gene) and Hind III. The L 1R fragment was then cloned into the 
Eca RI and Hind III sites of pMV361 and p2619, forming p361L 1R and p2619L 1R. 
respectively. Refer to Appendix 0, Figure 08 for an illustration of the cloning strategy. 
• The L 1 NlS- gene was cloned from pUC-L 1 NlS" into pMV361 and p2619, forming p361 L 1 NLs-
and p2619L 1 NlS-. respectively. The same method used. as described above for L 1R 
(Appendix 0, Figure 09). 
• L1. was sub-cloned cloned from p119L 1. Into pMV361 using Pvu IIIHpa I digests. forming 
the clone p361 L 1. (Appendix O. Figure 010). 
3.3.5.3. Cloning Into pMV281 NT, pAB28 and pSMT3 
• The full-length L 1 gene was cut out of pM-L 1 R by digestion with Bglli and Hind III, and the 
resultant L 1 fragment was sub-cloned into the Bam HI and Hind III sites of pAB26, pMV261 
and pSMT3, to form pAB26L 1 R, p261 L 1 R. and pT3L 1 R. respectively (Appendix 0, Figure 011 
and 013). 
• The L 1NlS- gene was cloned from pG-L1NlS-into pAB26, pMV261 and pSMT3, using the 
same methods as described a bove for t he full-length gene (Appendix 0, Figure 012 and 
013). 
57 
Chapter 3: Development of BCG Recombinants Expressing HPV-16l1 
3.3.5.4. Cloning into pNIV192 
• The cloning of L 1R into pNIV192, fonning pNVL 1R, was perfonned by Wendy Burgers (MSc, 
Dept of Medical Microbiology, University of Cape Town, 1996). 
3.3.6. SEQUENCING OF CLONES TO CONFIRM PCR FIDELITY AND CLONING 
After the clones were verified by restriction endonuclease digestion (Appendix A6), they were 
sequenced to confinn PCR fidelity and correct ligation at the cloning sites. In order to obtain 
clean DNA for sequencing, small scale DNA extractions were perfonned using the High Pure 
Plasmid Isolation Kit (Roche Diagnostics, Gennany) as described in Appendix A5.5. All 
primers were made by the DNA SynthesiS Unit (Department of Molecular and Cell Biology, 
University of Cape Town). Unless otherwise stated, all sequencing was perfonned at the 
Core Facility (University of Stellenbosch). 
• The pM-L1 R, pG-L 1 NlS-, pG-CBL 1 Rand pG-CBL1 NlS- clones were sequenced by DNA 
Sequencing Unit (Department of Molecular and Cell Biology, University of cape Town). using 
the M13 primers (Roche Diagnostics, Gennany). The M13 primers bind on either side of the 
multiple cloning sites of these vectors. 
• pAB26L 1 R IL 1 NlS-, p261 L 1 R IL 1 NlS- and p2619L 1 R IL 1 NlS- were sequenced with primers 26F 
(5'- TGGCGAACTCCGTTGTAGTG -3') and 26R (5'- GTTGGCTAGCTGATCACC -3') to 
assess the sequences at the cloning sites. Primer 26F binds upstream to the hsp60 
promoter in the vectors and thus sequences the promoter, the 5' cloning site and 5' end of 
the L 1 gene; primer 26R binds downstream to the L 1 gene and sequences the 3' cloning site 
and the 3' end of the L 1 gene. 
• p361 L 1 R IL 1 NlS- was sequenced with primers 361 F (5'- TCTGTGCGGAGACCTGGGCA -3') 
and 26R. 361 F binds upstream to the hsp60 promoter and thus sequences the promoter, 
the cloning site and into the 5' end of the L 1 gene. 26R sequences as mentioned above. 
• pT3-L1R was sequenced with primers T3F (5'- GGCAGTGAGCGCAACGCAA -3') and T3R 
(5'- GATAACGTTCTCGGCTCGATG -3'). Primer T3F binds upstream to the hsp60 promoter 
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and thus sequences through the promoter and Into the 5' end of the L 1 gene; T3R binds 
downstream to the L 1 gene and sequences the 3' cloning site and the 3' end of the L 1 gene . 
• Eight primers, shown below, were used to sequence the pCB112 (p112L 1R IL 1NLS-/L 1,) and 
pCB119 clones (p 119L 1 R IL 1 NLS-IL 1 e). These primers were designed to sequence the sense 
and anti-sense strands of approximately four 600bp overlapping regions which included the 
L 1 sequence, its promoter and leader sequence. 
CBAF: 5'- AGTGCTTGTGGTGGCATCC -3' 
CBAR: 5'- TCAACTTGGCACGTCTGGAG -3' 
CBBF: 5'- GTTGTCGGCGCCGATGTTG -3' 
CBBR: 5'- CGCTGTGTATCTGGATTG -3' 
CBCF: 5'- GTATCAGGATTACAATACAGGG -3' 
CBCR: 5'- TTTGCAGTAGCACCAGAGCC -3' 
CBOF: 5'- GGGCTGGTGCTGTTGGTG -3' 
CBOR: 5'- GGCAGTCGATCGTACGCTAG -3' 
• pCB119, was sequenced with primers CBBF and CBOR to confirm that EpiA was cloned in 
the correct orientation. When the p119L 1 BCGe and p112L 1BCGe clones were sequenced, the 
above primers, CBAF, CBAR, CBBF and CBDR were used as these primers bind to 
sequences in the vectors. The primers below were designed to prime within L 1 BCG. 
BCGL1CF: 5'- GTTCTACAACCCGGACACCC -3' 
BCGL 1BR: 5'- AGATGCCCACGCCCAGCGG -3' 
BCGL 1 OF: 5'- CCACAACAACGGCATCTGCTG -3' 
BCGL 1 CR: 5'- GGCGCACAGCGACATGTTGG -3' 
3.3.7. INTRODUCTION OF SHUTTLE VECTORS INTO BCG 
3.3.7.1. Electrotransfonnatlon of BCG 
The mycobacterial expression vectors were introduced into BCG by electroporation, which 
involves the administration of a high voltage to the cells which induces a transient state of 
competency. allowing the uptake of DNA (Jacobs at al., 1991). 
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Large scale plasmid DNA extractions were performed on the L 1-mycobacterial expression 
vector clones (Appendix A5.2). Competent BCG was prepared for electrotransformation 
(Appendix A2.2) and the vectors were introduced into the competent BCG, as described In 
Appendix A3.2. Briefly, plasmid DNA was mixed with washed BCG cells and placed in an 
electrogap cuvette (Bio-Rad Laboratories, Germany). The cellJDNA mixture was then 
subjected to an electric pulse using a GenePulser (Bio-Rad Laboratories, Germany) to allow 
uptake of DNA. The cells were incubated with medium to allow for the expression of the 
antibiotic resistance gene of the newly transferred plasmid, and then plated on solid medium 
containing the appropriate antibiotic. Single colonies were selected and analysed. 
3.3.7.2. Verification of BCG transfonnants 
Due to their thick, complex cell walls, DNA extraction from mycobacteria is not as efficient as 
from E. coli. It was therefore necessary to amplify the mycobacterial plasmid DNA by 
transforming it into E. coli. Briefly, plasmid DNA was extracted from mycobacterial 
transformants and then transformed into E. coil. Plasmid extractions were then performed 
on the E. coil recombinants and the DNA obtained was subjected to endonuclease digestion 
and agarose gel electrophoresis. To verify whether mycobacterial transformants contained 
integrated expression vectors, total DNA was extracted from the mycobacteria and Southern 
blot-hybridlsation was performed. These methods are described in detail In Appendix A4.1. 
3.3.8. ANALYSIS OF PROTEIN EXPRESSION BY rBCG 
3.3.8.1. Total protein extraction from BCG 
Mechanical methods have been developed for protein extraction from mycobacteria as these 
methods are more suitable than lysis buffers for efficient lysis of the thick mycobacterial cells 
walls. Total protein was extracted from BCG cultures using a bead-beating method 
described In detail In Appendix A11.1. The protein concentrations of the mycobacterial cell 
Iysates were determined using the Bio-Rad Protein Assay Kit (Blo-Rad Laboratories, 
Germany; Appendix A 11.2). 
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3.3.8.2. Sodium dodecyl sulphate· polyacrylamide gel electrophoresis (SDS-PAGE) 
The proteins from the cell Iysates were resolved by electrophoresis on a denaturing 
polyacrylamide gel (Appendix A 11.3). Protein gels were typically run in duplicate, after 
which, one gel was stained with Coomassie blue, while the other was used for westem 
blotting. Coomassie blue staining (Appendix A11.4) is based on non-specific binding of 
Coomassie blue dye to proteins. After staining, the gel was destained to remove background 
colour, and the proteins were detected as blue bands on a clear background. 
3.3.8.3. Western blot analysis 
The duplicate SDS-PAGE gel (section 3.3.8.2) was subjected to westem blotting (Appendix 
A 12.1), followed by i mmunodetection 0 f s pacific proteins. Immunodetection 0 f L 1 protein 
was carried out using the BM Chemiluminescence Blotting Substrate (POD) kit (Roche 
Molecular Biochemicals, Germany) according to the manufacturer's specifications (see 
Appendix A 12.2 for a detailed method). T wo H PV-16 L 1 specific monoclonal antibodies, 
namely H16.J4 and H16.D9, were used to probe for the L 1 protein on the westem blots. 
These antibodies are specific for denatured HPV-16 L 1 protein (Christensen at a/., 1996a). 
Purified HPV-16 VLPs were utilised as the positive control. 
3.3.9. L 1 mRNA QUANTIFICATION 
Due to the low production of HPV-16 L 1 protein by the BCG-L 1 recombinants, the L 1 mRNA 
production by these recombinants was investigated. Briefly, total RNA was extracted from 
BCG, and reverse transcribed into cDNA using random primers. Specific genes (cDNA) 
were then quantified by a quantitative PCR technique (LlghtCycler thermocycler instrument, 
Roche Molecular Biochemicals, Germany). 
3.3.9.1. RNA extraction and reverse transcription 
RNA extractions were performed on fresh BCG cultures or on frozen BCG samples 
(Appendix A14.1). Care was taken to harvest the cultures during the same growth phases. 
The FastRNA Blue Kit (Bio 101, USA) was used to extract RNA as per the kifs instructions 
(Appendix A14.1). To remove DNA contamination, the RNA samples were treated with 
deoxyribonuclease (DNase). The DNase kit, AMP-D1 (Sigma, USA), was used for this 
purpose, as per the kirs instructions (Appendix A 14.2). After DNase treatment, the RNA 
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samples were tested for the presence of DNA by PCR using the LightCycler (Appendix A9), 
with primers specific for HPV-16 L1 (947U23 and 1091L21; see below, section 3.3.9.2) and 
MT10SA, a small stable mycobacterial RNA ( Mariani e tal., 2000) (primers, 10SAF: 5'-
AGGGCCAGGTCGGTGGC -3' and 5'- AGATCCTGGACGATCGGC -3'). DNA-free RNA 
samples were reverse transcribed into cDNA using random primers. The 1 st Strand cDNA 
Synthesis Kit for RT-PCR (Roche Molecular Biochemicals) was utilised for this purpose, 
according to the manufacturer's instructions (see Appendix A14.3 for a detailed method). 
3.3.9.2. RNA/eDNA quantification 
The LightCycler (Roche Molecular Biochemicals) Is able to quantify the number of DNA 
copies of a specific template In an unknown sample, by comparing the PCR efficiency of the 
template in the unknown sample with that of known standard samples. The PCR reagents 
were obtained from the LightCycler • FastStart DNA Master SYBR Green I Kit (Roche 
Molecular Biochemicals). This PCR kit is specifICally adapted for use with the LightCycler 
instrument. This system uses SYBR Green I dye, which specifICally binds to double 
stranded DNA; this binding enhances the dye's fluorescence, which is then measured by the 
LightCycler. Primers were designed to amplify a small region of the HPV-16 L 1 gene, the 
Tn903 kanamycin resistance gene, and the M. bovis 16S rRNA gene. 
The following primers were used: 
HPV-16 L 1 gene (256bp product) 
947U23: 5'- ACTGCAAATTTAGCCAGTTCAAA ·3' 
1091 L21: 5'- CAT A TTCCTCCCCATGTCGTA -3' 
Tn903 kanamycin gene (286bp product) 
245U23: 5'· CGACCATCAAGCA TTTTATCCGT -3' 
5110L21: 5'· TGTTCAACAGGCCAGCCATTA-3' 
M. bovis 165 rRNA gene (268bp product) 
284U23: 5'- AGATACGGCCCAGACTCCTACGG -3' 
530L22: 5'· CAACGCGACAAACCACCTACGA -3' 
The primers were syntheSised by the DNA Synthesis Unit (Dept of Molecular and Cell 
Biology, University of Cape Town). 
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Standard DNA template samples were set up for each gene that was quantified. p119L 1. 
plasmid was used as a template for the HPV-16 L 1 and Tn903 kanamycin genes. Six 10-
fold serial dilutions were made with concentrations ranging from 12.Spg/~ (approx. 4.1x1010 
plasmid copies/~) to 1.2Sx10-4 pg/~ (approx. 4.1x105 plasmid copies/~). The standard DNA 
template for 16S rRNA was made by PCR amplification (Appendix A9) of DNA from wild-type 
Tokyo BCG (Appendix AS.4) utilising the 284U231S30L22 primers. The 165 rRNA PCR 
product was purified by gel electrophoresis (Appendices A7 and AS.6). Six 10-fold serial 
dilutions were made from the purified 16S rRNA PCR product, with concentrations ranging 
from O.4pg/~ (approx. 4.1 x1 010 copies/~) to 0.4x1 0-6 pg/~. 
To quantify the number of copies of a specific gene in an unknown cDNA sample, the 
unknown sample and the known standards (for that gene) were amplified on the LightCycler 
using the p rimers for the gene 0 f interest. T he P CR reaction mixtures and t hermocycler 
parameters were set up as described in Appendix A 14.4. The LightCycier software (Version 
3.S; Roche Molecular Biochemicals) was used to calculate the number of copies of the gene 
of interest in the unknown sample, relative to the number of copies of that in the standard 
samples. The program uses the standard samples to construct a standard curve, which is 
the linear regression line through the data points of the crossing points (cycle number) 
versus the log10 concentration of the standard samples. T he crossing point is the cycle 
number at which the log-linear region of the amplification fluorescence curve intercepts the 
cycle number axis. The crossing points of the unknowns are plotted against the standard 
curve and the concentrations are calculated. 
16S rRNA was used as the housekeeping gene (endogenous reference gene), according to 
which the cDNA (reverse transcribed from 16S rRNA) concentrations of the unknown 
samples were normalised. Once the amounts cDNA were normalised, the amounts of L 1 
cDNA could be directly compared. The kanamycin gene was used as a second 
housekeeping gene, to verify the accuracy of the 165 rRNA (cDNA) quantification. 
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3.4. RESULTS 
3.4.1. VECTOR CONSTRUCTION 
The L1R, L1NLS·, L1 e, and L1BCGe genes were successfully cloned into the mycobacterial 
shuttle vectors, to produce the constructs listed in Table 3.2, and shown In Figure 3.2. 
Subsequent to every PCR amplification of L 1 for cloning purposes, the amplification product 
was sequenced to verify PCR fidelity. All clones were also sequenced though the ligation 
sites, to ensure that the appropriate ligation reaction transpired. On the occasions that 
cloning or P CR errors were detected, t he clones were remade or PCR amplification was 
repeated. 
At two occasions, PCR errors in L 1 were detected and were not corrected, as these 
sequence errors did not alter the L 1 amino acid sequence. These errors were detected in 
plasmids pG-L 1S (section 3.3.3.3) and pG-L 1Nls- (section 3.3.3.2). Two point mutations 
were detected in pG-L 1 S, resulting in a codon change from CAT to CAC (L 1 's 47th codon), 
and a codon change from GAT to GAC (L 1's 439th codon). A single p oint mutation was 
detected In pG-L 1 NLS-, causing a codon change from TIT to ITA (L 1 's 420th codon). 
3.4.2. INTRODUCTION OF SHUTTLE VECTORS INTO BCG 
The mycobacterial shuttle vector-L 1 constructs (Table 3.2) were introduced Into BCG by 
electroporation. Recombinants containing extrachromosomal plasmlds were verified by 
endonuclease digestion and agarose gel electrophoresis; and recombinants containing 
Integration-proficient vectors were verified by Southern blot analysis. 
Analysis of the DNA migration patterns, of plasm ids obtained from BCG-L 1 recombinants, 
indicated that the majority of BCG electroporations resulted In mixed populations of 
recombinants, some containing the correct plasmid, and others containing genetically 
unstable plasm ids, from which regions of L 1 had been excised. In some cases, even though 
the electroporatlons were repeated several times, no stable recombinants were detected. 
The Integration-proficient vectors appeared stable by Southern blot analysis (Figure 3.3 
shows an example of a Southern blot). Table 3.3 summarises the BCG recombinants that 
were successfully made, and the recombinants that were always unstable. From the table, it 
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is clear that the unstable BCG recombinants were those that contained the 
extrachromosomal vectors which drove the expression of L 1 with the hsp60 promoter. The 
integration-proficient plasmids which used the hsp60 promoter appeared stable. The stability 
of these BCG recombinants will be discussed further in Chapter 4. The BCG recombinants 
that contained stable plasm ids were selected and used to produce stocks for animal 
immunisations (Chapter 5). 
Table 3.2. Mycobacterial shuttle vector - HPV~16 L 1 clones constructed during this study. 
Shuttle vector In8ert Clone name 
pNIV192 L1R ·pNVL 1R 
pSMT3 L1R pT3L1R 
L 1NlS"' pT3L1 NLS-
pMV261 L1R p261L1R 
L 1NLS- p261L1 NLS-
pAB26 L1R pAB26L 1R 
L 1NLS~ pAB26L 1 NLS-
p2619 L1R p2619L1R 
L1NL~ p2619L 1NLS-
pMV361 L1R p361L1R 
L 1NLS~ p361L 1NLS~ 
L1. p361L 1. 
pCB119 L1R p119L1R 
L 1NLS· p119L 1NLS-
L1. p119L 1. 
L1BCGe p119L 1scGe 
pCB112 L1R p112L1R 
L 1NLS- p112L 1NLS-
L1. p112L 1. 
L 1scGe p112L 1scGe 
* Clone made by Wendy Burgers (MSc. Dept of Medical Microbiology, University of Cape Town. 1996), 
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Integration-proficient constructs 




p381L1 ... r 
Figure 3.2. Diagrams of the mycobacterial shuttle vector - HPV-16 L 1 clones constructed during 
this study. P hsp6O, BeG hsp60 promo1Br; P MtrA, M. tuberculosis mtrA promoter; P M.lep 
18kDa, M. leptae 18kDa promo1Br; Kan R, kanamycin resistance gene; Hyg R, Hygromycin 
resistance gene; Tet R, tetracycline resistance gene; OriE, E. coli origin of replication; OriM, 
mycobac1erial origin of replication; EpiA; epitope tag; int, mycobac1eriophage L5 integrase gene; 
att, rnycobacteriophage L5 attachment site; FRAT 1, rnycobac1eriophage FRAT 1 in1Bgrase gene 
and attachment site; alpha antigen, BeG alpha antigen signal sequence; 19kDA, M. tuberculosis 
19kDa lpoprotein signal sequence. 
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Figura 3.2 (continued). Diagrams of the mycobacterial shuttle vector - HPV-16 L 1 clones 
constructed during this study. P hsp60, BCG hsp60 promoter; P MtrA, M. tubefCulosis mtrA 
promoter; P M.lep 18kDa, M. leprae 18kDa promoter; Kan R, kanamycin resistance gene; Hyg R, 
Hygromycin resistance gene; Tet R, tetJacyciine resistance gene; OriE, E. con origin of 
replication; OriM, mycobacterial origin of replication; EpiA; epitope tag; int, mycobacteriophage L5 
integrase gene; att, mycobacteriophage L5 attachment site; FRAT 1, mycobacteriophage FRAT 1 
integrase gene and attachment site; alpha antigen, BeG alpha antigen signal sequence; 19kDA, 
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Figura 3.2 (continued). Diagrams of the mycobacterial shuttle vector - HPV-16 L 1 clones 
constructed dUring this study. P hsp60, BCG hsp60 promoter; P MtrA, M. tuberculosis mtrA 
promoter; P M.lep 18kDa, M./eprae 18/cDa promoter; Kan R, kanamycin resistance gene; Hyg R, 
Hygromycin resistance gene; Tet R, tetracycline resistance gene; OriE, E. coli origin of 
replication; OriM, mycobacterial origin of replication; EpiA; epitope tag; int, mycobacteriophage L5 
integrase gene; att, mycobacteriophage L5 attachment site; FRAT 1, mycobacteriophage FRAT 1 
integrase gene and attachment site; alpha antigen, BCG alpha antigen signal sequence; 19kDA, 
M. tuberculosis 19kDa lipoprotein signal sequence. 
68 
Chapter 3: Development of BCG Recombinants Expressing HPV-16 L 1 
2 3 4 5 6 
bp ... • ~ 11494-+ 
50n -+ -2838 -+ 
Figure 3.3. Southem blot~hybridisation analysis of chromosomal DNA obtained from Tokyo 
rBCG-361 L 1NLS-' Three rBCG-361 L 1NLs- recombinants were assessed; lanes 1 and 2, contain 
DNA from the one recombinant, lanes 3 and 4 contain DNA from the other, and lanes 5 and 6 
from a third. The DNA in lanes 1, 3, and 5, was digested with Hind III, which cuts the integrated 
vector once, outside of the L 1 gene (it is difficult to predict the size of this band as one does not 
know where in the chromosome Hind III will cut, but it should be larger than the vector, ie. larger 
than 5919bp). The DNA in lanes 2, 4, and 6, was digested with Pvu II and Not I, excising a 
fragment of 3638bp, including the L 1 gene. The above image is the autoradiograph of the 
Southem blot after it was probed with labelled-HPV-16 L 1. 
3.4.3. ANALYSIS OF PROTEIN EXPRESSION BY rBCG 
The expression HPV-16 L 1 protein by the BCG-L 1 recombinants was investigated by SDS-
PAGE, followed by Coomassie blue staining or western blot analysis. Coomassie blue 
staining failed to detect L 1 protein production by the BCG-L 1 recombinants (Figure 3.4). 
Western blot analysis detected L 1 protein in rBCG-L 1 Iysates by the visualisation of faint 
bands of the expected size (55kDa, Figure 3.5). Due to the low expression of L 1 by BCG, 
this result could not be repeated. To determine the western blot assay sensitivity for HPV-16 
L 1; HPV-16 VLPs were serially diluted and detected by western blot analysis using the 
H16.J4 monoclonal antibody. The lowest detectable amount of VLP with this method was 
0.03J..Lg. As 10J..Lg of rBCG-L 1 lysate was routinely used in these assays, it was established 
that when L 1 was not detectable in rBCG-L 1 Iysates, the amount of L 1 protein was less than 
0.3% of the total protein in the samples. 
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Table 3.3. BCG-HPV-16 L 1 recombinants successfully made, including those that were 
unstable. 
Successful 
Recombinant Promoter Signal Sequence Nature of vector recombinant 
or unstable 
Tokyo pNVL 1R hsp60 None Integrated Successful 
Tokyo pT3L1R hsp60 None Extrachromosomal Unstable 
Tokyo pT3L 1 NlS- hsp60 None Extrachromosomal Unstable 
Tokyo p261 L 1R hsp60 None Extrachromosomal Unstable 
Tokyo p261 L 1 NlS· hsp60 None Extrachromosomal Unstable 
Tokyo pAB26L 1 R hsp60 a antigen Extrachromosomal Unstable 
Tokyo pAB26L 1NLS- hsp60 a antigen Extrachromosomal Unstable 
Tokyo p2619L1R hsp60 19kDa lipoprotein Extrachromosomal Unstable 
Tokyo p2619L 1 NlS· hsp60 19kDa lipoprotein Extrachromosomal Unstable 
Tokyo p361 L 1R hsp60 None Integrated Successful 
Tokyo p361 L 1 NLS- hsp60 None Integrated Successful 
Tokyo p361L 1. hsp60 None Integrated Successful 
Tokyo p119L 1R mtrA 19kDa lipoprotein Extrachromosomal Successful 
Tokyo p119L 1NlS- mtrA 19kDa lipoprotein Extrachromosomal Successful 
Tokyo p119L 1. mtrA 19kDa lipoprotein Extrachromosomal Successful 
Tokyo p119L1 ecGB mtrA 19kDa lipoprotein Extrachromosomal Successful 
Tokyo p112L 1R p18kDa a antigen Extrachromosomal Successful 
Tokyo p112L 1NLS- p18kDa a antigen Extrachromosomal Successful 
Tokyo p112L 1. p18kDa a antigen Extrachromosomal Successful 
Tokyo p112L 1ecGB p18kDa a antigen Extrachromosomal Successful 
Pasteur p361 L 1. hsp60 None Extrachromosomal Successful 
Pasteur p119L 1. mtrA 19kDa lipoprotein Extrachromosomal Successful 
Pasteur p119L 180GB mtrA 19kDa lipoprotein Extrachromosomal Successful 
Pasteur p112L 1. p18kDa a antigen Extrachromosomal SuccessfU 
Pasteur p112L 1BCGe p18kDa a antigen Extrachromosomal Successful 
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Analysis of the western blot (Figure 3.5), on which L 1 was successfully detected, shows L 1 
bands in the rBCG-361 L 1 NLS- and rBCG-119L 1 NLS- lysate lanes. L 1 was not detected in the 
rBCG-112L 1 NLS- lane, or in the negative control (wild-type BCG) lane. The position of the L 1 
bands in the BCG lysate lanes were at the same level as the most prominent band (L 1 
monomer, 55kDa) occuning in the HPV-16 VLP lane (not Shown). 
3.4.4. L 1 mRNA QUANTIFICATION 
Due to the low production of HPV -16 L 1 protein by the BCG-L 1 recombinants, the L 1 mRNA 
production by these recombinants was investigated. Total RNA was extracted from BCG, 
and reverse transcribed into cDNA using random primers. The number of copies of specific 
RNAs were measured by perfonning quantitative PCR on the cDNA. 
16S cDNA, L 1 cDNA and kanamycin cDNA quantification was perfonned on the standard 
and unknown samples (see Figures 3.6 and 3.7 for examples of 16S cDNA and L 1 cDNA 
quantification, respectively). The LightCycler program compared the PCR efficiencies of the 
unknown samples to the standard samples (of which the gene copy numbers were known), 
and detennined the concentrations (in cDNA copy number) of the 16S eDNA, L 1 cDNA and 
kanamycin cDNA in each unknown sample. To nonnalise the amount of RNA in the 
samples, each unknown sample was divided by a factor to nonnalise the number of 168 
cDNA copies at 1x104. The L 1 and kanamycin cDNA copy numbers of the unknown 
samples were then divided by the same factors, to obtain comparable data. 
To verify the accuracy of the 16S cDNA quantification, the kanamycin mRNA in the Tokyo 
rBCG-112L 1. and Tokyo rBCG-119L 1. samples were quantified and nonnallsed to 104 
copies of 16S eDNA. The p112L1. and p119L1. plasm ids utilise an identical kanamycin 
gene, which is expressed by the same promoter in both vectors; number of kanamycin 
mRNA copies relative to the 16S cDNA copies produced by these two samples should be the 
same. The relative number kanamycin mRNA copies were detennined at 35.1 for rBCG-
112L 1., and 32.7 for rBCG-119L 1. (Table 3.4; margin of error of 2.4 per 104 copies of 16S 
cDNA). 
72 
Chapter 3: Development of BCG Recombinants Expressing HPV-16 L 1 
Table 3.4. Quantification of HPV-16 l1 mRNA (cDNA) in BCG-L 1 recombinants. The 
amount of cDNA in each sample was normalised to the number of 16s rRNA-cDNA copies 
per sample, which enabled the copies of L 1 cDNA to be directly compared. RNA was 
extracted from either freshly-made rBCG cultures or frozen samples. 
L 1 cDNA copies per 104 188 cDNA Kanamycin cDNA copies per 104 168 
Sample 
copies cDNAcopies 
Freshly-made FrozenBCO FrozenBCO seo 
Tokyo rBCG-361 L 1. 15.0± 0.5 2.45 ± 0.08 Not tested 
Pasteur rBCG-361 L 1. 12.0 ± 0.12 1.20 ±0.052 Not tested 
Tokyo rBCG-112l1. 30.7 ±0.02 12.2 ±0.037 35.1 ±0.2B 
Tokyo rBCG-119L 1. 63.0 ±0.18 55.8 ± 2.39 32.7 ± 0.17 
*Pasteur rBCG-119L 1. Not tested 51.5 ± 1.5 Not tested 
'* Only 88% of the frozen rBCG-119L 1. (Pasteur) stock contains the L 1 gene, as a result of genetic 
instability. 
When comparing the number of L 1 eDNA copies between the freshly-made rBCG-L 1 eDNA 
samples (Table 3.4), it was evident that the integrating construct, p361 L 1., produced the 
least L 1 cDNA (and therefore the least L 1 mRNA), while the extrachromosomal vectors, 
p112L1. and p119l1., produced approximately 2- and 5-fold more L1 cDNA than p361L1., 
respectively. The number of L 1 copies in the samples from the frozen BCG-L 1 recombinants 
was reduced when compared with freshly-made BCG-L 1 recombinants. This reduction was 
greater for p361 L 1. (6- to 10-fold lower), than it was for p112L 1. and p119L 1., 2.5- and 1.2-
fold lower, respectively. 
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Figure 3.6. Quantification of 16S rRNA-cDNA in a Tokyo rBCG-361L1.cDNA sample. The 16S 
rRNA-cDNA was amplified from the rBCG-361 L 1. cDNA sample within the range of the standard 
samples. The amplification was performed in duplicate. The negative control sample (water) did 
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Figure 3.7. Quantification of L 1 cDNA (mRNA) in a Tokyo rBCG-119L1. cDNA sample. The L 1 
eDNA was amplified within the range of the standard samples. The amplification was performed 
in duplicate. The negative control sample (wild-type BCG eDNA) did not amplify, indicating that 
PCR amplification was specific for L 1. 
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3.5. DISCUSSION 
Three L 1 gene variants were cloned into a panel of E. coli - mycobacterial shuttle vectors, 
producing 20 HPV -16 L 1 expression vectors for assessment in BCG. Of these 20 clones, 12 
were stably introduced into BCG. Genetic instability, which was frequently detected in rBCG-
L 1, will be investigated further in Chapter 4. As the study evolved, more E. coli -
mycobacterial shuttle vectors became available, and additional HPV-16 L1 gene variants 
were investigated, leading to the production of a large number of BCG recombinants. 
Initially, the intention was to compare the L 1 in vitro expression between the various BCG-L 1 
recombinants; however, the low L 1 expression I evels prevented t his. Finally, in order to 
compare L 1 transcription levels, and also to rule out the vector defects, the BCG-L 1 
recombinants were assessed for their production HPV-16 L 1 mRNA. 
3.5.1. SELECTION OF HPV-16 L1 GENES 
Three HPV-16 L1 variants namely, L1 R, L1NLS-, and L1sCG were investigated. The amino 
acid sequence of L1R (and L1 NLS-) differs from the known high VLP-yielding L1 sequences, 
Phil and Sen32 (Touze et 81. ,1998), by 8 and 4 residues, respectively; however, there is no 
evidence to substantiate whether it is a high or low VLP-yielding sequence, as the L 1R is 
dissimilar to all sequences investigated by Touze et 81. (1998). L1 NLS- is expected to 
successfully assemble into stable VLPs (Chen et 81., 2001; Paintsil et 81., 1996), as only 22 
residues were deleted from the C-terminal. Zhou et 81. (1991c) showed that when cells were 
infected with vaccinia virus expressing HPV L 1, the L 1 protein accumulated almost 
exclusively in the nucleus of the infected cells, however, when the NLS was deleted, L 1 was 
distributed evenly throughout the cell. The NLS was removed to determine whether the 
cellular localisation of L 1 in rBCG-L 1 infected cells would have an effect on L 1 antigen 
presentation, and hence on the immune responses elicited by rBCG-L 1. To maximise the L 1 
yield in BCG, the L 1 gene was codon optimised to reflect commonly used BCG codons. The 
amino acid sequence utilised for this gene was based on the L 1 Phil sequence (Touze et 81., 
1998). Although the L 1 Phil sequence produces high VLP yields in the baculovirus 
expression system, it is unknown whether the same will hold true in a bacterial expression 
system. 
Although assembly of L 1 Into capsomeres and VLPs has been observed in Salmonell8 
(Nardelli-Haefliger et 81., 1997), E. coli does not support in vivo VLP formation (Chen et 81., 
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2001; Li et a/., 1997; Zhang et a/., 1998); and it is therefore unknown whether expression in 
Mycobacteria would facilitate VLP assembly. The only other group (Jabbar et a/., 2000) to 
study the expression of HPV proteins in BCG, established the expression of HPV-6b L 1 by 
western blot analysis but, did not investigate whether HPV-6b L 1 assembled into VLPs. The 
assembly of L 1 into capsomeres and VLPs is essential for the induction of conformatlonally-
dependent neutralising antibody responses (Rose et a/., 1998; Fligge et a/., 2001; Kimbauer 
et a/., 1992). One of the expression vectors (pCB112) utilised in this study directs 
heterologous protein out of the bacterium, and another to the bacterial cell wall (pCB119); if 
L 1 export is successful we believe that VLP formation in the mycobacterium would be 
prevented. If L 1 is successfully exported to the BCG cell wall, these monomers Will be 
unable to assemble into VLPs. If L 1 is secreted from the bacterium and can accumulate to 
sufficient quantities in the host cell nucleus, as directed by the nuclear localisation signal, 
VLP assembly may occur there, but the accumulation of sufficient L 1 in the host cell is 
unlikely. If VLP assembly occurs within the bacterium before export is able to take place, its 
export would be prevented. 
3.5.2. rBCG-L 1 INSTABILITY 
The above L 1 gene variants were cloned into a panel of E. co/i-mycobacterial shuttle vectors. 
These L 1 expression constructs were introduced in to BCG (Pasteur and Tokyo) with varying 
rates of success, as genetiC instability prevented the stable maintenance of some 
recombinants. It was clear that the unstable BCG recombinants were those containing 
extrachromosomal vectors which utilised the hsp60 promoter to drive L 1 expression. This 
instability, which was presumably a consequence of the overproduction of L 1, was most 
likely due to the accumulative effects of the high in vitro activity of hsp60 (Stover et a/., 
1991), and the multi-copy nature of the plasmids. The integration-proficient plasmids, which 
also utilised hsp60 to drive L 1 expression, were more stably maintained; suggesting that 
chromosomes are less prone to gene deletions, or that the presence of only one copy of the 
integrating vector per bacterium, compared to five copies of the extrachromosomal vectors, 
SUfficiently decreased L 1 expression and hence increased stability. The observation that the 
hsp60 promoter causes genetic instability of the vectors from which it expresses is not 
unique to this study, as this has been observed by other groups (AI Zarouni and Dale, 2002; 
Medeiros et a/., 2002; Stover et a/., 1991). In fact, Stover et a/. (1991) observed that 
expression of the HIV-1 gp120 gene, under the control of the hsp60 promoter, was lethal to 
BCG when expressed on an extrachromosomal vector, but not when expressed on an 
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integrative vector. The other extrachromosomal constructs (p112-L 1'* and p119-L 1 '*), 
although also present in multi-copies, were more stable than the hsp6O-driven vectors, as 
stable recombinants were obtained with all these constructs (although more often than not, 
electroporation produced a mixture of stable and unstable recombinants). The higher in 
vitro stability of the p112-L1 '* and p119-L1 '* constructs was presumably due to the weak in 
vitro activity of the M. leprae 18kDa and mtfA promoters (Dellagostin et al., 1995; Zahrt and 
Deretic, 2000). The stability of the BCG recombinants will be discussed in more detail in 
Chapter 4. 
3.5.3. EXPRESSION OF HPV-16 L 1 BY rBCG-L 1 
The expression of HPV-16 L 1 protein by rBCG-L 1 was not apparent by Coomassie staining, 
and was only detectable by westem blot analysis on one occasion, indicating that expression 
levels were very low. Attempts to up-regulate protein expression by heat-shock, and the 
investigation of the insoluble protein fractions, also failed to ascertain L 1 expression. It was 
established that L 1 was produced at concentrations below the detection threshold (0.03 IJg) 
of the analysis, which was detennined using purified HPV-16 VLPs. This equated to an L 1 
contribution of less than 0.3% of total rBCG protein. 
A comparison of the BCG and HPV-16 L 1 codon usage revealed that many L 1 codons were 
used extremely infrequently by BCG. In bacteria, transcription-translation coupling is 
believed to prevent the accumulation of non-functional transcripts, which have the capacity to 
fonn R-loop complexes with DNA, thus impeding transcription elongation (Gowrishanka and 
Harinarayanan, 2004). Bacterial mRNA production and stability are therefore influenced by 
the efficiency of the transcription-translation coupling, which in tum is influenced by the rate 
of translation. The importance of efficient translation prompted us to have the HPV-16 L1 
ORF re-synthesised to reflect commonly used BCG codons. Unfortunately, codon 
optimisation did not appear to increase the in vitro expression of L 1, as L 1 production was 
stili at concentrations below the western blot detection threShold. This low product/on of L 1 
made it impossible to compare expression levels and localisation between the BCG 
expression vectors. 
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3.5.4. L 1 mRNA QUANTIFICATION 
Other than a slow rate of translation, the poor L 1 expression by BCG may be attributed to a 
low rate of transcription, or a high rate of degradation by proteases; of which the latter is the 
most plausible. To test the former premise, the amount of L 1 mRNA produced by rBCG-L 1 
was quantified. Although the quantification method utilised can supply absolute values, it 
does not detect or compensate for PCR inhibitors present in the sample material; and may 
therefore be inaccurate, unless intemal controls are utilised. Quantification relative to a 
housekeeping gene (which is assumed to be constant) should, however, be accurate without 
compensating for differences in PCR efficiencies between samples. Even if the absolute 
values obtained from this study are deemed slightly inaccurate, there is still a large amount 
of L 1 cDNA (and therefore L 1 mRNA) present (1.2 X101 - 6.3 X101 copies of L 1 eDNA per 104 
copies of 165 cDNA [165 rRNA], which is a very abundant RNA). It is important to bear in 
mind that the promoters utilised here are strongly up-regulated in vivo, or under stress-
response conditions; and since these conditions were not employed during this study, 
relatively low amounts of mRNA were expected. The relative comparison of the L 1 mRNA 
copies between the freshly-made rBCG-L 1 samples provided interesting results. The 
integrating construct, p361 L 1 e, produced the least L1 mRNA, presumably due to the 
presence of only one L 1 gene per BCG chromosome. Although identical L 1 mRNA levels 
were anticipated from the BCG Tokyo p361L1 e and Pasteur p361L1 e samples, a difference 
of approx. 3 copies (per 104 165 cDNA copies) was obtained; which may be due to slight 
differences in culture growth or RNA extraction conditions, or due to expression differences 
that exist between BCG substrains (Burlein et al., 1994). However, the accuracy of this 
assay was determined at 2.4 per 104 copies of 165 cDNA, which may prevent the accurate 
comparisons of samples which have differences similar to this margin of error. The 
extrachromosomal vectors, p112L 1e and p119L1 e, produced higher levels of L 1 mRNA than 
p361 L 1e; which is likely due to the multiple copy nature of the former plasmids. p119L 1e 
produced more L 1 mRNA than p112L 1e, which suggests that the mtrA promoter (in p119L 1e) 
is more active than the M. leprae 18kDa promoter (in p112L1e) in vitro. The relative L 1 
mRNA copies were also investigated in frozen rBCG-L 1 stocks, as these stocks were utilised 
for animal inoculations, and their genetic stabilities were well characterised. The process of 
freezing the rBCG-L 1 samples reduced the expression of L 1 relative to 165 rRNA. This 
reduction could have been a consequence of RNA degradation during the freezing process; 
however, the L 1 RNA reduction was greater for p361 L 1 e than it was for the other two 
vectors. It therefore appears that the drop in temperature during the freezing process 
achieved a more rapid suppression of hsp60 promoter activity than it did with mtrA or 18kDa 
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promoter activity. Temperature reduction is known to cause specific suppression of some 
heat-shock proteins (Jones and Inouye, 1994), which concurs with the reduction in hsp60 
promoter activity seen here. mRNA was not analysed from the two recombinants (rBCG-
361L1 NlS- and rBCG-119L1NlS-) from which L1 protein was initially detected, as these were 
not considered especially strong L 1 producers due to the inability to repeat the detection of 
L 1 from these strains. 
The evidence of L 1 RNA expression from this study, and the effective use of the same 
vectors and/or promoters to achieve high foreign antigen expression in other studies 
(Himmelrich et a/., 2000b; Stover et al., 1993), makes it unlikely that the low expression of 
the L 1 protein is a consequence of low L 1 transcription. The low expression is also not likely 
due to inefficient translation. as codon optimisation did not increase L 1 production to 
detectable levels, and the instability Is an indication of high expression levels. Degradation 
by proteases therefore seems to be the most probable cause of the apparent low expression 
levels. The same conclusion was drawn by Chen et al. (2001), who were unable to express 
the HPV-16 and HPV-11 L 1 proteins in E. coli, even after rare codons were removed. The 
rate of degradation by proteases is a property of the antigen itself; which will be different for 
all proteins, and will be dependent on the system in which it is expressed. It would be 
interesting to compare wild-type and rBCG-L 1 gene regulation by BCG microarray, as this 
may corroborate protease up-regulation in rBCG. As mentioned in section 3.1.4, bacterial 
proteins are expressed to higher levels in BCG; this is evident by the Coomassie gel analysis 
(section 3.4.3) where the lysA gene product produced a very prominent band. Here the 
expression of lysA is driven by the hsp60 promoter, which is also utilised to drive L 1 
expression in this study, with expression levels nowhere near that of the lysA product. 
The in vitro protein expression levels, however, may not accurately Imitate the situation 
occurring in vivo, as the activity of the promoters utilised in this study are known to be 
induced upon infection of macro phages (Batoni et al., 1998; Zahrt and Deretic 2000). It 
would be interesting to investigate whether the expression of L 1 mRNA or L 1 protein levels 
increase after infection of macrophages with the BCG-L 1 recombinants used in this study. 
The next chapter provides a short review of in vitro and in vivo studies, which have reported 
genetic instability in recombinant mycobacteria. After which, the stability of the recombinants 
in the present study are assessed further. 
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4.1. INTRODUCTION 
In the previous chapter, the instability of the BCG-HPV-16 L 1 recombinants was reported. In 
vitro genetic stability of recombinant BCG is a necessity for long-term maintenance and 
large-scale production. In vivo stability is also required for the persistent delivery 
heterologous antigens to the immune system. This chapter provides a short review of the 
studies which have assessed in vitro and in vivo genetic stability of recombinant 
mycobacteria. Thereafter, the in vitro stabilities of the recombinants produced in the present 
study are investigated further. 
4.1.1. STABILITY OF HETEROLOGOUS GENES AND EXPRESSED PROTEINS 
When heterologous genes are expressed in bacteria, the bacteria are subjected to new 
conditions that are possibly suboptimal for normal bacterial growth. Depending on the type 
of protein or amount produced, the Mhealth" of the recombinant could suffer from effects 
ranging from slower growth (due to the metabolic burden of protein manufacture) to cell 
death (from protein toxicity). Selective pressures therefore existf or t he removal of such 
heterologous genes. The instability of foreign genes in mycobacteria has been reported 
frequently; some of these reports are described below. 
The hsp60 promoter appears to beget the majority of the foreign gene instability reports in 
mycobacteria, presumably a consequence of its high activity. Stover et al. (1991) noted that 
the expression of the HIV-1 gp120 gene under the control of the hsp60 promoter, from an 
extrachromosomal vector, was lethal to BCG, and that it was only possible to express this 
gene 0 n an integrative vector. A I-Zarouni and Dale (2002) reported instability in 95% of 
plasm ids, in the form of deletions in the hsp60 promoter region, when expressing the lacZ 
gene. No Instability was detected when utilising the 18kOa, 85A, and 19kOa promoters. 
When expressing l3-gal in M. smagmatis, Medeiros at al. (2002) observed gross 
modifications of the constructs that utilised the hsp60 promoter, but not in those that used 
the 18kOa promoter. They showed that within two subcultures of the cells containing the 
hsp60 construct, in liquid medium, 90% of the cells had lost their ability to express l3-gal. 
Kumar at al. (1998) studied the genetic rearrangements of the lacZ gene under the control of 
the hsp60 promoter i n M. smegmatis. They detected the disruption of t he lacZ gene by 
insertion sequences in integrating vectors, and by deletions in the lacZ gene and the hsp60 
promoter in extrachromosomal vectors, they however found these rearrangements to be rare 
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events. The frequency of the loss of lacl phenotype was 1.7x1 0-5 for integrative vectors and 
2x10-3 for extrachromosomal vectors. 
AI-Zarouni and Dale (2002) observed that deletions occurred during or soon after 
transformation, but not during subsequent growth. They therefore suggest that there is a 
transient lethal induction of the hsp60 promoter during electroporation. Another possible 
explanation for the high rate of rearrangements seen when the hsp60 promoter is utilised, is 
due its natural function of regulating Hsp60 production. Hsp60 is a chaperone protein that is 
up-regulated during conditions such as heat-shock due to the presence of non-native 
proteins, and is involved in assisting and directing the folding of unfolded or incorrectly folded 
proteins (Bukau and Horwich, 1998). In recombinant BCG the presence of unfolded 
heterologous proteins could up-regulate the hsp60 promoter, causing further production of 
the heterologous protein, and thus causing overt stress on the BCG recombinant. 
The attenuation of the growth of recombinant BCG relative to wild-type BCG has been 
described In vivo and in vitro. The ability of rBCG expressing the Borrelia burgdorferi OspA 
protein (extrachromosomal vector, hsp60 promoter, 18kDa lipoprotein signal) to replicate and 
persist In vivo was attenuated in comparison to wild-type BCG (Stover et al., 1993). BCG 
expressing the measles virus nucleoprotein on an extrachromosomal vector (copy number of 
5, hsp60 promoter) had a slower growth rate than wild-type BCG when grown in liquid 
culture, however, expression the same protein on an integrated vector (one copy per cell) did 
not alter the growth rate (Zhu et al., 1997). 
A few researchers have reported varying rBCG stabilities when expressing different portions 
of the same genes, suggesting a possible size determinant, or that some areas of a protein 
are more "toxic· than others. Bastos et al. (2002) found that BCG could not successfully 
express the full-length GP5 protein of porcine reproductive respiratory syndrome virus, due 
to the development of deletions and frame-shift mutations; however, a truncated form of the 
gene (lacking the first 90 5' base pairs) was stably expressed. Similarly, Lim et al. (1997) 
were not able to generate BCG recombinants that expressed aa 1-512 or aa 215-521 of the 
SIV gp11 0 protein, but aa 1-245 of the same protein was expressed well. 
Mederle a nd colleagues (2002) noted that when the H IV Gag a nd N ef proteins were co-
expressed in BCG from synthetic gag-nef operon, Gag was expressed efficiently, while the 
production of Nef was very low, suggesting differences in protein stability. A number of 
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studies have reported the presence of possible heterologous protein degradation on westem 
blots (Fennelly et s/., 1995; Miyajl et s/., 2001 ; Supply et s/., 1999). 
4.1.2. VECTOR STABILITY (IN VIVO AND IN VITRO) 
In addition to the stability of the heterologous gene In the expression construct, the retention 
of the whole expression construct by the BCG recombinant in the absence of antibiotic 
selection warrants assessment. This is partlculariy important in the in vivo situation, as 
persistent expression of heterologous protein is desired to allow for continual Immune 
stimulation. Studies of in vitro and In vivo stability, and comparisons between 
extrachromosomal and integrating vector stability are reviewed below. 
Haeseleer et s/. (1993) reported that BCG and M. smegmstis recombinants expressing the 
circumsporozoite protein of Plasmodium fsccipsrom (CSP) from an integrating vector (hsp60 
promoter) maintained stable expression for at least 10 weeks in the absence of selective 
pressure. Almost 100% of the colonies retained kanamycin resistance after 400 generations 
of growth without antibiotic selection in the case of M. smegmstis, and 50 generations In the 
case of BCG. lee et s/. (1991) found that after culturing M. smegmstls for 30 generation 
without antibiotic selection, there was no loss of the integrative vector, but 65% of the 
colonies containing an extrachromosomal vector were no longer kanamycin resistant. 
28 and 100 days after immunising mice with rBCG containing an extrachromosomal vector 
expressing HIV Gag and Nef. Medene et s/. (2002) 40 and 75% of colonies isolated from 
mouse spleens, respectively, had lost their resistance to kanamycin. However, when 
integrated vectors were utilised less than 15% of the colonies had lost their resistance to 
kanamycin after 100 days. 2 and 16 weeks after immunlsing guinea pigs with a BCG·/scZ 
recombinant (extrachromosomal, PAN promoter). 54 and 60% of BCG harvested from spleen 
and lymph nodes, respectively, had lost the IscZ phenotype (lagranderie et s/., 1993). Four 
weeks after immunislng macaques with rBCG expressing SIV Nef. Gag or Env 
(extrachromosomal vectors). M edene et s/. (2003) tested the genetic stability 0 f the B CG 
isolated from draining lesions. They found that. of the total number of BCG colonies isolated, 
only 56% were stili kanamycin resistant, and of these colonies 58% contained the gsg gene, 
17% contained the nef gene. and 9% contained the env gene, indicating differing gene 
stabilities or different levels of rBCG growth attenuation. In human trial patients rBCG·OspA 
(extrachromosomal vector, hsp60 promoter) was cultured from the vaccination sites 1~24 
83 
Chapter 4: Genetic Stability of BCG Recombinants 
days after vaccination; of the BCG colonies isolated, only 67-80% were still resistant to 
kanamycin (Edelman at a/., 1999). 
Some studies, on the other hand, have reported high stabilities of extrachromosomal vectors. 
Stover at a/. (1991) noted that 2-4 weeks after immunisation of mice with BCG expressing 13-
gal from an extrachromosomal vector, all BCG colonies removed from the spleens 
expressed 13-gal and were resistant to kanamycin. 55 days after inoculating mice with BCG 
expressing HPV-6 L 1 (extrachromosomal vector, hsp70 promoter), all 3 randomly picked 
colonies (harvested from spleens) were positive for expression of the L 1 protein (Jabbar at 
a/., 2000). 10 weeks after inoculation of mice with rBCG-gp63 (extrachromosomal vector, 
hsp60 promoter), the BCG harvested from the spleens produced equal numbers of colonies 
on plates with or without kanamycin, confirming plasmid maintenance (Connell at a/., 1993). 
4.2. STUDY OBJECTIVES 
The aim of this chapter was to assess the in vitro genetic stability of the BCG-HPV-16 L 1 
recombinants generated in this study, and to characterise the plasmid rearrangements. 
Culturing rBCG-L 1 with antibiotic selection will provide us with an idea of the recombinanfs 
potential for long-term maintenance; while culturing rBCG-L 1 without the presence of 
antibiotics will provide insights into the length of in vivo foreign antigen expression. 
4.3. METHODS 
4.3.1. IN VITRO PLASMID STABILITY WITH ANTIBIOTIC SELECTION 
To determine the frequency of plasmid rearrangements in originally stable BCG 
recombinants, the recombinants were grown in liquid culture, and tested for the presence of 
the L 1 gene at various stages. 
Directly after electroporation, BCG colonies were selected and grown in 10ml of medium to 
an OD600 of between 0.5 and 0.8 (approximately 10 generations after picking the colony), as 
described in Appendix A3.2. Each culture was then halved; the one half was frozen, while 
the other half was used to verify whether a successful transformation event had transpired 
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(Chapter 3, section 3.3.7). Stable recombinants were thawed and grown in 100ml of 
Sauton's medium, containing kanamycin, until an ODeoo of between 0.5 and 0.7 had been 
attained (Appendix A 1.2). The recombinant had now been though approximately 16 
generations since the colony had been picked. The cells were prepared for animal 
immunisations and then frozen (Appendix A15). Before the immunogenlclty of the BCG-L 1 
recombinants were investigated, the stocks were tested for plasmid stability. An aliquot of 
frozen rBCG-L 1 (inoculation stock) was allowed to thaw, and the cells were harvested by 
centrifugation. Plasmid DNA was extracted from the cells and was then transfonned into E. 
coli, as described in AppendixA5.3. T his method was effective at separating a possible 
mixed population of stable and rearranged plasm ids that may have developed in the rBCG-
L 1 culture. 20 E. coli colonies were selected and grown in 5ml of liquid medium. Plasmid 
DNA was extracted from these cultures and then digested with restriction endonucleases to 
detect the presence of the L 1 gene and its promoter. PCR was used to verify the presence 
of the L 1 gene in the BCG-L 1 recombinants containing integrated vectors. After the frozen 
BCG stocks were allowed to thaw, they were serially diluted in Sauton's medium, and plated 
to obtain single colonies (Appendix A 1.2). PCR reaction mixtures were set up as described 
in Appendix A9, using the CBF and CBR primers to amplify the L 1 gene. Colonies were 
picked and added directly to the PCR reaction mixtures. A typical thennocycler reaction 
profile was utilised (Appendix A9), except for a n extended initial denaturing step (10min), 
which was used to promote lysis of the bacteria. 
The effect of further culturing was Investigated. Frozen recombinant BCG stocks (inoculation 
stocks) were grown in 100ml of Sauton's medium, and the presence of L 1 was again 
investigated, as described above. The recombinants had now been though approximately 
24 generations In liquid culture since the colony picked after electroporation; and 
approximately 44 generations In total, as it was estimated that a BCG colony fonns in 20 
generations of growth. 
4.3.2. SEQUENCING OF rBCG-L 1 STOCKS 
Although restriction endonuclease analysis of the BCG recombinants can detect large gene 
alterations, small changes may possibly go undetected. The recombinants were therefore 
sequenced to detennine whether point mutations or small deletions had occurred. 
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Stable BCG-L 1 recombinants were either sequenced directly after electroporation (Table 3.3, 
Chapter 3) or after they had been prepared as inoculation stocks. Plasmid DNA was isolated 
from the BCG recombinants and introduced into E. coli (Appendix A5.3). The plasmid DNA 
was then purified from the E. coli recombinants using the High Pure Plasmid Isolation Kit 
(Roche Diagnostics, Germany; Appendix A5.5). These DNA samples were then sequenced, 
as described in Chapter 3, section 3.3.6, to obtain sequence of the promoter and L 1 gene 
region. 
In order to sequence L 1 from BCG containing integrated vectors, the chromosomal BCG 
DNA was extracted (Appendix A5.4), and the hsp60/L 1 region was amplified by PCR with the 
361F and 26R primers (as described in section 3.3.6). The hsp601L 1 PCR amplification 
product was then cloned into the pGEM-T vector, using the pGEM-T Easy kit (Appendix 
A8.3). The cloned hsp60/L 1 regions were then sequenced using the M13 primers, and the 
CBCR, CBDR and CBDF primers (section 3.3.6). 
4.3.3. SEQUENCING OF PLASMID REARRANGEMENTS 
As noted in Chapter 3, transformation of certain constructs resulted in stable recombinants, 
however, transformation of other constructs resulted in mixed populations of stable and 
unstable recombinants, or in transformants that all contained plasmid rearrangements. A 
number of unstable recombinants (detected directly after transformation) were sequenced to 
further characterise the excisions . 
. Plasmid DNA was prepared as described above (section 4.3.2). The BCG Tokyo 
recombinants containing unstable pAB26L 1R, p261L 1R. and p261L 1NLS- were sequenced 
with primers 26F and 26R. Pasteur rBCG-112L1e was sequenced with the CBAF primer. 
Two unstable Pasteur rBCG-119L 1 BCGe recombinants were sequenced with primers CBAF, 
CBBF and CBCF. Unstable Tokyo rBCG-119L 1e was sequenced with primers CBAF, CBBF 
and BCGL 1CF. The primers are described in section 3.3.6. The sequencing was performed 
at the Core Facility (University of Stellenbosch). 
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4.3.4. IN VITRO rBCG·L 1 STABILITY WITHOUT ANTIBIOTIC SELECTION 
It is widely accepted that recombinant bacteria eventually loose their plasmid ONA when the 
selective pressure to keep it is removed; and that recombinant bacteria containing integrated 
heterologous ONA are often more stable than those containing extrachromosomal plasm ids 
(Haeseleer st al., 1993; Matsumoto at al., 1996). To provide an indication of the stability and 
length of expression of the BCG-L 1 recombinants in animals (Le. in the absence if antibiotic 
selection), the BCG-L 1 recombinants were cultured In liquid medium without the addition of 
antibiotics. 
50ml of Sauton's broth containing kanamycin (16.7jlg/ml) was inoculated with rBCG-L 1 and 
grown on a roller at 3'PC until an 00800 of between 0.5 and 0.8 was attained. The 
kanamycin was removed from the cells by centrifugation (3000rpm for 1 Om in) and re-
suspension in 50ml of Sauton's medium. The washing step was repeated twice. After the 
washes, the cell pellet was resuspended in 50ml Sauton's medium and the 00800 was 
measured. 0.5ml of this culture was used to inoculate 50ml of Sauton's medium, without 
kanamycin. The culture was grown on a r oller at 3'PC until an 0 0 600 of 0.5 to 0.8 was 
reached. Again, 0.5ml 0 f this culture was u sed to inoculate 50ml of medium, which was 
grown as above. This was repeated 4 times until approximately 26 generations were grown 
without antibiotic selection. A generation was measured as a doubling of the 00800• After 26 
generations of growth without antibiotics the culture was serially diluted and spread on 7H10 
agar plates, either with or without antibiotics. The number of colonies on the antibiotic-
containing and non-anti biotic-containing plates was compared; and the percentage of 
bacteria retaining antibiotic resistance was calculated. 
4.4. RESULTS 
4.4.1. IN VITRO PLASMID STABILITY WITH ANTIBIOTIC SELECTION 
The stability of the BCG-L 1 recombinants, that appeared to be stable directly after 
electroporation, was tested after further culturing in liquid medium containing antibiotics, by 
assessing for the presence of the L 1 gene and promoter. The table below (Table 4.1) 
summarises the percentage of stable recombinants after 16 and 24 generations of growth in 
liquid medium with antibiotics. While some recombinant BCG-L 1 cultures stably maintained 
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the L 1 gene, other cultures lost the L 1 gene at varying rates. BCG containing the 
integration-proficient construct, p361 L 1.. and the extrachromosomal p112L 1 R/L1 elL 1 NLS-
1L1 BCG. (L 1*) constructs (except for Pasteur rBCG-112-L 1.) were 100% stable. Overall, 
recombinants containing the p119L 1* constructs were less stable than the p361 L 1. and 
p112L 1* recombinants. The Pasteur recombinants (excluding the integrated recombinants) 
appeared to be less stable than their Tokyo counterparts. 
Table 4.1. Percentage of recombinant BCG retaining the L 1 gene after 16 and 24 
generations of growth in liquid medium with antibiotics. 
Subatraln and plaamld 
Integrated plaamlda: 
Tokyo rBCG-361 L 1. 
Pasteur rBCG-361 L 1. 
Extrachromosomal plaamlda: 
Tokyo rBCG-112L 1R 
Tokyo rBCG-112L 1NLs-
Tokyo rBCG-112L1. 
Tokyo rBCG-112L 1BcGe 
Pasteur rBCG-112L 1. 
Tokyo rBCG-119L 1R 
Tokyo rBCG-119L 1. 
Tokyo rBCG-119L 1 BCGe 
Pasteur rBCG-119L 1. 
Pasteur rBCG-119L 1 BCGe 
nd, not determined 
Percentage bacteria containing the 
promoter and L 1 gene 
After 16 generatlona 
100 (assayed for L 1 only) 
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4.4.2. SEQUENCING OF rBCG .. L 1 STOCKS 
BCG-L 1 recombinants that appeared stable by restriction enzyme mapping were sequenced 
to confinn their sequence fidelity. No extensive changes were observed, however, point 
mutations were detected within the L 1 gene of the Tokyo rBCG-112L 1. and Tokyo rBCG-
361L 1. recombinants. No amino acid changes resulted from these mutations. The 
mutations were as follows: 
• Tokyo rBCG-112L1. had two point mutations: At L1 nucleotide 141 there was a 
change from T to C (codon change from CAT to CAC). and at L 1 nucleotide 1317 
there was a change from T to C (codon change from GAT to GAC). 
• Tokyo rBCG-361L 1. had two point mutations: At L 1 nucleotide 90 a change from C 
to G was detected (codon change from CGC to CGG); and at L 1 nucleotide 114 a 
change from A to G was found (codon change from GGA to GGG). 
4.4.3. SEQUENCING OF PLASMID REARRANGEMENTS 
Sequencing 0 f the genetically altered p lasmids c onfinned the d ata 0 btained by restriction 
endonuclease analysis; that deletions h ad occurred in the L 1 gene a nd Its promoter. As 
seen in Figure 4.1, the genetic rearrangements ranged from deletions spanning the entire L 1 
gene and promoter region, to smaller deletions within the L 1 gene. Often, these deletions 
occurred in non-essential sequences adjacent to the L 1 gene, such as the /ys A gene. The 
deletions did not occur at sequence-specific sites. 
4.4.4. IN VITRO rBCG-L 1 STABILITY WITHOUT ANTIBIOnC SELECnON 
After 26 generations of growth in liquid medium without antibiotic selection, the r BCG-L 1 
cultures were tested for plasmid stability. The cultures were spread onto plates, either with 
or without antibiotics. and the number of colonies was compared to detennine the 
percentage of bacteria that had retained their antibiotic resistance (Table 4.2). It was 
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(BCG Tokyo and BCG Pasteur) containing the Integration-proficient vector, p361 L 1., were 
100% stable after 16 generations. Although the stability of the Integrated recombinants was 
not detennlned after 24 generations, we believe that the integrated recombinants were more 
stable than the extrachromosomal recombinants, because in contrast to the 
extrachromosomal recombinants, both BCG Tokyo and BCG Pasteur integrated 
recombinants were 100% stable after 16 generations, and enhanced stability of integrated 
BCG recombinants has been observed In other studies (Stover et a/., 1991; Kumar et a/., 
1998). 
The BCG Tokyo recombinants containing the p112L1* constructs were 100% stable at 24 
generations; showing a higher stability than the Tokyo recombinants containing the p119L 1* 
constructs, which Is possibly due to the stronger promoter of p119L1 * (see discussion 
Chapter 3). It is possible that the Pasteur p112L 1, construct was 0% stable after 16 
generations if a deletion mutant appeared ear1y In the culture, which then outgrew the 
slower-growing stable recombinants. The BCG Pasteur recombinants (excluding the 
integrated recombinants) were less stable than their Tokyo counter parts. A study by AI-
Zarouni and Dale (2002) also detected varying degrees of instability between different BeG 
substralns, however, they detected gene deletions in BCG Tokyo and BCG Moreau more 
frequently than in BCG Pasteur. There was a large difference between t he stabilities of 
Tokyo rBCG-119L1R (15.8% stable) and rBCG-119L1, (100% stable at 16 generations), but 
due to the Similarity of these constructs it is unlikely that they assert significantly different 
stresses on BCG. In this case is likely that an ear1y deletion mutant appeared in the Tokyo 
rBCG-119L 1 R culture. 
Sequencing of the deletion mutants confinned that deletions had occurred in the L 1 gene 
and its promoter. None of the excisions occurred at exactly the same sites, indicating that 
there were no sequence-specific areas that were prone to recombination. Many deletions 
occurred In non-essential sequences adjacent to L 1, such as the Iys A gene, as the 
expression of this gene also places a metabolic load onto the bacteria. The Iys A gene is 
only necessary for bacterial survival in lysine auxotrophic BCG mutants CN. Jacobs, Dept. of 
Microbiology and Immunology, Albert Einstein College of Medicine, unpublished), 
Screening of recombinants by restriction enzyme digestion, Southem blot analysis, or PCR 
has limitations as point mutations or s mall deletions would go undetected. The BCG-L 1 
recombinants that appeared stable were therefore sequenced to verify the sequence fidelity 
of the L 1 gene and promoter. Very few point mutations, and no significant changes, were 
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observed in the L 1 sequences of the BCG-L 1 recombinants. Point mutations were only 
detected in two recombinants, which did not resutt in amino acid sequence changes. This 
was surprising as although many large genetic alterations occurred to reduce the expression 
of L 1, no significant point mutations or small deletions took place. 
4.5.2. IN VITRO rSCG-L 1 ST ABIUTY WITHOUT ANTIBIOTIC SELECTION 
The BCG-L 1 recombinants containing integrated vectors were more stable than the 
extrachromosomal constructs when grown without antibiotic selection. On average, 85% of 
the bacteria in the cultures containing Integrating vectors were stili antibiotic resistant after 26 
generations of selection-free growth, but only 25% of the bacteria In the cultures containing 
extrachromosomal constructs remained antibiotic resistant. These resutts concur with other 
studies (Lee et a/., 1991; Mederte at a/., 2002). The study by Mederte et a/. (2002), in which 
rBCG were Isolated from mouse spleens 100 days post immunisation, found that 75% of the 
rBCG containing an extrachromosomal construct had lost t heir a ntiblotic resistance, while 
over 85% of the rBCG containing an integrative vector retained antibiotic resistance. 
Measurement of t he loss/retention of antibiotic resistance is a relatively crude method of 
detennlning the loss of the entire construct, as it does not account for possible deletion 
mutants that have lost the antibiotic resistance gene, but have maintained the remainder of 
the construct. It Is thought that deletion mutations will be minimal compared with the loss of 
the entire construct, especially with respect to extrachromosomal constructs. It is noteworthy 
to point out that although these In vitro studies can detennine stability trends, they may not 
accurately reflect the stability situation In vivo. Assuming that stability is tied to expression 
levels, these constructs may be less stable In vivo, because of promoter Induction. 
Although stability Is an important issue with all BCG recombinants, little literature Is available 
on methods to Increase plasmid stability In BCG. Baud et a/. (2002) established that codon 
optimisation ofthe HPV-16 L 1 gene, for expression in Salmonel/a, increased plasmid stability 
In vi1iO; however, in the present study codon optimisation may have decreased plasmid 
stability, due to a possible Increase of L 1 expression levels. Auxotrophic mutants could be 
exploited to increase plasmid maintenance; for example, mutants lacking the ability to 
synthesis diaminoplmelae (DAP), due to the disruption of the asci (aspartate-semlaldehyde 
dehydrogenase) gene, are unable to complete cell wall synthesis and therefore lyse. For 
ascr mutants to survive they would be forced to maintain a plasmid carrying the wild-type 
asd gene (Cirillo et al .• 1995). The pCB112 and pCB 119 vectors utilised in this study contain 
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the /ys A gene, which is necessary for bacterial survival in lysine auxotrophic BCG mutants 
~. Jacobs, Dept. of Microbiology and Immunology, Albert Einstein College of Medicine, 
unpublished). Although these methods will ensure plasmid maintenance in the absence of 
antibiotic selection, gene deletions will not be prevented. 
The use of inducible promoters may help with respect to the prevention of gene deletions in 
vitro; however, for these promoters to be effective their in vitro activity will have to be 
negligible, with strongly inducible activity in vivo. Even low expression can cause instability, 
as noted in this study with the p119L 1* and p112L 1* constructs, even though L 1 expression 
is driven by promoters with weak In vitro activity (mtrA and M. leprae 18kDa, respectively). 
The most promising Inducible promoters to date are those of the M. smegmatis acetamidase 
enzyme. Acetamidase is Induced in the presence of amides, such as acetamide, butyramide 
and formam ide, enabling the organism to utilise these amides as their sole sources of carbon 
(Roberts et a/., 2003; Parish et a/., 1997). Under induced conditions acetamidase levels can 
increase to 100-fold that of the un-induced state, compriSing up to 10% of total cell protein. 
The functionality of this system has been demonstrated by the successful expression of 
luciferase (Gordon et a/., 1994) and the M. leprae 35kDa protein (Triccas et a/., 1998) in M. 
smegmatis. The system is unfortunately not perfect as even in the absence of an Inducer, a 
low basal level of acetamidase expression exists (Roberts et a/., 2003). More work will have 
to be done to gain a better understanding of this system. 
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5.5. DISCUSSION 
5.5.1. IMMUNITY INDUCED IN GUINEA PIGS BY IMMUNISATION WITH FRESHLY-
MADE rBCG-L 1 CONSTRUCTS 
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5.5.5. HPV-16 PSEUDOVIRION NEUTRALISING ANTIBODY ASSESSMENT 
5.5.6. ASSESSMENT OF ANTIBODIES IN GENITAL SECRETIONS 
5.1. INTRODUCTION 
A wide range of immune responses have been detected to foreign antigens expressed by 
BCG. In the introduction to this chapter these animal studies will be summarised, and factors 
which influence the Immunity generated to recombinant BCG, including route of administration. 
dose, prior exposure to BCG, and foreign protein localisation. will be reviewed. The 
introduction is followed by the evaluation of the Immune responses elicited by the BCG-HPV-
16 L 1 recombinants that were constructed during this project. 
5.1.1. IMMUNE RESPONSES TO HETERLOGOUS PROTEINS 
A multitude of BCG recombinants have been produced that effectively express and generate 
immune responses to proteins of viral, bacterial, parasitic. and mammalian origin (these are 
summarised in Table 5.1). Similar to the immune responses induced following wild-type BCG 
vaccination (Chapter 2. section 2.5), these BCG recombinants most often elicit strong Th1 
cellular responses (mainly CD4+ T cell activation, with IL-2, IL-12 and IFN-y production) to the 
heterologous antigens that they express; however, some BCG recombinants elicit strong CDe+ 
T cell and antibody responses to these proteins. Not only have these recombinants been 
found to be immunogenic in murine. guinea pig. and primate models, but they have been 
shown to provide protection in murine models of measles (Fennelly et al.. 1995). 
Streptococcus pnaumoniaa infection (Langermann et al., 1994a), Lyme disease (Stover at al .• 
1993). tetanus (Fuerst at al., 1992). listeriosis (Grode at al., 2002), leishmanisasis (Connell at 
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The immune responses generated to the these foreign antigens are dependent on a number of 
factors (discussed below) which indude the nature of the antigen itself, dose, route of 
Inoculation, amount of protein expressed, and the cell compartments Into which the protein is 
directed. 
5.1.2. FACTORS AFFECTING IMMUNE RESPONSES TO HETERLOGOUS PROTEINS 
5.1.2.1. BCG substraln 
As described in section 2.2, BCG substrains differ somewhat in their immunogenicitles, this 
therefore has a direct effect on the immune responses elicited to foreign antigens expressed 
by these substralns. Also, the ability of the BCG substrain to persist and multiply in vivo will 
contribute to the sustained expression of its foreign antigen, and thus to the continued 
stimulation of the immune system. In studies comparing the Immunogenicity of live versus 
heat-killed rBCG expressing the fragment C (ToxC) of the tetanus toxin, the heat-killed 
recombinant produced insignificant levels of serum antibodies to ToxC, and could not protect 
against challenge with tetanus toxin; while the live rBCG produced high antibody tltres, and 
completely or partially protected mice from challenge (Fuerst at al., 1992; Stover at al., 1991). 
These results, together the observation that one immunisation with rBCG can lead to an 
immune response that develops slowly, but that increases 0 ver many weeks (Fuerst at al., 
1992; Hayward at al., 1999; Leung at al., 2000); point to the importance of the persistence of 
rBCG. 
A comparison of five commonly used BCG substralns (Glaxo, Tokyo, Pasteur, Prague and 
Russian) by Lagranderie at al. (1996), revealed that these substralns differ in their abilities to 
persist and to elicit protective immunity in mice. Of all the substrains, BCG Prague and Tokyo 
were least able to multiply and persist In target organs after immunisation. These results 
correlated well with their ability to protect against challenge with rBCG-/acZ: while 
Immunisation with the Pasteur, Glaxo or Russian substralns caused the effICIent elimination of 
rBCG-LacZ, the Tokyo and Prague substrains did not show significant protection. When the 
immunity to these substralns was investigated, they found that the all had similar capacities to 
Induce proliferative responses and cytokine production; however, BCG Prague and Glaxo 
induced Significantly weaker CTL responses than the Pasteur and Russian substrains; and the 
Tokyo substraln was totally ineffective at Inducing CTLs. Of the substrains. BCG Tokyo 
elicited the lowest levels of anti-PPD antibody. Burlein et aI. (1994) showed that expression of 
foreign genes could differ between substrains. They found that while some substrains (Danish 
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and Pasteur) readily expressed B. b urgdorferi OspA a nd HIV-1 pg120, the Tokyo s ubstrain 
was unable to produce these antigens, even though identical vectors were utilised. In contrast, 
AI-Zarounl and Dale (2002) found no clear difference in expression of the foreign gene 
between the three BCG substrains used (Pasteur, Tokyo and Moreau). They did, however, 
find differences in vector stabilities: BCG Tokyo being the most stable and BCG Moreau the 
least stable. They went on to suggest that the differences in expression of foreign proteins by 
different BCG substrains observed by other researchers could be due to undetected vector 
instabilities. 
5.1.2.2. Dose and route of administration 
The recommended human BCG dose varies with BCG substrain, method of administration and 
age of recipient. The Pasteur substraln is administered at 4x104 to 5x105 colony forming units 
(cfu) per dose, Glaxo at 2x1OS to 1x108 cfu per dose, while Tokyo is administered at 3x1d' cfu 
per dose (Smith and Starke. 1999). Presently, the majority of countries administer BCG via the 
intradermal (i.d.) route. South Africa has recently changed the BCG inoculation regimen from 
percutaneous (multiple puncture) to the i.d. route (personal communication, Maureen 
Dennehy, State VaCCine Institute. South Africa; Kibei at al., 1998). as this method administers 
a more accurate dose. Considerable differences also exist in vaccination schedules between 
countries. The WHO recommends a single dose at birth; however, many countries give a dose 
at birth, with repeated doses during childhood (Smith and Starke, 1999). 
The BCG dose plays a key role in shaping the Th11Th2 nature of the immune response. Low 
BCG doses elicit a predominantly Th1 (cell-mediated) immune response, and Is independent of 
the route of inoculation (Power at al., 1998). Power at al. (1998) observed that immunising 
mice with very low numbers of BCG (40 cfu i.v., 400 cfu s.c .• or 2000 cfu i.d.) were able to 
induce detectable cell-mediated responses to BCG. For the induction of antibodies to BCG 
high dosed were more effective and were dependent on route; an tv. dose of 4x105 cfu was 
effective, but a dose of 4x108 cfu given s.c. induced almost no detectable antibodies to BCG. 
The high doses induced mixed Th1fTh2 immune responses. Hayward at al. (1999) found that 
immunisation of mice with E. coli heat labile enterotoxin (LT-Bh) alone induced a Th2-
dominated (antibody) response, however, when L T -Bh was expressed by rBCG, the response 
to LT-Bh was shifted to a predominantly Th1 response. An I.p. immunisation of mice with 108 
cfu of rBCG-LT-Bh did not elicit LT-Bh-speciflc antibodies, but larger doses of 107 and 1cf cfu 
lead to progressively greater serum IgA and IgG responses. 
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Kremer at al. (1996) compared a panel of routes (Lv., i.p., S.C., or i.n) when they immunised 
mice with a single dose (8x108 cfu for all routes) of rBCG expressing glutathione S-transferase 
of Schistosoma mansoni (Sm28GSn. Serum antibody responses to Sm28GST were 
generated by all immunisation routes, the strongest being elicited by the I.p. and i.v. routes 
(lgG, not IgA). Antibody responses were enhanced by a booster dose. Analysis of the 
antibody isotypes indicated that i.v. and i.n. immunisation elicited a dominant Th1 response, 
s.c. immunisation produced a T h 1 response that gradually became a mixed T hlTh2 profile. 
while i.p. gave a mixed profile directly after immunisation. Lagranderie at al. (1998) 
investigated mucosal routes of administering a mixture of rBCG expressing SIV antigens (Env, 
GAG, Net) in mice. The oral and rectal doses were 1.5x1 09 cfu of each rBCG over 5 days; the 
Ln. dose was 107 cfu of each rBCG, and the respiratory dose was about 5x108 cfu of each 
rBCG. A II routes Induced similar CTL responses. T he highest H IV-specific I gA antibodies 
were detected in the faeces, moderate levels were found In bronchoalveolar lavage samples, 
and vaginal secretions contained negligible levels. High titres of HIV-specific serum IgG were 
obtained by all vaccination routes, with a preferential IgG1 isotype response (Th2). It therefore 
appears that dominant Th1 (lgG2a isotype) responses are obtained following parenteral 
immunisation (Gheorghiu at al., 1994; Kremer at al., 1996). while mucosal Immunisation 
preferentially stimulates Th2 responses. 
Langermann at al. (1994b) observed a dose response when mice were immunised tn. with 
rBCG-OspA. An i.n. dose of 1 ff cfu was unable to elicit detectable B. burgdorfari OspA-
specific antibodies, a dose of 105 cfu produced an Intermediate level, while 108 and 1 rI cfu 
produced high antibody titres. Mucosal administration tends to elicit greater serum and 
mucosal IgA responses than do the parenteral forms of immunisation. Intraperitoneal 
immunisation of rBCG-OspA (2x108 cfu) elicited high titres of serum IgG. but no serum IgA; i.n. 
Immunisation (with 2x108 cfu). on the other hand, produced sustained low titres of serum IgA 
as well as IgG antibodies. Intranasal but not i.p. immunisation with rBCG-OspA elicited an IgA 
response in vaginal washes (Langermann at al., 1994b). Kawahara at al. (2002b) compared 
single routes (J.d., I.r., and Ln.) and combinations of routes (i.dJi.r., or s.e.n.r.) in guinea pigs. 
The combined I.d.n.r route proved best at eliciting the highest titres of specific IgA and IgG 
antibodies, and cell-medlated Immunity to rBCG expressing the HIV-1 V3J1 peptide. In a 
phase I clinical trial to test the safety and immunogenicity of rBCG-OspA, adult volunteers were 
Immunised i.d. with four escalating doses ranging from 2x1 ff to 2x107 cfu over 28 weeks. The 
vaccine was deemed safe. but none of the doses generated detectable antibodies to OspA. 
even though similar doses successfully induced Immunity in mice (Edelman at al .• 1999; Stover 
at aI •• 1993). 
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5.1.2.3. Prior exposure to BeG 
One of the suggested explanations for the low and varied protective effICaCY of the BCG 
vaccine against M. tuberculosis is prior exposure to environmental mycobacteria (Agger and 
Andersen, 2002; Hess and Kaufmann, 1999). Studies have found that when cows have been 
sensitised to environmental bacteria, the protective affect of subsequent BCG vaccination Is 
adversely affected (Buddie at al., 2002). Therefore, a major concern surrounding the 
development of recombinant BCG vaccines is whether prior vaccination with wild-type BCG will 
adversely affect the immunity induced to recombinant BCG vaccines. 
One group has completed a number of studies in which the effect of BCG-primlng on the 
Immunity Induced by rBCG-LacZ and rBCG-Nef in mice was Investigated (Gheorghlu at al., 
1994; Lagranderie at a/., 1997a; Lagranderie at aI., 1996). They showed that mice that had 
been immunlsed with wild-type BCG were partially protected from challenge with rBCG-lacZ, 
as the growth of recombinant BCG In the mouse organs (spleen and lymph nodes) was 
reduced. Proliferative responses to p-gal and Net were also reduced by varying degrees (0-
40% reduction) In BCG-primed mice, depending on the length of time between priming and 
rBCG vaccination. Antibody responses to pegal, however, were dramatically Increased In the 
BCG-primed mice. These Increased responses were apparent after one or two rBCG 
immunisations, and could be detected several months after rBCG immunisation. The antibody 
stimulatory effect was not due to polyclonal stimulation of B cells or to the non-specific 
adjuvant effect of BCG. 
5.1.2.4. Protein localisation and amount of protein produced 
A review of the literature established that, as one would expect, the more foreign protein that Is 
produced by rBCG, the stronger the immune response that develops to that protein. Although 
the utilisation of secretory or membrane-targeted signal sequences often leads to an overall 
reduction in the levels of the foreign protein. these sequences generally lead to amplified 
immune responses by improving antigen delivery. 
Abomoelak at aI. (1999) showed that a BCG recombinant expressing large quantities of 
pertusslsltetanus hybrid protein (S1-TTC) (hsp60 promoter) was signifICantly more 
immunogenic than the lower S1-TTC expresser (85A promoter. 10-fold lower expression). 
Only the high expresser was able to elicit anti-S1-TTC antibodies and an IL-2 response. 
Similarly, (3-gal-speciflc antibody and IFN-y responses were considerably higher In mice when 
p-gal was expressed by rBCG under the control of a strong promoter (PblaF), as compared to 
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a weaker promoter (PAN) (Lagranderie et al., 1997b). Langermann et a/. (1994a) showed that 
although S. pneumoniae PspA production was highest when expressed in rBCG as a 
cytoplasmic protein, only rBCG producing PspA as a secreted (PspA signal) or membrane-
bound protein (19kDa lipoprotein signal) elicited responses capable of protecting mice against 
S. pneumoniae challenge. Himmerlrich et al. (2000) compared a panel of vectors expressing 
the E. coli MalE protein in BCG. They observed that the highest MalE producers were the 
BCG recombinants that secreted MalE, and that these were also the recombinants that elicited 
the highest MalE-specific Immune responses. The two secretory constructs elicited antibody 
and T cell responses to MalE, while the cytoplasmic and lipoprotein constructs did not. Of the 
two secretory constructs, the one producing the highest levels of MalE generated a more rapid 
and a higher level of antibodies; it also produced high IFN-y and proliferative responses, while 
the lower producer failed elicit specific proliferative responses and produced only a low level of 
IFN-y. Mederle et al. (2002) compared three BCG recombinants expressing a synthetic SIV 
nef-gag operon. An unstable extrachromosomal vector with high Gag expression (1 % of total 
BCG protein) and a stable integrated construct with low expression (0.14% of total BCG 
protein) failed to elicit Gag-specific IFN-y responses in mice after a single immunisation. The 
low, but persistent level of Gag production by the integrated construct was, however, sufficient 
to Induce a humoral response. A second integrative vector with high, stable Gag expression 
(1 % of total BCG protein) was able to elicited Gag-specific IFN-y responses. It therefore 
appears that a threshold level of heterologous protein expression by rBCG must be reached 
before specific memory T cells are primed. 
A comparison of BCG recombinants expressing the OspA protein of B. bugdorferi as a 
cytoplasmic, secretory (a antigen signal) or membrane-anchored protein (19kDa or OspA 
lipoprotein signals), revealed that although the highest OspA production was by the cytosolic 
construct, It produced the lowest levels of OspA-specific antibodies (which were not apparent 
before boosting). T he secretory construct produced intermediate a ntibody levels, while the 
membrane constructs produced the highest levels of OspA-specific antibodies (titres 100 to 
1000 fold higher than the other constructs (Stover et al., 1993). rBCG expressing E. coli L T-Bh 
as either a cytoplasmic, membrane-associated (19kDa signal), or secreted protein (a antigen), 
displayed Similar levels of L T -Bh production, but only the membrane-associated and secretion 
constructs elicited significant levels of LT-Bh-specific serum IgA antibodies in mice (Hayward 
et al., 1999). Grode et al. (2002) investigated the immune responses to rBCG expressing the 
p60 protein of L. monocytogenes as either a cytoplasmic, membrane-associated (19kDa 
lipoprotein signal), or secreted protein (Ag85B secretion signal). While the secreting and 
membrane constructs evoked good protection from listeriosis, 80% and 100% respectively, 
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cytosollc expression failed to protect. In vivo depletion of the T cell subpopulations revealed 
that the secretory rBCG construct mediated protection with CD4+ T cells, while a combination 
of CD4+ and COS+ T cells were Involved in the protection conferred by the membrane 
construct. 
5.1.2.5. Animal Strain 
The immune responses to foreign antigens delivered by rBCG are under a complex set of 
genetic influences, and include susceptibility to BCG and ability to respond to the delivered 
antigen. The vast majority of rBCG studies have tested Immune responses in mice, but guinea 
pigs. macaques, and human volunteers have also been utilised (see Table 5.1). Guinea pigs 
are probably the most relevant small animal model for the assessment of Immunity to 
recombinant BCG. They are used routinely for testing tuberculosis infection as they resemble 
tuberculosis Infection In humans clinically. pathologically and immunologically (Horwitz st 81., 
2000). 
Multiplication of BCG in mice is controlled by the Seg locus, Which has two allelic fonns, 
susceptible (Sest) and resistant (serf) (Gras st 8/.,1981; Lagranderie st 81., 1997b). The low 
immunogenlcity of recombinant BCG In certain strains of mice can be explained by the Inferior 
multiplication of BCG in these strains, which in tum leads to the expression of less 
heterologous protein. Lagranderie st 81. (1997b) investigated the Immunogeniclty of rBCG-(3-
gal In a number of mouse strains. They found that rBCG recovery from C3HIHeJ mice (serf> 
was low, which corresponded to a low antibody response to (3-gal. Although BALB/c and 
C57BU6 mice are both Scrf. J3-gal-specific antibodies were produced in BALBlc and not in 
C57BU6; this occurs since BALB/c and C3H/HeJ mice are able to respond to lower doses of 
J3-gal than C 57BU6 mice. Similarly, H Immel rich s t 81. (2000) found t hat immunity to MalE 
varied in different strains of mice when expressed by a weak rBCG-MaIE producer, but 
detected strong responses in all strains when Immunised with a high MalE producer. When 
Stover st 81. (1993) assessed 24 inbred and outbred mouse strains for relative antibody 
responsiveness to OspA produced by rBCG, they detennined that the antibody responses to 
OspA did not correspond to the strain's BCG susceptibly/resistance alleles; this was most likely 
due to the high OspA production by rBCG. 
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Table 5.1. Immune res~nses elicited to foreiBn ~roteins e~ressed b~ recombinant BeG. 
Antigen Source AntIgen Exp ..... lon .ystem Animal model Immune .... ponse to foreign antigen Reference 
Viral 
HN-1 Gag, Pol, Env Extrachromosomal vector Mice Antibody (ab) and CTL responses (CD8+ T Aldovlni and Young, 
Hsp70 promoter ceIHnediated). IFNy and Il-2 production. 1991 
Nef Extrachromosomal vector Mice Proliferative immune responses. Winter at aI., 1991 
GroESlgroEl1 promoter 
V3 envTcell Extrachromosomal vector Mice A specific CTl response that was MHC Kameoka at al., 
epitope (19aa) a antigen secretion system class I restricted. 1994 
V3 envTcell Extrachromosomal vector Guinea pig SpecifIC antibody, DTH and CTL responses. Honda at al., 1995 
epitope (15aa) a antigen secretion system In vitro neutralising abs. 
Mice Specific CTl responses (MHC-I restricted) 
Passive protection against HIV-1 challenge 
in SCIDlhu mice using immune serum. 
Mice Prolonged (1 year) high titre V3-specific IgG Hiroi at al., 2001 
abs, with In vitro neutralising activity after 
nasal immunisation. 
V3 envT cell Extrachromosomal vector Guinea pigs After oral immunisation of freeze-dried Kawahara et al., 
epitopesof a antigen promoter and signal rSCG proliferative responses were detected 2oo2a 
principle sequence when testing PBMCs, splenocytes and 
neutralising intestinal intraepitheliallymphocytes. 
region DTH responses to V3 could be detected 1.5 
(Codon years after invnUnlsation. 
optimised for Enhanced rBCG immunogenicity by Kawahara et al., 
BCG) combined intrarectal and intradermal 2OO2b 
immunisation. High titres of serum IgG and 
19A. Production of IFN--y and Il-2. Antigen 
specific Th1-type memory cells maintained 
for more than 2 years. 
Chujoh et al., 2001 Neutralising abs (In vitro). 
SN Gagepitope Extrachromosomal Rhesus No Gag-specific abs were detected. Yasutomi at aI., 
Hsp70 promoter monkeys SpecifIC CTl responses (CD8+, MHC class 1993; Yasutomi et 
1 restricted). No protection from SIV al., 1995 
challenge. 
Net Extrachromosomal Mice Proliferative and CTl responses. WInter at al., 1995 
PAN promoter CTl activity of intestinal intraepithelial 
CD8P+ T cells after oral administration. 
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Table 5.1 (continued). Immune responses elicited to foreign proteins expressed by recombinant BeG. 
Antigen Source Antigen expression system Animal model Immune .... pon .. to foreign antigen Reference 
Nef-Gag fusion Extrachromosomal and integrative Mice Anti-Gag IFN-y-producing CD4+ cells, and Mederle et al., 2002 
PblaF promoter anti-Gag aba. 
No immune response to Nef. 
Nef, Env, Gag Extrachromosomal Mice Immunisation with a rBCG cocktail elicited Lagranderie at al., 
PAN or PblaF promoters systemic IgA and IgG responses (against 1998 
Env and Gag) and strong cn. responses 
against all antigens, after mucosal 
immunisation. 
Gag, Pol, Env Extrachromosomal Rhesus SIV-speciflC IgA and IgG ab responses. Leung at al., 2000 
and Net Hsp70 promoter monkeys Cn. and helper T cell proliferation. 
N-tenninal of Extrachromosomal Mice Strong en. and ab responses after 3 lim at al., 1997 
env (aa 1-245) PbIaF promoter immunisations. in vitro neutral Ising aba. 
Guinea-pigs SpecifIC IgA abs in faeces after oral 
Immunisation. 
Net. Env. Gag Extrachromosomal Cynomolgus A single inoculation (I.d.) of a mixture of 3 Mederle at al., 2003 
PAN or PblaF promoters macaques BCG recombinants elicited Cn. and IFN-y 
responses to all 3 antigens (Nef, Env. Gag). 
Mucosal boosting elicited mucosal loA, but 
not serum IgG or Iymphoprollferation. 
Animals were not protected from challenge 
with pathogenic SIVrnac251. 
Measles virus Nucleocapsid Extrachromosomal Mice Speciftc humoral and proliferative Fennelly et al., 1995 
(N) protein Hsp60 promoter responses. Low titre in vitro neutralising 
19 kDa lipoprotein, or no signal aba. Protection from viral challenge. 
Nucleocapsid Extrachromosomal or integrative Rhesus The extrachromosomal construct elicited Zhu etat., 1997 
(N)proteln Hsp60 promoter macaques aba after one inoculation, while 2 
inoculations of the integrative construct 
were needed to produce similar ab levels. 
rBCC-N did not protect from measles virus 
challenge. 
Hepatitis C virus cn. epitope of Extrachromosomal vector Mice NS5a-specific MHC class 1-restricted C08+ Uno-Furuta at al., 
non-structural a antigen promoter and signal cn. response. Protection against 2003 
protein 5a sequence chalenge with vaccinia virus expressing 
(NS5a) NS5a. 
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Table 5.1 (continued). Immune responses elicited to foreign proteins expressed by recombinant BeG. 
Antigen Source Antigen Exp ..... lon system Animal model Immune response to foreign antigen Reference 
HPV HPV-6b L1 Extrachromosomal Mice L 1-specific ab, DTH and proliferative Jabbar et al., 2000 
and HPV-16 Hsp60 and hsp70 promoters responses. E7 -specific ab, DTH, CTL and 
E7 proliferative responses. 
No protection from E7 -expressing tumour. 
Rabies virus nucleoprotein Extrachromosomal Mice Long lasting and progressively increasing da Cruz et al., 2001 
B-cell and T- Hsp60 or 18kDa promoter ab response. Higher ab titres than elicited 
cell epitopes by commercial rabies vaccine (Rai-SAD). 
Porcine GP5andM Extrachromosomal Mice Neutralising ab and IFN-y responses by Bastos et al., 2002 
reproductive proteins Hsp60 promoter rBCG expressing a truncated GP5. 
respiratory 19 kD lipoprotein or no signal 
syndrome virus 
Bacterial 
Streptococcus Surface protein Extrachromosomal Mice High titre ab response. Langermann et al., 
pneumonlae A (PspA) Hsp60 promoter Protection against challenge. 1994a 
PspA secretion signal, 19 kDa Passive protection against challenge in 
lipoprotein, or no signal CBAIN mice using immune serum. 
E. coli ~a1 Extrachromosomal Mice A single immunisation produced high titres Stover et al., 1991; 
Hsp60 promoter of ~al-speclfic abs, CTL responses, and Fuerst et al., 199 
IFN-y production. 
~al a antigen promoter and signal Mice High ab titres against ~I, which peaked Kumar et al., 1999 
sequence 10 weeks atter a single Inoculation. 
Production of Th-1 cytokines (IF~ & IL-2). 
Down regulation of IgE ab response. 
~al Extrachromosomal Mice (BALBlc) High titre ab responses after two Murray et al., 1992 
PAN or PblaF promoters inoculations. Proliferative responses (CD4+ 
and CD8+ T cells) and IFNy production. 
Guinea pigs Prolonged antibody responses, CTL (CD4+ Lagranderie et al., 
T cells) and DTH response following oral 1993 
and respiratory immunisation of guinea 
pigs. Serum and intestinal IgA abs. 
Mice (BALB/c, High titre ab responses only in BALB/c mice Lagranderie et al., 
CBA. C57BU6, immunised with the PAN construct. 1997b 
C3H) Abs in all strains immunised with PblaF 
construct (stronger expresser). 
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Table 5.1 (continued). Immune responses elicited to foreign proteins expressed by recombinant BeG. 
Antigen Source Antigen expression system Animal mod., Immune response to foreign antigen Reference 
MalE Extrachromosomal Mice MalE-specific abs, pro/iferation and IFN'"'Y Himmelrich .t .,., 
19kDa, Perp, or PblaF promoters prodUCfjon when utilising the double 2000 
19kDa lipoprotein signal,.rp secretion signal construct. 
signal (secretion), double signal Negligible or low responses with the other 
consisting of BIaF and MalE constructs. 
sequences, or no signal sequence 
B subunit heat Extrachromosomal Mice Serum IgA and IgG ebs after oral Ha~rd .t al., 1999 
labile Hsp60 or 19kDa promoters immunisation. The highest ab titres were 
enterotoxin a antigen, 19kDa Dpoprotein, or no elicited with cell wall associated-antlgen 
signal expression. 
ClostridIum Protective Extrachromosomal Mice High titre abs to ToxC after a single Stover .t al., 1991; 
tetani fragment C of Hsp60 imlTlJnisation. Fuerst .t al., 1992 
the tetanus Mice developed complete or partial 
toxin (ToxC) protection from challenge. 
Corynebacterium Non-toxic Extrachromosomal Mice Anti-CRM197 abs were generated, but Miyaji .t al., 2001 
diphtheriae mutant of PblaF promoter were unable to neutralise diphtheria toxin 
diphtheria toxin B-lactamase secretion signal activity in an in vitro assay. 
(CRM197) and Diptheria toxin neutralising abs were 
Tetanus toxin generated when rBCG-CRM197 and rBCG-
tragmentC FC were Immunised together. 
(FC) Mice, guinea I.p. immunisation of mice with a rBCG- Mazzantinl 9t al. 
pigs CRM197 and rBCG-FC combination 2004 
produced a Th2 Immunoglobulin profile. 
Antisera from guinea pigs immunised with 
rBCG-CRM197 and rBCG-FC neutralised 
both diphtheria and tetanus toxins. 
Borrelia Outer-surface Extrachromosomal Mice High titre ab response, cn responses, and Stover .t al .• 1993 
burgdorferi protein A Hsp60 promoter protection against In vivo challenge. 
(OspA) a antigen, 19 kDa or OspA Prolonged-protective systemic IgG and IgA Langermann 9t al., 
lpoprotein signals, or no signal immune responses (more than one year). 1994b 
0spA Extrachromosomal Human The rBCG vaccine was safe, but did not Edelman .t al., 1999 
Hsp60 promoter volunteers elicit anti-OspA abs in any of the 
19 kDa lpoprotein Signal volunteers. 
Vibrio cholera. Toxin B Extrachromosomal Mice Intranasal immunisation elicited serum and Blat at al., 2003 
subunit Hsp60 mucosallgA responses. 
a antigen signal 
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Table 5.1 (continued). Immune responses elicited to foreign proteins expressed by recombinant BeG. 
Antigen Source Antigen Exp ..... 1On .ystem Animal model Immun ..... pon •• to foreign antlg.n Reference 
80trIeteila S1-TIC (S1 Extrachromosomal Mice Specific neutralising antibodies against Abomoelak at al., 
pertussis subunit of Hsp60 promoter (no signal), or TIC, and IL-2 production to both S1 and 1999 
pertussis toxin 85A promoter with its signal TIC only after immunisation with the hsp60 
fused to ToxC) sequence construct. 
M. tuberculosis 30kDa major Extrachromosomal Guinea pigs Strong cutaneous DTH responses. Horwitz at al., 2000 
secretory M. tuberoulosis JOkDa protein Enhanced protection against challenge 
protein promoter when compared with wiJd..type BCG. 
ESAT-6 Extrachromosomal Mice, guinea Enhanced protection against challenge with Pym at a/., 2003 
Hsp60 promoter pigs M. tuberculosis. 
Ust.eria pSG Extrachromosomal Mice Protection against Iistet10sls after Grode at a/., 2002 
monocytogenes Hsp60 promoter immunisation with the secretory or 
Ag85B secration signal, 19kDa membrane-anchoring constructs, but not 
lipoprotein signal, or no signal with the cytosolc construct. 
M.lepraa 18kDa protein Extrachromosomal Mice SpecifIC humoral, proliferative responses, Baumgart at a/., 
Hsp65 promoter and DTH skin reactions. 1996 
Protozoa 
Schistosoma Glutathione S- Extrachromosomal vector Mice i.p., i.v., s.c.. and I.n. immunisation elicited Kremer at a/., 1996 
manson; transferase Hsp60 promoter prolonged (over 1 year) SpecifIC ab (mainly 
(Srn28GST) IgG2a) responses. 
Toxoplasma GRA1 Extrachromosomal Mice, sheep Immunisation of mice failed to Induce Supply at a/., 1999 
gondil 85A antigen promoter and signal measurable GRA1-speciflC humoral or 
sequence ceilular responses, and conferred very 
limited protection against T. gondil 
challenge. Immunisation of sheep failed to 
elicit GRA 1-specific abs. but did produce 
proliferative and IFN-y responses. 
Lelshman;a Surface Extrachromosomal Mice Protection against challenge in resistant Connell at a/., 1993 
major proteinase hsp60 promoter CBA mice, but not susceptible BALB/c 
Gp63 mice. 
Surface Extrachromosomal Mice BALB/c mice were protected against Abdelhak at m .• 
proteinase PAN promoter chalenge when immunised with rSCG the 1995 
Gp63 Pblaf promoter and signal Pblaf construct. 
sequence for secretion 
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Table 5.1 (continued). Immune responses elicited to foreign proteins expressed by recombinant BCG. 
Antigen Source Antigen Expression system Animal model Immune response to foreign antigen Reference 
Laishmania LCR1 Extrachromosomal Mice Immunisation with rBCG-lCR 1 provided Streit at al., 2000 
chagasi hsp60 promoter better protecting immunity against L. 
chagasi infection than Immunisation with 
LCR1 protein alone. 
Plasmodium Clrcumsporo- Extrachromosomal Mice SpecifIC ab and proliferative responses. Zheng at a/., 2002 
falciparum zoite protein Hsp70 Production of IL-2 and IFN...,. 
(CSP) 
Plasmodium 15kDa Extrachromosomal Mice Immunisation with rBCG Induced greater Matsumoto et BI •• 
yoeHi fragment of a antigen promoter and signal protection against blood-parasite Infection 1998; Matsumoto at 
merozoite sequence than immunisation with MSP1 protein and al., 2000 
surface protein adjuvant. 
(MSP-1) 
Human 
IL-2 Integrative vectors Mice Secretion of active IL-2 which augmented Kong and Kunimoto, 
a antigen promoter and signal the immune response to BCG, thus 1995 
sequence or hsp60 promoter enhancing BCG clearance. 
IL-2.IL-18 Extrachromosomal Mice rBCG-IL-2 (but not rBCG-ll-18) improved Young at al., 2002 
hsp60 promoter BCG's ablity to induce and maintain a 
a antigen for secretion strong type1 immune response. Stronger 
proliferative, IFN-y, and IgG2a responses 
were elicited after rBCG-ll-2 vaCCination. 
rBCG-IL-2 vaCCination did not enhance 
BCG's protective immunity against M. bavis 
challenge. 
Il-18 Extrachromosomal Mice rBCG-IL-18 augmented BCG's ability to Biet at a/., 2002 
hsp60 promoter Induce type1 immune response, with 
a antigen for secretion greater production of IFN-y. Il-10 and 
granulocyte-macrophage colony-stimulating 
factor; but with decreases production of 
serum IgG. 
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5.2. STUDY OBJECTIVES 
The objective was to evaluate and compare the immunity elicited by the BCG-HPV-16 L 1 
recombinants constructed during this study (Chapter 3). Since the potential use of rBCG-L 1 
as a prophylactic vaccine for HPV was under evaluation, the focus of the assays lay in 
testing the ability of rBCG-L 1 to generate antibodies that were specific for HPV-16 L 1; 
however, cell-mediated immunity was also assessed. Guinea pigs were the animals of 
choice, as they are the most relevant small animal model for the assessment of immunity to 
mycobacteria. 
5.3. MATERIALS AND METHODS 
5.3.1. SOURCE OF ANIMALS 
Outbred Dunkin-Hartley guinea pigs, weighing 200-400g were obtained from South African 
Vaccine Producers (South Africa) and were housed in the UCT Animal Unit. All animal 
protocols were approved by the UCT Animal Research Review Committee. Immunlsations, 
serum and organ collections were perfonned by trained animal technologists. 
5.3.2. PREPARATION OF IMMUNOGENS 
rBCG-L 1 and wild-type BCG were prepared for animal Immunisations by growing the 
cultures to middle log phase, followed by centrifugation and re-suspension in PBS, as 
described in Appendix A 15. The BCG Immunisation samples were either used directly after 
preparation, or were frozen at -BOOC a nd thawed just prior to immunisation. T he genetic 
stabilities of the immunisation stocks were tested prior to use (section 4.2.1). 
HPV-16 VLPs were produced by the recombinant baculovirus system, and were supplied by 
Robert Rose (University of Rochester, Rochester, New York, USA) 0 r the Department of 
Molecular and Cell Biology (UCT, South Africa). Phosphate-buffered saline (PBS) was used 
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5.3.3. ANIMAL IMMUNISATIONS AND SAMPLE COLLECTION 
5.3.3.1. Immunisation of guinea pigs with freshly-made rBCG-L 1 for comparison of 
expression vectors 
Guinea pigs were anaesthetised by intramuscular (i.m.) administration of ketamine/rompun in 
the hind leg. Pre-immune blood samples were collected by cardiac puncture, and the guinea 
pigs were then immunised by Lm. injection in the hind leg (the opposite leg to that used for 
anaesthesia) with a 100lli dose of BCG, containing 2x106 colony forming units (cfu). Four 
groups of 4 animals each, received either rBCG-361L1R' rBCG-112L1 NLS-, rBCG-119L1 NLS-, 
or wild-type BCG. All BCG was of the Tokyo substrain. One to 2ml of blood were collected 
by cardiac puncture every 1 or 2 weeks. 
The blood was kept at room temperature for 2 hours to comp/ete the clotting process, and 
then separated by centrifugation at 3000rpm for 10min. The sera were collected and stored 
at -80°C. Booster immunisations were administered 4 and 13 weeks after the first 
immunisation. Antibodies specific for HPV-16 VLPs were measured by enzyme linked 
immunosorbent assay (ELISA), as described in section 5.3.4.1. 
5.3.3.2. Immunisation of guinea pigs for comparison of freshly-made versus frozen! 
thawed rBCG-L 1, and Investigation of priming with wild-type BCG 
Guinea pigs were anaesthetised as above. Pre-immune blood samples were collected and 
the guinea pigs were spilt into 4 groups. One group, of three animals, was immunised 
subcutaneously (s.c.) with 2x106 cfu of wild-type Tokyo BCG, and received booster 
inoculations, of the same dose and route, 4 and 12 weeks after the first dose. Two groups, 
of 7 animals each, were primed subcutaneously with 2x106 cfu of wild-type BCG, after which 
they were immunised intramuscularty or subcutaneously with 4.6x106 cfu of rBCG-112L 1 NLS-. 
Both groups were then boosted with 2x106 cfu of rBCG-112L 1NLS-, 4 and 12 weeks after the 
first rBCG-112L 1 NLS- immunisation. Two groups, of 6 guinea pigs each, were immunised s.c. 
with 4.6x106 cfu of rBCG-112L 1NLs- and were boosted s.c. with 2x106 cfu of rBCG-112L 1NLS-, 
4 and 12 weeks afterwards; while the one group received freshly-made BCG, the other 
received frozen/thawed B CG. Another group, 0 f 6 guinea pigs, was immunised I.m. with 
4.6x106 cfu of frozenlthawed rBCG-112L1 NLS-, and was boosted i.m. with 2x106 cfu of 
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Table 5.2. Guinea pig immunisation schedule utilised for comparison of freshly-made versus 
frozenlthawed rBCG-L 1, and to investigate priming with wild-type BCG 
Wild-type Immunl8atlons 
Group name BeG ~rime 
4 weeks prior to Week 0 Week 4 Week 12 
week 0 
i.m rBCG-112L 1NLS- only none i.m rBCG-112L 1NLS- Lm rBCG-112L1NLs- i.m rBCG-112L 1NLS-
s.c. rBCG-112L 1NLS- only none s.c. rBCG-112L 1NLS- s.c. rBCG-112L1NLs- s.c. rBCG-112L1NLS-
s.c. wild-type prime + i.m. s.c. wild-type Lm rBCG-112L 1NLS- Lm rBCG-112L 1NLS- Lm rBCG-112L 1NLS-
rBCG-112L 1 NLS- boost 
s.c. wild-type prime + s.c. s.c. wild-type 
rBCG-112L 1 NLS- boost 
s.c. rBCG-112L1NLS- s.c. rBCG-112L1NLs- s. c. rBCG-112L 1 NLS-
S.c. wild-type only none s.c. wild-type s.c. wild-type s.c. wild-type 
One to 2ml of blood were collected every 2 weeks by cardiac puncture. The blood samples 
were allowed to clot at room temperature for 2 hours, after which they were separated by 
centrifugation at 3000rpm for 1 Omin. The sera were collected and stored at -SO°C. Two 
weeks after the last immunisation, the guinea pigs were tested for delayed-type 
hypersensitivity (DTH) responses to PBS, purified protein derivative of tuberculin (PPD, 
O.2J.1g/animal), sodium carbonate buffer (pH 9.6), intact HPV-16 VLPs (5J.1g/animal) and 
disrupted HPV-16 VLPs (5J.1g/animal); as described in section 5.3.4.3. Antibodies specific for 
HPV-16 VLPs were measured by ELISA, as described in section 5.3.4.1. 
5.3.3.3. Immunisation of guinea pigs with frozenlthawed BeG for comparison of 
expression vectors, doses and routes 
Guinea pigs were anaesthetised as above. Pre-immune blood and vaginal wash samples 
were collected. The guinea pigs were immunised, either, Lm. in the hind leg, or intradermally 
(i.d.) on the back. Before the i.d. inoculations were performed, the hair on the backs of the 
guinea pigs was cut with an electric hair clipper. Two negative control groups, of four 
animals each, were inoculated with 100J.11 of either PBS or rBCG-361-GAG (2x108 cfu, a HIV-
1 GAG BCG recombinant; obtained from Robin Thomas, Division of Medical Virology, 
Department of Clinical Laboratory Science, UCT). A positive control group, of 6 guinea pigs, 
was inoculated with 15J.1Q of HPV-16 VLP. Seven groups, of 6-8 animals, were inoculated 
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i.d. (unless otherwise indicated) with 2x106 cfu of either. rBCG-361L1 •• rBCG-112L1Nls-, 
rBCG-112L1Nls- (i.m.). rBCG-112L1 •• rBCG-112L1BCGe, rBCG-119L1 •• or rBCG-119L1BCGe. 
Two groups, of 6 animals, were given a lower dosage (1x104 cfu) of rBCG-361L 1. or rBCG-
119L 1 BCGe. All BCG was of the Tokyo substrain. 
Booster immunisations, of the same routes and doses. were administered 4, 8, and 12 
weeks after the Initial immunisation. One to 2ml of blood were collected by cardiac puncture 
every 1 or 2 weeks. Blood was kept at room temperature for 2 hours to complete the clotting 
process, and then separated by centrifugation at 3000rpm for 1 Om in. The serum was 
collected and stored at -BO°C. Vaginal washes were performed on the female guinea pigs 
(which comprised a half of each group), using 50fJI of PBS. The wash samples were 
collected 2 weeks after each immunisation, and were stored at -BODC. Six weeks after the 
3n:1 booster dose, the last dose was administered, and 3 weeks later the guinea pigs were 
tested for DTH responses (described in section 5.3.4.3) to PBS. PPD (0.2j.1.g/animal). and 
HPV-16 VLPs (5Jl9/animal). Serum and vaginal antibodies. specific for HPV-16 VLPs. were 
measured by ELISA. as described in section 5.3.4.1. 
HPV-16 pseudovirus neutralisation assays (described in 5.3.4.4) were performed using 
serum from the above mentioned guinea pigs. The prebleed serum and week 20 serum from 
one animal from each of the following groups were tested: rBCG-361L 1., rBCG-112L 1NlS-, 
rBCG-112L1., rBCG-112L1BCGe. rBCG-119L1., or rBCG-119L1BCG., HPV-16 VLP. rBCG-
GAG, and PBS. 
5.3.4. IMMUNOLOGICAL ASSAYS 
5.3.4.1. Detection of serum and vaginal antibodies by ELISA 
Antibodies specific for HPV-16 VLPs were detected by indirect enzyme-linked 
immunosorbent assays (ELlSAs). Serum antibodies were detected by ELISA according to 
the procedure described In Appendix A16.1. Serum dilutions of 1:40 were utilised. HPV-16 
VLP-speclfic antibodies in guinea pig vaginal wash samples were detected by ELISA using 
the polyvinyl alcohol and polyvinylpyrrolidone blocking method (Appendix A16.2) to minimise 
non-speclfic antibody binding. The vaginal wash samples were dOuted 1:5 before use. 
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5.3.4.2. Endpoint antibody titre determination 
The titres of HPV-16 VLP-specific serum antibodies were determined by ELISA, using the 
polyvinyl alcohol and polyvinylpyrrolidone blocking method (Appendix A 16.2). The sera were 
serially diluted by factors of 3, starting from 1 :40 and ending at 1 :787320. The antibody titres 
were calculated as the reciprocal of the highest dilution where the 00 was '22x that of the 
1 :300 dilution of the prebleed. 
5.3.4.3. DTH skin reaction measurement 
The delayed-type hypersensitivity (DTH) skin reaction is an antigen-dependent reaction, 
which includes erythema, induration and monocytic or neutrophilic infiltration at the site of 
antigen injection, within 24 to 72 hours. These reactions are dependent on both CD4+ and 
CD8+ memory T cells. The deposition of fibrinogen from the blood vessels, and to a lesser 
extent, the influx of T cells and monocytes, causes the tissue become indurated (Black 
1999). 
Briefly, the hair on the back of each guinea pig was removed, and antigens were 
administered by intradermal injection into this area. The Inoculation sites were observed 24, 
48 and 72 hours after inoculation and the induration (swelling) was measured at each site 
using calipers. This method is described in detail in Appendix A 17. 
5.3.4.4. Neutralislng antibody assay 
Due to the difficulty of infecting laboratory animals with HPV, in vitro methods have been 
developed for the investigation of neutrallsing antibodies to this virus. The neutralisation 
assays were performed by John Schiller (Laboratory of Cellular Oncology, National Cancer 
Institute, Bethesda, USA) as reported by Pastrana at al. (2004). This assay is based on the 
ability of pseudoviruses to transfer plasmid DNA, carrying a secreted alkaline phosphatase 
(SEAP) reporter gene, into cells. Antibody neutralisation of the pseudoviruses prevents the 
delivery of the plasmid into the cells, and hence prevents SEAP expression. Neutralisation 
titres were defined as the reciprocal of the highest serum dilution that caused at least a 50% 
reduction in SEAP activity. 
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5.4. RE5UL T5 
5.4.1. COMPARISON OF THE IMMUNITY INDUCED IN GUINEA PIGS BY 
IMMUNISATION WITH FRESHL Y-MADE rBCG-L 1 CONSTRUCTS 
Guinea pigs were immunised three times with freshly-made rBCG-L 1 (rBCG-112L 1NLS-, 
rBCG-119L 1 NLS-, or rBCG-361 L 1 R) or wild-type BCG. Figure 5.1 (A) shows that antibodies 
reactive with HPV-16 VLPs were detectable in all rBCG-L1-immunised groups after three 
immunisations. Figures 5.1 (B-D) depict the same results as Figure 5.1 (A), but here the 
groups are shown individually, and error bars have been included. The results are displayed 
as the group mean ratio of the ELISA OD492nm value to the OD value of the prebleed of each 
animal. This was necessary because the pre bleed OD ELISA values varied greatly (from 
OD492nm of 0.054 to 0.20) between the outbred guinea pigs. When the VLP-specific antibody 
responses were averaged, all rBCG-L 1 inoculated groups showed a significant difference to 
wild type-inoculated animals after the third inoculation (P<0.05, week 17). After the 3rt! 
inoculation (week 17) the rBCG-112L1 NLS-, rBCG-119L1 NLS-, and rBCG-361L1R groups 
showed significant differences to the wild-type group (P=0.03, P=0.03, and P=0.04, 
respectively). No significant differences were observed between the rBCG-L 1-immunised 
groups (P>0.6, week 17). 
A subset of the above animals was chosen for the assessment of antibody titres. Sera 
obtained on the 17th week of the study (Figure 5.2), from the wild-type BCG- and rBCG-
361L 1R-immunised guinea pigs, were analysed for antibody titres specific for HPV-16 VLPs. 
High L 1-specific antibody titres of 3420-29160 were elicited in the rBCG-361L 1R-immunised 
animals. The titres to L 1 were 3- to 81-fold higher than the background levels observed in 
the animals Immunised with wild-type BCG. 
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5.4.l . THE EFFEC T OF WlLD.TYPE BCG PRIMING ON THE IMMUNITY INDUCEO IN 
GUINEA PIGS BY raCG.!..1, AND THE COMPARISON BETWEEN FRESHL Y.MADE 
AND FROZENITHAWED rBCG-l. 1 
BeG \MId-type Drimmg 
TII.s amlTl8l study WIS conducted 10 Investlg.te wllelher pnOl" ommums.,ron Wlttl BeG WOuld 
prevent sub~q..,en' Immurll'Y to recomb1n8n1 BCG The Immune responses et.cJted in 
gWlea pigs \hal had been prrned Wlth .... 1I1Mype BeG ilnd tIlen boosted WIth rBeG-
112ll ....... , were compared to 8111m,Is thaI were invnumsed wdn rBCG-112l1j<&s, but lhat 
h,d nOl been pl'Vl'1lchy.1h wUd-type BeG 
Figures 53 (A-C) illustrate antibodies reactwI IMIh HPV_16 VlPs FIgure S 3 (Al rndude$ 
the "I'()UPS ommu",sed by both the subcutaneous and Intr.lmuscular routes FIgures S 3 (B 
and C) dlsptay the same results as FlQure S 3 (A) . but here the groups lIave been split up 
according to route of immunIsation and error ba~ have been included All groups 
II'I1mu",sed WIth rflCG-11211f&.S'" . whetner with or WIthout wild-type BeG primIng ellated 
'" 
SIgn ificant serum antIbody levels, when compared to the wild·type BCG negative control 
group. The. animals immun;sed s.c. with rBCG-l1 (withol.ll a wild-type BCG pnme) elicited 
sogniftCant levels o f V LP-specific a ntibodies when compared w ~h t he wild -type BCG-only-
rmmunised group after lhe 3'" mmunisation (week 14, P:O.057 , Figure 5.3 B). but not after 
the 2''' immunisation (week 6. P:0.54) . On the other hand. the animais primed with wild-
type BCG and boosted with 5 c. rBCG-L 1 developed significant specifIC antibodies after the 
2"" and 3'" rBCG-112L 1"'5- immunisalions when compared Wlth the wild-type BCG-.only 
group (weeks 6 and 14. P"0 ,05 and P"0.011 . respecllvely). 1 he a nimals thai h ad been 
primed with a dose of wild-type BCG followed by S.c, rBCG-L 1 boosts had genemled higher 
levels of anli-VLP antibodies than the s,c. rBCG-L t-only group (Figure 53 B): these 
responses were slgnilicanUy different after the 2'" and 3" rBCG-t 12L ! .. .s- boosts (weeks 6 
and t4 , P:O.Ol and P:O,022. respectively), 
The w~d-type BCG primeJl.m rBCG-L 1 boost group elicited sigmficant levels of VLP-specific 
ant ibodies when compared with the wil(Hype BCG-onty group at week 6 (""0.017, Figure 
5.3 C) and at week 14 (F'=O.OOI). The I.m rBCG-Lt-only group was not signiflCan~y 
diffefent 10 the wild-type BCG-only group at week 6 (~O 28) but was sign;t;cantly dMerent 2 
weeks after the 3"' inocula~on (""0.014. week 14). The wild·type BCG primer! m rBCG-L 1 
boost Inoculation regimen elOcited higher levels 01 anli-VLP antibodies than Ihe I,m, rBCG-L 1-
only 'mrnunisation regimen (week 6. P=-0.OO7: week 14 , ,0..0,04). 
The inoculation routes dk! nol appear significant (F igure 5.3 A) . The antl-VLP-16 antibodies 
generated by the wild·type BCG primeis'{:. rBCG-L I boost and Ihe wild-type BCG pnmefo,m, 
rSCG-L 1 boost vaccination regimens were not significantl y different (P"0,428 at week 6; 
P:0.68 at week 14), The an~-VLP-16 annbody responses generaled by the s.c. rBCG.L1-
only and the i.m rBCG-L1-only Inoculation regimens were also not significantly different to 
each other (,0,,0.42 at week 6: P:O.33 at week 14). 
Freshly·made versus fr<l.,enlll\awed rSCG-L 1 
Freshly-made and frozen/thawed BCG-L 1 recombinants were tested in the guinea pig model. 
to determine whether an immunogenicity d ifferen~e eldsted between Ihe two methods of 
preparation (Figure 5.4), Two weeks after the 2"" r6CG-L 1 inoculation (week 6), the freshly-
made rBCG-L I had eliC~ed a sigrlfficantly greater anl~L 1 antibody response than 
f.ozen/thawed rBCG-L1 (P=O.016); however. 2 weeks after the 3'" inoculation (week 14). no 
diffe.ence was observed between the 2 gr<lUpS (F'=0.61 5). 
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01 gUIIle8 pig. WI1h t,esnly-made or Irozenllh3Wed ,BCG-1121 I ...... Gil""'" pog$ ~re ,rrrnunrsed 81 
~ek 0 4 and 12 WI1h Tokyo ,BCG· 11 21.. I ... r (rep'e$efIte<l by a,"OWS) The (laW a'e TtI)oe5entea '" 
In. mean ,atlO 01 the 00 ...... ~~ Iue to lilt! 00 cf the prebieea '" SEM 
The loeslHMoe rBCG.t I group _ ,ogn ,!.cantly ddTerent to I!le wttd .1)'p1! BCG-ot>t\t group at weoek 6 
I f>:O 0311) 8nd it week II (f>:0 OlS) Th. (to;zenltt>_ rSCG--!..l g;o"l' was sogndicar1'y d,lferen! to 
1he WIkI-I)'pI! BCG-<ln ly group 8\ weekti 1P-~02) 8no 8t week 14 (~02) 
OTH skID reaelions 
To Investigate Ine am'9'8n-speelfic T-ceil mmuMV elICited n r13CG·LI _immunrsed gunea 
pogs OTH 5l<In tes ts wele pertonn.ed (Frgure 5 5) to ppo, hact HPV·16 VLPs and disrupted 
HPV_16 VLPs AI grot.rpt ~nisec wIIn reCG-ll e!relled OTh Skirl reactroos to intact anC 
disrupted HPV-16 L 1 \lLPs while the wild·type conll'~ animals diD not Tne reaclKlfl!l were 
on a~erage greatest 48 houn; after OTH anUgen InoculatIOn and were often s~1I promO'lem 
afler 72!\Ours No ammals Developed ,eactlons 10 PBS or to carDonate Dul'fer (nO! Irrown) 
Indicalng tl'liI1 the reactlOtll we<e ant,gen-specific 
All anrnals 'rTrnunrsed WIth BCG (wold-type or r13CG-ll) showed pos~,.. OTH reactions 10 
OPO The Ihdurauon reaclions 10 PPO In Ihe group ""1'IU_ ~ramuSCUlarty Wllh reCG·L I 
were signifiCantly smaler Ihan the OPO responses In Ine suDcut_ousl)'-rnmumsed groups 
(P<.O 05) The Siles of \tie skin reacuons !O PPO WI a. the stJDcuta'leouslV·,nYl'hlfllled 
groups weill stmllar (p>0 05) 
". 
A. DISrupted ~ 
0 
50 .. ....."pollC&l .. '1 .... , ...... .... 'IIOO-l'_ 
Ie .. ,,. .... Ie .aoo-U_I 
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.m rljOO."'""", 
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Figu re 5.5. Delaye-Hype hvperMlft5rtIVlty 51"" ,,,Clions dlSlll.te<l tly guinil. P<l5 Gu.,ea pigs INtI,. 
Immun...:l 'Min """' Iy.m_ (hun) Or rrcUnilnawed Ina '"DeO) Tokyo rBCG·' 12Ll ... r ......" bOOlte, 
""... tt _lea 4 fro:! , 2. Or "'1, were p,."e-d Wltl1 an Oi'M'IunlA*on 01 wik!.lype TOOI'/O 9::G In::I me", 
DOosU'd wI\!1 To kyo tSCG- 112\. ' .. r 4 8 and 115weotQ Ifterwa,.,. DTH '''<;'101'11 _re meawM<l 46 
hoY,. llIe" d l'looollW)n 01 d.rtJ~ HPV·'8 L 1 VLPs ,AI , .. lOCI VLPs 18). or PPO Ie) T .... ,esul15 
. re "p,et.se(I os IIIe mel" DTH reecllOn flU In mm. SEM 
'" 
The OTH reaCllons to both imaa and disrupted VLPs were slgndicantly gAialer In !he 
anmals that reelllVed a priming dose 01 wlloHype BCG pm>e, followed by a Lm_ rSCG-t j 
immunisation, than lhey weAl in the 1m rSCG-tI-on/y group (P-O 014 and P:Q034 
respectlvelyl . T ile average Indur!llJOn response displaYed I.l\llhe 8CG WlId·type p.-rnels.c. 
rSCG-t1 anImals, 10 Inlact and dIsrupted VlPs, was grll8181 man thai oIlhe s.c. rSCG·L I· 
only anImals. Ilowftvef the d,fhtlence was IlOI sigMlcanl (P>O.OS). The OTH rnactlonS 10 
VLPs were sim'ar (P>Q.OS) in the groups mmunlsed w~h freshly,made rBCG·L 1 and with 
frozen/th.awed rSCG-ll. 
.5.4.3. COMPARISON OF EXPRESSION VECTORS, DOSES, CODON OPTlMISAnON 
AHD IMMUNISATION ROUTES ON THE IMMUNITY INDUCED IN GUINEA PIGS 
BY VACCINATION WITH rSCG·ll 
The an~body and DTH responses ellc iled by gu,nea pIgs lollowlr.g Immunisation w~h a panel 
of BCG-L I recombinants were compared The Immune respOnses Induced by different 
rSCG·ll doses. roules of InoculaTIon, and effects of II eodon OPtrmisal ion and II truncallOO 
wern also compare<!. Figure 5.6 (A) Indlldes all the BCG·lI re«mcrinanlS, ({lUTes and 
doses lesTed: and provldes an overaU picture dIlle systemic antIbodies reactr1/9 w~h Hpv· 
16 VLPs. AU the groups, WIth the exception of 3, tllal were irnmunksed WIIh rflCG-t I, eIioted 
sognrfrcant leyerS 01 antrbodles kI Hpv·16 VLPs (Fig ~_6), Of lhe 3 groups lhat had fa~ed to 
elldl U·spect!1c immunity, two had been immun:S9d WIth low doses (10"' dul 01 r9CG-
I 19111l(:Go or rBCG-36ll1. The thua group had treen Immunlsed WIth a high dose (:!lela" 
cluj d rBCG·112L I .. Figures ~.6 (S-F) depoct the same results 81 FIgUre ~ 6 (A), bUI here 
specific groups are compare<! and error bar.I have been rnetuded 
CoropanSOf) ot e~pres$ion vectors 
AI the hrgh dose (:!lela" cluj, I9CG·11211. was the ol'lly construct that la~ed to elJC~ 
s!pnlfrcamly higtler leyels of anh-L t antibodies ttlan the BCG control (rSCG·GAG) group 
(P>oO.075, week 20, Figure ~6 B) Ttlere does hO'o'o9ver appear to be a trend 01 Increasing 
antIbodies In the rSCG·11211. group, and greater anmal numbers may ha~, produced a 
srgniflcanl result. The anU-l I anllbodies measured In the rBCG·I t 9L 1. and rBCG·361l1. 
groups WOfa hlllher than those In the rSCG-GAG group (P<0.05, week 20. Figure ~.6 B). 
S!pniflciln~y more HPV.16 LI·specifrc antibodies wer, IndUCed by rSCG·361L1 . than by 
rBCG- It 2l1 . (P"O.04): howeyer, 00 difference was Observed between the rBCG·361 L l . and 
rSGG-119LI . {P=O,31) groups. and no dillerence belween Ihe rSGG-1 12LI . and rBGG-
119L I . (P=O I) groups The level 01 L l_speeWlc antibodies induced by rSCG-119L 1 EICGo was 
not signilicanUy dille rent to Ihat induced by rSCG - 112L l ee ... (P=O.7, week 20 Fogure 5,6 G) 
Allhough there appears 10 be a 9rooual increase In L l-anlibody levels in Ule rBCG-GAG-
immunlSed groop. these anbbody levels are not significantly higher than those in the PBS-
immunised group (P=O 14, week 20) Whereas 3 or 4 immunlSaloons WIth rBCG-l1 were 
necessary to ellCiI sign ificanl levels of antibodIes to L I . h igh anlibOdy levels were eliCiled 
after the fi rst pulilied HPV-16 VLP immumsabon (ralio of prebleed of 20 25!7 3 at week 4, 
dala not shown) 
---
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- ---
" I I I I I 0 
" 
, , , 
" , 
, 
• • 1 • • • • , I • • , 
• , 
, 
• • , • • • " " .. " " M w_. 
Figure 5.5 jA). HPv-16 L 1 v LP-5peClhc system.: antlbOOy les(>OIi!ieS Induced 101low1!1g ,"""unisatlOfl 
01 gu.., u pigs With rSCG-l1 I'" ~Ied on the~) Gu.nea PIllS _ 'e ommuntsed I a 01 1m j only 
IBCG- t t211 ...... ) 31 weeks 0 , 4 6 12 a rlCl 16 weeks (lePlesenled by allOWS) With eltnel. PBS. rBCG -
GAG 01 re<:;<lmbd1,.,.,t BCG e"Pressi "1I HPv-16 LI M <JOse'S wese b iO' c/u, hcel't wne re IOOlCilted 
by -i<:M' dOSe" ( to' cful Trre <lata ale replesenled as !he mean ratio oI lhe 0 0 _ va lue to the CD 
~alue 01 1I1e pre~ The average valiJe obta..,ea from me VLP· 16 onmo.f llsed anomais was 
20.25. 7 3 at _eI< 4 aoo 34 06. I S 3 al week a (I'l0l shown on groph ) 
._-, .... " -p, I 
B. Com"".I.on Of • • p, .... ion o· -. PeS ,Bcx:»e1.C'AG 
veeD, •• ",,_"rIg wild· ~ rllc:o.JelLl . • o . . rBCG. I .Zl'. -0- .1ICG-111iIl1. 
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F igu.. 5.t (8 _ C). HI'V-16 LI V\..P-spe<:'1Jc .",~ "",lC><>dy rI!'SDOmes II'duced '_"'II 
IITlmlJnORtlOn of gUrIi!3 1'9' _ r8CG-L 1 , ... losIed '" !hi! legend) Qu,nea P'9" we", mmurusoe<J i d Of 
,m (0I'Iy rBCG-"21. ' ..... _);01 _5 0 4 II. 12 _ 16 weeks (~n:ed Dy " '''''''''I wnn e~, PBS 
.BCG.GIG Of Ie(:~nl BeG e . pre uong H""'·16 L 1 AI doses we'" 2>:10" ctu . unless otnelWlSe 
IhOlCOltea Tile diil:ll at<! ~sen!eO ~ !hi! mean '''''0 01 me 00 .. _ value to tile OD V;l~ of !hi! 
pre_~SEM 
Codoo Oplm tSatlOfl 
In con trast to the rSCG·112i..1. construct Immunis.ahon wrth rBC(;'l12L l~ (expressng 
codon-optimised ll ) elict!ed s,gn lficanl levels of antl-L 1 antj)odll!s (Fogure 5 6 OJ At WfIeIl 
20. !he level of Ll-speclic anUbod,es e!ialed by rSCG-112L Isc:Go was J1j9'1ef than thai 
elicited by .BeG·GAG (p--a OIXlot ). and nigher than thai e lICited by rSCG-l l2Ll. (P>o O 002) 
,,. 
... 
COdon opWnlPlion of L 1. oo-ver. did nol alwJys •• auh in In Increased immune response 
to 11 , .s rBCG-t1911 BCOt (eooon opIi~ed) and r8CG-119L1 . (non-codon optimised) 
pl'OOuc«l .!miII, levels oIl1 ,.nbbDdies (,P.O 43, __ 20, Figure 5 6 E) 
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Figure 5.11 (0 and E). 1-PY·16 L1 VlP.-pec1flc .yil8!lu: InllOOC1y ,~ nluc:«l tolloww'Q 
immun_ olgunea pigs willi rBCc.L 1 (n Isled in !he llgend) Gulnei ~wer.lmrnunrMd I,d 0< 
,m (only rBCG-112L ' __ 1 ill weeQ 0, 4, e, 1211nC1 111_ (""PI_led by IrT_l -. 11_. PeS 
rSCG-GAG, 01' reoorTIbtliint BOO 1I><pr1l...-.g HP\I·16 L 1 AI _ were blO' clu. unle. 0I\eI'WIIIe 
IhCl ..... !a;t The data aN rep.eee,,\ed II I1e ~iln ratio 01 1M 00_ VIIu. 10 me 00 Villue 01 Ihe 
",ebllled ~ SEM 
'" 
Dose comparison 
The Immllne responses elicFted by th e recombinants. rBCG· II 9L1 BCC>o Q( reCG·361L 1 .. 
were assessed al two doses When admlntSlered in the larger dose (2Xl0~ Cflll , these 
re(:ombinant$ 5l1CCesSl'uty elicited antibody responses 10 VlP$. Neither recombinanl eljc~ed 
signifICant antl-ll antibody levels at the low dose (10' cfu). when compared to rBCG-GAG 
(P>O,05, week 20. Figures 5.6 F and G). 
F. , e CG.119L1 0CG0 ata 
dOH 01 biO' O. Ixl0' 
G. 18CG..361l1"""" ata 
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Figure 5.G If and GI, HPV'-16 Ll VlP-specrfic aySlemic antibody teIjXIn8eS ilducec following 
'mnu:,usation 01 gu",oo PI9S \<11m t8CG-L1 (as IiBted in the legem) Gulnea pigs were n1ml11l lsed I d o. 
1m (on~ tSCG-112L 1 ..... ) at weeks O. 4, 8, 12 and 18 weeks (represented by 3""""'jwilll ",rtne., PElS, 
tSCG-GAG, Qt 'ecomOl1ant BCG expr", .. ing HPV·16 L 1 AI dOseS were 2.>clO' C/U , U'lless o\tll!rwi5e 
tndlc:ated The data are 'S!)re5el1!e<1 as the fm'an r.otiQ 01 ~ OD_ value 10 the OD valu", 01 the 
pretllHd ~ SEM 
,., 
Roule compao:;Ol\ 
11\ pre~lOI,Is gl.lI1ea pogs Sludies (sectIOnS 54 I al\d 54 2) BCG was admllllstered 
imramuscularty nowever rt was decided to m ange to Intradermat admlmstration tor tne 
CUIlll"' study For compaJl$OI\ 10 lllese pi'eVlOUs stud,es. in willen rBCG·11211tu· was 
adml",~ered I m tne prestrt study IndJd!!(! i,m and I d ,mmumsalloll!i 01 r8eo-I 12l1tf..5. 
tmramuSCUlar Immumsanon WIIn lOe NlS-truneated L1 r!COl'l1b1nam, r8CG-112L1 /<S'. d,d 
no! plodUCed slgMocanl levels 01 aJ1b.L 1 amlbodies wt1en compared 10 tile rBCG-GAG 
control (P=O '63. week 20 FIgure 5.5 H) In contrasl. i d mlmunisation WIIn tne same 
recorrtHnanl successfully elICIted amlOOdles to LI (P=O 0084 at week 20) 
• ~I.on 01 ' .d . .",., .P8$ '~I·GOG 
..c:tl..,." ,ou tes 01 ,1ICG-1121.1_ 1.4 ,eoo.ll21.I_,-", 
admlnillrat.oon , J , 
r I I • • 
T T I • • • I 1 • • • , T I , , I 
. ".,,~¥ ... ~ n! ., . .. ••. -0 • 
• • • • • • , • • • • w_ 
, 
FIg~r. 5.11 (H) . HPV·16 II VLP'I!l"C,!,c sy&lemiCanut)Ody resoom;esln<ll!Ced '-"9 ........... Ls;I\IOn of 
gu.neil pogl.....m rSCG--L1 (~Inted n tile IegeMl Gune. pog_ ""' .. mmun<Sed , <\ or I m (ont,' rSCG-
112l l ... d 11 __ 0, 4 8 12 ilnd 18 _u (~_nted by MIOWS) ""til elt/ler, PBS. rBCG-GAG. Or 
~nl BCG exp!e-M1t9 Hl'V·16 U AJI dO$el _II 2. '0' C!U unless otherwise ind ,c~te<l Tile 
o.~.re reDfetolffited~. the lTIean ",tlO 01 tile 00_ v.rue to tM 00 Vlllue 0I111e preb!eea '" SEM 
NlS lruocaliOO 
r8CG·1 12L I , and rSCG·11 2L 1''''5' were compafed 10 Invesl llf!le whether the deletion ol lhe 
L 1 noclellf loclI~5allon 5'gnal (NLS) would a!fecl lhe Immune responses eli(;lled 10 LIThe 
construct eKpfes,sing lul~lerl9tn L 1 r8CG·11 2L 1 .. l aded 10 ellCll s,gnlrocam levels of anll·l\ 
antibodies ., gUll1ea PIQs (P-O 075 ~ek 20: Figure 56 I), nowever Immunisation wiln the 
NLS-truneated L I reeomblflsm rBCG·112L I,u ' successfully did:;o {P=0.OOS 4. week 20) 
I. Com~"o.on 01 full-lenglh 
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F'IIUf, 56 !I). HPV·16 L 1 VlP.lpee,hc . yslerne lIt'llbOdy responses 0><l1Jee<j 1010wlrlg Imm""lSal.", of 
QU ... a Illfil' 'Nun!SCG-L 1 (,..11511Id In IheleogeOO) Gume3 pg. we,e ""m........ea I <I or I m (only rBCG· 
112l1 ... r l at ~ O. 4, 1:1 12 Qr<l 16 weeU [representee! by w rDWS) ""'" ermer PBS. r8CG-GAG, Or 
reoomlJO-"ml !)CG IIlIprns~ f-FV_ HI L' Ali doses IIIerl! 2>1 rf elll unleSS otherwISe ondl(o;)!e<l TM 
Oal' are ~,esenleo all \he mean rato of {r.e 00_ ."""'10 the 00 ~al~ oIlhe pre!lleoe<l. SEN 
Aol,bO(j"'!Q aen,tal secrel'0!!5 
Vaginal wash samples wer. coll~led from Ihe g'linl!i pigs 2 weeks aner the SO!'COfKI ana 
'ounh mmuni$8~on$ aM were lested lor Ihe presence 01 anflood,es s~Clfic 10. HPV·16 
VLPs (Figure 51) Aller Ih. foo.Jllh mmurnsatloo strong VI..P·SpeerflC responses were 
deleclellin a numtler 01 the rSCG·L1 ·immunlsea al1tfl'lal, (especafy In Ihe rSCG-36ILt .. 
rBCG-119L I. and rBCG·119L IBCOo groups): ~ver. I~rge v~natJOns tletwt!1!fl anImalS 
with in the same group. reduced It'Ie group ~verages SUl)stan tlOllly AIthollQn the anbbodlf:s 
elicited In the raCG.361ll .. raCG-\ 191.. I, and rSCG-II9L l lCOo groops were :.2-fold thoilt 
otlservld in theIr respect ... e pre-waSh samples only It'Ie rBCG·11911. grOtlp ellctted a 
response that wU more IMrlIWlCe Ihal of Ihe reCO-361-GAG C011uol group The average 
ant lbOOy level In the rSCG_II91 I, group was 3 limes Ihal 01 th' reCG-361 -GAG control 
group (P=O 02 aft" lhe 1000nh ImmUf1lSabon) 
High levelS of \ILP-$pt'C/;c ;tnbl)Odles _,. dllided In It'll vagInal washes lrom the VlP-I6-
ImmtA'llsed animalS AIt,r the 'ountllnvnunos;J!lon Ihe II'IIe,age anbbody level f1 Ihls group 
was 15 ).fola thal 01 the PBS contrOl O'OIJp ("""0 003) 
'" 
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,ec;o.l1t\. 100,," '3--
f9CG.lIS'LI.",.. _ e--. , 
'1IIC(;."IIlIoogoo .... "" .. ~ 
B. PPD , , • • • " " - , 
,8CG-(;O.G I '+ 
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Flgu'e 5.8. Qo>layecI.'~ "'1'P'!,&eI'llClVCy""" ~t:l6QIi1yeo Dy 011"'" ~ G\.W1e~ DogII we<e 
!fNf1IJn....-d t:I or, m lonfy fBCG ,,21..1....-) ""'''' ef1e< PBS. VLP. <BCG-GAG. 01 .. _ .... u 9CG 
."pres .. ng !-PV·'6l1 (.1lsIed MlOve) The an""l$ .eoe,ved 5 ,,"mu1l$8llOnS,'--'~ _ ,1I1eMI. 
1>e!Wee" Ndl adm,n15lrabOn AIlt:l....,._re 2. 'o"cfu unlet& ,ndoc:JIet:I oy·lowdoM· (10' du) Dn; 
, .. acllons"""e "...,HUred 48 .... aile<' 11 '1IOQJ1Mlon of HPV·16 VLP (AI PPO (Sl 01 PBS 11\011_1 
The 'HUlts _ e>+""iIMed .. ~ OlH ~iICIJOn W"'" mm • SE'" No OTH 'UCI ..... developed 10 
PeS", lI<1y oI1I'Ie ... ""al$ (RQI sIlOW1'I) 
'" 
tile anllT'lats thaI were Immunosed intradermall~ Wllh rBCG-1 12L 1 ""y displayed signifK:ilm 
skin reactions 10 VLP, Ille an~11 imml.llllsed Intraml.lscl.l13r1y with Ihe same recombinant did 
noe (P>oO (5) With Ille excep~on 01 Ihe low BCG dOse and Intraml.lscl.ltany Immunised 
groups Ihe DTH reaclions to VLPs were similar (P>0 .05) in a ll other rBCG·L l .lmml.ln ised 
groups 
No animals developed skin reactions to PBS No rBCG-361·GAG·immun lsed a",mals 
clevetoped Induration reactions to HPV-16 VlP (P>O 05). All groups Imml.lnised w~h BeG 
(rBeG-GAG or ,BCG·L1) diSplayed poSiHve s~(n reactlOOS to PPO. which wele 01 5lm~ar 
magnitude (P>O 05) 
Hpv· 1S psel.ldOVlrlon npUlijl llSilign 
An In Vitro neutra lisation alsay was performed. which I. based on Ihe abil ity 01 SEAP HPV· 
16 psei.idovll"l.lSf:!1 10 Ilansler the SEAP reponer gane into cens. Neutralisation btres were 
defined as the reclplocal 01 the highest llefl.lm dilution thaI C8I.lS!ld al least a 50% reduction 
In SEAP activ ity The prebleed ser ....... and week; 20 serum from one antmal of each of the 
above menlloned gUinea pig groups were tested lor neutrahsrng ant ibodies (Table 5 3) 
Tabls 5.3. SEA? pseudOVlrl.l5 neutrall$lltlon assay to test whether rSCG-L I eriClled HPV.16 
specific neutraliSlng anbbodies In gl.llrrea t*gs 
Immunogen 
"" ,BCG-GAG 
,BCG-361 L I, 
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The only serum that was shown to cause neutralisation of HPV-16 pseudovlruses was that of 
the VLP-immunised animal; which produced a 50% neutralisation titre of 43700 (Table 5.3). 
All other samples induding prebleeds (not shown) and post-immunisation sera of the rBCG-
L 1. rBCG-GAG, and PBS immunised animals were negative at serum dilutions of 1 :20. All 
samples, including that of the VLP-immunlsed animal, were negative in the BPV 
neutralisation control assay, at serum dilutions of 1 :20. Serum was considered positive for 
neutralising antibodies if Its HPV-16 neutralisation value was at least 4-fold higher than that 
of the HPV-18 assay. This assay was repeated and the results confirmed (Debbie Stewart; 
Department of Clinical Laboratory Science, University of Cape Town). 
5.5. DISCUSSION 
The aim of this research was to investigate the possibility of utilising rBCG, expressing HPV-
16 L 1. as a prophylactic vaccine for HPV; I therefore focused on the ability of rBCG-L 1 to 
generate antibodies that were specific for HPV-16 L 1 VLPs. HPV-16 VLP-specific cell-
mediated immunity was also assessed, as these responses would be valuable for the 
elimination of infected cells, when sterilising antibody immunity fails to occur. The primary 
objective of this study was to find a suitable end product vaccine, this influenced the 
approach to the project; and accordingly it was only of secondary Importance to compare 
results from the BCG-L 1 recombinants in a carefully controlled manner. 
5.5.1. IMMUNITY INDUCED IN GUINEA PIGS BY IMMUNISATION WITH FRESHLY· 
MADE rBCG-L 1 CONSTRUCTS 
In the first animal experiment, guinea pigs were immunised three times with freshly-made 
rBCG-L 1 (grown to the correct OD by the day of immunisation, and harvested just prior to 
immunisation). Here the ability of rBCG expressing two HPV-16 L 1 variants. full-length HPV-
16 L1, and L1 without the NLS (L1 NLS-. 22 aa C-terminal truncation). to elicit antibodies 
specific for HPV-16 L 1 was demonstrated. Guinea pigs were utilised as they share a 
number of similarities with humans in their response to mycobacterial infection, clinically, 
pathologically and immunologically (Horwitz at al., 2000; McMurray, 1994). The outbred 
nature of the guinea pigs, which often resulted in large immune response variations between 
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individual animals, also more closely resembles the anticipated situation for the human 
population. Although there were animals in each group that responded very strongly, some 
animals did not respond, thus creating large standard deviation values and low probability 
values. For each rBCG-L 1 construct, three immunisations were required before a sharp 
increase in the antibody level was observed; the need for repeated immunisations is most 
probably a consequence of low L 1 expression. The antibody levels elicited by the three 
different rBCG-L 1 constructs were comparable, which suggests that there may be an upper 
threshold of L 1 expression in BCG, however, we cannot make direct comparisons, as the 
constructs were expressing different L 1 variants. High anti-L 1 antibody titres (3240-29160; 
3- to 81-fold higher than those observed in the wild-type BCG-immunised animals) were 
observed in the rBCG-361 L 1 R-immunised animals. These titres are comparable with other 
guinea pig immunogenicity studies, in which viral proteins were delivered by rBCG (Lim et 
a/., 1997; Honda at a/., 1995). The moderate antibody response seen in the one wild-type 
BCG-immunised animal was most likely due to the strong non-specific adjuvant properties of 
BCG (Fuerst at a/., 1992). Gradually increaSing non-specific antibody responses have been 
noted by other groups, after immunisation of guinea pigs with BCG (Lim at a/., 1997; 
Lagranderie et a/., 1993). 
It should be noted that, although the VLPs against which the sera were routinely tested are 
referred as "VLPs", one can not assume that all the L 1 protein present in these samples is in 
an assembled form, as breakdown products and linear species can be expected to form 
dUring the coating of the ELISA plates. The possibility therefore exists that L 1-posltive sera 
from rBCG-L 1-lmmunised animals may bind to linear L 1 forms and linear surface epitopes on 
VLPs/capsomeres or to conformational epitopes on VLPsicapsomeres. or to a mixture of 
both. Preliminary ELiSAs with sera from the above guinea pigs, which were performed in 
parallel on plates coated with VLPs In PBS or In carbonate buffer (causing breakdown of 
VLPs) resulted in similar data being obtained from the utilisation of both buffers, and hence 
only VLPs in PBS were utilised for further serum analysis. 
5.5.2. COMPARISON BElWEEN FRESHLY-MADE AND FROZENITHAWED rBCG..t.1 
In subsequent experiments, the use of frozen BCG immunisation stocks was preferred, as 
these could be consistent from one Immunisation to the other, and could be tested for 
genetic stability before they were used. When freshly-made immunisation stocks were 
compared with frozenlthawed stocks, the freshly-made rBCG-L 1 elicited a significantly 
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greater anti-L 1 antibody response when measured two weeks after the 2nd rBCG-L 1 
inoculation; however, 2 weeks after the 3n:1 inoculation, no difference was observed between 
the two groups. After the 2nd freshly-made rBCG-L 1 immunisation, a steady increase in anti-
VLP antibody levels was elicited; however, the increase in the antibody levels elicited by 
frozen/thawed rBCG-L 1 was preceded by an initial lag phase, suggesting that BCG needed a 
recovery stage. At the end of the study, the DTH reactions to VLPs were comparable in the 
groups immunised with freshly-made rBCG-L 1 and with frozenlthawed rBCG-L 1. Although 
the antibody levels were comparable after the 3n:1 immunisation, the antibody levels produced 
by freshly-made rBCG-L 1 in this animal study were lower those elicited in the previous study 
by the same rBCG-L 1 construct (rBCG-112L 1NLS-); suggesting possible inconsistencies in 
the preparation of fresh rBCG. A study with larger animal numbers and more rBCG-L 1 
constructs would need to be performed to confirm the differences between immunogen 
preparations; however, the impracticality of utilising fresh rBCG preparations for large-scale 
vaccination roll-out does not warrant such an investigation. 
5.5.3. THE EFFECT OF WILD-TYPE BCG PRIMING ON THE IMMUNITY INDUCED IN 
GUINEA PIGS BY rBCG-L 1 
A concern surrounding the development of recombinant BCG vaccines is whether prior 
vaccination with wild-type BCG would adversely affect the immunity induced to recombinant 
BCG vaccines. This question is often asked because one of the suggested explanations for 
the poor efficacy of BCG vaccination is that prior exposure to environmental mycobacteria 
primes the immune response, causing a more rapid control of the BCG vaccination dose, 
and a consequent reduction in the immune response elicited to it (Agger and Anderson, 
2001; Hess and Kaufmann, 1999). This was confirmed by Buddie et a/. (2002) when they 
showed that when cows had been sensitised to environmental bacteria, the protective affect 
of subsequent BCG vaccination was adversely affected. Similar results have been obtained 
with live recombinant Salmonella vaccination, where prior immunisation with the carrier strain 
and, to a lesser extent with a heterologous strain, reduced the immune responses to foreign 
proteins delivered by subsequent immunisation with recombinant Salmonella (Roberts et a/., 
1999; Kohler et a/., 2000). In contrast to these results, a number of studies established that 
prior immunological experience with Salmonella enhanced the immune responses to 
heterologous proteins carried by the same strain (Whittle and Verma, 1997; Bao and 
Clements, 1991). A group investigating the effect of BCG-priming on the immunity induced 
by rBCG-LacZ In mice (Gheorghiu et a/., 1994; Lagranderie et a/., 1997a; Lagranderie et a/., 
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1996). showed that antibody responses to p-gal were dramatically increased in the BCG-
primed mice. however. proliferative responses were reduced. Also of interest is the 
observation by Mazzantini at al. (2004). of the adjuvant effect of rBCG-CRM197 (diphtheria 
toxin) on the antibody response induced to rBCG-FC (tetanus toxin). when these 
recombinants were delivered simultaneously. In the current study. I found that wild-type 
BCG-primed guinea pigs elicited enhanced L 1-specific antibody responses, when compared 
with non-primed animals. The wild-type BCG-primed guinea pigs also showed a trend of 
increased L 1 cell-mediated responses. as these animals displayed larger DTH Induration 
reactions. It Is thought that the augmentation of the immune responses observed in BCG-
primed animals is. as suggested by Gheorghlu at al. (1994). a result of the activation of 
BCG-specific T cells. leading to enhanced macrophage activation and enhanced antigen 
presentation of both the mycobacterial and recombinant proteins. 
5.5.4. COMPARISON OF EXPRESSION VECTORS, DOSES, CODON OP'rlMISATION 
AND IMMUNISATION ROUTES ON THE IMMUNITY INDUCED IN GUINEA PIGS 
BY VACCINATION WITH rBCG-L 1 
In the final guinea pig study, comparisons were drawn between a panel of rBCG-L 1 
constructs; aspects such as type of expression vector, codon optimisation. dosage, route of 
immunisation, and NLS deletion were compared. Large differences in the antibody levels 
were observed between animals within the same groups. as noted before. and hence 
significance values were often low. Antibody levels were compared with that of the rBCG-
GAG control group and not to the PBS group. as the non-specific response observed In the 
rBCG-GAG group was considerable. As seen previously. at least three immunisations were 
required before noticeable increases in antl-L 1 antibody levels were observed. On the other 
hand. only one immunisation with purified VLPs was required to induce high levels of 
antibodies to L1. The rBCG constructs. rBCG-112L1e and rBCG-112L1NLS-, utilising the 
pCB112 expression vector. consistently elicited the lowest antibody responses; which Is 
possibly a consequence of a weak promoter (18kDa) driving L 1 expression. In fact, rBCG-
112L 1 e was the only construct that failed to elicit significant levels of antibodies to L 1. when 
administered at the high dose. Although the average antibody response in the rBCG-
361L1e-Immunised animals was greater than that in the rBCG-119L1 e-immunised animals. 
the difference between them was not significant. The only clear reason. therefore, for a 
possible preference of rBCG-361 L 1 e over rBCG-119L 1 e would be due to its superior stability. 
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DTH skin reaction tests were performed to measure cell-mediated immunity; these Type IV 
Hypersensitivity reactions are dependent on both CD4+ and CD8+ memory T cells, but with a 
predominance of MHC class II-restricted CD4+ T cell activity, and hence an association with 
a Th1 cytokine profile (Ohtani et a/., 2004; Black. 1999). All rBCG-L 1 constructs. when 
administered at the higher dose. successfully induced L 1-specific DTH reactions. The potent 
cellular immunity adjuvant properties of BCG are evident here, because immunisation with 
rBCG-112L1 e, which failed to elicit a significant antibody response to L 1, successfully 
induced a DTH response was comparable to that induced by the other recombinants. The 
DTH reactions displayed by the rBCG-L1-immunised animals followed the typical Type IV 
Hypersensitivity reaction profile. with maximum induration appearing 48 hours after the skin 
test. Interestingly. the DTH reactions displayed by the VLP-immunised animals to the VLP 
skin tests did not follow the typical Type IV profile, in that these reactions started to decrease 
after 24 hours. There is a small possibility that these responses were caused by the non-
specific activation of the inflammatory response, or by a IgG-mediated-Type III 
Hypersensitivity response; however these reactions develop 1-2 hours after the skin test 
(Ponvert and Scheinmann, 2003), and unfortunately the animals were first examined 24 
hours post skin test. 
rBCG-L 1 dosage and route of inoculation both played important roles in the induction of 
immune responses. The low rBCG-L 1 dose (104 cfu) failed to elicit Significant antibody or 
cellular responses to L 1, but the same recombinants at the high dose (2x106 cfu) delivered 
sufficient L 1 for the induction of a response. The low dose was not sub-immunogenic, since 
responses were induced to BCG (PPD). but not to L 1 because of its low expression. 
Intramuscular immunisation of rBCG-112L 1 NLS- was not as efficient as the i.d. route at 
eliciting antibody or cell-mediated immunity to L 1. 
rBCG-112L 1 BCGe elicited more antibodies than rBCG-112L 1 e. providing evidence that either 
codon optimisation increased the amount of L 1 expressed by BCG. or that the presence of 5 
CpG-lslets on the optimised gene provided an enhanced adjuvant effect over the native gene 
(containing one weak CpG-islet at position 1184). However. in the case of rBCG-119L 1e. its 
codon optimised equivalent. rBCG-119L 1 BCGe. did not induce a higher antibody level. This 
again suggests that there is an upper threshold level of L 1 expression in BCG. rBCG-
112L 1 BCGe can express more L1 than rBCG-112L 1 e because the threshold has not been 
reached in rBCG-112L 1e. but since L 1 expression in rBCG-119L 1e is already at the threshold 
level. codon optimisation can not enhance expression further. It's difficult to speculate the 
cause of this apparent threshold. but it may possibly be due to a limited number of 
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chaperones, which bind to newly produced L 1, and in the process of trying to fold it, also 
protect it from degradation. Since this chaperone-bound L 1 is protected from degradation, 
this may be the L 1 that is generating an immune response. When the amount of L 1 is in 
excess of that which can be bound to the chaperones, then the unbound L 1 is rapidly 
degraded, and hence does not mount an immune response (William Bourn, personal 
communication; Department of Clinical Laboratory Science, University of Cape Town). 
The removal of the NLS, as in the rBCG-112L 1NLS- construct, also successfully enhanced 
the immune response induced to L 1. Here the improved immune response could have been 
a result of superior L 1 presentation in the BCG-infected cells, or increased expression of the 
truncated protein, of which the former is more likely since the truncation was only by 22 
amino acids. 
5.5.5. HPV·16 PSEUDOVIRION NEUTRALISING ANl'IBODY ASSESSMENT 
The finding that neutralislng antibodies were not detectable in the sera from the rBCG-L 1-
immunised animals, suggests that, either, L 1 could not assemble into VLPs or capsomeres 
within BCG, or if VLPs did form, the conformational epitopes were destroyed during 
lysosomal degradation of BCG. The former is more likely, since L 1 production in rBCG-L 1 
was not high enough to be detected, and it is therefore unlikely that the concentration would 
have been sufficient for VLP formation. This observation is of considerable concern since 
the proposed use of our rBCG-L 1 vaccine was as a prophylactic one, and hence the need for 
neutralising antibodies. 
5.5.6. ASSESSMENT OF ANTIBODIES IN GENITAL SECREl"IONS 
Since the genital tract is the site of HPV infection, the core objective of a prophylactic HPV 
vaccine is the generation of antibody and cell-mediated responses at the genital mucosa. In 
our study, L 1-specific antibodies were detected in the vaginal wash samples from a number 
of the rBCG-L 1-immunised animals, especially in the rBCG-361 L 1e, rBCG-119L 1e and 
rBCG-119L1 BCGe groups. Again, as a result of large differences between animals in the 
same groups, when averaged, only the rBCG-119L1e group elicited a L 1-specific response 
that was Significantly higher than that seen in the BCG control group. The groups with the 
highest anti-L 1 serum antibody levels (VLP, rBCG-361L 1e, and rBCG-119L 1e), also boasted 
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the highest average genital antibody levels; suggesting that the vaginal IgG antibodies 
originated by transudation from serum. It would be interesting to investigate mucosal routes 
of delivery, such oral or nasal, as these routes are expected to generate stronger responses 
at the genital mucosa. 
In summary, rBCG-L 1 elicited VLP-specific antibody and cell-mediated immune responses 
that were dependent on expression vector, dose, route of immunisation and L 1 variant. 
rBCG-361L 1e, and rBCG-119L 1e induced the highest serum antibody levels, but only rBCG-
119L 1e generated significant VLP-specific vaginal antibody responses. The low level of L 1 
expression by these recombinants required a strategy of multiple Immunisations; however, 
the use of purified VLP necessitated only one immunisation to induce a strong antibody 
response. While immunisation with VLP generated neutralising antibodies, immunisation 
with rBCG-L 1 failed to do so. Codon optimisation increased immunity to L 1, but only to an 
upper threshold level, and it is unknown whether this is a consequence of increased 
expression or CpG adjuvant effects of the codon optimised gene. The deletion of the L 1 
NLS appeared to increase the immune response, possibly by improving its presentation in 
rBCG-L 1-infected cells. Finally, prior immune exposure to wild-type BCG did not prevent the 
development of an immune response to rBCG-L 1, but in fact, increased it. 
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6.1. INTRODUCTION 
In this chapter I investigated the ability of recombinant BCG, expressing HPV"16 L 1, to 
protect mice against challenge with recombinant vaccinia viru~HPV-16 L1 (rW-L1R); which 
we have described previously (Marais et al., 1999). The difficulty experienced with the 
propagation of HPV in culture, and the lack of animal models for HPV, have hindered the 
development of animal models to evaluate papillomavirus protection. The rW-L 1 R challenge 
model is therefore a valuable tool for investigating the efficacy of candidate HPV vaccines. 
The rW-L 1R challenge model was first described by Marais et a/. (1999), in which mice 
immunised with HPV-16 VLPs elicited a T cell response that was able to provide protection 
against intraperitoneal (i.p.) challenge with rW-L 1R. The T cell responses were 
characterised by a Th1 cytokine profile, with some Th2 IL-2 production. Protection was 
demonstrated by a 4.61og10 reduction In the ovarian tltres of rW-L 1R In vaCCinated BALB/c 
mice, and a 2.31og10 reduction in vaccinated C57 BU6 mice. 
Recombinant vaccinia virus (rW) is widely used as a laboratory expression system due to its 
broad host range and large capacity for foreign DNA. Vaccinia virus (VV) replicates within 
the cytoplasm of infected cells, allowing heterologous proteins to enter the MHC dass 1 
pathway. and thereby inducing CDS+ CTL responses (Moss. 1996). Early. intermediate. and 
late pox promoters are available for the control of heterologous gene expression by rW. It 
has been shown that antigens expressed by rW from early pox promoters are able to induce 
CTL responses to these antigens; however, late pox promoters are not able to induce CTL 
responses to the antigens that they express (Bronte et a/., 1997; Zhou et a/., 1991 b). rW 
gene products are not expressed on the W envelope and are not directly accessible to 
antibodies (Zlnkemagei et al., 1990); rW challenge therefore allows for evaluation of cell" 
mediated, rather than neutralislng antibody Immune mechanisms. 
A number of groups have shown that vaccination can successfully control challenge with rW 
(Bachmann et al., 1994; Belyakov et a/., 1998; Binder and Kundig 1991; Kent et al .• 1998; 
Murata et al., 2003; Pancholl et al., 2003; Uno-Furuta at a/., 2003). Binder and KOndlg 
(1991) showed that mice immunised with vesticular stomitis virus (VSV) were protected from 
challenge with rW expressing the VSV nudeoprotein, and that t he predominant Immune 
response was a CDS-mediated CTL response. They showed that In mice depleted of CDS+ 
T cells, the rW virus was able to initiate an Infection equivalent to that in non-immunised 
mice. Depleting the challenged mice of CD4+ T cells had no effect, and the immunised mice 
were able to clear the rW infection. Bachmann et al. (1994) immunised mice with the 
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nucleoprotein (NP) of VSV and then challenged intraperitoneally with recombinant W-VSV-
NP. The immunised mice displayed 5.6 log10 specific protection from W-VSV-NP. In 
another study, mice Immunlsed intrarectally with a HIV-1 peptide vaccine (PCLUS3·18I11B) 
showed similar levels of protection to Bachmann's group after Intrarectal challenge with 
recombinant W expressing the HIV-1 gp160 (Belyakov et al., 1998). Murata et al. (2003) 
showed that immunisation of mice with hepatitis C (HCV) virus-like particles lead to a >5 
log10 reduction In vaccinia titres after challenge with rW expressing HCV proteins 
(wHCV.S); a DNA vaccine expressing the same HCV proteins, however, only displayed 1 
log10 protection after challenge with vvHCV.S. Uno-Furuta et aI. (2003) showed that mice 
immunlsed with a BCG recombinant expressing the CTL epitope, NS5a, of HCV 
demonstrated s peciflc protection of approx. 2.5 log10 when challenged with rW·HCV-NS. 
They determined that the major Immune response present in the mice was of the Th1-type, 
with production of IFN-y, IL-2 and IL·12. 
6.2. STUDY OBJEC·nVES 
The primary aim of this study was to determine the In vivo CTL responses elicited to BCG-L 1 
recombinants in mice, by measuring the level protection in a rW·L 1R challenge model. The 
humoral responses that were generated to the BCG-L 1 recombinants were measured, and 
compared with the rW-L 1R protection levels, to determine whether antibodies could be 
correlated with protection. Finally, the cell-mediated responses generated by rBCG-L 1 were 
investigated further by means of a cytotoxicity assay and by the measurement of coa+ T cell 
IFN-y production. 
6.3. MATERIALS AND METHODS 
6.3.1. ANIMALS 
Inbred BALB/c (H-i» mice, 8-12 weeks old, were obtained from South African Vaccine 
Producers (South Africa) a nd were housed in the U CT Animal Unit. A II a nimal protocols 
were approved by the UCT Animal Research Review Committee. Immunisatlons, serum and 
organ collections were performed by trained animal technologists. 
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6.3.2. CLONING INTO THE VACCINIA VIRUS SHUTTLE VECTOR 
The HPV-16 L 1 gene was cloned into the vaccinia virus shuttle vector, pSC65, fonning 
pSC65-L 1, as we have previously described (Marais et a/., 1999). This cloning strategy 
inserted the L 1 gene downstream of the constitutive, synthetic earlyllate promoter, P ElL. 
The pSC65 shuttle vector also contains anE. coli origin of replication (CoIE1), an ampicillin 
resistance g ene, a nd a ~-D galactosidase (LacZ) gene, which is under the control 0 f the 
poxvirus early/late p7.5 promoter. The multiple cloning site and LacZ gene are flanked by 
regions of the poxvirus thymidine kinase (TK) gene, which facilitates homologous 
recombination into the non-essential TK gene in the wild-type W genome. The interruption 
of the TK gene by this insertion also provides a selection mechanism for the recombinant 
viruses. In the presence of the thymidine analogue, 5-bromodeoxyuridine (BUdR), TK 
competent viruses (TK+) allow phosphorylation of BUdR, which is lethally incorporated into 
the virus genome. When the TK gene is interrupted in recombinant Ws, BudR is not 
phosphorylated, and hence has no lethal effect (Chakrabarti et a/., 1985). 
pSC65-L 1 was amplified by large scale plasmid preparation (Appendix A5.2); and was then 
linearised with Sca I, to ensure double crossover recombination (Di Marais, personal 
communication). 
6.3.3. RECOMBINANT VIRUS FORMATION 
Recombinant rVV-L 1 R was developed, as described in Appendix A22. Briefly, CV-1 cells 
were infected with vaccinia virus (Western Reserve strain; obtained from Dr John Williamson 
St Mary's Hospital, London) for 1 hr; after which DMEM medium and transfectlon medium 
(containing DOTAP and linearised pSC65-L1) were added to the cells. Transfection was 
allowed to proceed for 15min at room temperature. The infectedltransfected cells were then 
incubated at 37°C for 2-3 days, until cytopathic effect (cpe) was detected. To discern 
whether the transfection had been successful, the cells were subjected to 5-bromo-4-chloro-
3-indoyl-13-D galactosidase (X-gal) staining (see Appendix A23 for protocol). During this 
staining method, ~-galactosidase present in rVV-infected cells hydrolyses X-gal and results 
in the fonnation of blue cells. Cells from duplicate wells, that had not been stained, were 
frozen and thawed to release the newly-fonned recombinant virus. The expression of L 1 by 
rVV-L1R was confinned by immunofluorescence of infected CV-1 cells (MaraiS et a/., 1999; 
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Oi Marais is acknowledged for the final rW-L 1R recombinant and the immunofluorescence 
assay). To reduce contamination by wild-type vaccinia virus, the newly formed rW-L 1R viral 
stocks were put through several rounds of plaque purification and serial passage in HuTK" 
cells with BUdR selection (Appendix A22). until only blue plaques were detectable by X-gal 
staining. 
6.3.4. LARGE-8CALE VIRUS PROPAGATION IN EGGS 
Both rW-L1R and rW-GAG (an HIV-1 GAG W recombinant, from Therlon Biologics 
Corporation) were grown to high titres on the chorio-allantoic membranes of 11 day old 
fertilised chicken eggs. The resultant viral stocks were titrated on CV-1 cells. These 
protocols are described in detail in Appendices A24 and A25. 
6.3.5. MOUSE IMMUNISATIONS AND rVV·L 1R CHALLENGE 
6.3.5.1. Immunisation with Tokyo rBCG·L 1 
Groups of three female BALB/c mice were immunised I.p. with either HPV-16 VLP (10 
~mouse), BCG wild-type, rBCG-361L1R, rBCG-361L1 NLS-, or rBCG-NVL1R. The BCG 
doses were 2x1 cf cfu/mouse and were prepared immediately prior to immunisation 
(Appendix A15). All the BCG Inocula were of the Tokyo substrain. A control group of 3 mice 
received no immunisations. The mice were given booster inoculations, of the same dose 
and route, 4 and 8 weeks after the first inoculation. Two weeks after the last boost, the mice 
were challenged I.p. with 108 plaque forming units (pfu) of rW-l1R per mouse. Five days 
post-challenge the ovaries were harvested and homogenlsed to release the virus (Appendix 
A26). The virus obtained f rom group was pooled and t he viral loads were measured by 
titration In triplicate on CV-1 cells (Appendix A25). 
Retro-orbital blood samples were collected from each mouse at the beginning of the study, 
and just prior to challenge. Humoral responses to HPV-16 VLPs were investigated by ELISA 
(Appendix A16.2). In order to reduce non-SpecifIC binding of serum to trace amounts of 
baculovirus and insect cell proteins present In the VLP preparations, with which the ELISA 
plates had been coated, the serum samples were incubated for 1.5hrs at room temperature 
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in the presence of baculovirus/sf9 insect cell extract (kindly supplied by R. Rose, Rochester 
University, Rochester, USA) before they were added to the ELISA plates. A serum dilution 
of 1 :20 was utilised. 
6.3.5.2. Immunisation with Pasteur rBCG·l1 
Groups of 8 female BALB/c mice were immunised s.c. with either PBS, HPV-16 VLP (10 
fJ.g/mouse), BCG wild-type, rBCG-361 L 1. or rBCG-119L1.. The BCG doses were 2x106 
cfu/mouse, and were prepared from frozen stocks (Appendix A1S). All the BCG inocula were 
of the Pasteur substrain. The mice were given booster inoculations of the same dose and 
route, 4 and 8 weeks after the first inoculation. Two weeks after the last boost the mice were 
challenged I.p. with 108 pfu of rVV/mouse. Four mice from each group of 8, were challenged 
with rVV-L 1R, while the other four were challenged with the control virus, rVV-GAG. Five 
days postooChalienge the ovaries were harvested and homogenised to release the virus 
(Appendix A26). Each mouse was assessed for viral load, which was measured by titration, 
in triplicate, on CV-1 cells (Appendix A2S). 
Retro-orbital blood samples were collected from each mouse at the beginning of the study, 
and just prior to challenge. Humoral responses HPV-16 VLPs were investigated by ELISA 
(Appendix A 16.2). Before the sera were added to the ELISA plate, they were incubated with 
baculovlruS/insect cell extract, as described above. A serum dilution of 1 :20 was utilised. 
6.3.6. IMMUNISATION OF MICE WITH PASTEUR rBCG·l1 FOR INVES'rlGATION 
OF INTRACEllULAR CYTOKINE AND CTl RESPONSES 
As our lab had established immunological assays for the detection of responses to the HIV 
gp120 CTL epitope, we evaluated the cell-mediated immune responses to this epitope after 
immunisation with rBCG-119L 1 •. The HIV gp120 CTL epitope was included in the EpiA tag, 
which was cloned downstream of the L 1 gene. The detection of immune responses to this 
epitope after rBCG-119L1. immunisation would provide evidence of successful antigen 
delivery, and L 1 gene read-through. 
Twenty BALB/c mice received a single subcutaneous Inoculation behind the neck, with 2x106 
cfu of Pasteur rBCG-119L1 •. Two weeks later Inguinal lymph nodes cells were prepared, 
and were stimulated for 6 days in the presence of gp120 peptide. Intracellular cytokine flow 
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cytometry with rat monoclonal anti-mouse C03, COB and IFN-y was used to detect gp120 
peptide-specific COB+ cells producing IFN-y, after a further 4 hour stimulation in the absence 
or presence of the peptide (described in detail in Appendix A20). 
A CTl assay was also perfonned to measure ability of the mouse lymphocytes to cause 
specific lysis of gp120-puised p815 cells. Briefly, effector cells were prepared from mouse 
lymph nodes (above), as described in Appendix A19. The cytotoxic activity of the effector 
cells was tested in triplicate against PB15 (mouse mastocytoma, MHC class I cells) target 
cells, that had been labelled with 51 Chromium (51Cr) and had been pulsed with gp120 peptide 
(Appendix A21). The 51Cr released from the lysed target cells was measured, and reported 
as a percentage of specific lysis for each effector:target ratio utilised. 
6.4. RESULTS 
6.4.1. HUMORAL RESPONSE ELICITED IN MICE AFTER IMMUNISATION WITH TOKYO 
rBCG·L1 
The humoral immunity elicited In BALBlc mice was assessed following 3 immunisations with 
rBCG expressing HPV-16 L1. Two serum samples were collected: One before the start of 
the immunisations, and the other two weeks after the third immunisation (just prior to the 
challenge). The sera were tested for antibody responses specific for HPV-16 VlPs. 
The VlP-immunised animals, and the rBCG-NVl1 rrimmunised group elicited significant 
levels of antibodies to HPV-16 VlPs, when compared with the relevant controls (Figure 6.1; 
P<O.04). The VlP-immunised animals elicited the most notable VlP-specific antibody 
response, which was significantly greater than that generated by t he rBCG-l1-immunised 
animals. The BCG recombinants that failed to elicit Significant levels of antibodies (P>O.13) 
were both based on the pMV361 vector. 
6.4.2. PROTECTION FROM rW-L1R CHALLENGE AFTER IMMUNISATION WITH 
TOKYO rBCG-L 1 
We had already establiShed that immunisation with HPV-16 VlPs was able to protect mice 
from challenge with NV-l1 R (Marais st al., 1999). In the current study I investigated whether 
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Flgu.e 6 .1. Syit.mrc anribo<ly r"'5PO~ spe-clfrc 10. HPV_t6 L1 VlPs iooyced in mt<:e loIiOWlng 
Immunisa:Ja1 w1h To-kyo rBCG-L 1 (rBCG-.361 L I, rBffi.3SIL I .... , 0' IBCG·NVl 1.1 MICe were 
Immunrsl!<l 3 times at. 4 week Ifltemis Blood samplK were coll~ed 2 W10eks fo la...mg Ihe 3'" 
Immuntsatron H e data art tep.esented as the g.ouo mean OD_ .3t1OS to the group me3n 
Il<eb!eed ..."I\le % geM 
BALB/c mICe were Immunlsed 3 limes wrth rBCG·L 1 (BCQ.361l t. rBCQ.361l I .. , . 0' IBCQ. 
N\IL 1.1, and !hen cha llenged with V03CCorlla \llrus expressing 11 Five days after the rvv-l1 ~ 
challenge the vill:Cln la virus Iltres In the ovaries were titrated The vaccinia vrus obtained 
from each group of mice was pooled and lhe viral load was measured by IItration In lIiplicale 
For each group the average amount of vaccinia virus per mouse was calculated and is 
pre~enled Table 0 I and Flgu.e (; 2 The degree of prote-ction i~ pre~ented as the 10\1' 0 plu 
dIfference between the g({)IJps 
Mice immunisad wnh VLPs we.e protected oy , 42 log," when compared to the "n_ 
Inoculated control group Wik!.type 8CG·immunised animals did nol illICit a non·spec~1C 
protective response as no reduction In tVV-L1 ~ trtres was obsllrved when comparing thIS 
group to Ihe non·immunrslld group Thll amount of rvv·L 1 ~ r!!Covered from mlC~ mmunrsed 
With ""Id·type BeG appears grllatllr than that recovered from the non·mmunislld animals 
nowever, IhlS difference IS nol slgn,flcam {P=D 2341 Antmals Immunlsed w~h rBCG·NVL 1 ~ 
d lspla~d low levels of ll·speclfic protecuon wnen compared to the wild·type BCG--
'" 
Immunised animals (f':O 0043) Animals vacconaled With r8CG·36ILI A and rBCG· 
361 L I,u' were afforded enhanced prolectlon from oW·L IR challenge when compared to 
rBCG·NVL1.. Animals irnmunised wilh reCG·361L l ... s· were protected by 0 5 logoo more 
than lhose Immunlsed Wllh rBCG·361L lR (f':O.041 )_ 
Table 6.1, Protection 'rom rW·L1R chattenge in mice Immunised wIth Tokyo reCG·L1 
(BCG·361 L1R, reCG·361Ll,u·, or rBCG·NVL1 .. ) Protectoon afforded by vaccinabon is 
represenled by the 10g'Q reduction In virat l itre compared to the control groups (non· 
Inoculated or eCG wild.type). No mice were afforded 100% protection 
I rW-Ll . plu l log" plul I 
log" reduction l og" reduction compared with the 
Immunogen mouse mouse ·'no Inoculation" compared with the 
,~, 
Wlld-type BeG group 
No inocul. tlon 1.26 ~ 10" •. , " - (P .. 0 2301) 
BCG wikl-type 
I.S8 ~ 1()' ., " (Tokyo) (P . 0.2301) -
VlP· 16 ~79 ~ lo' ". '" , .52 (p .. 0 0(02) (p . 0_0001) 
-~ 
.BCG-36Il' . 2_0. , 0' OS " (To~yo) " (p- a 006) (P - 0 001ll) 
rBCG·36Il1 ...... 631 . 10' ••• 
U " (Tokyo) (p .. 0 0(009) (p .. 0 (00037) 
rBCG·NVlI . 589 x 10' '" '" 
0<, 
(Tokyo) (P - 0017) (p .. 0 0(43) 
~r-oc"b,n 
I I VLP-'6 • 1 42 1Dg" • -i \\\I:!-t)'po ElCG .-, 
,1ICG-:J> l l l"'· J fto 1.41Dg., 
,OCG·:lI5'" '. i 09 "'II" 
+< . 0.4210\1" .ecG-NIILI. 
., , 
" • " log" rW-L I . pf\I!m<>uM 
Figure 6.2. F'fotec!k)n !,om ,W·l1 . cMllenge In rmce immunO;ed w;!h Tokyo rBCG -l 1 (BeG·36IL I • . 
rBCG·361L1 ....... 0' r BCG-NVL1~) Ov&rian Well of rW ·l ' . we'e meas,.ed 5 days aile. !he 
cllDUer>ge ,nd a,e e xp'essed as Ihe aVB,age log" ,W-lf " phi/moose '" SEM The log" reducllon, in 
W ~tres a.e Illustrated 10. selected g.oup1l . 
'" 
6,4,3, e Tl RESPONSES AND COS" T LYMPHOCYTE IFN.y PROOUCTION IN MICE 
IMMUNISED WITH PASTEUR r8CG,ll 
In CMpter 2, the ex;slence ommunologica!1y "Weak" (Glaxo, Tokyo) and "strong" {Pasteur, 
Dan,sh) sub~tralllS, was discussed A study by Lagranderie III BI. (1996) alSO re\lealed thllt 
these substralnt; differ In thei r ab~~ies 10 persist and to elicit protect"'" immunny In mICe 01 
BII the strains. Ihe Tokyo Sl ra,n was least able to multiply and persiS! III VM), and was lhe 
most Ineffe Clive stmln at ,nducfng Clls in mice. This informatoon prompted UI 10 _5e$S 
rSCG-l I immUnisation in mice using Pasteur recombinall1S. 
The ~I ular immune respOIlses elicited by Pasteur r8CG·119L1. WIlle assesse<! by a 
peptide-specifIC cytotoxiCIty assay and by Ihe wwes!lgatoon 01 IFN.y produc~Of1 by COB" T 
cells. These assays were directed at the HIV gp 120 ClL spltope, which was cIooBd 
down5Uearn, in frame wrth the L I gene ANer a songle s.c. iJ'lOCUlahOn of r8CG·1 19l I., the 
immune responses thai were elicited to the HIV 9Pl 20 CTl epitope, present In the EpIA lag, 
w en! nJea$Ufed From FlQule 6 3 it is dear thai, although the lysis of lhe tonlrol pS15 eells 
was high. a signifocanUy larger percentage of gpl2().pulsed p8 15 !arget celli was lysed, this 
was masl evident at !he 6'\ effedor.target rat,O, at whiCh there was a specifIC lysis of 36% 
These ITIICtI also showed 91'120 peptide·spec;fic COS' eeauillo' al levels alm051 S-fojd above 
background (Figure 6.4), wifh S 5% oI lhe CDS' T eel" produCing IFN-y when stimulated w,th 
IIP120 peplide. as opposed to I S'llo . wilen not SImulated. 
6 .• . 3. HUMORAL RESPONSE ElIClTEO IN MICE AFTER IMMUNISATION WITH 
PASTEUR r8CG-l l 
The humoral immunity eliCIted ill 8ALBlc mice was UMS$ltd loIow,ng 3 immun'sanons wilh 
Pasteur .BCG eXllfeSS4flll HPV-16 II (rSCG-361l I., or rSC(;. 11 9L I.) Animals ommunised 
with raCG-36IL I. eliOled signorocant levels r$ am,bgdies specillc; fOf Hpv· 16 VLPs (Figure 
6.5: P<O.O(4). but tile rBCG·I \9L I.·immuno&ed a<*llals fa~ed to produce l \ antibody levels 
greater Ihan that observed In the 8CG COOlrol group (P:O 74) The hlghes! ll-specif'1C 
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rBCQ..119l1." -...d by, .. 0 ........ NNI)'. Two ..... -'I., .Ilnglt "'mun~Oon wiIh 
Pas""'r r6CG-l 191.1 •. !he fVIk: .:MIy '" hi "- T tvrnphoc:ytM _ "_led UINIg gp 120-P\IfS«I 
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Figure 5.5. System.: antJboa~ re5PO(15eS spec<fu: for HPI,I-,6 Ll VlJ's Induced ., IIl1ce following 
,mmuOo;..)ton WJ!~ Pasteur rSCG-<" l (rBCG -J6I L I~ '" ,BCG- I 19L 1.) Moce were ",un...."oe<J 3 limes 
8t, 4 week .. terv.! !s BIooo S<lmple'S \<>efe coIle<;te<J 2 weeks 11)!k>Nng Ihe 3~ ommuM.atlo" Tn.. data 
.re rep'e5ented as:l1 e go:>up mean 0 0 .. _ r.l i0510rne group mean p'e~leed valve ~ SEM 
6.4.4. PROTECTION FROM NV4.1 ~ CHALLENGE AFTER IMMUNISATION WITH 
PASTEUR rBCG.L 1 
SAL8Ic mice were irnmunise(! 3 times w~h rBCG·L 1 (rBCG-361L '°. or rBCG- 119L 1.) and 
then eha l~ged with I\IV-L' H or rW-GAG Five days afler the cha llenge. each mouse was 
assessed for vaCCinia vtralload For each group, the aver.lge amount of vaccinia VIruS per 
mouse was calculated 
In O(der to ,nvesligale non·spec,ffC protection of vaCCInia virus, m~ were challenged w~h a 
recombinant vaec in,a VIruS expressing an irrele'o'anl antigen (HIV GAG) (Table 62. Figure 
66) Moce immunised WIth VLPs were not protecled from rVV·GAG challenge MICe 
Immunlsed wrth BCG (wild·l~pe or rSCG·L 1) showed non·speclf>e prote<:tion. which ranged 
rrom , 25·0 91 1Og,0. Most ImpOrlanuy IS that the rVV·GAG protection le~els observed in the 
Wllo-Iype- and rSCG-LI 'Immumsed anomals were similar (P>O la. th'll the prote<:toon was 
dissimilar) 
L l·speclfIc protection was IIlVestigated by challenge wilh rVV·L 1" (Table 6.3 Figure 6 7) 
Mice thaI were Immun,sed with VLPs were afforded L '·speciflC prole;;I ion of 2.94 log ,~ rVV· 
'" 
L 1" wnen compared With the PBS·vaccinated ammals Wild·type" mmumsed mice showed a 
non-specific prolectlOn of 07 log" Mice vaccinated WIth rSCG·361Ll . or rBCG·lt9L1 . 
showed Ll·speclfic protection of 195 Iog lO and 1.81 109,1), respeclively Tile protectIOn 
afforded by the rBCG-II 9L I . and rBCG·J61L1. vaccines were not significantly different to 
each other (~O.S8). 
Table 6.2. Prole<:tlOl1 fonn tVV·GAG Challenge, In mice Immun,sed with PaSleur rBCG·L 1 
(rBCG·J61L I •. or rBCG-119L I.), Protection afforded by vaccina~on is repreSented by tne 
log", reduction in Viral titre compared to the control rnmunogens (PBS Of wild·type BCG). 
IVV-GAG plu I Log" ptul 
Log" ,edu.o:lion Log" reduction 
Immunogen compa,ed WItt> compared wlln :::d. 
~~ mouse 
PBS g 'oup ~E'!!!C~9.!9<' 
'" 
380.10' "" 
- 1 25 
-
IP" 0 0023) 
_0 16 _ I 41 
VlP-16 550~tO ' 5.74 (P = 0418 ) (P = 0 0007) 
BCG wfkj -type 214.10' '" '" I -(Pasteur) (P = 00023) 
,BCG.1 19t.I, 363.10' '" - 023 "" (Pasteur) (P:oQ,0023) (P = O.34) 
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361L 1 ~ o r I9CG-t 191.. I.! eva",m tlnH 01 rVV-GAG were measu,ed 5 d3yt1 aile' tile challenge and 
3re e>;>ressed iOS \I\lI"a~ log", rW--GAG pfulmouse ~ SEM The log" re<luct>OllS in VV litres a'e 
illuSlrated fa, ""leered lI"'ups 
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Table 6.3 . Protect.on from rW·L1R challenge, in rruce IIl1muOised wHh Pasteur rSCG·L1 
(rSCG-361L I, or rBCG· 119L 1. ) Protection afforded by vaccinatio n is represented by the 
log,o reduction in vira l tItre compared with the control tmmunogens (PBS o r Wild-type BeG) 
No mice wt!fe afforded 100% p rotection 
rW·Ll . plu l Log"pful 
Log" rflduclion Log" reduction 
Immunogen compared with cO/'np;l red with the mous .. ~"~ the PBS g roup w,ld· type SCG group 
t,07 . tO' 
- 0.7 
'" 8.Q3 - (P·006) 
123.tO' 
, .. 22. 
VLP-16 '" (p - 0 000032) (p . 0 0003<4) 
BCG wild·type 2 H ~ to' " 733 -
(Pasteur) (P "O,OS) 
,SCG·119Lt. 3.31 . ,0' 
2.51 '" '" (Pasteur) (p . 0.00055) (p . 0 ()().tS J 
rBCG·361L1. 2,40. to' 
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Figure 6.7. f'rotec1«>n from fW.L1. chanenge. ,n mice ,rnmun,sed with Paste .... rBCG-ll (rBCG-
36t L I" or 'SCG 119L 1.) o.arian Iltles 01 fW-L 1. were mea&ured 5 days after the chanenge and are 
expressed as average log ," rW·L 1~ pfulrnouse" $EM The i<>g,o reductions in W b1res are ilustraled 
lor se le<1ed groups 
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Chapter 6: Vaccinia Virus Murine Challenge Model 
6.5. DISCUSSION 
This chapter focused on the ability of recombinant BCG, expressing HPV-16 L1, to protect 
mice against challenge with recombinant vaccinia vlrus-HPV-16 L 1 (rVV-L1R)' The use of 
mucosal and cutaneous animal PV models (Campo at aI" 1993; Suzich et aI" 1995b), and 
the development of in vitro pseudovlrions systems (Pastrana at aI" 2004) have somewhat 
overcome difficulties experienced with the propagation of HPV in culture and the lack of 
animal models for HPV, The rVV-L 1R surrogate challenge model was developed as another 
tool for testing HPV vaccines (Marais at a/., 1999). Since heterologous gene products are 
not expressed on the rW surface, neutralising antibody Immune mechanisms do not playa 
role In protection; instead, rW challenge allows for the evaluation of cell-mediated 
responses by allowing heterologous proteins to enter the MHC class 1 pathway. It is 
therefore accepted that CDS+ CTL responses are responsible for protection against 
challenge with rVV (Uno-Furuta at a/. 2003; Moss, 1996; Marais at aI" 1999; Binder and 
KOndig, 1991). The antibody responses generated to the rBCG-L 1 recombinants were 
assessed, and the antibody levels were compared to the corresponding levels of rVV-L 1 R 
protection. Finally, the ceil-mediated responses generated by rBCG-L 1 were investigated by 
means of a cytotoxicity assay and by the measurement of COS+ T ceIlIFN""Y production. 
6.5.1. PROTECTION FROM rW-L 1R CHALLENGE AFTER IMMUNISATION WITH 
TOKYO rBCG-L 1 
In the first challenge experiment, BALB/c mice were immunised 3 times with Tokyo rBCG-L 1 
or HPV-16 VLPs, after which they were challenged with rVV-L 1R, The VLP-immunised mice 
were afforded protection of 1.42 log10. this was regarded as a good level of protection 
because V LP-Immunisation was seen as t he II gold standard" to which 0 ther i mmunogens 
would be compared. When calculated as % of virus cleared, the VLP-Immunised mice 
cleared 96,2% of the rVV-L 1 R. Although animals Immunlsed with the rBCG-NVL 1 R construct 
were afforded a low level of rVV-L 1R protection, immunisation with the rBCG-361L1 
constructs (rBCG-361L1R and rBCG-361L1 NLS-) afforded high levels of protection, with 
rBCG-361L1 NLS- achieving similar protective levels to VLPs (96.0% protection). In Chapter 
5, rBCG-L 1 expressing NLS-deficlent L 1 elicited higher antibody responses than full-length 
L 1; here the removal of the NLS enhanced the cell-mediated immunity to L 1, as rBCG-
361L1 NLs- induced greater protection than rBCG-361L1R. It is still unclear whether this 
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enhanced immune response is a result of superior L 1 presentation in the BCG-infected cells, 
or due to increased expression of the truncated protein. The challenge results can not be 
compared directly with those obtained in the Marais at al. (1999) study (4.6 log10 rW-l1R 
protection in BALB/c mice that were immunised once, i.p., with 10J.1Q of HPV-16 VLP), as the 
dose, route of inoculation and rW-L 1R stock were dissimilar. 
It is interesting to note that the absence of an anti-L 1 antibody response to rBCG-L 1 did not 
indicate the failure of rBCG-L 1 to elicit anti-L 1 immunity, as anti-L 1 cellular immunity (rVV-
L 1R protection) could occur in the absence of anti-L 1 antibodies. Although the rBCG-NVL 1R 
construct showed the lowest protective ability, it induced the highest antibody levels (possibly 
a response skewed to Th2), while the rBCG-361 L 1 constructs, which showed good 
protective ability, failed to induce antibodies to L1 (response skewed to Th1). This again 
confirms that rVV-L 1 R protection in this model is mediated by cellular rather than antibody 
responses. It is unclear why the responses generated by the rBCG-361 L 1 and rBCG-NVL 1 R 
constructs were along different arms of the immune response, since the doses were 
equivalent, the vectors are both integration proficient, and both express L 1 cytoplasmically 
with the hsp60 promoter. These vectors do, however, have different integration sites, which 
may influence L 1 transcription. 
6.5.2. CTL RESPONSES AND CDS+ T LYMPHOCYTE IFN"'}' PRODUCTION IN MICE 
IMMUNISED WITH PASTEUR rBCG·L 1 
The knowledge that, of all the BCG substrains, BCG Tokyo Induces the weakest immune 
responses in mice (Lagranderie at al., 1996), prompted us to investigate rW -L 1 R protection 
after immunisation with Pasteur BCG-L 1 recombinants. Firstly, the immunity Induced by 
Pasteur rBCG-L 1 was assessed by a peptide-specific cytotoxicity assay and by the 
investigation of IFN-y production by CD8+ T cells. A Single inoculation with rBCG-119L1 e• 
induced a strong cellular immune response to the HIV CTL tag, that achieved speCific lysis of 
36% in a cytotoxic assay, and CD8+ T cell IFN-y production that was almost 5-fold above 
background. This experiment reassured us that our BCG recombinants could correctly 
deliver CTL epitopes for association with MHC class I molecules and presentation to CD8+ T 
cells. Although BCG is known to predominantly activate the CD4+ T Th1-type immune 
response, the secretion of IFN-y and IL-2 by Th1 cells (Esser at al., 2003; Mutis at al., 1993). 
is thought to mediate CTL and DTH activity (Ada, 1999; UnO-Furuta at al., 2003). 
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6.5.3. PROTECTION FROM rW-L 1R CHALLENGE AFTER IMMUNISATION WITH 
PASTEUR rBCG-L 1 
For the second rW-L 1R challenge experiment, BALB/c mice were immunised 3 times with 
Pasteur rBCG-L 1 or HPV-16 VLPs, after which they were challenged with rW-L 1R. Unlike in 
the BCG Tokyo challenge experiment, wild-type BCG Pasteur showed a non-specific 
protection of 0.7 log10. After taking this into account, the L 1-specific protection afforded by 
rBCG-119L1 e and rBCG-361L1e was 1.81 log10 and 1.95 log10, respectively (98.5% and 
98.89% protection, respectively). VLP immunisation effectively protected from rW-L 1R 
challenge, and cleared 99.89% of challenge virus. Unfortunately one can not compare 
protection levels induced by Tokyo and Pasteur rBCG-L 1, as these experiments were 
performed at different times, and challenge virus and VLP inoculates may not have been 
identical. Superior immune responses were, however, expected from the BCG Pasteur 
recombinants, as the Tokyo substrain has an inferior ability to persist and generate immune 
responses in mice (Lagranderie at al., 1996); and this was apparent in these experiments 
with regard to both humoral and cell-mediated immune responses. 
The above rW-L 1 R challenge experiment was accompanied by a rW-GAG challenge, to 
test for the non-specific clearance of vaccinia virus. VLP-immunised mice did not clear rW-
GAG, however, mice immunised with BCG (whether wild-type or rBCG-L 1) showed non-
specific protection from rW-GAG challenge. Most Importantly, the observation that the 
levels of rW-GAG protection were similar in animals immunised with wild-type BCG and 
rBCG-L 1, indicated rBCG-L 1 elicited L 1 protective immunity during the rW-L 1 R challenge. 
The level of non-specific rW-GAG protection was slightly greater than that afforded by the 
wild-type BCG-immunisation of the rW-L 1 R challenge experiment; however, these values 
are not directly comparable as the total amount of rW-L 1 Rand rW-GAG obtained from the 
PBS-immunised mice was significantly different, and this will have had an affect on the 
protection dynamiCS. 
It was interesting that rBCG-361L 1e elicited antibodies to VLPs, but rBCG-119L 1e failed to do 
so. since of both these recombinants achieved similar levels of rW-L 1 R protection. Analysis 
of the initial rW-L 1R challenge experiment revealed that immunisation with a particular 
Tokyo BCG-L 1 recombinant either elicited an antibody response, or afforded rW-L 1R 
protection, but not both; here this is the same for Pasteur rBCG-119L 1e, which failed to elicit 
antibodies, but did protect from rW-L 1R challenge. In contrast, the Pasteur rBCG-361L 1e 
recombinant effectively induced both humoral and cellular Immunity, which can perhaps be 
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attributed to its integrative nature, allowing sustained antigen production from increased 
genetic stability. 
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7.1, HPV VACCINE CONSIDERATIONS AND POTEN'nAL USE OF RECOMBINANT BCG 
Cervical cancer is the second most prevalent cancer among woman worldwide and the most 
common cancer among woman in developing countries. South African women are at a 
particularly high risk of developing cervical cancer, with an ASR of 30.5 per 100 000 (Sitas et 
al., 1998). There is naturally considerable interest in the development of vaccines for HPV, 
especially for use in developing countries, where the disease burden is high and resources 
for widespread screening and follow-up procedures are limited. Recently, phase 2 trials 
utilising VLPs have produced encouraging results, achieving protection against HPV 
infection and reducing the development of HPV-related CIN (Koutsky et al., 2002; Harper et 
al., 2004). 
It is generally accepted that a prophylactic vaccine for HPV would aim to provide neutralising 
antibody protection at the genital mucosa. Several studies have demonstrated that when 
systemic neutralising antibodies to L 1 are present, they provide protection from mucosal PV 
challenge, as observed in experimental animal models (Kimbauer et al., 1996; Suzich et al., 
1995) and in natural infection in women (Ho et al., 2002). Prophylactic PV vaccines focus on 
the delivery of L 1 VLPs. In animal and human studies, VLP vaccines have been well 
tolerated and have induced high titres of neutralising antibodies (Brown et al., 2001; 
Christensen et al., 1994; Harro et al., 2001; Rose et al., 1994b; Tobery et al., 2003, Evans et 
al., 2001b). Studies in the cow, rabbit and dog, have also shown that immunisation with 
VLPs can protect against challenge with homologous virus (Breitburd et al. o 1995; 
Christensen et al., 1996b; Kimbauer et al., 1996; Suzich et al., 1995). In order to elicit a 
neutralising antibody response it is required that L 1 is in the form of capsomeres or intact 
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VLPs, as the presentation confonnational epitopes is essential. Studies using disrupted or 
denatured VLPs have induced low neutralising antibody responses, and have afforded little 
protection from challenge in animal models (Breitburd et al., 1995; Suzich et al., 1995; 
Kimbauer et al., 1992) 
Although much emphasis is placed on the development of neutralising antibodies in the 
genital tract, these antibody responses are usually not long-lasting, and sterilising immunity 
rarely occurs (McGhee et al., 1992). Local cell-mediated responses will therefore be vital for 
elimination of infected cells. Several findings substantiate the role of the cell-mediated 
response in the clearance of established HPV infection, these include, the detection of 
mucosallgA and IgG antibodies in women with persistent infection (Sasagawa et al., 2003; 
Bontkes et al., 1999b), the observation that individuals with cell-mediated immune 
deficiencies have an increased risk of infection with HPV (Koutsky, 1997), and the finding 
that regressing HPV-tumours are infiltrated with macro phages and T lymphocytes (Coleman 
et al., 1994; Heller et al., 2003). Although therapeutic studies focus on the early proteins of 
PV, VLPs can induce CTL responses that are capable of inducing regression of L 1-
expressing tumours in mice (Ohlschlager et al., 2003), BPV lesions in cows (Kirnbauer et al., 
1996); and genital warts in humans (Zhang et al., 2000), which suggests that L 1 could be 
used as a therapeutic vaccine for genital HPVs. In the above study by Zhang et al. (2000), 
regression of genital warts was observed in 76% of HPV-6b VLP-immunised subjects, in 
contrast to regression of 0-29% observed in non-immunised control groups. Although L 1 
expression is generally thought to be limited to the superficial layers of the epidennis, Zhang 
et al. (2000) attributed the observed wart regression to L 1-specific T-cell mediated lysis of 
HPV infected basal keratinocytes, in which L 1 was being expressed, but at levels too low to 
be detected. 
An ideal HPV vaccine would be affordable, would protect from the most prevalent high-risk 
HPV types and/or clear the lesions caused by them, and would have a low incidence of side-
effects. VLPs can meet many of these criteria, but their production expense make them 
unlikely candidates for large-scale use in developing countries. The cost of vaccinating an 
individual with HPV VLP, in a 3 injection protocol with a booster required every 10 years, has 
been estimated at US$ 100 per injection (Sanders and Taira, 2003). Because affordability is 
a key factor for vaccine production in South Africa, this study investigated the use of live 
recombinant BCG, as a HPV vaccine vector. A number of factors contribute to the cost-
effectiveness of recombinant BCG vaccines: complicated purification procedures are not 
required, its potent adjuvant properties prevent the need for additional adjuvants, an 
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extensive cold chain for maintenance of effICaCY is not required. and distribution networks 
already exist. The main HPV vaccination target population would be adolescent giris. 
however. it may be advantageous to deliver HPV vaccines at birth, with a possible booster 
dose just before the sexually active stage, due to the risk of acquiring HPV at birth or ear1y in 
life (Cason et al., 1995). BCG would be perfectly suited to a vaccination schedule such as 
this. as it is routinely administered at birth, and is unaffected by maternal antibodies (Hanson 
at al .• 1995). 
Numerous rBCG studies have established its ability to elicit neutralising antibodies to viral 
proteins (Bastos at al., 2002; Fennelly at al., 1995; Hiroi et al., 2001; Chujoh at al., 2001). 
suggesting that rBCG-HPV L 1 could possibly induce neutrallslng antibodies to L 1. Nardelli-
Haefiiger at al. (1997) demonstrated that HPV-16 L 1 expressed In recombinant attenuated S. 
typhimurium assembled Into VLPs, suggesting the possibility that VLP or capsomere 
assembly could also take place In other bacterial systems, such as BCG, and thus display 
the necessary conformational e pitopes for t he Induction 0 f n eutralising antibodies. r BCG 
expressing cotton tall rabbit papiliomavirus (CRPV) L 1 has been shown to partially protect 
rabbits from CRPV challenge (Govan at al .• 2004). indicating that rBCG has potential as a 
vector for a prophylactic HPV vaccine. Mucosal administration of BCG effectively induces 
sustained specific mucosal immunity (Lagranderie at al., 1998; Langermann at al.. 1994b; 
Blet at al .• 2003). which will be important for the control of mucosal HPV infections. 
If a HPV vaccine fails to provide sterilising immunity, a cell-medlated response will necessary 
for the elimination of infected cells. An rBCG-L 1 vaccine should be able to provide the 
appropriate cell-medlated response. Mycobacterial antigens are predominantly processed 
by MHC class II molecules, and thus BCG is a potent activator of a CD4+ Th1-type cellular 
Immune response (Esser at al., 2003; Mutls at al., 1993); however. numerous BCG 
recombinants have also elicited strong CD8+ ClL responses to heterologous antigens 
(Meder1e at al .• 2003; Honda at al., 1995; Uno-Furuta at al., 2003; Lim at al., 1997). 
The follOwing sections summarise and discuss the development and pre-cllnical investigation 
of candidate rBCG-HPV-16 L 1 vaccines. rhls chapter will conclude by discussing whether 
these vaccines fulfilled the requirements of a HPV vaccine, and the possible future rBCG-
HPV-16 L 1 vaccines. 
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7.2. SUMMARY AND DISCUSSION OF KEY RESULTS 
7.2.1. Construction and stability of rBCG-L 1 
Three HPV-16 L 1 gene variants, namely L 1R, L1 NLs-, and L 1800, were acquired or 
constructed for evaluation in BCG. Because the formation of VLPs or capsomeres is 
necessary for the presentation of conformational epitopes, it was necessary to express the 
full-length L 1 gene, or short C-terminal truncations thereof. L 1 R was supplied by Robert 
Rose (University of Rochester, Rochester, New York, USA), and was utilised for the majority 
of the rBCG-L 1 constructs. L 1 NLS· was formed by a 66 base-pair (22 amino acids) truncation 
at the 3' terminal of L 1R, in order to remove the L 1 nuclear localisation signal. The NLS was 
removed to Investigate whether the cellular localisation of L 1 in rBCG-L 1 infected cells would 
have an effect on L 1 antigen presentation, and hence on the immune responses elicited by 
rBCG-L 1. L 1 NlS- is expected to be proficient at VLP assembly (Chen et a/., 2001; Paintsil at 
a/., 1996). The L 1 BeG sequence was generated by employing commonly used BCG codons. 
The L 1BCG amino acid sequence was based on the Phil sequence. described by Touze at a/. 
(1998) ash igh V LP-yielding I n the b aculovirus system. P hi! d iffers from L 1 R by 8 amino 
acids. L 1 R, L 1 NlS·, and L 1 BeG were cloned into a panel of E. coil - mycobacterial shuttle 
vectors, producing 20 HPV-16 L 1 expression vectors for assessment in BCG. 
The introduction the L 1-expression vectors into BCG often generated unstable recombinants, 
which had excisions of the L 1 gene. As a consequence of this genetic Instability, only 12 of 
the 20 clones were introduced into BCG In their intact form. The 8 unstable plasmids had 
two common features: they were all extrachromosomal In nature, and they all drove L 1 
expresSion with the hsp60 promoter. Vector Instability in BCG is not unique to this study, 
and is frequently detected in vectors utilising the hsp60 promoter to drive heterologous gene 
expression (AI Zarouni and Dale, 2002; Medeiros at a/., 2002; Stover et aI., 1991). The 
integration-proficient plasmids which utilised hsp60 to drive L 1 expression were stably 
maintained. suggesting that chromosomes are less prone to gene deletions, or that the 
presence of only one Integrated L 1 gene copy per bacterium reduced the expreSSion of L 1 
sufficiently to increase BCG stability. The other extrachromosomal constructs, p112-L 1 * and 
p119-L1*, were more stable than the hsp6O-driven extrachromosomal vectors, as 
recombinants were obtained with all these constructs. The higher In vitro stability of the 
p112-L 1 * and p119-L 1 * constructs was presumably due to the weak in vitro activity of the M. 
lapree 18kDa and mtrA promoters (Dellagostin at a/., 1995; Zahrt and Deretic, 2000). 
Restriction enzyme analysis and sequencing of the unstable expreSSion plasm ids revealed 
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that the gene deletions present in these constructs ranged from deletions spanning the entire 
L 1 gene and promoter region, to smaller deletions within the L 1 gene. These gene excisions 
were never found to occur at exactly the same sites, indicating that there were no sequence-
specific areas that were prone to recombination. Stable constructs were sequenced as point 
mutations or small deletions would not have been detected by restriction enzyme digestion 
or PCR. Surprisingly, no small gene deletions or significant point mutations were detected, 
since large genetic alterations occurred frequently. 
It is interesting to note that although I assumed that the observed plasmid instability was a 
consequence of overproduction of L 1, the level L 1 protein production by rBCG was typically 
too low to be detected «0.3% of the total rBCG protein). The evidence of L 1 RNA 
expression from this study, and the effective use of the same vectors and/or promoters to 
achieve high foreign antigen expression in other studies (Himmelrich et a/., 2000b; Stover et 
a/., 1993), makes it unlikely that the low expression of the L 1 protein is a consequence of low 
L 1 transcription. The low expression is also not likely due to inefficient translation, as codon 
optimisation did not increase L 1 production to detectable levels. The observation that the 
expression of bacterial antigens can account for over 10% of total BCG protein (/ysA gene 
product, this study; Fuerst et a/., 1992; Stover et a/., 1993; Langermann et a/., 1994), but that 
expression viral antigens rarely exceeds 1% of BCG protein (Aldovini and Young, 1991; 
Winter at aI., 1991; Mederle at 8/., 2002), suggests that the incorrect folding a viral antigens 
in this bacterial system facilitates their degradation by proteases. This assumption is 
strengthened by the high rate of instability observed when utilising the hsp60 promoter. 
Because hsp60 is a heat-shock promoter (Bukau and Horwich, 1998), it will be up-regulated 
in the presence of non-native proteins (in this case L 1 protein), which will cause further 
production of these non-native protein, causing overt stress on the BCG recombinant. 
Two categories of rBCG stability are of importance, the first being the stability in the 
presence of antibiotic selection, which is essential for the long-term maintenance and large-
scale production of recombinant BCG, the second being the retention of the expression 
vector in the absence of antibiotic selection, which provides an indication of the length of in 
vivo foreign antigen expression. BCG-L 1 recombinants containing integration-proficient 
vectors were more stable than the extrachromosomal recombinants, providing an advantage 
over the extrachromosomal constructs for long-term maintenance and sustained in vivo 
expression. Enhanced stability of integrated BCG recombinants has also been observed in 
other studies (Mederle et a/., 2002; Stover et a/., 1991; Kumar et a/., 1998). 
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Extrachromosomal recombinants may have the advantage of a higher copy number with the 
potential of higher protein expression, but their stability seems to be a limitation. 
Although stability will be of concem for all BCG recombinants, limited literature is available 
on methods for increasing plasmid stability in BCG. Baud et al. (2002) found that codon 
optimisation of the HPV-16 L 1 gene, for expression in Salmonella, increased plasmid stability 
in vivo; in the present study, however, codon optimisation for expression in BCG may have 
decreased plasmid stability, due to a possible increase of L 1 expression levels. Auxotrophic 
mutants could be exploited to enhance plasmid maintenance in the absence of antibiotic 
selection (Cirillo et al., 1995), however this does not diminish the risk of foreign gene deletion 
events. The use of inducible promoters, like that of M. smegmatis acetamidase (Roberts et 
al .• 2003; Parish et al., 1997). seem promising as these may help with respect to the 
prevention of gene deletions in vitro; however, for these promoters to be effective their in 
vitro activity will have to be negligible, with strongly inducible activity in vivo, since even low 
expression may cause instability. 
7.2.2. Immunogenicity of rBCG-L 1 in small animals 
The immune responses elicited by the rBCG-L 1 constructs produced during this study were 
assessed in guinea pigs and mice. The majority of the animal studies were performed with 
guinea pigs, as they share a number of similarities with humans in their response to 
mycobacterial infection (Horwitz et al.. 2000; McMurray, 1994). Although these studies 
assessed both humoral and cell-mediated immunity, the focus was on the ability of rBCG-L 1 
to generate antibodies specific to HPV-16 L1, since the aim of this research was to 
investigate the possibility of utilising rBCG-L 1 as a prophylactic vaccine for HPV. The mouse 
studies focused on the in vivo CTL responses elicited to rBCG-L 1, by measuring the level of 
protection in a rW-L1R challenge model. In addition to the rVV-L1R challenge, humoral 
responses were assessed, and cell-mediated responses were investigated further by means 
of a cytotoxicity assay and by the measurement of IFN-y production by CDS+ T cells. A 
summary of all the immune responses induced by rBCG-L 1 are tabulated in Appendix F. 
The combined results from the guinea pig and mouse studies demonstrated that 
immunisation with rBCG-L 1 successfully elicited VLP-speclfic antibody and cell-mediated 
immune responses that were dependent on expression vector, dose, route of immunisation 
and L 1 variant. These results therefore also established that, although L 1 expression could 
not be detected by western blot, all the rBCG-L 1 constructs were expressing low amounts of 
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L 1. The low expression of L 1 necessitated the employment of a vaccination regimen 
consisting of more than 3 rBCG-L 1 immunisations for the induction of a strong antibody 
response. On the other hand, a single inoculum of purified HPV-16 L 1 VLP elicited high 
levels of antibodies to L1. In guinea pigs the rBCG-361L1e and rBCG-119L1e constructs 
induced the highest serum antibody levels, while the rBCG constructs utilising the pCB112 
expression vector consistently elicited the weakest antibody responses; which is possibly a 
consequence of its weaker promoter (18kDa). rBCG-L 1 dosage and route of inoculation 
both played important roles in the induction of immune responses. This was evident when 
the low dose (104 cfu) failed to elicit significant antibody or cellular responses to L 1, but the 
same recombinants at a higher dose (2x106 cfu) delivered sufficient L 1 for the induction of a 
response. Intramuscular immunisation was not as efficient as the Ld. route at eliciting 
antibody or ceU-mediated Immunity to L1. When administered at the 2x106 cfu dose, all 
rBCG-L 1 constructs successfully induced L 1-specific DTH reactions, which is evidence of 
BCG's potent cellular immunity adjuvant properties. 
The L 1 variants played a small role with respect to immune responses elicited to them, 
and/or with respect to the L 1 expression levels within BCG. Codon optimisation of L 1 for 
expression in BCG quite likely increased L 1 expression levels over native L 1 levels, as 
rBCG-112L 1 eCGe elicited higher levels of antibodies than rBCG-112L1 e. However, in the 
case of rBCG-119L 18 (native L 1), its codon optimised equivalent, rBCG-119L 1ecGe, failed to 
induce higher antibody levels, illustrating that numerous factors contribute to the 
accumulation of L 1 in BCG. The observation that the anti-L 1 antibody levels elicited by 
rBCG-361L 1e and rBCG-119L 18 were of similar magnitude, and that rBCG-119L 1ecGe did not 
elicit significantly more antibodies than rBCG-119L1 e, suggests an upper threshold level of 
L 1 expression in BCG. This putative threshold is likely facilitated by protease degradation 
and mediated by chaperones. The removal of the L 1 nuclear localisation signal appeared to 
enhance the immune response over full-length L 1; this was apparent by the enhanced 
antibody response induced to L1 in guinea pigs by rBCG-112L 1NLS-, and by the superior 
protective ability of rBCG-361L 1NLS- in the rVV-L1 mouse challenge model. It is uncertain 
whether these enhanced immune responses are as a result of improved L 1 presentation in 
the BCG-infected cells, or increased expression of the truncated protein. 
In view of the fact that the chief objective of a prophylactic HPV vaccine is the generation of 
immune responses at the genital mucosa, the detection of L 1-specific antibodies in the 
vaginal secretions of a number of rBCG-L 1-immunised animals, especially in those 
immunised with rBCG-361L1e, rBCG-119L1e and rBCG-119L 1ecGe, was an important result. 
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These vaginal IgG antibodies were thought to have originated by transudation from the 
serum. It would have been interesting to investigate mucosal routes of delivery, such as oral 
or nasal. as these routes are expected to generate stronger responses at the genital 
mucosa. 
The question of whether prior vaccination with wild-type BCG could adversely affect the 
immunity induced to recombinant BCG vaccines is not an unwarranted one, and needed to 
be investigated. The present study eased these concerns, because prior immune exposure 
to wild-type BCG increased the immune responses elicited to rBCG-L 1. Similar results were 
obtained by Gheorghiu et a/. (1994), who investigated the immunity induced by rBCG-LacZ. 
I concur with this group's suggestion that the enhanced immune responses observed in 
BCG-primed mice were a result of the activation of BCG-specific T cells, leading to improved 
macrophage activation and enhanced antigen presentation of both the mycobacterial and 
recombinant proteins. 
The observation that rBCG-L 1 did not elicit detectable neutralising antibodies in guinea pigs 
was perhaps the result that will most limit the use of rBCG-L 1 as a prophylactic HPV vaccine. 
This finding suggests that VLPs or capsomeres were not formed within BCG, and hence the 
conformational epitopes necessary for the Induction of neutralislng antibodies were not 
created. However, as mentioned above (section 7.1), too much emphasis may be placed on 
the development of neutralising antibodies in the genital tract, as these antibody responses 
are usually not long-lasting, and sterilising immunity rarely occurs (McGhee et a/., 1992). 
Consequently, local cell-mediated responses will be required for the elimination of infected 
cells. A rBCG-L 1 vaccine should be able to provide the appropriate responses for the 
elimination of these infected cells as the cell-mediated adjuvant properties of BCG are well 
documented; with numerous recombinant BCG studies demonstrating strong CD4+ and 
CD8+ CTL responses to heterologous antigens (Mederle at a/., 2002; Murray at a/., 1992; 
Mederle et a/., 2003; Honda at aI., 1995; Uno-Furuta at aI., 2003; Lim et a/., 1997). Here I 
have demonstrated that immunisation of mice with rBCG-L 1 elicited antlgen-specific CD8+ 
responses, and antigen-specific cytotoxicity. Furthermore, I showed that mice immunised 
with rBCG-L 1 were afforded L 1-specific protection of up to 98.89% from challenge with rW-
L 1 R. confirming the induction of strong CD8+ CTL responses. 
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7.3. POTENTIAL OF rBCG-L 1 AS A HPV VACCINE 
This study demonstrated the ability of recombinant BCG expressing HPV-16 L 1 to elicit L 1-
specific antibody and cell-mediated responses in small animals. Although the cell-mediated 
immune responses were substantial, the antibody responses were considerably lower that 
those elicited by purified VLPs, and hence a strategy of multiple immunisations was required. 
The potential for these vaccine candidates to proceed to human testing is therefore low. 
The main obstacle impeding the success of the rBCG-L 1 vaccine candidates is poor L 1 
expression. If L 1 expression could be improved, the need for multiple immunisations would 
be decreased. Higher L 1 expression, and thus higher L 1 protein monomer concentration, 
would increase the likelihood VLP fonnation in BCG, thereby also improving the possibility of 
neutralising antibody induction. If our premise is correct and the low L 1 levels are a 
consequence of degradation, it will be difficult to increase expression levels. Co-expression 
of chaperones could possibly be employed to increase native L 1 folding and thus decrease 
degradation. 
The second obstacle is the high rate of high genetic instability, which is directly linked to 
heterologous protein expression. Integrated expression vectors provide enhanced vector 
stability, and gene stability can be increased with the use of inducible promoters. If the 
export of L 1 from rBCG can be optimised, this could also lead to enhanced stability. The use 
of short epitopes may increase stability and possibly increase protein expression levels, by 
decreasing burden, but this would not be optimal for a prophylactic HPV vaccine where full-
length L 1 protein is needed for the fonnation of confonnational epitopes. rBCG may 
therefore be better suited as a therapeutic HPV vaccine, where early HPV proteins or 
epitopes would be expressed, and where antibody responses are not as vital as cell-
mediated immunity. 
Finally, the cost-effectiveness of recombinant BCG vaccines, especially in a developing 
country setting, may make it viable to utilise these vaccines in combination with other types 
of HPV vaccines, where recombinant BCG could prime or boost immunity to HPV antigens. 
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A1. BACTERIAL CULTURE PREPARA1'ION 
A1.1. E. coil 
A starter cultum, of approximately 5ml of 2x yeast tryptone (YT) broth, was inoculated with a single 
colony of E. coli DHa bacteria, and was grown ovemight at 37OC. with vigorous shaking. The following 
day. the bacterial cultum was diluted 1/100 In 50-100ml of 2xYT broth in a flask 5-10 times the cultum 
volume. The cullum was incubated at 37OC. with vigorous shaking, until the appropriate cullum optical 
density (at 600nm) was attained. The appropriate antibiotic was added to the medium to pmvent the 
growth of non-l9COmbinant bacteria, and hence select for I9CQmbinant bacteria. Kanamycin (Novo 
Nordisk. SA) was used at a final concentration of 5OJlQIml; Ampicillin (Sigma-Aldrich, Gennany) was 
added at a final concentration of 50JlQlml; and Hygromycin B (Roche Diagnostics, Gennany) was used 
at a final concentration of 200JlQlmi. 
2xYT agar was used as solid medium. After the bacteria wem spread on 2xYT agar, they wem 
inverted and incubated ovemight at 37OC. 
A1.2. Mycobacteria 
Mycobacteria wem grown in Middlebrook 7H9 medium (Ditco, Detroit, USA) or Sauton's liquid medium 
(Appendix B2). Clumping was mduced by the addition of Tyloxapol (Sigma). Starter cultul9S of 5-
10ml were grown at 37"C as stationary cu~ul9s for 7-14 days. The starter cu~um was then used to 
inoculate 5O-100ml of medium, which was grown at 37°C In roiling bottles for 7-14 days. 
7H10 (Ditco, Detroit, USA), supplemented with 10% albumin dextrose catalase (State Vacdne 
Institute, South Africa), was used as solid growth medium. The plates wem inverted and incubated at 
37't for 3-5 weeks for BCG. Pliorto plating, the bacterial suspension was vigorously passed through 
a 26 gauge needle, to reduce clumping. The plates wem sealed In plastic bags to pmvent them from 
drying out during the long Incubation times. 
When appropriate, the following antibiotics wam utilised: Kanamycin (Novo Nordisk) was used at a 
final concentration of 16.7JlQ1ml; and Hygromycin B (Roche Diagnostics) was used at a final 
concentration of 50J.IQ/ml. 
A2. PREPARArlON OF COMPETENT CELLS 
A2.1. Preparation of competent E. coil 
The E coli strain DH5a was used for manufacture of competent cells according to the method of 
Chung and Miller (1988). A single colony of bacteria was inoculated into 5ml of 2xYT broth and was 
grown ovemight at 370C with shaking. 0.5ml of this cultum was used to inoculate 50ml of 2xYT, which 
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was grown to early log phase (00Il10 0.2-0.4). and harvested by centrifugation at 5 OOOrpm for 5min at 
40C (Beckman J2-21 centrifuge). The supernatant was discarded and the cell pellet was re-
suspended in 1/10111 the culture volume of Ice oold TSB solution (Appendix B3). Glycerol was added to 
a final ooncentration of 10% (vlv). the cells were allquoted and frozen at -BOOC. 
A2.2. Preparation of competent BCG 
Competent myoobacteria were prepared for electrotransformation acoording to the procedure of 
Jaoobs et al. (1991). 5O-10Oml of liquid medium were inoculated wHh BCG. as described in Appendix 
A1. and grown at 37"C untU an 00., between 0.4 and 0.7 was attained. Once the purity of the culture 
was verified by Ziehl-Neelson stain (Appendix A13). the cells were colleded by centrifugation at 
4000rpm for 10min at 25°C (JA-21 rotor. Beckman J2-21 centrifuge). The cells were washed by re-
suspending the cell pellet in 40ml of distilled water and oolleding as above. The washing step was 
repeated with water a"ld then again with 10% (vlv) glycerol. The cells pellet was finally re-suspended in 
3-6mlof 10% glycerol. Eledrocompetent BCG preparations were kept at room temperature. and were 
used within 1 hr of preparation. 
A3. TRANSFORMATIONS 
A3.1. Transfonnatlon of competent E. coil 
Frozen aliquots of oompetent cells were albwed to thaw on ice. One to 100ng of DNA were mbed 
with 100J,J1 of competent cells. and left on ice for 3Omin; after which. the celVDNA mixture was placed 
at 42"C for 2min. After the addition of 900jJ.l of 2xYT broth the cells were incubated at 37"C for 3Omin. 
to allow expression of the antibiotic resiStance gene of the newly transferred plasmid. The transformed 
bacteria were plated on 2xYT agar oontaining the appropriate antibiotic. 
A3.2. Electrotransfonnatlon of competent BCG 
A 100J,J1 volume of competent cells was mixed with 0.1-1 J,Jg of plasmid DNA. and Incubated at 370C for 
5mln In a 0.1cm eledrogap cuvette (Bio-Rad Laboratories. Germany). It was important that neither the 
cells nor the DNA contained high ooncentratlons of salts. which can result in arcing when a vo"age Is 
applied to the cuvette. The cuvette was placed in a GenePulser set at 1 .8kV and 25J,LF. with the Pulse 
Controler (Bio-Rad Laboratories. Germany) set at 1000 Ohms. A single pulse was sent through the 
cuvette. 9OOJ,J1 of Middlebrook 7H9 or Sauton's medium were added to the cells, which were then 
incubated at 37"C for 4hr. to albw expression of the antibiotic resista"lce gene of the newly transferred 
plasmid. 1ooJ,J1 of the expreSSion mixtures were spread onto Middlebrook agar 7H10 (Difoo. Detroit. 
MI. USA) plates. supplemented with 10% albumin dextrose catalase, oontaining the appropriate 
antlbbtic. and Incubated at 37°C for 3-6 weeks. Single colonies were picked and grown to bg phase 
in 10ml cultures. 5ml of each culture was used to analyse for successful transfOrmation. Glycerol was 
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added to the remainder of the culture. at a final concentration of 10% (vlv). and the cells were frozen at 
-800C. 
A4. SELECTION AND VERIFICA110N OF TRANSFORMANTS 
A4.1. Verification of E. coil nnsformants 
Transformation mixtures were spread onto plates (containing the appropriate antibiotics), and were 
incubated overnight. Single colonies were chosen. and small scale plasmid extractions were 
performed (Appendix AS.1). The DNA obtained was subjected to endonuclease digestion and gel 
electrophoresis (Appendices A6 and A7) to determine whether the cells contained the correct DNA. 
A4.1. VerlflcaUon of BCG transformanla 
Due to their thick, complex cell walls, DNA extraction from mycobacteria is not as efficient as from E. 
coli; it was therefore necessary to amplify mycobacterial DNA by transforming it into E. coli. This was 
done by first extracting plasmid DNA from mycobacterial transformants (Appendix AS.3), and then 
transforming these plasmids into E. coli. Small scale plasmid extractions were performed on the E. 
coli recombinants (3-S E. coli recombinants tested per BCG colony) (Appendix AS.1), and the DNA 
obtained was subjected to endonuclease digestion and gel electrophoresis (Appendices A6 and A7). 
If it was determined that an E. coli recombinant contained the vector of interest, it was assumed that 
the corresponding mycobacterial transformant contained the same. 
To verify mycobacterial transformants containing expression vectors that had Integrated into the 
chromosome, total DNA was extracted (Appendix AS.4) and Southern blot-hybridisation analysis was 
performed (Appendix A10) to verify recombinants. 
AS. PREPARATION OF DNA 
AS.1. Small scale plasmid extraction from E. coil 
This protocol was based on the method described by Ish-Horowicz and Burke (1981), employing an 
alkaline/sodium dodecyl sulphate (SDS) lysis method. A single colony of recombinant bacteria was 
picked and inoculated into Sml of 2xYT broth containing the appropriate antibiotic and grown overnight 
at 37°C with shaking. Two mililitres of culture were transferred to a 2ml tube (Eppendorf), and the 
cells were harvested by centrifugation at 14 OOOrpm for 2min in a microfuge. The supernatant was 
discarded and solutions 1. 2 and 3 (Appendix 84) were added sequentially. The cells were first re-
suspended in 0.2m! of solution 1. after which, 0.4ml of solution 2 was added to facilitate cells lysis and 
degrade chromosomal DNA. After Smin at room temperature, 0.3m! of solution 3 was added. This 
mixture was left on ice for 5min to neutralise the mixture and to precipitate the cellular protein and 
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membrane material. The flocculant was removed by centrifugation at 14 000 rpm for 15min in a miCl"O--
centrifuge, and the clear supematant was transferred to a new 1.5ml tube. The plasmid DNA was 
precipitated by adding O.S volumes of isopmpanol, and collected by centrifugation at 14000 rpm for 
10min. The supematant was decanted and the DNA pellet was washed with 3001-11 70% (vlv) ethanol. 
The ethanol was removed and the DNA was allowed to dry before dlssoMng it in an appmpriate 
amount of sterile, distilled water. 
M.2. Large scale plasmid extraction from E. coli 
For preparation of up to 100119 of plasmid, the NudeobondQl) AX PC-Kit 100 (Machery-NageI, 
Gennany) was used accon:ling to the manufacturer's instructions. This method is also based on an 
alkaline/sodium dodecyl sulphate (50S) lysis method, with further DNA purification in the AX100 
column (a silica-based, anion-exchange column). Recombi'lant bacteria were gmwn In 5O-100m1 of 
2xYT bmth, ovemlght at 37°C with shaking. The bacterial cells were then harvested by centrifugation 
at 5 OOOrpm for Smln at 4°C (Beckmann J2-21 centrifuge, JA-20 mtor). The supematant was 
discan:led and the bacterial pellet was re-suspended in 4ml of buffer 51 (50mM TrisIHCI, 10mM EDTA, 
1ooJ.lg Rnase Alml). The re-suspended bacteria were mixed with 4ml of buffer 52 (200mM NaOH, 
1 %505) and incubated at mom temperature for Smi'l. 4ml of buffer 53 (2.8M KAc) were added to the 
suspension which was then i'lcubated for Smln on ice. The cellular debris were separated by 
centrifugation at 12 Ooorpm for 30mln at 4°C (Beckmann J2-21 centrifuge). The supematant was 
loaded onto the AX 100 column and allowed to flow thmugh. The column was then washed with 8ml 
of buffer N3 (1OOmM TrisIH3P04, 1S% ethanol, 1150mM KCI). The purified plasmid DNA was eluted 
fmm the column with 2ml of buffer NS (100mM TrisIH~04, 1S% ethanol, 1000mM KCI). The eluted 
plasmid DNA was precipitated with 0.7 volumes of lsopmpanol and collected by centrifugation at 14 
ooOrpm in a mlcmfuge for 10min. The pellet was washed with 70% ethanol and dissoNed in an 
appmpriate volume of distilled water. 
M.3. Plasmid extraction from BCG 
10ml of Middlebmok 7H9 or Sauton's medium, containing the appropriate antibiotic, were inoculated 
with a single colony and then incubated at 37"<: for 10-1S days, with occasional shaki'lg. The 
AlkallneJSDS lysis method (described In Appendix AS.1 ) was utilised for the DNA extraction, except for 
a modification of the initial cell re-suspension step, during which lysozyme (final concentration of 
10mglml; Roche Diagnostics, Gennany) was added to the 51 buffer, and incubated ovemight at src, 
to aid cell lysis. The mycobacterial plasmid DNA was transfonned into competent E. coli DHa. cells 
(Appendix A3.1) and plated to fonn single colonies. Small scale plasmid extractions (Appendix A5.1) 
were perfonned on the E. coli colonies and the DNA was subjected to restriction enzyme analysis and 
agarose gel electrophoresis (Appendices AS and A7) to verify the presence of the correct clone. 
M.4. Chromosomal DNA extracUon from BCG 
Chmmosomal DNA was extracted from BCG by a method adapted from Ausubel et at. (1987). A BCG 
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colony was inoculated into 10ml Middlebrook 7H9 or Sauton's medium containing antibiotics, and 
incubated at 370C with occasiOnal shaking for 10-15 days. 4m1 of cells were collected by 
centrifugation, and the cell pellet was re--suspended in 5001.11 of Tris-EDTA (TE) buffer. 501.11 of 
lysozyme (10mg/ml) were added, and the mixlure was Incubated at 370C for 1hr. 701.11 of 10% sodium 
dodecyl sulphate (SOS) and 31.11 of Proteinase K (20mg/ml) were added, and the mixture was 
incubated at 65°C for 10min. 1001.11 of 5M NaCI were added, and the solution was mixed well. The 
solutiOn was mixed well with 801.11 of CT ABlNaCI solution (Appendix B5), and was incubated at 650C 
for 10min. CTAB precipitates the cell wall debris, denatured protein and polysaccharides; while 
nucleic acids stay in solution. To remove the CT AB-protelnlpolysacchar1de complexes, an equal 
wlume (8001.11) of chlorcform:isoamyl alcohol (24:1) was added, the solution was wrtexed, and then 
separated at 14000rpm for 5min In a desktop centrifuge. The aqueous supematant was transferred to 
a 1.5ml tube, 0.6 wlumes of isopropanol were added and the sample was placed at -Boac for 3Omln. 
The DNA was then collected by centrifugation at 14 OOOrmp for 10min in a desktop centrifuge. The 
supematant was discarded and the DNA pellet was washed with 3001.11 70% (v/v) ethanol. The ethanol 
was removed a1d the DNA pellet re-suspended i'I 501.11 of distilled water. 
AS.s. Preparation of DNA for sequencing 
The High Pure Plasmid Isolation Kit (Roche Diagnostics, Gennany) was utilised as per the kit's 
instructiOns. Briefly, 2ml of an ovemight DH5a E. coli culture (Appendix A 1.1) was collected by 
centrifugation. The cells were resuspended in 250J,tI of the kit's Suspension Buffer (50mM Trls-HCI, 
10mM EDTA, 100J,tl RNase Alml~ and then lysed by the addition of 250J,tl of Lysis Buffer (0.2M NaOH, 
1% SDS). 35OJ,tI of Binding Buffer (4M guanidine hydrochloride, 0.5M potassium acetate) were added 
to precipitate the cell debriS and chromosomal DNA. The precipitate was separated by centrifugatiOn. 
The supematant was iOaded into a High Pure filter tube and was transferred through the filter column 
by centrifugation. The filter was washed with 700J,tl of Wash Buffer II (20mM NaCl, 2mM Trls-HCI, 
80% ethanol) by a centrifugation step. 50J,tl of Elution Buffer (10mM Tris-HCI) were added to the filter 
tube, a1d the plasmid DNA was eluted Into a mlcrofuge tube by centrifugation. 
AS.6. DNA purtflcatlon from aga.".e gel 
DNA was purified from agarose gel with the QIAqulck gel extraction kit (Qiagen, Germany), according 
to manufacturers instructiOns. After restriction enzyme digestiOn and agarose gel electrophoresis 
(Appendices A6 and A7) the relevant DNA fragments were excised from the agarose gel with a 
scalpel. The gel fragments were add to a mlcrofuge tube and weighed. 3 wlumes of the kit's Buffer 
QG (3OOJ,tI per 100jJQ of gel) \Y8re added, and the gel was allowed to dissolve at 50ac for about 1Omln. 
The gel mixlure was transferred through a MinlElute filter tube by centrifugation. After the filter was 
washed with the kit's wash buffer, the DNA was eluted with 50J,ll of water. 
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A6. RESTRICTION ENDONUCLEASE DIGESTION 
Restriction endonucleases and incubation buffers were supplied by Roche Diagnostics (Gennany). 
Unless otherwise specified, restriction endonuclease digestions were carried out according to the 
method described by Sam brook at al. (1989); in a 10-201J1 volume, including between O.S and 10IJg of 
DNA, 1-21J1 10X incubation buffer, and between 3 and 10 units of enzyme. Enzymatic digestion was 
stopped by the addition of SX loading buffer. If enzyme buffers were compatible, multiple restriction 
enzymes were combined in a single digest, if their. If not, the digestion was done sequentially and the 
DNA was purified to remove the first buffer using the QiAquick gel extraction kit (Appendix AS.S). 
A7. AGAROSE GEL ELECTROPHORESIS 
Agarose gel electrophoresis was performed using the submerged horizontal gel slab method, as 
described by Sambrook at aI. (1989). Agarose was prepared at concentrations ranging from 0.8 to 2% 
(wJv) in 1 X Tris-acetate buffer. Ethidium bromide was added at a final concentration of 0.1 j.lQ/ml. DNA 
samples were mixed with SX loading buffer, which were then added to the wells. Electrophoresis was 
performed at SO-100 volts for 1-3hrs, using a PSSOOX DC Power Supply (Hoefer Scientific 
Instruments, San Francisco, USA). Standard DNA size markers were electrophoresed alongside 
samples to determine the DNA fragment sizes. After electrophoresis, the DNA fragments were 
visualised on an ultraviolet (UV) light box (UVP Incorporated, USA). The gel was photographed with a 
Kodak DC120 digital camera, and analysed with Kodak Digital Science 10 (version 2.0.3) software. 
AB. CLONING 
AB.1. Preparation of vector and Insert DNA 
Veder and insert DNA were prepared by digestion with the appropriate restriction endonuclease/s 
thereby creating compatible termini for cloning. The digested DNA samples were electrophoresed, 
and the relevant fragments were excised and purified from the gel (Appendix AS.S). 
AB.2. Ligations 
Ligations were carried out in a volume of 10IJI; containing vector and insert DNA (which were generally 
mixed together in a ratio of 1 :3), 1 J.11 of T4 DNA ligase (1U/IJI, Roche Diagnostics), and 11J1 of ligation 
buffer (Roche Diagnostics). The ligations were carried out ovemight at 1S"C, after which the ligation 
mixtures were used to transform competent E. coli, as described above (Appendix A3.1 ). 
AB.3. Cloning of PCR products 
pMOS~/ua TA cloning kit (Amersham, Buckinghamshire, UK) 
Ligation was performed as per manufacturers' instructions. 
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The ligation mixture contained: 
1/.11 10X DNA ligase buffer 
0.5/.11 100mM DTT 
0.5"" 10mMATP 
1/.11 pMOS vector (SOng) 
2-3/.11 PCR product 
0.5/.11 T 4 DNA ligase 
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The ligation mixture was made up to 10"" with water and then incubated at 16"C for 2hrs. 1"" was 
transformed into 100J1l of competent DHSa cells. 
pGEM-T Easy cloning kit (Promega. Madison. WI. USA) 
Ligation was performed as per manufacturers' instructions. 
The ligation mixture contained: 
5/.11 2X DNA ligase buffer 
1/.11 pGEM-T Easy vector 
2-3/.11 PCR product 
1"" T 4 DNA ligase 
The volume was made up to 10/.11 with water. The ligation mix was incubated at 25°C for 1 hr. or at 4°C 
for 16hrs; after which 5"" was transformed Into competent E. coli DHa cells. 
ABA. Verification of clones 
Transformants were selected as described in Appendix A4.1. The DNA obtained from the 
transformants was subjected to endonuclease digestion and gel electrophoresis to determine whether 
the desired recombination event had transpired. When the desired recombinant was found. a large-
scale plasmid preparation was performed. 
AS. POLYMERASE CHAIN REACTION 
Primers were designed according to the guidelines described by Rolfs et sl. (1992), and evaluated on 
Primer Designer for Windows Version 2.0 (Scientific and Educational Software, Pasadena, USA). 
All reagents were supplied by Takara Bic (Japan) or Roche Molecular Biochemicals (Germany). 
Reaction volumes were typically 50/.11 and contaned the following: 
10x buffer Sui 
(1OmM Tris-HCI. 1.5mM MdCb. 50mM KCI, pH 8.3) 
Taq DNA polymerase 1 unit (U) 
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each at a final concentration of 200uM 
10-50 pmol of each primer 
Distilled water to make the reaction volume to 49J.11 
1 J.11 of template DNA or water (no DNA control) was added to each tube. 
The amplification reactions were performed in a GeneAmp PCR System 9700 (Perkin Elmer, USA) 
thermocycJer. The PCR reaction parameters were as follows: 
• Initial Denaturation at 94°C for 3min 
• Denaturation at 94°C for 45sec } • Primer annealing at 40-43°C for 30sec 5 cycles • DNA synthesis at 72°C for 2min 
• Denaturation at 94°C for 45sec 
} 30cycles • Primer annealing at 55-65°C for 30sec 
• DNA synthesis at 72°C for 2min 
• Final DNA synthesis at 72°C for 4min 
When the Lightcycler thermocycler (Roche Molecular Biochemicals, Germany) was utilised, the 
reactions contained the following: 
10x buffer 2ul 
(10mM Tris-HCI, 1.5mM MgCI2, 50mM KCI, pH 8.3) 
Taq DNA polymerase 1 unit (U) 
MgCb (25mM) 4J.11 
dNTPs (2.5mM) 
Bovine serum albumin (20mglml) 
1.6J.11 
2J.11 
1J.11 SYBR Green I dye (1/1000 dilution, Roche) 
Primers 5 pmol of each primer 
Distilled water to make the reaction volume to 18J.11 
2J.11 of template DNA 
The PCR reaction parameters on the Lightcycler thermocycler were as follows: 
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MeHing curve Ssec 
o sec (temperature transition of 0.20°Clsec) 
A10. SOUTHERN TRANSFER OF DNA ONTO A MEMBRANE AND HYBRIDISATION WITH A 
LABELLED OLIGONUCLEOTIDE PROBE 
BCG chromosomal DNA, containing integrated expression vector DNA, was digested and transfell'ed 
onto a nylon membrane. The membrane was then probed with a labelled L 1-specific oligonucleotide 
to verify the presence of the L 1 gene. The method utilised was a modification of that described by 
Smith and Summers (1980). 
A10.1. Southern transfer 
DNA was Isolated from BCG using the CT AB method (AppendiX S.4) and subjected to restriction 
endonuclease digestion and agarose gel electrophoresis. The agarose gel was soaked in 0.2SM HCI 
for 10min to introduce nicks in the DNA by depurinatlon. which assists in the transfer of large DNA 
fragments to the nitrocellulose membrane. The DNA was then denatured by soaking the gel in 
denaturing solution (Appendix 86) for 30min with gentle shaking (Red Rotor PR70 shaker, Hoefer 
Scientific Instruments, San Francisco, USA). After which, the gel was neutralised by soaking it in 
neutralising solution (Appendix B6) for 4Omin. 
A capillary transfer apparatus was set up. The gel was placed upside down a glass support that was 
coveled by a wick of Whatman 3MM chromatography paper that extended into a reseNelr of transfer 
solutkm (10X sodium Citrate. SSC). A piece of Hybond-N nylon hybridlsation membrane (Amersham 
PLC, UK) was cut to frt exactly over the gel. The membrane was soaked in the transfer solution for 
Smln and placed on the gel. Three pieces of Whatman 3MM paper were soaked in transfer solution 
and placed on the membrane, followed by a Scm-thick layer of absorbent paper towelling and a weight 
of approximately 1 kg. The flow of liquid by capillary action from the bottom reservoir, through the gel 
and membrane Into the absorbent towels resuHs in the transfer of DNA from the gel onto the 
membrane. Transfer was allowed to take place ovemight. The apparatus was disassembled, and the 
DNA was cross-linked onto the membrane in a UV cross-linker (Hoefer SCientific Instruments, San 
FranCisco, USA). 
A10.2. Labelling of the probe and hybrfdlsatlon 
Once cross-linked, the membrane was soaked In pre-hybridisation solution (Appendix B7). This took 
place at 68"C, with shaking, for 2-4hrs (Hybaid Incubator, South African SCientific Products, SA). The 
HPV-16 L 1 gene was labelled and used to probe for L 1 DNA on the Southem blot. HPV-16 L 1 was 
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isolated from pUC-l1 by restriction enzyme digestion and agarose gel electrophoresis. The L 1 band 
was purified from the agarose gel, as described i"I Appendix AS.6. 
The probe was labelled with dlgoxigenin (DIG}dUTP according to the instructions of the DIG High 
Prime DNA Labelling and Detection Starter Kit 2 (Roche Molecular Biochemicals). Briefly, 
approximately 1 Jlg of DNA was denatured at 100°C, chilled quickly In an ice/ethanol bath, mixed with 
DIG-High Prime, and incubated at 37°C for 20hrs. DIG-High Prime generates labelled probe 
according to the random primed labelling technique. 
When the pre-hybridlsation step was completed. the labelled probe was placed in a boiling water bath 
for 1 Om in, to denature the DNA. The probe solution was then added to the pre-hybridisation solution, 
in which the membrane had been Incubati"lg. Hybridisatlon was allowed to proceed from 4hrs to 
ovemight at 68DC, with gentle shaking. 
A10.3. Washing and developing 
The membrane was washed to remove un-hybridlsed probe. The washes were first performed with a 
2X SSC. 0.1% SDS (w/v) solution at room temperature; and then with a O.SX SSC, 0.1% SOS (w/v) 
solution at 68°C. 
A10.4. Datactlon and photographic development 
The membrane was incubated for 30min at room temperature in blocking solution, consisting of 0.1M 
MaleiC add buffer (Appendix B7) and 1X blocking reagent (Roche Molecular Biochemicals). Anti-
Digoxigenln-AP antibody was added to the blocking solution, in which the membrane had been 
incubati"lg. Antibody binding was allowed to proceed for 30min at room temperature, with gentle 
shaking. Unbound antibody was washed off with large volumes of washing buffer (Appendix B7); after 
which the membrane was equilibrated in detection buffer (Appendix B7) for Smin. The membrane was 
then covered with the kit's CSPD Ready-to-use solution (chemiluminescence substrate). The 
membrane was sealed in plastic and exposed to Agfa Cul1x RP1 X-ray film. The X-ray was developed 
as described In AppendixA12.3. 
A11. ANALYSIS OF PROTEIN EXPRESSION BY BCG 
A11.1. Total protein extraction from BCG 
Due to the thick mycobacterial cell wall, protein extraction methods that make use of lysis buffers are 
often not suitable for the extraction of protein from mycobacteria. A mechanical bead-beating method 
was therefore utilised to extract protein from BCG. 
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BGG was grown to mid-log phase (00600 0.S-O.7) in 100ml of Sauton's broth, and the cells were 
harvested by centrifugation at SOOOrpm for 10min (Beckman J2-21 centrifuge, JA-10 rotor). To 
investigate up-regulation of protein expression by the heat-shock response, some cultures were 
incubated at 4soG for 30min before collecting the cells. The cell pellet was re-suspended in 
phosphate-buffered saline (PBS), and centrifuged as above to wash the cells. The cell pellet was then 
re-suspended in Sml PBS, and was placed into 2ml screwcap tubes (Quality Scientific, USA). 100-
200~1 of 0.1mm-diameter zirconia spheres (Biospec Products, USA) were placed into the tubes. The 
tubes were placed into a FastPrep FP120 machine (Bio 101, USA) and processed for four 30 second 
periods at speed 6. The tubes were cooled in ice between each processing period. The FastPrep 
machine shakes the tubes at very high speeds, which in the presence of the spheres, effectively lyses 
most bacteria. The tubes were centrifuged at 10 OOOrpm for 10min (Eppendorf Desktop centrifuge, 
Germany) to sediment the cellular debris and silica/ceramic spheres. The supematant fluid (containing 
the soluble protein fraction) was collected. The bead/cell debris pellets were resuspended in 10% 
50S and boiled for 30min. The supematant, containing the insoluble protein fraction, was removed 
after centrifugation as above. 
A11.2. Protein assay 
The Bio-Rad Protein Assay kit (Bio-Rad Laboratories, Germany) was used as specified in the kit's 
protocol. This assay is based on the observation that the optical density of Coomassie Brilliant Blue 
G-2S0 shifts from 46Snm to S9Snm when protein binding occurs. The kit was used to determine the 
concentration of protein extracted from BGG cultures, and hence, the amount of protein to use for 
50S-PAGE analysis. Several dilutions of bovine serum albumin (BSA; Roche Diagnostics, Germany) 
were prepared, with concentrations ranging from 1 to 2S~g/mi. These were used to plot a standard 
curve. 0.8ml of the BSA standards, and appropriately diluted BGG ceillysates, were placed into clean 
2ml tubes. 0.2ml of the Dye Reagent Concentrate was added to each tube, and mixed well. The 
00595 of each sample was measured and the concentrations of the unknown samples were 
determined by plotting their ODs against the standard curve. 
A11.3. Sodium dodecyl sulphate - polyacrylamide gal electrophoresis (SDS-PAGE) 
A discontinuous system was used in which a large-pore gel (stacking gel) was layered above a 
separating (running) gel. A gel mouk::l was made by ·sandwiching- one alumina and one glass plate 
(1OcmX10cm) together, with 0.7Smm spacers between the plates on either side. A 12.S% acrylamide 
running gel (Appendix B8) was poured into the gel mould and was overlaid with water-saturated n-
butanol to exclude oxygen (to aid polymerization) and to create a flat gel surface. The gel was left at 
40C ovemight to polymerise completely. A 2-3cm deep 4% acrylamide stacking gel (Appendix B8) was 
poured above the running gel and a comb was Inserted. Polymerisation was left to proceed for about 
1hr. The comb was removed and the gel-sandwlch- was clamped into the electrophoresis apparatus 
(Hoefer Mighty Small SE2S01260, San FranCiSCO, USA). The buffer chambers were filled with tank 
buffer (Appendix B8). 
178 
Appendix A: General techniques 
The BCG protein samples were diluted to 1 J.lg/J.l1 in PBS, and then combined with the same volume of 
2X treatment buffer (Appendix B8). The proteins were denatured in a boiling water bath for 5min, and 
then cooled on ice. 20jJI (10J.lQ) of the treated protein sample were baded per well. The gel was 
electrophoresed at 20mA, until the tracking dye reached the bottom of the gel. A molecular weight 
mari<er (LMW Electrophoresis Calibration Kit, Phannacia Biotech, USA) was electrophoresed 
alongside the protein samples, for estimation of protein sizes. The gel apparatus was disassembled, 
and the gel was carefully removed from the glass plates. Protein gels were generally run in duplicate, 
and either stained with Coomassie blue or used forwestem blotting. 
A11.4. Coomassle blue staining 
Coomassie blue staining is based on non-specific binding of Coomassie blue dye to proteins. After 
electrophoresis, the gel mould was disassembled carefully and the gel was placed in Coomassie blue 
staining solution (Appendix B9), and was left to shake gently on a rotary shaker (Red Rotor PR70, 
Hoefer Scientific Instruments, San Francisco, USA) for 1.5hrs. The methanol-acetic acid solutbn 
effectively fixes the proteins on the gel. The staining solution was poured off and the gel was washed 
in destaining solution I (Appendix B9) for 30min to remove the majority of the background stain. The 
gel was then washed in destaining solution II (Appendix B9) until it was sufficiently destained. Once 
destained, the gel was placed on a light box and photographed (Kodak DC120 digital camera). 
A12. WESTERN BLOT PROTEIN ANALYSIS 
A12.1. Western blot protein transfer 
After electrophoresis, the SDS-PAGE gel was equilibrated in Towbin transfer buffer for 15 min. A 
Hybond-P membrane (polyvinylidene difluoride [PVOF] membrane; Amersham Phannacia Biotech, 
UK) was cut to the size of the gel, and prepared by wetting It first in methanol, and then in Towbin 
transfer buffer. Two 1 cm high stacks of Whatman 3MM chromatography paper were soaked in Towbin 
transfer buffer. The one paper stack was placed on the anode of the western bbt transfer apparatus 
(Transblot Semi-Dry Transfer Cell, Bio-Rad LaboratOries, Gennany), folbwed by the membrane and 
the gel. The other stack of saturated paper was placed on the gel. Transfer was albwed to proceed at 
200 rnA for 2hrs. 
A12.2. Invnunodetectlon of proteins on western blot 
Immunodetection of specific proteins was carried out using the BM Chemiluminescence Blotting 
Substrate (POD) kit (Roche Molecular Biochemicals, Gennany) according to the manufacturers' 
specifications. After westem blotting was completed, the PVDF membrane was blocked for 1 hr at 
room temperature in 1% blocking solution, which consisted of the kit's blocking solution diluted in tris-
buffered saline (TBS). The primary antibody (HPV-16 L 1-specific) was diluted in 0.5% blocking 
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solution; and the membrane was incubated in this solution for 16hrs at 4OC. The membrane was 
washed in 3 large \Ulumes of TBST (TBS with 0.1% Tween 20), and then once in O.S% blocking 
solution, to remove unbound antibody. The secondary antibody (a horseradish peroxidase [HRPJ-
labelled antibody, specific for the species of the primary antibody) was diluted in O.S% blocking 
solution, and incubated with the membrane for 30-60min at room temperature. The membrane was 
then washed 4x with TBST, and sealed between two pieces of transparent plastiC. The kit's detection 
reagent was prepared, and added to the membrane for 1 min. The detection substrate (Iuminol, a 
cyclic diacylhydrazide) is o>cidised by horseradish peroxidase (HRP, POD) in the presence of hydrogen 
peroxide, and as a result, emits light. The membrane was exposed to X-ray film for 1-5min, and then 
developed. 
A12.3. X-ray development 
Autoradiographs were developed by immersing in developer for 3min, stopper solution for 1min, and 
fixer solution for 4m in. They were and washed in water, dried and viewed on a light box. 
A13. ZIEHL-NEELSON STAIN OF BCG 
The purity of BCG cultures was verified by means of the Ziehl-Neelson stain. Cells were heat-fixed onto a 
glass slide, and were then stained with carbol fuchsin, with intermittent heating for Smin. The slide was 
washed with water and decolourised with a 3% acid-alcohol solution. The cells were counter-stained with 
methylene blue for 30sec, and were then washed with water. Mycobacteria appear as red rods as they are 
acid-fast, and hence are not decolourised by the acid-alcohol wash. Other bacteria are decolourised by 
the acid-alcohol wash, and therefore take up the blue stain (Prescott et al., 1993). 
A14. QUANTIFICATION OF BCG RNA 
A14.1. RNA Extraction 
RNA extractions were performed on freshly-rnade BCG cultures or on frozen BCG samples. rBCG 
cultures were grown to middle log phase (00Il00 0.S-O.7) in SOml of Sauton's medium (Appendix A1.2). 
The cells were then collected by centrifugation, at 4000rpm for 10min at 4"C, and re-suspended in 
200J,11 of water. RNA was also extracted from frozen BCG inoculation stocks (Appendix A 1S). 
The FastRNA Kit, Blue (Bio 101, USA) was utilised for the RNA extractions, as per the kit's 
instructions. Briefly, 5OOJ,d of CRSR-Blue (chaotropic RNA stabilising reagent), SOOJ,d PAR (phenol 
acid reagent), 100111 CIA (chloroform isoamyl alcohol), and 200J,d of the BCG re-suspension were 
added to a FastPrep Blue tube (containing lysing matrix). The tube was placed in a FastPrep FP120 
machine (Bio 101, USA), at processed at speed 6, for three 30sec periods. The tube was cooled on 
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ice between each processing period. The FastPrep instrument shakes samples at very high speeds, 
allowing mechanical disruption c:t cells by the lysing matrix. The tube was spun at 14000rpm for 15min 
in a microcentrifuge to separate the phases, and pellet cell debris. The top phase was removed and 
placed in a clean tube. 5ooJ.1l CIA was added and mixed well. The phases were separated again, and 
the top phase was removed and placed in a new tube. 500111 of DIPS (DEPC-treated isopropanol 
solution) was added, and the RNA was allowed to precipitate at room temperature for 1min. The RNA 
was collected by centrifugation at 14oo0rpm for 5min. The RNA pellet was washed twice with 250J.1l of 
SEWS (ethanol washing solution), allowed to dry, and then re-suspended in 100111 of SAFE (RNase-
free water). The RNA sample concentration was measured and calculated as described in Appendix 
AS.7. DEPC-treated water (Appendix B1 0) was utilised for all RNA dilutions. 
A14.2. DNase Treatment of RNA 
RNA samples were treated with deoxyribonuclease (DNase) to remove all DNA contcrnination. The 
DNase kit, AMP-D1 (Sigma, USA), was utilised for this purpose, as per the kit's instructions. This 
process involved the addition of 1 unit of DNase and a 10x reaction buffer to 11lg of RNA, and a 15min 
incubatbn step at room temperature. The reaction was stopped with the addition of the kit's stop 
solution (50mM EDTA) and with a 10mln heating step at 70OC. 
A14.3. cDNAsynthesls I Reverse transcrfptlon of RNA 
The 1 st Strand cDNA Synthesis Kit for RT-PCR (Roche Diagnostics, Germany) was utilised to 
synthesise cDNA, according to the manufacturer's Instructions. 11lg of RNA (extracted from BCG was 
added to a mixture of reactbn buffer, MgCI2, dNTPs, random p(dN)s primers, RNase inhibitor, and 
AMV reverse transcriptase. The reaction mixture was incubated at 250C for 10min to allow primer 
annealing to take place, 42°C for 80min for cDNA synthesis, 990C for 5min to deactivate the reverse 
transcriptase, and then at 40C for 5min to cool. The eDNA concentration was measured (Appendix 
AS.7) and then stored at -20OC. 
A14.4. cDNAampllflcatlon and quantification using the LlghtCycler 
The LightCycler - FastStart DNA Master SYBR Green I Kit (Roche Molecular Biochemicals, Germany) 
was used for the quantification of the cDNA. This PCR kit Is specifically adapted for use with the 
LightCycler instrument. All PCR components, excluding the template DNA and primers were supplied 
with the kit, and were mixed according to the kit's instructions. The kit contains the FastStart Taq DNA 
polymerase, which has been shown to reduce non-specific amplification. SYBR Green I dye 
specifically binds to double stranded DNA, this binding enhances Its fluorescence, which is then 
measured by the LightCycler instrument. 
A typical reactbn mixture contained the following reagents per reaction: 
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FastStart Mastermix 2~ 
(containing Taq DNA polymerase, dNTPs, SYBR Green dye, 10x reaction buffer) 
MgCb (25mM) 2.4J.11 
Forward primer (5pmoV~) 2J.11 
Reverse primer (5pmoV~) 
H20 
DNAI cDNA template (50-1oong) 
The PCR reaction parameters were as follows: 
• Initial Denaturation at 95°C for 10 min 
• Denaturation at 95°C for 0 sec 
• Primer annealing at 57°C for 10 sec 
• DNA synthesis at 72°C for 10 sec 
A melting curve was then obtained by running the following DNA Denaturation step: 
• 40°C for 5 sec 
• 95°C for 0 sec (with a temperature transition of O.20°C/sec) 
• 40°C for 0 sec 
A15. PREPARATION OF BeG FOR IMMUNISATIONS 
100ml of BCG was grown in Sauton's medium, in rolling bottles, to middle log phase (00600 0.~.7). 
The cell concentration (in cfulml) was calculated using the equation that a BCG cuHure 00Il00 
measurement of 1.2 Is approximately 2x108 cfulml (Stover at a/., 1993). The cuHure was either used 
Immediately. or was frozen at -800C. When used freshly, the cells were pelleted by centrifugation at 
3000rpm for 10min (Beckman J2-21 centrifuge, JA-20 rotor), and then re-suspended PBS. The cells 
were used for immunisation within an hour preparation. The concentration of the inoculation sample 
was then more accurately determine by serial dilution in Sauton's medium and plating on 7H10 
medium (6 plates per dilution~ In order to prepare the frozen inoculation stocks, the cuHure was 
sedimented as described above, and the pellet was re-suspended in PBS (with 10% vlv glycerol) to an 
approximate concentration of 4x108 cfu/ml. The cell suspension was aliquoted and then frozen at -
80°C. Once the inoculation stocks had been frozen for approximately 7 days, an aliquot was thawed 
and plated to accurately determine the BCG concentration (cfuhnl). Just prior to Inoculation, an aliquot 
was thawed and diluted in PBS to an appropriate concentration. 
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A16. DETECTION OF ANTI-L1 ANTIBODIES BY ENZYME LINKED IMMUNOSORBENT ASSAY 
(ELISA) 
A16.1. Non-fat milk blocking method 
HPV-16 VLPs were diluted in PBS, to a roncentration 2J19/ml, and were added to the wells (100llllwell) 
of a 96-well curvecl-bottomed microtitre plate (Nunc-lmmuno™, Denmark). The plate was placed at 
4°C ovemight to allow the VLPs to coat the wells. The wells were washed three times with PBS using 
a LP55 Sanofi plate washer (pasteur Diagnostics, Paris, France), to remove unattached antigen. The 
wells were then blocked with 200JJI of 1 % milk solution (Elitela milk powder in PBS) for 2hrs at room 
temperature. The plate was washed three times, as above. The sera were diluted 1 :40 in 1% milk 
solution, and 100JJI were added in duplicate wells. The plate was incubated at 37°C for one hour, and 
then washed three times with PBS. The peroxidase-conjugated serondary antibody, rabbit anU..guinea 
pig-HRP immunoglobulins (DAKO, Denmark) was diluted 1 :2000 in 1% milk solution, and was added 
to the wells. The plate was incubated at 370C for 1 hr, and then washed as before. The substrate, 1,2-
phenylenediamine dlhydrochlortde (OPD; DAKO, Denmark) was made according to the manufacture's 
instructbns; using 12ml distilled water, 4 OPD tablets and Sill H~2. OPD is a chromogenic substrate 
for horseradish peroxidase, which develops a yellow rolour upon hydrolysis. The substrate solution 
was added, and the rolour reaction was allowed to proceed for S to 10min, after which, the reaction 
was stopped with the addition of O.SM H2S04• The absorbance was read using the Anthos ELISA plate 
reader (Labtech Instruments) at 492nm, with a reference filter of 620nm. 
A16.2. Polyvinyl alcohol and polyvinylpyrrolidone blocking method 
A modified polyvinyl alcohol (PVA)-blocking ELISA (Studentsov at al., 2002) was utilised to minimize 
non-specific binding. A 96-well curved-bottomed microtitre plate was coated with HPV-16 L 1 VLPs 
ovemight, as described above (A 16.1). The wells were then blocked for 3hrs at room temperature with 
300JJI of PVA blocking solution (O.S% PYA in PBS, pH 7.4) per well. The plate was washed six times 
with PBS. Sera were diluted with PYA blocking solution, and 100JJI were loaded onto the plate in 
duplicate. The plate was incubated at 37°C for 1 hr, and then washed six times with PBS. The 
peroxidase-conjugated secondary antibody was diluted 1 :2000 in a O.S% PYA and 0.8% 
polyvinylpyrrolidone (PVP) solution in PBS, and was then added to the plate. The plate was incubated 
at 37°C for 30min, after Which it was washed six times with PBS. Detection was performed with OPD 
substrate, as described above. 
A17. DELAYED·TYPE HYPERSENSITIVITY SKIN REACTIONS 
The hair on the back of each guinea pig was cut with an electric clipper, and was further removed with 
a depilatory cream (No Hair, Veetla). Each animal received a number of SOIlI intradermal injections in 
the hairless region of the back. The inocula included PBS (pH 7.4), purified protein derivative of 
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tuberculin (PPO, MT702.703, 0.2tJ.9/anlmal), 0.1M sodium carbonate buffer (pH 9.6), intact HPV-16 
VlPs (5tJ.9/animal) and denatul9d HPV-16 VlPs in carbonate buffer (5",g/animal). The denatured 
VlPs were mac:le by leaving them In 0.1 M sodium carbonate bufferfor 2 hours before inoculatiOn. The 
inoculatiOn sites were observed 24, 48 and 72 hours after inoculation and the diameter of erythema 
and induration was measured at each site using calipers. 
A18. MAMMALIAN CELL CULTURE CONDITIONS AND MEDIUM 
The African green monkey kidney (CV-1) and Human TK' 143B (HuTK') cell lines were obtained from 
the American Type Tissue Culture Collection (Rockville, MA, USA). These cells were grown as 
monolayers in SO-20OmI tissue culture flasks (Greiner, Germany), in Oulbecco's Modified Eagle's 
Medium (OM EM; Gibco, UK), containing 10% fetal calf serum (FCS; Sigma-Aldrich, Germany), 
0.15mglml penicillin (P; Gibco), 0.25mg/ml streptomycin (S; Gibco), and 1% FungizDne (F; Gibco). 
The cultures were Incubated at 37°C in a humidified 5% C~ Incubator. Confluent cell layers were spilt 
by adding trypsin-EOTA solution (Gibco, UK) for 5-10mln to 11ft the cells, and then by diluting the 
cel1s115 to 1/10 in fresh OMEM "";th 1 0% FCS and PSF. 
Mouse lymphocytes and P815 (mouse mastocytoma, MHC class I) cells were cultul9d in suspension 
in RPM I medium (Gibco, Paisely, UK), at 3~ in a humidified 5% C02 incubator. RPMI complete 
medium was prepared by the addition of 10% FCS, 0.15mg/ml P, 0.25mglml S, 1% F, and 2J.1M ~­
mercaptoethanol (Gibco). 
A19. PREPARATION OF EFFECTOR CELLS 
The Inguinal lymph nodes from a group of mice were collected aseptically, and were pooled in 1 Oml of 
RPMI, with 10% FCS (Appendix A18). A single cell suspension was prepared by pushing the lymph 
nodes through a sterile metal grid (pore size 0.5mm, Sigma) with the plunger of a 2ml syringe. 10mlof 
RPMI were poured through the grid to collect residual cells. The cell suspension was placed into a 
50ml conical centrifuge tube, into which a further 20ml of RPMI were added. The cell suspension was 
centrifuged at 1500rpm for 10min (Jouan CR412 centrifuge) to pellet the cells. The supematant was 
decanted and the cells were washed by re-suspending the cell pellet in 40ml of RPMI. The 
centrifugation and washing steps were repeated. The cells were collected again by centrifugation and 
the cel pellet was re-suspended in SOml of RPMI complete medium (Appendix A 18). 
10~ of the cell suspension were diluted with Trypan Blue, and counted in a Neubauer counting 
chamber. The cell concentration was adjusted to 10x10' cellslml with RPMI complete medium, In a 
200m1 tissue culture flask (Greiner, Germany). Gp120 peptide (obtained from the NationallnstHute for 
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Biological Standams and Control. Hertfordshire. UK) was added to the cells. at a final concentration cI 
411g/ml. and the cells were Incubated at 370C n a humidified 5% C~ incubator (Forma Scientific)forS 
days. After day six, the cells were transferred to a 50ml tube and collected by centrifugation at 
1500rpm for 5min. The supernatant was decanted and the cells were re-suspended in 30mlof RPMI. 
The cell concentratIOn (both live and dead cells) was adjusted to 15-30x1 Ol/ml with RPMI. The cell 
suspension was transferred to 10ml conical-based tubes. and the cells were carefully under1aid with 
Sml of Lympholyte-M (Cedar1ane). This gradient was spun at 2200rpm (Jouan CR412 centrifuge) for 
20mln at room temperature. to separate the cells. After centrifugation. the cells at the interface were 
removed and added to a conical-based tube. The cells were collected by centrifugatIOn at 1500rpm 
and washed by re-suspension In 10ml RPMI. The washing step was repeated 3 times. The cells were 
finally re-suspended in 1-5ml of RPMI complete medium and counted. These effector cells were used 
in immunogeniclty studies as required. 
A20. DETECTION OF CDS-8PECIFIC INTRACELLULAR IFN..., BY FLOW CYTOMETRY 
For each group of mice. a 200ml tissue culture flask (Greiner) was seeded with 50ml cI P815 cells. at 
a concentration cI 0.2x10B cellslml of RPMI complete medium (Appendix A18). The cells were 
incubated overnight. and then collected by centrifugation at 1500rpm for 5min. The supematant was 
dlscartled; the cells were re-suspended n5ml of RPMI complete medium. and then counted. 
P815 cells. gp120 peptide. effector cells (Appendix A 19). and Brefeldin A were added to 4 FACS tubes 
as follows: 
Tubes 
CD3/FITCJPE+pep CD3/CD8I1FN+pep CD3/FITCJPE-pep CD3/CD8/IFN-pep 
PSi5 cells 3xi0s 3xi0' 3xi0s 3x10B 
Gpi20 peptide 
0.6J.11 0.6111 - -(4mglmQ 
Effector cells 3xi01 3xi01 3xi0B 3x10s 
Brefeldln A 0.6J.11 0.6J.11 0.6J.11 0.6J.11 
RPMI complete medium was added to each tube to a total volume clSOO",. The cells were mixed and 
incubated for 3 hours. After Incubation. the content of each tube was mixed with 1 ml of FACS buffer 
(PBS. 1% FCSt 0.02% sodium azide). The cells were collected by centrifugation at 1500rpm for Smin, 
and the supematant was discartled. The cells pellets were re-suspended in 75111 of bloCking buffer 
(141~1 Facs Buffer. 1~1 CD1SJ32 (Scientific Group). 3.75~1 normal mouse serum. and 3.75~1 nonnal rat 
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serum), and left on ice for20min. The cells were washed with 5ml of FACS buffer, and then collected 
by centrifugation, as before. 
75~ of diluted antibody were to the tubes as follows, and then left on ice for 30min: rat monoclonal 
anti-mouse CD3 APC (1 :25 dilution) to all of the tubes, rat monoclonal anti-mouse IgG2a FITC (1 :50) 
to the CD3IFITCIPE tubes, and rat monoclonal anti-mouse CDB FITC (1 :50) to the CD3/CDB/IFN 
tubes. All antibodies were from 8D-Phannlngen. The cells were washed twice in FACS buffer (as 
above) and the cell pellets were each re-suspended in 3ml of 1x FACSLyse (Scientific Group) for 
10min at room temperature. The cells were washed twice in FACS buffer, as before, and then re-
suspended in 1ml of FACS buffer overnight, at 4°C. The cells were collected by centrtfugation, and the 
supernatant was discarded. 1 ml of 1x PermWash solution (Scientific Group) was added, and the cells 
were left on ice for 15min. The cells were collected by centrifugation and the supernatants were 
discarded. 
Rat IgG1 PE isotype and IFN-y PE antibody were diluted 1:50 with PermWash solution. 150111 of 
lsot~ or antibody were added to the appropriate tubes, which were then left on ice for 30min. The 
cells were washed twice with PermWash solution, and re-suspended in 900~ of FACS buffer. A 
FACS Caliber flow cytometer (Becton-Dickinson, San Jose, CA) was used to perform the 
immunophenotyping and intracellular cytokine analysis. 
The number of gated events for IFN-y and CDB in the CD31FITC/PE and CD3ICDB/IFN tubes were 
calculated as follows: 
For IFN-y: 
ForCDB: 
UR x gated events of CD3/CDB/IFN 
gated events of CD31FITCIPE 
CUR + LR) x gated events of CD3/CDB/IFN 
gated events r:I CD31FITCIPE 
=A 
=8 
The percentage of IFN-y-producing cells, as a percentage of CDB cells, was calculated as follows: 
IFN-y positive events: UR of CD3ICDB/IFN tube minus A 
CDB positive events: CUR + LR) of CD3/CDB/IFN tube minus 8 
% IFN-y-producing cells as a % of CDB = IFN-v positive events x 100 
CDB positive events 
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A21. 51CHROMIUM-RELEASE CYTOTOXIC KILL ASSAY 
Preparation of target cells 
P815 cells were labelled with 51Chromium (51 Cr; Amersham). 5ml of healthily growing cells 'Here 
collected by centrifugation and re-suspended in 200~1 of 51Cr (2mCi/ml). The cells were incubated at 
37"C with 5% CO2 for 1.5hrs, with gentle shaking every 15min. The cells were washed 3 times in 10ml 
RPMI, counted, and then diluted in RPM I complete medium to 1x105cellslml. The cells were split into 
2 tubes. The cells in one tube 'Here pulsed with gp120 peptide, by the addition of peptide at a final 
concentration of 21J9/ml. 
Preparation of effector cells 
Effector cells were prepared (Appendix A 19), and were adjusted to a concentration of 1 Ox1 08 cellslml. 
Kill assay 
50~1 of the p815 target cells, unpulsed and gp120-pulsed, were added in triplicate to a round-
bottomed, sterile 96-we1l microtitre plate (Nunc, Denmark). The effector cells were serially diluted and 
added to the same wells at varying concentrations to achieve final effector:target ratios of 200:1, 
100:1,50:1,25:1,12:1,6:1,3:1 and 1:1. To determine spontaneous 51Cr release, effectors were not 
added to the target cells, instead, medium was used. To detennine maximum 51Cr release, 5% Triton 
X-100 (Sigma-Aldrich) was added to the target cells. 
The plates were incubated for 4hrs at 37°C in a 5% CO2 incubator. 1 OO~I of supematant was removed 
from each well and added into Durham counting vials. The gamma radiation in each tube, measured 
as counts per minute (cpm), was determined using a Packard gamma counter. 
The % of specific sample lysis for the triplicate wells of each effector.target ratio was calculated as 
follows: 
% specific lysis = mean sample com - mean spontaneous com x 100 
mean maximum cpm - mean spontaneous cpm 
A22. RECOMBINANT VACCINIA VIRUS FORMATION 
African green rronkey kidney (CV-1) cells were grown in a six well plate (Nunc, Denmark) until 60-80% 
confluency. Wild-type vaccinia virus was diluted to 3x1 as viruseslml in virus diluent (DMEM with 1 % 
1M Hepes-buffered-sallne, Gibco), and was added to each well (0.5mllwell). Cell infection was 
allowed to proceed for 1hr, with occasional agitation. The transfection mixture was set up by 
incubating 101JQ of linearised pSC65-L 1 and 60J.1/ of DOTAP (Boehringer Mannhein, Germany) at room 
temperature for 10-15min. The virus inoculum was removed from the cells, and 2ml of fresh DMEM, 
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containing 4% FCS and PSF, and the transfection medium were mixed, and added to the cells. The 
infectedltransfected cells were incubated for 2-3 days, until cytopathic effect (cpe) was detected. The 
cells were then stained with X~al (Appendix A23) to dlscem whether the transfection had been 
successful. Cells from duplicate wells, that had not been stained, were re-suspended in 200IJI of virus 
diluent; and freezelthawed repeatedly to lyse the cells and release the virus. 
To eliminate contamination by wild-type vaCCinia virus, the newly formed rVV-L 1 R viral stocks were put 
through several rounds of plaque purification and serial passage in HuTK" cells with BUdR selection. 
HulK cells were grown in 6-well plates until 80% confluent. These cells were then infected with the 
newly formed rW-L 1 R for 1 hr. The virus inoculum was removed from the cells and replaced with 2ml 
of selection medium, consisting of DMEM with 10% FCS and 25J.1Q/ml BUdR (Sigma, St Louis, USA). 
After a 3-day incubation, the medium was removed and the infected cells were overlayed with a 1:1 
mixture of DMEM and 2% low melting point agarose (SeaPlaque, FMC Bio Products), containing 
25J.1Q/ml BudR and 250J.1Q/ml X~al, for detection of recombinant plaques. The agarose mixture was 
added at 42°C, and allowed set at room temperature for 10min. The cells were incubated ovemight at 
370C with 5% C02. The incorporation of the LacZ gene into the recombinant virus allows for the visual 
distinction between non-recombinant and recombinant virus plaques. Blue plaques, indicative of rW-
L 1 R infection, were picked using a Pasteur pipette and added to 200IJI of virus diluent. The infected 
cells were stored at -20OC or freezeJthawed 3 times, and used for the next round of purification. 
A23. X-GAL STAIN 
CV-1 cells were grown in a 6-well plate to 80% confluency. The cells were infected with rW-L 1 R for 2 
days, after which they were washed with PBS and fixed with 1 ml of 4% para-formaldehyde, for 10 
minutes at room temperature. The cells were washed with PBS, and then covered with X~al stain 
solution (in 1 Om Is; 9.2ml PBS, 0.2ml of 50rng/ml X~al, 0.2ml of 250mM ferricyank:1e, 0.2ml of 250mM 
ferrocyanide and 0.2ml of 100mM MgCI2). The cells were incubated at 370C until blue plaques were 
visible (2-16hrs). 
A24. VACCINIA VIRUS PROPAGATION IN EGGS 
Infection of eggs with W 
Vaccinia virus was grown to high titres on the chorio-allantoic membranes (CAMs) of 11-day~1d 
fertilised chicken eggs. To view the structures within an egg, a light beam was shone through the egg, 
in a dark room. The eggs were placed on their sides and marked on the round side (at the air sac), 
and on the flatter side (top most side) near a vein. Small holes were made in the shell near the marks 
(mentioned above), taking care not to break the membranes. The hole at the air sac was slightly 
enlarged with a needle. A drop of sterile PBS was placed at the top hole, and the top membrane was 
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loosened with a needle, which let the PBS run In, onto the top amniotic membrane. A drop of melted 
wax was placed next to this hole. The air was then sucked out of the air sac hole with a rubber bulb, 
causing the top membrane to drop. The eggs were incubated for 1-2hrs, to let the chicks settle. 1001-11 
of virus (103_106 pfu) were injected Into the top hole of each egg, without punctunng the chorio-
allantoic membrane. The hole was sealed with the wax, and the eggs were Incubated at 37°C for 3 
days. 
Extraction of vil1JS 
The eggs were held on their sides, with the inoculation hole at the top. Starting from air sac hole, the 
shell of each egg was cut in half with a pair of scissors. The top half of the shell, containing the 
Infected membrane, was retained, while the rest of the egg was discarded. Poxes could be seen as 
white dots on the membrane. The egg shell and un Infected membrane were cut aNay and discarded. 
The Infected membranes were nnsed in 200ml of PBS. Three or 4 membranes were placed In a 
cooled McCartney bottle, containing approximately 1.5-2 em of glass beads (2-4 em In diameter). 
Three ml of Mcilvaine's buffer (Appendix B11) and 1ml of Arklone· (1,1,2-tnchloro-1,2,2-
tnfluoroethane; AECI, South Afr1ca), an organic solvent, were added to each bottle; and the bottles 
were shaken vigorously for two minutes, to disrupt the membranes and release the virus particles. 
The virus suspension was subjected to centrifugation at 1 Ooorpm (approximately 600g) for 10mlns at 
4°C, to sediment the membrane debris. The supemata1ts were transferred to new McCartney bottles 
and left on ice. Three ml of Mcilvaine's buffer were added to the glass beads/membrane debris and 
the bottles were shaken again for 2mln. The bottles were centrifuged as before. The supernatants 
were transferred to new McCartney bottles, and were left on Ice for 1.5hrs. The McCartney bottles 
were spun at 2000rpm for 15mln, to remove remaining membrane debns from the supemata1t. The 
supernatants were transferred to a Beckman· centrifuge tUbe. and underlain with 5001-11 of sterile 36% 
(w/v) sucrose solution (In PBS). The tubes were centrifuged at 11 OOOrpm for 1hr (Beckman J2-21 
swlng-out rotor). The supemata1t was discarded and the virus pellet was re-suspended gently 
overnight in 1 ml Mcilvaine's buffer at 4°C. 
A25. VACCINIA VIRUS TrrRATION AND ZIEHL NEELSON CARBOL FUCHSIN 
STAINING 
CV-1 cells were grown In a 24-well plate (Nunc, Denmark) until approximately 80% confluent. 
Vaccinia virus was senally diluted in virus diluent. 200~ of the 1a-a to 10'" dllutbns were utilised to 
infect cells, In tnplicate. The Infection was allowed to proceed for 2hrs at 37°C, with occasional 
shaking. The virus Inoculum was removed and 1 ml of fresh OM EM with 10% FCS and PSF was 
added. The infection was allowed to progress until cpa was evident, this usually occurred 2-3 days 
after Infection. The medium was removed from the cells. and then approximately 0.5ml Ziehl Nealson 
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Carbol Fuchsin was added to each well. The wells were washed carefully with water, and allowed to 
dry. The plaques were counted and the number of pfu per ml was calculated for the undiluted virus. 
A26. EXTRACTION OF VACCINIA VIRUS FROM MOUSE OVARIES 
The ovaries of each mouse were finely chopped with a sterile scalpel. The chopped ovaries and 1 ml 
of MCilvaine's buffer were transferred to a Ten Broeck grinder and then homogenised with 30 grinding 
strokes. The ovary homogenate was transferred to a 2ml tube, and subjected to 3 freezelthawed 
cycles. Cell debris was removed from the ovary preparation by centrifugation at 2000rpm for 1 Omin. 
The virus In the supematS'lt was titrated (Appendix A26), and the number of vaccinia virus pfusfmouse 
was calculated. 
A27. STATISTICAL TESTS 
Data were compared using the Student t-test. Data were considered significantly different at P :s; 0.05. 
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APPENDIX B: SOLUTIONS, BUFFERS AND MEDIA 
81. A1bumln-dextrose complex (ACe) 
Bovine albumin factor V 
Glucose 
Distilled water 
The solution was filter--sten7ised and stored at 4°C. 
82. Sauton's broth 
KH2PO. 
MgSO •. 7H20 
L-asparagine monohydrate 
Glycerol 

















The pH was adjustad to 7.4 with 0.1 M Kel. The volume was adjusted to 1 litre, and the 
solution was autoclaved. 
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The solution was placed on a stirrer to dissolve the NaCI, CTAB (n-acety/-N, N, N,-trimethyl 
ammonium bromide) was edded and heated to 65·C if necessary. The volume was edjusted 
to 100 ml and the solution was stored at room temperature for no longer than 6 months. 






















The pH was edjusted to 7.0 with a few drops of 10N NaOH and the volume mede up to 1 
litre. The solution was autoc/aved and stored at room temperature. 
87. DIG hybridlsatlon solutions: 
Pre-hybrldlsatlon solution 
5XSSC 
1X blocking reagent (Roche Molecular Biochemicals, Germany) 
0.02% SDS 
0.1 % N-Iauroylsarcosine 
Maleic acid buffer 
0.1 M Maleic acid 
0.15M NaCI 
NaOH to pH 7.5 
Washing buffer 
0.1 M Maleic acid buffer 
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Acrylamide is a neurotoxin and was weighed out wearing gloves and a gas mask. The solution 
was warmed at 55 'C to dissolve the components, it was filter sterilised and stored in the dark at 4 
'C. 





The pH was adjusted to B.B with Hel and made to 200ml with distilled water. 





The pH was adjusted to 6.B with HCI and made to 50ml with distilled water. 
Separating (running) gel (12.5% acrylamlde) 
Monomer solution 
4X running gel buffer 
10%505 
Distilled water 
10% ammonium persulphate 
TEMED (N,N,N',N' tetramethyl-ethylenediamine) 
Stacking gel (4% acrylamlde) 
Monomer solution 










2X Treatment buffer 
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89. Coomassle blue stain solutions: 
Staining solution 












81 D. OEPC-tnlated water 














The solution was left at room temperatura for 10min, and then autoclaved to inactivate the 
DEPC. 
811. Mcilvaine's buffer 
0.1 M citric acid 





The pH was edjusted to 7.4, and made up to 1000ml with distilled water. The solution was 
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Appendix E: HPV-16 L 1 sequences 



























HindIII ApaI PvuII Ll start codon 
I I I I 
AAGCTTTCGG GCCCGCAGCT GACA'l'GTCGC TGTGGCTGCC GTCGGAGGCC ACCGTGTACC 
TGCCGCCGGT GCCGGTGTCG AAGGTGGTGT CGACCGACGA GTACGTGGCC CGCACCAACA 
TCTACTACCA CGCCGGCACC TCGCGCCTGC TGGCCGTGGG CCACCCGTAC TTCCCGATCA 
AGAAGCCGAA CMCAACAAG ATCCTGGTGC CGAAGGTGTC GGGCCTGCAG TACCGCGTGT 
TCCGCATCCA CCTGCCGGAC CCGAACAAGT TCGGCTTCCC GGACACCTCG TTCTACAACC 
CGGACACCCA GCGCCTGGTG TGGGCCTGCG TGGGCGTGGA GGTGGGCCGC GGCCAGCCGC 
TGGGCGTGGG CATCTCGGGC CACCCGCTGC TGAACAAGCT GGACGACACC GAGAACGCCT 
CGGCCTACGC CGCCAACGCC GGCGTGGACA ACCGCGAGTG CATCTCGATG GACTACAAGC 
AGACCCAGCT CTGCCTGATC GGCTGCAAGC CGCCGATCGG CGAGCACTGG GGCAAGGGCT 
CGCCGTGCAC CAACGTGGCC GTGAACCCGG GCGACTGCCC GCCGCTGGAG CTGATCAACA 
CCGTGATCCA GGACGGCGAC ATGGTGGACA CCGGCTTCGG CGCCATGGAC TTCACCACCC 
TGCAGGCCAA CAAGTCGGAG GTGCCGCTGG ACATCTGCAC CTCGATCTGC AAGTACCCGG 
ACTACATCAA GATGGTGTCG GAGCCGTACG GCGACTCGCT GTTCTTCTAC CTGCGCCGCG 
AGCAGATGTT CGTGCGCCAC CTGTTCAACC GCGCCGGCAC CGTGGGCGAG AACGTGCCGG 
ACGACCTGTA CATCAAGGGC TCGGGCTCGA CCGCCAACCT GGCCTCGTCG AACTACTTCC 
CGACCCCGTC GGGCTCGATG GTGACCTCGG ACGCCCAGAT CTTCAACAAG CCGTACTGGC 
TGCAGCGCGC CCAGGGCCAC AACAACGGCA TCTGCTGGGG CAACCAGTTG TTCGTGACCG 
TGGTGGACAC CACCCGCTCG ACCAACATGT CGCTGTGCGC CGCCATCTCG ACCTCGGAGA 
CCACCTACAA GAACACCAAC TTCAAGGAGT ACCTGCGCCA CGGCGAGGAG TACGACCTGC 
AGTTCATCTT CCAGCTCTGC AAGATCACCC TGACCGCCGA CGTGATGACC TACATCCACT 
CGATGAACTC GACCATCCTG GAGGACTGGA ACTTCGGCCT GCAGCCGCCG CCGGGCGGCA 
CCCTGGAGGA CACCTACCGC TTCGTGACCT CGCAGGCCAT CGCCTGCCAG AAGCACACCC 
CGCCGGCccc GAAGGAGGAC CCGCTGAAGA AGTACACCTT CTGGGAGGTG AACCTGAAGG 
AGAAGTTCTC GGCCGACCTG GACCAGTTCC CGCTGGGCCG CAAGTTCCTG CTGCAGGCCG 
GCCTGAAGGC CAAGCCGAAG TTCACCCTGG GCAAGCGCAA GGCCACCCCG ACCACCTCGT 
CGACCTCGAC CACCGCCAAG CGCAAGAAGC GCAAGCT~ TCGAT 
ClaI 
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APPENDIX F: SUMMARY OF rBCG·L 1 EXPRESSION AND IMMUNITY 
Table F1. Summary of rBCGML 1 expression and immunity in guinea pigs 
DTHskin Antl-L 1 antibody L1 mRNA Antl·L 1 antibody Recombinant expression response In serum reaction to response In genital L1 secretions 
Tokyo p361 L 1 R nd ++ nd nd 
Tokyo p361L1e + +++ +++ + 
Tokyo p119L1NLS- nd ++ nd 
Tokyo p119L 1e +++ +++ +++ ++ 
Tokyo p119L1BCGe nd ++ +++ + 
Tokyo p112L1NLS- nd ++ +++ 
Tokyo p112L1e ++ +++ 
Tokyo p112L 1BCGe nd ++ +++ 
-. not significantly positive; +,Iow; ++, moderate; +++, high; nd, not determined 





Pasteur p361 L 1 e 








Antl·L 1 antibody 
response In serum 
++ 
+++ 
Level of protection from 
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